<SEC-DOCUMENT>0001062822-25-000016.txt : 20250325
<SEC-HEADER>0001062822-25-000016.hdr.sgml : 20250325
<ACCEPTANCE-DATETIME>20250325160524
ACCESSION NUMBER:		0001062822-25-000016
CONFORMED SUBMISSION TYPE:	PRE 14A
PUBLIC DOCUMENT COUNT:		19
CONFORMED PERIOD OF REPORT:	20250320
FILED AS OF DATE:		20250325
DATE AS OF CHANGE:		20250325

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			LEXICON PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001062822
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				760474169
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		PRE 14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30111
		FILM NUMBER:		25768272

	BUSINESS ADDRESS:	
		STREET 1:		2445 TECHNOLOGY FOREST BLVD.
		STREET 2:		SUITE 1100
		CITY:			THE WOODLANDS
		STATE:			TX
		ZIP:			77381
		BUSINESS PHONE:		2818633000

	MAIL ADDRESS:	
		STREET 1:		2445 TECHNOLOGY FOREST BLVD.
		STREET 2:		SUITE 1100
		CITY:			THE WOODLANDS
		STATE:			TX
		ZIP:			77381

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LEXICON PHARMACEUTICALS, INC./DE
		DATE OF NAME CHANGE:	20070426

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LEXICON GENETICS INC/TX
		DATE OF NAME CHANGE:	20000126
</SEC-HEADER>
<DOCUMENT>
<TYPE>PRE 14A
<SEQUENCE>1
<FILENAME>lxrx-20250325.htm
<DESCRIPTION>PRE 14A
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:2b1dddfe-05bf-4b11-93bd-da68508bbfaf,g:4ab81c16-7e5c-4f22-90a2-d745a11935f6,d:29f56aa9946248519609c20b75df062f-->
<html xmlns:lxrx="http://www.lexpharma.com/20250325" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns="http://www.w3.org/1999/xhtml" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>lxrx-20250325</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-2">PRE 14A</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-3">0001062822</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-4">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="lxrx-20250325.xsd"/></ix:references><ix:resources><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">lxrx:LonnelCoatsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">lxrx:MichaelS.ExtonPh.D.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:EqtyAwrdsInSummryCompstnTblForAplblYrMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:IndividualAxis">lxrx:LonnelCoatsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:EqtyAwrdsInSummryCompstnTblForAplblYrMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:EqtyAwrdsInSummryCompstnTblForAplblYrMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:IndividualAxis">lxrx:LonnelCoatsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:IndividualAxis">lxrx:LonnelCoatsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:IndividualAxis">lxrx:LonnelCoatsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:IndividualAxis">lxrx:LonnelCoatsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:EqtyAwrdsInSummryCompstnTblForAplblYrMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:IndividualAxis">lxrx:MichaelS.ExtonPh.D.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:IndividualAxis">lxrx:MichaelS.ExtonPh.D.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:IndividualAxis">lxrx:MichaelS.ExtonPh.D.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:IndividualAxis">lxrx:MichaelS.ExtonPh.D.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:IndividualAxis">lxrx:MichaelS.ExtonPh.D.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:EqtyAwrdsInSummryCompstnTblForAplblYrMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:EqtyAwrdsInSummryCompstnTblForAplblYrMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:EqtyAwrdsInSummryCompstnTblForAplblYrMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i29f56aa9946248519609c20b75df062f_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, DC. 20549</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SCHEDULE 14A</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Rule 14A-101)</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INFORMATION REQUIRED IN PROXY STATEMENT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SCHEDULE 14A INFORMATION</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Proxy Statement Pursuant to Section&#160;14(a) of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">the Securities Exchange Act of 1934</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Filed by the Registrant x</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Filed by a Party other than the Registrant</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Check the appropriate box:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.847%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:46.707%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.847%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.199%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%">x</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Preliminary Proxy Statement</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%">o</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Confidential, for Use of the Commission Only</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%">o</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Definitive Proxy Statement</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(as permitted by Rule 14a-6(e)(2))</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%">o</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Definitive Additional Materials</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%">o</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Soliciting Material Pursuant to Rule&#160;14a-11(c)or Rule&#160;14a-12</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-1">LEXICON PHARMACEUTICALS, INC.</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Name of Registrant as Specified In Its Charter)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Payment of Filing Fee (Check the appropriate box):</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:26.608%"><tr><td style="width:1.0%"/><td style="width:25.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:71.977%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%">x</span></div><div><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">No fee required.</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"/><td style="width:1.962%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.838%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%">o</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fee computed on table below per Exchange Act Rules&#160;14a-6(i)(1) and 0-11.&#160;</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.34pt">Title of each class of securities to which transaction applies:&#160;&#160;N/A</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.34pt">Aggregate number of securities to which transaction applies:&#160;&#160;N/A</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.34pt">Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):&#160;&#160;N/A&#160;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.34pt">Proposed maximum aggregate value of transaction:&#160;&#160;N/A</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.34pt">Total fee paid:&#160;&#160;$0</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.081%"><tr><td style="width:1.0%"/><td style="width:2.591%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.209%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fee paid previously with preliminary materials:&#160;&#160;N/A</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Check box if any part of the fee is offset as provided by Exchange Act Rule&#160;0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.34pt">Amount Previously Paid:</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.34pt">Form, Schedule or Registration Statement No.:</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.34pt">Filing Party:</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.34pt">Date Filed</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i29f56aa9946248519609c20b75df062f_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="text-align:center"><img src="lxrx-20250325_g1.jpg" alt="image0a01a04.jpg" style="height:53px;margin-bottom:5pt;vertical-align:text-bottom;width:153px"/></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">April ___, 2025</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TO OUR STOCKHOLDERS:</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">I am pleased to invite you to attend the 2025 annual meeting of stockholders of Lexicon Pharmaceuticals, Inc. to be held on Monday, June 2, 2025 at 8:00 a.m. CDT.  The annual meeting will be held entirely online and you will be able to attend and participate by visiting </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">http://www.virtualshareholdermeeting.com/LXRX2025</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, where you will be able to vote electronically and submit questions.  You will not be able to attend the annual meeting in person.  We are taking measures so that our stockholders may still meaningfully participate in the annual meeting notwithstanding the virtual platform.  You will need the 16-digit control number included with these proxy materials to attend the annual meeting.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Your vote is important, regardless of the number of shares that you hold.  Whether or not you plan to attend the annual meeting, I hope you will vote as soon as possible, either electronically on the Internet, by telephone or by signing and returning the enclosed proxy card.  You can revoke any prior proxy by attending the annual meeting and voting electronically during the meeting or by otherwise revoking your proxy as described in the proxy statement.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Thank you for your ongoing support of and continued interest in Lexicon Pharmaceuticals.</span></div><div style="padding-left:216pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Sincerely,</span></div><div style="padding-left:216pt;text-align:justify"><span><br/></span></div><div style="padding-left:216pt;text-align:justify"><span><br/></span></div><div style="padding-left:216pt;text-align:justify"><span><br/></span></div><div style="padding-left:216pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Michael S. Exton, Ph.D.</span></div><div style="padding-left:216pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Chief Executive Officer</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i29f56aa9946248519609c20b75df062f_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LEXICON PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2445 Technology Forest Blvd., 11th Floor</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Woodlands, Texas 77381</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(281) 863-3000</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTICE OF ANNUAL MEETING OF STOCKHOLDERS</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TO BE HELD JUNE 2, 2025</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TO OUR STOCKHOLDERS:</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The annual meeting of stockholders of Lexicon Pharmaceuticals, Inc. will be held on Monday, June 2, 2025 at 8:00 a.m. CDT.  The annual meeting will be held entirely online at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">http://www.virtualshareholdermeeting.com/LXRX2025</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  At the annual meeting, stockholders will consider and vote on the following matters:</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the election of the two Class I directors named in this proxy statement;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a proposal to ratify and approve an amendment to our 2017 Equity Incentive Plan increasing the total number of shares of our common stock that may be issued pursuant to stock awards granted under the plan from 55,000,000 to 75,000,000, all of which may be granted as incentive stock options;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a proposal to ratify and approve an amendment to our 2017 Non-Employee Directors&#8217; Equity Incentive Plan increasing the total number of shares of our common stock that may be issued pursuant to stock awards granted under the plan from 2,000,000 to 4,000,000;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a proposal to amend our Sixth Amended and Restated Certificate of Incorporation to effect, at the discretion of our board of directors, a reverse split of our common stock, at a ratio within a range of 1-for-10 to 1-for-50, at any time prior to our 2026 annual meeting of stockholders and with the actual ratio to be determined within that range at the discretion of our board of directors;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an advisory vote to approve the compensation paid to our named executive officers;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a proposal to ratify and approve the appointment of Ernst &amp; Young LLP as our independent auditors for the fiscal year ending December 31, 2025; and</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acting on any other business that properly comes before the annual meeting.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You are entitled to vote at the annual meeting only if you are the record owner of shares of our common stock at the close of business on April 3, 2025.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is important that your shares be represented at the annual meeting whether or not you plan to attend online. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Please cast your vote electronically on the Internet, by telephone or by signing and returning the enclosed proxy card as promptly as possible.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  If you attend the annual meeting online, and wish to do so, you may revoke the proxy and vote electronically at the annual meeting.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:216pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By order of the board of directors,</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:216pt"><span><br/></span></div><div style="text-align:justify;text-indent:216pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Brian T. Crum</span></div><div style="text-align:justify;text-indent:216pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Secretary</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Woodlands, Texas</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">April ___, 2025</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i29f56aa9946248519609c20b75df062f_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LEXICON PHARMACEUTICALS, INC. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2445 Technology Forest Blvd., 11th Floor</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Woodlands, Texas 77381</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(281) 863-3000</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.818%"><tr><td style="width:1.0%"/><td style="width:23.942%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.802%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.009%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.254%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.493%"/><td style="width:0.1%"/></tr><tr style="height:9pt"><td colspan="6" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PROXY STATEMENT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FOR</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANNUAL MEETING OF STOCKHOLDERS</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">To Be Held June 2, 2025</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GENERAL INFORMATION</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Purpose of this Proxy Statement </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have prepared this proxy statement to solicit proxies on behalf of our board of directors for use at our 2025 annual meeting of stockholders and any adjournment or postponement of such meeting.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notice of Internet Availability of Proxy Materials</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As permitted by rules adopted by the Securities and Exchange Commission, we are providing access to our proxy materials over the Internet.  Accordingly, beginning on April ___, 2025, we are mailing to our stockholders a notice containing instructions on how to access our proxy materials, including our proxy statement and annual report, and vote electronically over the Internet.  The notice also provides instructions on how stockholders may request a paper copy of our proxy materials free of charge.  Our proxy materials may be accessed by stockholders at any time after the date of mailing of the notice.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Date, Time and Place of Annual Meeting </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The annual meeting will be held on Monday, June 2, 2025 at 8:00 a.m. CDT.  The annual meeting will be held entirely online at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">http://www.virtualshareholdermeeting.com/LXRX2025</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the online format facilitates stockholder attendance and participation by leveraging technology to allow us to communicate in a safe, effective and efficient manner with our stockholders. This online format also empowers stockholders around the world to participate at no cost. We have designed the online format to enhance stockholder access and participation and protect stockholder rights by, among other things, providing stockholders multiple opportunities to submit questions for the annual meeting and offering live technical support for all stockholders attending the annual meeting online.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to attend the annual meeting, you should use the control number provided on your proxy card or notice of Internet availability of proxy materials. If your shares are held by an intermediary, such as a broker or bank, instructions for attending the annual meeting should also be provided on the voting instruction card provided by such intermediary.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Matters to Be Considered at the Annual Meeting</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the annual meeting, our stockholders will be asked to consider and act upon the following matters:</span></div><div style="margin-bottom:5pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the election of the two Class I directors named in this proxy statement;</span></div><div style="margin-bottom:5pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a proposal to ratify and approve an amendment to our 2017 Equity Incentive Plan increasing the total number of shares of our common stock that may be issued pursuant to stock awards granted under the plan from 55,000,000 to 75,000,000, all of which may be granted as incentive stock options;</span></div><div style="margin-bottom:5pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a proposal to ratify and approve an amendment to our 2017 Non-Employee Directors&#8217; Equity Incentive Plan increasing the total number of shares of our common stock that may be issued pursuant to stock awards granted under the plan from 2,000,000 to 4,000,000;</span></div><div style="margin-bottom:5pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a proposal to amend our Sixth Amended and Restated Certificate of Incorporation to effect, at the discretion of our board of directors, a reverse split of our common stock, at a ratio within a range of 1-for-10 to 1-for-50, at any time prior to our 2026 annual meeting of stockholders and with the actual ratio to be determined within that range at the discretion of our board of directors;</span></div><div style="margin-bottom:5pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an advisory vote to approve the compensation paid to our named executive officers; and</span></div><div style="margin-bottom:10pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a proposal to ratify and approve the appointment of Ernst &amp; Young LLP as our independent auditors for the fiscal year ending December 31, 2025.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our board of directors does not intend to bring any other matters before the annual meeting and has not been informed that any other matters are to be presented by others.  Our bylaws contain several requirements that must be satisfied in order for any of our stockholders to bring a proposal before one of our annual meetings, including a requirement of delivering proper advance notice to us.  Stockholders are advised to review our bylaws if they intend to present a proposal at any of our annual meetings.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shares Entitled to Vote </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You are entitled to vote at the annual meeting and at any postponement or adjournment thereof if you were the record owner of shares of our common stock as of the close of business on April 3, 2025, the record date for the annual meeting established by our board of directors.  On the record date, __________ shares of our common stock were outstanding.  If you were the record owner of shares of our common stock on the record date, you will be entitled to one vote for each share of common stock that you own on each matter that is called to vote at the annual meeting or at any postponement or adjournment thereof.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Quorum</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We must have a quorum to conduct any business at the annual meeting. This means that at least a majority of our outstanding shares eligible to vote on each proposal at the annual meeting must be represented at the annual meeting with respect to such proposal, either in person during the annual meeting or by proxy.  Cast abstentions are counted for purposes of determining whether a quorum is present.  In addition, shares held by intermediaries that are voted for at least one matter at the annual meeting will be counted as being present for purposes of determining a quorum for all matters.  This is true even if the beneficial owner&#8217;s discretion has been withheld for voting on some or all other matters (commonly referred to as a &#8220;broker non-vote&#8221;).</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Vote Necessary to Approve Proposals</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Class I directors will be elected by a plurality vote.  As a result, the two persons receiving the greatest number of votes will be elected to serve as our Class I directors. Withholding authority to vote for a director nominee will not affect the outcome of the election of directors.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ratification and approval of the amendment to our 2017 Equity Incentive Plan will require the affirmative vote of the majority of the votes cast with respect to such matter. Any abstention from voting or broker non-vote with respect to such matter will not count as a vote for or against the amendment and will not affect the outcome of the proposal.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ratification and approval of the amendment to our 2017 Non-Employee Directors&#8217; Equity Incentive Plan will require the affirmative vote of the majority of the votes cast with respect to such matter. Any abstention from voting or broker non-vote with respect to such matter will not count as a vote for or against the amendment and will not affect the outcome of the proposal.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The approval of an amendment to our Sixth Amended and Restated Certificate of Incorporation to effect a reverse split of our common stock will require the affirmative vote of the holders of a majority of the outstanding shares of our common stock as of the record date.  Any abstention from voting with respect to such matter will have the same effect as a vote against the proposal.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The approval on an advisory basis of the compensation paid to our named executive officers will require the affirmative vote of a majority of the votes cast with respect to such matter.  Any abstention from voting or broker non-vote with respect to such matter will not count as a vote for or against the compensation paid to our named executive officers and will not affect the outcome of the advisory vote.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ratification and approval of the appointment of Ernst &amp; Young LLP as our independent auditors for the year ending December 31, 2025 will require the affirmative vote of a majority of the votes cast with respect to such matter.  Any abstention from voting or broker non-vote with respect to such matter will not count as a vote for or against the appointment of Ernst &amp; Young LLP and will not affect the outcome of the proposal.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any other business that may properly come before the annual meeting for a vote will require the affirmative vote of a majority of the votes cast with respect to such matter unless a greater vote is required by law or our charter or bylaws.  Any abstention or broker non-vote with respect to any such matter will not count as a vote for or against the proposal and will not affect the outcome of the proposal.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">How to Vote Your Shares </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You may vote electronically during the annual meeting at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">http://www.virtualshareholdermeeting.com/LXRX2025</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or by proxy.  To ensure that your shares are represented at the annual meeting, we recommend you vote by proxy even if you plan to attend the annual meeting online.  Even if you vote by proxy, if you wish, you can revoke your proxy and vote electronically at the annual meeting.  If you want to vote at the annual meeting but your shares are held by an intermediary, such as a broker or bank, you will need to obtain from the intermediary either proof of your ownership of such shares as of April 3, 2025 or a proxy from such intermediary authorizing you to vote your shares at the meeting.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You may receive more than one proxy depending on how you hold your shares.  If you hold your shares through an intermediary, such as a broker or bank, you may receive materials from them asking you how you want your shares to be voted at the annual meeting. </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">How to Vote by Proxy</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">By Internet or Telephone.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  You may vote electronically on the Internet or by telephone by following the instructions contained on the notice of Internet availability of our proxy materials.  If you hold your shares through an intermediary, such as a broker or bank, please follow the voting instructions contained on the voting card used by the intermediary.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">By Mail</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  If you request a paper copy of our proxy materials, you may vote by mail by completing, dating and signing the proxy card provided and mailing it in the pre-addressed envelope enclosed with the paper copy of our proxy materials.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">How Your Proxy Will Be Voted </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Giving us your proxy means that you are authorizing us to vote your shares at the annual meeting and at any adjournment or postponement thereof in the manner you direct.  You may vote for our nominees for election as Class I directors, or withhold your vote for any one or more of those nominees.  You may vote for or against the ratification and approval of the amendment to our 2017 Equity Incentive Plan, the ratification and approval of the amendment to our 2017 Non-Employee Directors&#8217; Equity Incentive Plan, the approval of an amendment to our Sixth Amended and Restated Certificate of Incorporation to effect a reverse split of our common stock, the approval on an advisory basis of the compensation paid to our named executive officers and the ratification and approval of the appointment of Ernst&#160;&amp; Young LLP as our independent auditors for the year ending December&#160;31, 2025, or abstain from voting on those proposals.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our nominees for election as Class I directors become unavailable for any reason before the election, we may reduce the number of directors serving on our board of directors, or our board of directors may designate substitute nominees, as necessary.  We have no reason to believe that any of our nominees for election as Class&#160;I directors will be unavailable.  If our board of directors designates any substitute nominees, the persons receiving your proxy will vote your shares for such substitute(s) if they are instructed to do so by our board of directors or, in the absence of any such instructions, in accordance with their own best judgment. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If you vote by proxy but do not specify how you want your shares voted, your shares will be voted in favor of our nominees for election as Class I directors, in favor of the ratification and approval of the amendment to our 2017 Equity Incentive Plan, in favor of the ratification and approval of the amendment to our 2017 Non-Employee Directors&#8217; Equity Incentive Plan, in favor of an amendment to our Sixth Amended and Restated Certificate of Incorporation to effect a reverse split of our common stock, in favor of the approval on an advisory basis of the compensation paid to our named executive officers and in favor of the ratification and approval of the appointment of Ernst &amp; Young LLP as our independent auditors for the year ending December 31, 2025.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If you vote by proxy and any additional business properly comes before the annual meeting, the persons receiving your proxy will vote your shares on those matters as instructed by our board of directors or, in the absence of any such instructions, in accordance with their own best judgment.  As of the date of this proxy statement, we are not aware of any other matter to be raised at the annual meeting. </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">How to Revoke Your Proxy </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You may revoke your proxy at any time before your shares are voted by providing our corporate secretary with either a new proxy with a later date or a written notice of your desire to revoke your proxy at the following address: </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lexicon Pharmaceuticals, Inc.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2445 Technology Forest Blvd., 11th Floor</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Woodlands, Texas 77381</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attention: Corporate Secretary </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You may also revoke your proxy at any time prior to your shares having been voted by attending the annual meeting online and notifying the inspector of election of your desire to revoke your proxy.  Your proxy will not automatically be revoked merely because you attend the annual meeting online. </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inspector of Election </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Broadridge Financial Solutions, Inc. will count votes and provide a representative who will serve as an inspector of election for the annual meeting.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">List of Stockholders Entitled to Vote </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A list of our stockholders entitled to vote at the annual meeting will be available online for inspection during the annual meeting.  The stockholder list will also be available for inspection for ten days prior to the annual meeting at our corporate offices located at 2445 Technology Forest Blvd., 11th Floor, The Woodlands, Texas.  Any inspection of this list at our offices will need to be conducted during ordinary business hours.  If you wish to conduct an inspection of the stockholder list, we request that you please contact our corporate secretary before coming to our offices. </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Solicitation of Proxies and Expenses </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are asking for your proxy on behalf of our board of directors.  We will bear the entire cost of preparing, printing and soliciting proxies.  We will send notices of Internet availability of proxy materials and, if requested, paper copies of our proxy materials to all of our stockholders of record as of the record date and to all intermediaries, such as brokers and banks, that held any of our shares on that date on behalf of others.  These intermediaries will then forward the notices and, if requested, paper copies of our proxy materials to the beneficial owners of our shares, and we will reimburse them for their reasonable out-of-pocket expenses for forwarding such materials.  Our directors, officers and employees may solicit proxies by mail, in person or by telephone or other electronic communication.  Our directors, officers and employees will not receive additional compensation for their solicitation efforts, but they will be reimbursed for any out-of-pocket expenses they incur.  No solicitation of proxies will be made by specially engaged employees or paid solicitors.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Householding</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As permitted by rules adopted by the Securities and Exchange Commission, we are delivering a single notice of Internet availability of proxy materials, annual report and proxy statement, as applicable, to any household at which two or more stockholders reside if we believe the stockholders are members of the same family, unless otherwise instructed by one or more of the stockholders.  We will promptly deliver separate copies of these documents upon the written or oral request of any stockholder at a shared address to which a single copy of the documents were delivered. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If your household received a single set of any of these documents, but you would prefer to receive your own copy, or if you share an address with another stockholder and together both of you would like to receive only a single set of these documents, please follow these instructions:</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">If your shares are registered in your own name, please contact our transfer agent, Computershare Inc., and inform them of your request by calling them at (877) 854-4583 or writing them at P.O. Box 505000, Louisville, Kentucky 40233-5000 or 462 South 4th Street, Suite 1600, Louisville, Kentucky 40202 for overnight correspondence.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="margin-bottom:8pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If an intermediary, such as a broker or bank, holds your shares, please contact Broadridge and inform them of your request by calling them at (800) 542-1061 or writing them at Householding Department, 51&#160;Mercedes Way, Edgewood, New York 11717.  Be sure to include your name, the name of your brokerage firm and your account number.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Appraisal Rights</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Appraisal rights are not available to our stockholders in connection with the matters to be considered at the annual meeting.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i29f56aa9946248519609c20b75df062f_16"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PROPOSAL NUMBER 1:</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ELECTION OF DIRECTORS</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our board of directors, which currently has eight members, is divided or &#8220;classified&#8221; into three classes.  Directors in each class are elected to hold office for a term ending on the date of the third annual meeting following the annual meeting at which they were elected.  The current term of our Class I directors will expire at this annual meeting.  The current terms of our Class II and Class III directors will expire at our 2026 and 2027 annual meetings of stockholders, respectively.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The board of directors has nominated and urges you to vote for the election of the individuals identified below, who have been nominated to serve as Class I directors until our 2028 annual meeting of stockholders or until their successors are duly elected and qualified.  Each of these individuals is a member of our present board of directors.  Your signed proxy will be voted for the nominees named below unless you specifically indicate on the proxy that you are withholding your vote.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nominees for Class I Directors</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following individuals are nominated for election as Class I directors: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"/><td style="width:24.491%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.669%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.426%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.014%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Name</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Age</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Position with the Company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year First</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Became a Director</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raymond Debbane</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman of the Board of Directors (Class I)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2007</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ivan H. Cheung</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director (Class I)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Raymond Debbane</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has been a director since August 2007 and became chairman of our board of directors in February 2012.  Mr. Debbane is president and chief executive officer of The Invus Group, LLC, which he founded in New York in 1985 as the exclusive investment advisor of Benelux-based Artal Group S.A.  Mr. Debbane serves as chairman or director of a number of private companies in which Invus or Artal Group S.A. have invested.  He previously served as a director of WW, Inc. from 1999 until May 2023 and of Blue Buffalo Pet Products, Inc. from 2007 until April 2018 when Blue Buffalo was acquired by General Mills, Inc.  Before founding The Invus Group, Mr. Debbane was a manager in the Paris office of The Boston Consulting Group, Inc., where he did consulting work for a number of major European and international companies.  Mr. Debbane holds an M.B.A. from Stanford University, an M.S. in food science and technology from the University of California at Davis, and a B.S in agricultural sciences and agricultural engineering from American University of Beirut.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mr. Debbane provides us with the benefit of his extensive financial markets and investment expertise gained in more than 30 years of leading the identification, selection, negotiation and oversight of a wide range of investments in his role as president and chief executive officer of The Invus Group, as well as his background in strategic consulting across a broad range of industries developed while with The Boston Consulting Group.  Mr. Debbane is a designee of Invus, L.P. and its affiliates pursuant to our stockholders&#8217; agreement with Invus described under the heading &#8220;Transactions with Related Persons&#160;- Arrangements with Invus.&#8221;</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ivan H. Cheung</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has been a director since December 2024, has been chief executive officer and a director of NextPoint Therapeutics since January 2024 and has served as senior advisor to TPG Growth since September 2023.  Mr. Cheung previously served in a series of executive leadership positions at Eisai Co., Ltd., where he worked for 18 years, most recently as chairman and chief executive officer of Eisai Inc. from 2016 to July 2023 and strategic advisor from August to December 2023.  Prior to joining Eisai, Mr. Cheung spent seven years with Booz Allen Hamilton, Inc., where he held a variety of consulting positions.  Mr. Cheung holds a B.S.E. from Duke University and an M.B.A. from Harvard University.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mr. Cheung provides us with the benefit of his extensive experience in a wide variety of disciplines within the pharmaceutical industry, including the development and commercialization of pharmaceutical products, the management of pharmaceutical marketing and sales efforts and the planning and execution of strategic initiatives, as well as his organizational and management skills developed in his numerous leadership positions with Eisai and other organizations.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Board of Directors recommends that stockholders vote &#8220;FOR&#8221; the foregoing nominees for election as Class&#160;I directors.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Current and Continuing Directors</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The current directors of the Company are identified below:</span></div><div style="text-align:justify;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.935%"><tr><td style="width:1.0%"/><td style="width:34.430%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.617%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:55.653%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Name</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Age</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Position with the Company</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raymond Debbane</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman of the Board of Directors (Class I)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Philippe J. Amouyal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director (Class III)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Samuel L. Barker, Ph.D. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1) (2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director (Class II)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ivan H. Cheung </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director (Class I)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael S. Exton, Ph.D.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer and Director (Class III)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Christopher J. Sobecki</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director (Class II)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diane E. Sullivan </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director (Class III)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Judith L. Swain, M.D. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2) (3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director (Class II)</span></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Member of the Audit Committee</span></div><div style="padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Member of the Compensation Committee</span></div><div style="padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Member of the Corporate Governance Committee</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding the business experience of Mr. Debbane and Mr. Cheung is set forth above under the heading  &#8220;- Nominees for Class I Directors.&#8221;</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Philippe J. Amouyal</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has been a director since August 2007 and is a managing director of The Invus Group, LLC, a position he has held since 1999.&#160; Previously, Mr. Amouyal was a vice president and director of The Boston Consulting Group, Inc. in Boston, Massachusetts, where he coordinated the global technology and electronics practice through most of the 1990s.&#160; Mr. Amouyal also serves as director of CAVA Group, Inc. and at a number of private companies in which Invus or Artal Group S.A. have invested.  He previously served as a director of WW, Inc. from 2002 until February 2019 and of Blue Buffalo Pet Products, Inc. from 2007 until April 2018 when Blue Buffalo was acquired by General Mills, Inc.  Mr. Amouyal holds an M.S. in engineering and a DEA in management from Ecole Centrale de Paris and was a research fellow at the Center for Policy Alternatives of the Massachusetts Institute of Technology.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mr. Amouyal provides us with the benefit of his broad business and financial experience, as well as his expertise in compensation and performance management and the assessment and prioritization of research and development projects, gained in his active participation in the identification, selection, negotiation and oversight of investments by The Invus Group and his consulting experience with The Boston Consulting Group.  Mr. Amouyal is a designee of Invus, L.P. and its affiliates pursuant to our stockholders&#8217; agreement with Invus described under the heading &#8220;Transactions with Related Persons - Arrangements with Invus.&#8221;</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Samuel L. Barker, Ph.D.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has been a director since March 2000 and served as chairman of our board of directors from 2005 to 2012. Dr. Barker previously co-founded and served as president and chief executive officer of Clearview Projects, Inc., a provider of partnering and transaction services to biopharmaceutical companies.  Dr. Barker served in a series of leadership positions at Bristol-Myers Squibb Company until his retirement in 1999.  His positions at Bristol-Myers Squibb included service as executive vice president, Worldwide Franchise Management and Strategy; president, United States Pharmaceuticals; and president, Bristol-Myers Squibb Intercontinental Commercial Operations.  Dr. Barker also previously held executive positions in research and development, manufacturing, finance, business development and sales and marketing at Squibb Pharmaceuticals.  Dr. Barker currently serves as a director of Cyclacel Pharmaceuticals, Inc.  Dr. Barker received his B.S. from Henderson State College, his M.S. from the University of Arkansas and his Ph.D. from Purdue University.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dr. Barker provides us with the benefit of his extensive experience in a wide variety of disciplines within the pharmaceutical industry, including the development and commercialization of pharmaceutical products, the identification, evaluation and negotiation of collaborative agreements, and the management of pharmaceutical marketing and sales efforts, as well as his organizational and management skills developed while serving in his various leadership positions at Bristol-Myers Squibb and Clearview Projects.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Michael S. Exton, Ph.D.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has been a director since July 2024 and served for fourteen years in a series of senior leadership positions at Novartis, most recently as cardiometabolism therapeutic head from August 2022 to June 2024.  In such role, Dr. Exton led the global cross functional commercial therapeutic areas of cardiovascular and metabolic disease, with key responsibilities in discovery, development, commercial launch preparation, business development, investor relations and media engagement.  Dr. Exton&#8217;s previous positions with Novartis included vice president and global head, cardiovascular renal and metabolism franchise from November 2021 to August 2022 and vice president and head, cardiovascular renal and metabolism </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">franchise of Novartis USA from January 2018 to August 2022.  Prior to joining Novartis, Dr. Exton was director of business development with Invida Pty Ltd and spent nine years with Eli Lilly Australia, where he held a variety of research, business development and commercial positions.  Dr. Exton holds a B.Sc. and a Ph.D. in neuroscience from the University of Newcastle and a Ph.D. in immunology from the University of Essen, Germany.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dr. Exton provides us with the benefit of his extensive experience in a wide variety of disciplines within the pharmaceutical industry, including research, development, commercialization and the evaluation and negotiation of strategic acquisitions, licensing and partnerships, as well as his organizational and management skills developed in his numerous leadership positions with Novartis and other pharmaceutical companies.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Christopher J. Sobecki</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has been a director since August 2007 and is a managing director of The Invus Group, LLC, which he joined in 1989.  Mr. Sobecki is currently a director of a number of private companies in which Invus or Artal Group S.A. have invested.  He previously served as a director of WW, Inc. from 1999 until May 2023.  He holds a B.S. in industrial engineering from Purdue University and an M.B.A. from Harvard University.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mr. Sobecki provides us with the benefit of his diversified business and financial experience, including a particular expertise in risk assessment and business strategy development, and relationships in the financial community gained in his active participation in the identification, selection, negotiation and oversight of investments by The Invus Group and his service as a director of public and private companies.  Mr. Sobecki is a designee of Invus, L.P. and its affiliates pursuant to our stockholders&#8217; agreement with Invus described under the heading &#8220;Transactions with Related Persons&#160;- Arrangements with Invus.&#8221;</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Diane E. Sullivan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has been a director since July 2023 and founded her own consulting firm in May 2020, which specializes in strategy development and commercialization for life sciences companies.  From May 2020 until August 2021, Ms. Sullivan served as the Chief Commercial Officer of DalCor Pharmaceuticals.  From November 2018 to April 2020, Ms. Sullivan served as Chief Commercial Officer of The Medicines Company, until its acquisition by Novartis.  Prior to her time at The Medicines Company, Ms. Sullivan was an independent commercialization and market access consultant from October 2017 to November 2018. Ms. Sullivan also previously held senior positions at AstraZeneca, Pfizer, Wyeth and GlaxoSmithKline in a variety of disciplines, including market access, strategy, marketing, brand management, business development and integration.  Ms. Sullivan served as a director of OrthogenRx, a privately held medical device company, from May 2018 until it was acquired by Avanos Medical in January 2022 and currently serves as a director of Amarin. Ms. Sullivan received a B.A. from Dickinson College.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ms. Sullivan provides us with the benefit of her extensive experience in a wide variety of disciplines within the pharmaceutical industry, including market access, marketing, brand management, operations, research and development, capital allocation, partnerships and strategic collaborations, corporate governance, corporate finance, and mergers and acquisitions, as well as her organizational and management skills developed in her numerous leadership positions with a variety of pharmaceutical companies.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Judith L. Swain, M.D.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has been a director since September 2007.  Dr. Swain is chief medical officer of Physiowave, Inc. and was appointed a director of Wellcome Leap, a foundation supported by Wellcome Trust, in 2024.  She previously served as founding director of the Singapore Institute for Clinical Sciences, dean for translational medicine at the University of California, San Diego, chair of the Department of Medicine at Stanford University, and on the medical faculties of the University of Pennsylvania and Duke University.  She has previously served in a number of national and international leadership roles and as a director or member of the scientific advisory boards for a number of biomedical technology companies and is co-founder of Synecor, LLC.  Dr. Swain served as a director of Prometheus Biosciences, Inc. from February 2021 until June 2023 when Prometheus was acquired by Merck &amp; Co.  Dr. Swain received her B.S. from the University of California, Los Angeles and her M.D. from the University of California, San Diego.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dr. Swain provides us with the benefit of her extensive medical and scientific research experience gained in her more than 30 years as a practicing physician and research scientist, as well as her organizational and management skills developed in her numerous leadership positions with a variety of prominent research and academic institutions.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div id="i29f56aa9946248519609c20b75df062f_473"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PROPOSAL NUMBER 2:</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RATIFICATION AND APPROVAL OF AMENDMENT TO 2017 EQUITY INCENTIVE PLAN</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use stock options, restricted stock units and other stock awards as a part of our overall compensation program in order to align the long-term interests of our employees with those of our stockholders.  These awards are made principally under our 2017 Equity Incentive Plan, the purpose of which is to secure and retain the services of employees, directors and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consultants, and to provide them with incentives to exert maximum efforts for our success by giving them the opportunity through the granting of stock options, restricted stock units and other stock awards to benefit from increases in the value of our common stock.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2017 Equity Incentive Plan currently provides that no more than 55,000,000 shares of our common stock may be issued pursuant to stock awards granted under the plan, all of which may be granted as incentive stock options.  We are asking that stockholders ratify and approve an amendment to the 2017 Equity Incentive Plan increasing the total number of shares that may be issued pursuant to stock awards granted under the plan by 20,000,000 shares to 75,000,000 shares, all of which may be granted as incentive stock options, with the objective of maintaining the availability to our board of directors of this portion of our overall compensation program.  The proposed amendment to the plan was approved by our board of directors, subject to stockholder approval, on February&#160;13, 2025.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms of the 2017 Equity Incentive Plan are summarized below and the complete text of the plan is set forth in Appendix A to this proxy statement, in each case reflecting the amendment described above.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Board of Directors recommends that stockholders vote &#8220;FOR&#8221; the ratification and approval of the amendment to our 2017 Equity Incentive Plan.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Administration of the Plan</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The plan is administered by our board of directors, or a committee appointed by the board, which determines the recipients and types of awards to be granted, including the number of shares subject to the award and any relevant vesting schedules.  The compensation committee of the board of directors presently administers the plan.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Awards under the Plan</span></div><div style="margin-bottom:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The plan permits the following types of awards:</span></div><div style="margin-bottom:5pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">incentive stock options;</span></div><div style="margin-bottom:5pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">nonstatutory stock options;</span></div><div style="margin-bottom:5pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">stock bonus awards; </span></div><div style="margin-bottom:5pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restricted stock awards;</span></div><div style="margin-bottom:5pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restricted stock unit awards;</span></div><div style="margin-bottom:5pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">stock appreciation rights; and</span></div><div style="margin-bottom:10pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">performance stock awards.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Awards granted under the plan are evidenced by agreements that specify the terms and conditions under which they are granted.  All awards granted under the plan are subject to the terms and conditions contained in the applicable agreement and the plan.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Eligibility</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Awards other than incentive stock options may be granted to employees, directors and consultants.  Incentive stock options may be granted only to employees.  As of April 3, 2025, approximately ____ persons were eligible to participate in the plan, including approximately ____ employees, seven non-employee directors and ____ consultants.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shares Subject to the Plan</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total number of shares of common stock that may be issued pursuant to awards under the plan shall not exceed in the aggregate 75,000,000 shares, all of which may be granted as incentive stock options.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any award expires, lapses, or is terminated or forfeited for any reason, the shares subject to that award will continue to be available for the grant of awards under the plan, provided that if shares are not delivered to the holder of an award because (1) the right to receive such shares is surrendered in a &#8220;net exercise&#8221; of a stock option or (2) such shares are withheld in satisfaction of the withholding of taxes incurred in connection with the exercise of a stock option or stock appreciation right or the issuance of shares under a stock bonus award, restricted stock award, restricted stock unit award or performance stock award, the surrendered or withheld shares will not be available for subsequent issuance under the plan.  Common stock issued as or on the exercise of awards under the plan may be either authorized and unissued shares or reacquired shares.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of April 3, 2025, there were outstanding under the plan (1) stock options to purchase a total of _________ shares of our common stock, (2) no stock bonus awards, (3) no restricted stock awards, (4) restricted stock unit awards to receive a total of __________ shares of our common stock, (5) no stock appreciation rights and (6) no performance stock awards.  On a pro forma basis to reflect the increase in the number of shares reserved for issuance under the plan, __________ shares remained available for issuance of new awards under the plan at that date.  From the founding of our company in 1995 until that date, a total of __________ shares of our common stock were issued under the plan and its predecessors upon the grant, exercise or vesting of awards granted under the plan.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The stock options granted under the plan are evidenced by agreements that specify the number of shares of our common stock which may be purchased at a certain specified price and contain other terms and conditions, such as vesting and termination provisions.  All stock options granted under the plan are subject to the terms and conditions contained in the applicable stock option agreement and the plan.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expiration and Termination</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The term of each stock option is stated in the applicable stock option agreement.  In no event, however, may a stock option be exercised more than ten years after the date the option is granted.  In the case of an incentive stock option granted to a 10% stockholder, the maximum term is five&#160;years from the date the option is granted.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Option Exercise Price</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exercise price of stock options granted under the plan is determined by the plan administrator at the time the stock option is granted.  Stock options must have an exercise price that is no less than 100% of the fair market value of our common stock on the date of grant.  </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair market value of a share of common stock on a particular date is equal to the previous day&#8217;s closing sales price (or the closing bid price, if no sales were reported) of the common stock if the common stock is listed on any established stock exchange or traded on the Nasdaq Stock Market.  If there is no regular public trading market for the common stock, the fair market value of the common stock is determined by the board of directors.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Consideration for Exercise of Options</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consideration to be paid for shares to be issued upon exercise of a stock option, including the method of payment, shall be determined by the administrator and may consist entirely of (1)&#160;cash or (2), at the discretion of the board of directors, (a) by delivery of other shares of our common stock, (b)&#160;according to a deferred payment or other similar arrangement, (c) by means of a &#8220;net exercise&#8221; of the option, or (d) in any other form of legal consideration acceptable to the board.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Bonus Awards and Restricted Stock Awards</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms and provisions of stock bonus awards and restricted stock awards shall be as set forth in the grant instrument.  A stock bonus may be awarded in consideration for past services actually rendered to the company.  Shares awarded under a stock bonus or restricted stock award may, but</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">need</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">not be subject to a repurchase or forfeiture right on behalf of the company in accordance with a vesting schedule in the event the participant&#8217;s employment is terminated.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted Stock Unit Awards and Stock Appreciation Rights</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms and provisions of restricted stock unit awards and stock appreciation rights shall be as set forth in the grant instrument.  The price of a common stock equivalent used as the basis from which appreciation is determined for purposes of a stock appreciation right shall be as the administrator shall determine, but not less than 100% of the fair market value on the date the stock appreciation right is granted.  Restricted stock unit awards and the exercise value of a stock appreciation right may be paid in shares of common stock, cash, a combination of common stock and cash, or other consideration, as determined by the administrator and set forth in the grant instrument.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Performance Stock Awards</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms and provisions of performance stock awards shall be as set forth in the grant instrument.  Any type of award available under the plan may be designated as a performance stock award and subject to performance conditions based on business criteria or other measures of performance, with a performance period not to exceed ten years.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Provisions</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Limits on Transfer of Awards</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In general, plan participants may not sell, pledge, assign, transfer or otherwise dispose of any awards other than by will or the laws of descent or distribution and the plan participant alone may exercise his or her awards during his or her lifetime.  Awards other than incentive stock options may be transferred only if permitted under the agreement that evidences the terms of the award.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Adjustments on Changes in Capital Structure or on Change of Control</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we effect a stock split, reverse stock split, stock dividend, redemption, combination, reclassification or other similar change affecting our capital stock, adjustments reflecting the change will be made in (1)&#160;the aggregate number of shares of common stock authorized for issuance under the plan; (2)&#160;the number of shares underlying each outstanding award; and (3)&#160;if applicable, the price per share of each award.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a change in control transaction shall occur, the surviving or acquiring corporation shall assume all awards or provide a substitute similar award.  If the surviving or acquiring corporation fails to so provide such assumption or substitution, then awards held by those participants whose employment has not been terminated will be accelerated in full and the awards will subsequently terminate if not exercised.  Any other awards outstanding under the plan will terminate if not exercised (if applicable) prior to the event.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amendment or Termination of the Plan</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The board may at any time amend, alter, suspend or discontinue the plan, but no amendment, alteration, suspension or discontinuation which would impair a participant&#8217;s rights under any previous grant may be made without the consent of the participant.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Term of the Plan</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No awards may be granted under the plan after the day before the tenth (10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) anniversary of the date the plan was adopted by our board of directors, which occurred on February 9, 2017.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">United States Federal Income Tax Consequences</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a brief summary of certain of the federal income tax consequences of certain transactions under the plan based on current federal income tax laws.  This summary is not intended to be exhaustive and does not describe state or local tax consequences.  Additional or different federal tax consequences to the employee, director or consultant or to our company may result depending on considerations other than those described below.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nonstatutory Stock Options</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In general, optionholders will not recognize any taxable income at the time they are granted nonstatutory stock options.  When an optionholder exercises a nonstatutory stock option, he or she will recognize ordinary income measured by the excess of the then fair market value of the shares over the exercise price and we will be entitled to a deduction for a corresponding amount.  Different rules apply to options that have a &#8220;readily ascertainable fair market value,&#8221; as that phrase is defined in regulations promulgated under Section&#160;83 of the Internal Revenue Code of 1986.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When an optionholder sells or otherwise disposes of shares that were acquired by exercising nonstatutory stock options, any amount that the optionholder receives in excess of the sum of (1)&#160;the exercise price of the shares as of the date of exercise and (2)&#160;the amount includable in income with respect to such option, if any, such sum being the optionholder&#8217;s &#8220;basis&#8221; in the shares, will, in general, be treated as a long&#8209;term or short&#8209;term capital gain, depending on the holding period of the shares.  We are not entitled to any tax deduction in connection with an optionholder&#8217;s sale or disposition of the shares.  If an optionholder receives less than his or her basis in the shares, the loss will, in general, be treated as a long&#8209;term or short&#8209;term capital loss, depending on the holding period of the shares. </span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Incentive Stock Options</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Optionholders will not be taxed on the grant or exercise of an incentive stock option that qualifies under Section&#160;422 of the Internal Revenue Code, unless an alternative minimum tax liability is triggered.  When an optionholder sells or otherwise makes a taxable disposition of shares that he or she acquired by exercising an incentive stock option, the optionholder will recognize a capital gain on the excess of the amount realized on disposition over the exercise price of the incentive stock option, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">provided that the optionholder has not disposed of the shares until at least two years after the date the option was granted and one year after the date the optionholder exercised the option.  Failure to comply with these holding requirements will result in ordinary income treatment for the gain.  Unless the optionholder disposes of shares received on exercise of the incentive stock option before meeting the applicable holding period requirements, we will not be entitled to a deduction with respect to the grant or exercise of the incentive stock option.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event an optionholder makes a &#8220;disposition&#8221; of the shares received on exercise of an incentive stock option before meeting the two&#8209;year or one&#8209;year holding period requirements, the gain on the disposition, to the extent of the lesser of (1)&#160;the excess of the fair market value of the shares on the date of exercise over the exercise price or (2)&#160;the excess of the amount realized on disposition over the exercise price, will be treated as ordinary income to the optionholder, and we will generally be entitled to a corresponding deduction.  The balance of the gain, if any, realized on such a disposition will be treated as long&#8209;term or short&#8209;term capital gain, depending on the holding period of the shares.  To the extent that an optionholder is entitled to capital gains treatment, we will not be entitled to a corresponding deduction for such gain.  If the amount realized at the time of the disposition is less than the exercise price, the optionholder will not be required to treat any amount as ordinary income, provided the disposition is of a type that would give rise to a recognizable loss.  In such event, the loss will be treated as a long&#8209;term or short&#8209;term capital loss depending on the holding period of the shares.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Bonus Awards</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In general, if an individual receives a stock bonus award, he or she will be taxed on the fair market value of the shares on the date the shares are issued.  We will be generally entitled to a deduction for a corresponding amount.  When a stock bonus award is subject to forfeiture restrictions, an individual will not recognize any taxable income at the time he or she is granted the award, but upon the lapse of the restrictions applicable to such award, that person will recognize ordinary income equal to the fair market value of the shares on the date the restrictions on the award lapsed, and we will be entitled to a deduction for a corresponding amount.  If, upon a taxable disposition of the shares, the stockholder receives more or less than his or her basis in the shares, the gain or loss will be a long&#8209;term or short&#8209;term capital gain or loss, depending on the holding period of the shares, measured from the date that the receipt of the shares was taxable to the stockholder.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Awards</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In general, an individual will not recognize any taxable income at the time he or she is granted an award of restricted stock, but upon the lapse of the restrictions applicable to such award, that person will recognize ordinary income equal to the fair market value of the shares on the date the restrictions on the award lapsed less the purchase price for such shares, and we will be entitled to a deduction for a corresponding amount.  If the stockholder sells or otherwise disposes of such shares in a taxable disposition, the sale or disposition will be subject to the same treatment described above for a taxable disposition of shares acquired upon an exercise of a nonstatutory stock option.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Unit Awards</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In general, an individual will not recognize any taxable income at the time he or she is granted a restricted stock unit award.  Upon settlement of a restricted stock unit award, the individual will recognize ordinary income equal to the fair market value of the cash or shares actually received by the individual.  We will be generally entitled to a deduction for the corresponding amount.</span></div><div style="margin-bottom:11pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Appreciation Rights</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In general, an individual will not recognize any taxable income at the time he or she is granted stock appreciation rights.  Upon exercise of a stock appreciation right, the individual will recognize ordinary income equal to the fair market value of the cash or shares received by the individual upon exercise.  We will be generally entitled to a deduction for the corresponding amount.</span></div><div style="margin-bottom:11pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Performance Stock Awards</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In general, the designation of any award as a performance stock award will not have any effect on the federal income tax consequences applicable to such award.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing summary does not constitute a definitive statement of the federal income tax effects of awards granted under the Plan.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New Plan Benefits Table</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2025, the compensation committee of our board of directors approved a mix of annual stock option and restricted stock unit awards under the plan to eligible executive officers and other employees, as described below under the heading &#8220;Executive and Director Compensation - Compensation Discussion and Analysis - Long-Term Stock-Based Incentive Awards.&#8221;  The following table presents information regarding the number of annual stock options and the dollar value of annual restricted stock units awarded to the following individuals or groups of individuals in 2025:</span></div><div style="margin-bottom:8pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">each of the individuals listed in &#8220;Executive and Director Compensation - Summary Compensation Table for 2024&#8221;;</span></div><div style="margin-bottom:8pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">all current executive officers, as a group; </span></div><div style="margin-bottom:8pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">all current directors who are not executive officers, as a group; and </span></div><div style="margin-bottom:8pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">all non-executive officer employees, including all current officers who are not executive officers, as a group. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The compensation committee retains broad discretion over the granting and amount of awards under the plan.  As a result, it is not possible to determine any additional benefits or amounts that will be received by any individual participant or group of participants in the future.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.532%"><tr><td style="width:1.0%"/><td style="width:61.583%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.547%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.732%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name and Position</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares Underlying Stock Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dollar Value of Shares Underlying Restricted Stock Units </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Michael S. Exton, Ph.D.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,264,690&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,049,304&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Chief Executive Officer and Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Brian T. Crum</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">765,730&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">354,791&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Senior Vice President and General Counsel</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Craig B. Granowitz, M.D., Ph.D.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">910,170&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">421,712&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Senior Vice President and Chief Medical Officer</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Alan J. Main, Ph.D.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">753,090&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">348,932&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Executive Vice President, Innovation and Chemical Sciences</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lonnel Coats</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Former Chief Executive Officer and Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Jeffrey L.Wade</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Former President and Chief Financial Officer</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Kristen L. Alexander</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">185,540&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">128,950&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Vice President, Finance and Accounting</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thomas A. Garner</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Former Senior Vice President and Chief Commercial Officer</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Executive Group</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,499,920&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,517,937&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-Executive Director Group</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-Executive Officer Employee Group</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,127,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,108,536&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;____________________&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-top:3pt;padding-left:40.5pt;padding-right:27pt;text-align:justify;text-indent:-11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Based on the closing price of our common stock on the Nasdaq Global Select Market of $0.695 per share on February&#160;12, 2025, the last trading day prior to the date of grant.</span></div><div><span><br/></span></div><div id="i29f56aa9946248519609c20b75df062f_481"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PROPOSAL NUMBER 3:</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RATIFICATION AND APPROVAL OF AMENDMENT TO 2017 NON-EMPLOYEE DIRECTORS&#8217; EQUITY INCENTIVE PLAN</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have used stock options, restricted stock units and restricted stock awards as a part of our overall compensation program in order to align the long-term interests of the non-employee members of our board of directors with those of our stockholders. These awards are made principally under our 2017 Non-Employee Directors&#8217; Equity Incentive Plan, the purpose </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">of which is to secure and retain the services of non-employee directors, and to provide them with incentives to exert maximum efforts for our success by giving them the opportunity through the granting of stock options, restricted stock units and restricted stock awards to benefit from increases in the value of our common stock</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2017 Non-Employee Directors&#8217; Equity Incentive Plan currently provides that no more than 2,000,000 shares of our common stock may be issued pursuant to stock awards granted under the plan.  We are asking that stockholders ratify and approve an amendment to the 2017 Non-Employee Directors&#8217; Equity Incentive Plan in order to increase the total number of shares that may be issued pursuant to stock awards granted under the plan by 2,000,000 shares to 4,000,000 shares, with the objective of maintaining the availability to our board of directors of this portion of our overall non-employee director compensation program.  The proposed amendment to the plan was approved by our board of directors, subject to stockholder approval, on February&#160;13, 2025.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms of the 2017 Non-Employee Directors&#8217; Equity Incentive Plan are summarized below and the complete text of the plan is set forth in Appendix B to this proxy statement, in each case reflecting the amendment described above.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Board of Directors recommends that stockholders vote &#8220;FOR&#8221; the ratification and approval of the amendment to our 2017 Non-Employee Directors&#8217; Equity Incentive Plan.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Administration of the Plan</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The plan is administered by our board of directors, which oversees the grant of awards under the plan and determines the recipients and provisions of each award granted, including the type of award granted, the number of shares subject to such award and any relevant vesting schedules.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Awards under the Plan</span></div><div style="margin-bottom:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The plan permits the following types of awards:</span></div><div style="margin-bottom:5pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">nonstatutory stock options;</span></div><div style="margin-bottom:5pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restricted stock unit awards; and</span></div><div style="margin-bottom:5pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restricted stock awards.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Awards granted under the plan are evidenced by agreements or notices that specify the terms and conditions under which they are granted. All awards granted under the plan are subject to the terms and conditions contained in the applicable agreement or notice and the plan.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Eligibility</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Awards may only be granted to non-employee directors under the plan. Seven of the eight members of our board of directors are currently eligible to participate in the plan.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shares Subject to the Plan</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total number of shares of common stock that may be issued pursuant to awards under the plan shall not exceed in the aggregate 4,000,000 shares after giving effect to the amendment described above. Non-employee directors may not be granted awards under the plan with an aggregate grant date fair value of more than $500,000 during any calendar year, taken together with any cash fees paid to such non-employee director in compensation for service on our board of directors during such calendar year.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any award expires, lapses, or is terminated or forfeited for any reason, the shares subject to that award will continue to be available for the grant of awards under the plan, provided that if shares are not delivered to the holder of an award because (1) the right to receive such shares is surrendered in a &#8220;net exercise&#8221; of a stock option or (2) such shares are withheld in satisfaction of the withholding of taxes incurred in connection with the exercise of a stock option or the issuance of shares under a restricted stock or restricted stock unit award, the surrendered or withheld shares will not be available for subsequent issuance under the plan. Common stock issued as or on the exercise of awards under the plan may be either authorized and unissued shares or reacquired shares.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of April 3, 2025, there were outstanding under the plan (1) stock options to purchase a total of ________ shares of our common stock, (2) restricted stock unit awards to receive a total of _________ shares of our common stock and (3) no restricted stock awards.  On a pro forma basis to reflect the increase in the number of shares reserved for issuance under the plan, __________ shares remained available for issuance of new awards under the plan at that date.  From the founding of our </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">company in 1995 until that date, a total of ___________ shares of our common stock were issued under the plan and its predecessors upon the grant, exercise or vesting of awards granted under the plan.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options granted under the plan are evidenced by agreements or notices that specify the number of shares of our common stock which may be purchased at a certain specified price and contain other terms and conditions, such as vesting and termination provisions. All stock options granted under the plan are subject to the terms and conditions contained in the applicable stock option agreement or notice and the plan.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expiration and Termination</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options granted under the plan have a term of ten years from the date of grant, subject to earlier termination upon the occurrence of certain events. In no event, however, may a stock option be exercised more than ten years after the date the option is granted.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Option Exercise Price</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options awarded under the plan have an exercise price of 100% of the fair market value of our common stock on the date of grant. The fair market value of a share of common stock on a particular date is equal to the previous day&#8217;s closing sales price (or the closing bid price, if no sales were reported) of the common stock if the common stock is listed on any established stock exchange or traded on the Nasdaq Stock Market. If there is no regular public trading market for the common stock, the fair market value of the common stock is determined by our board of directors in good faith in a manner consistent with Section 409A of the Internal Revenue Code.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Consideration for Exercise of Options</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consideration to be paid for shares to be issued upon exercise of a stock option, including the method of payment, may be paid, to the extent permitted by law, in any combination of (1) cash, (2) delivery of other shares of our common stock, or (3) &#8220;net exercise&#8221; of any stock option with a term expiring in less than one year from the date of exercise.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted Stock Unit Awards</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms and provisions of restricted stock unit awards shall be as set forth in the grant instrument.  Restricted stock unit awards may be paid in shares of common stock, cash, a combination of common stock and cash, or other consideration, as determined by the board of directors.  Unless otherwise determined by the board of directors, dividend equivalent rights shall not be credited to any restricted stock units that are granted.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted Stock Awards</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms and provisions of restricted stock awards shall be as set forth in the grant instrument.  Shares awarded under a restricted stock award may, but</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">need</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">not be subject to a repurchase or forfeiture right on behalf of the company in accordance with a vesting schedule in the event the participant&#8217;s service to our company is terminated.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Provisions</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Limits on Transfer of Awards</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In general, non-employee directors may not sell, pledge, assign, transfer or otherwise dispose of any awards other than (i) by will or the laws of descent or distribution, (ii) in certain circumstances, by instrument to an inter vivos or testamentary trust and (iii) by gift to a member of such non-employee director&#8217;s immediate family.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Adjustments on Changes in Capital Structure or on Change of Control</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we effect a stock split, reverse stock split, stock dividend, redemption, combination, reclassification or other similar change affecting our capital stock, adjustments reflecting the change will be made in (1) the aggregate number of shares of common stock authorized for issuance under the plan; (2) the number of shares underlying each outstanding award; and (3) if applicable, the exercise price per share subject to each outstanding stock award.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a change in control transaction shall occur, the surviving or acquiring corporation shall assume all awards or provide or substitute similar awards. If the surviving or acquiring corporation refuses to so provide such assumption or substitution, then the vesting of awards granted under the plan will be accelerated in full and the awards will subsequently terminate if not exercised, as applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a change in control transaction shall occur and the surviving or acquiring corporation assumes the awards granted under the plan, but any non-employee director is not elected or appointed to the board of directors of the surviving or acquiring corporation, then the vesting of that non-employee director&#8217;s awards shall be accelerated by 18 months.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amendment or Termination of the Plan</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The board of directors may at any time amend, alter, suspend or discontinue the plan, but no amendment, alteration, suspension or discontinuation which would impair the rights of a non-employee director under any previous grant may be made without such non-employee director&#8217;s consent.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Term of the Plan</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No awards may be granted under the plan after the day before the tenth (10th) anniversary of the date the plan was adopted by our board of directors, which occurred on February 9, 2017.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">United States Federal Income Tax Consequences</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a brief summary of certain of the federal income tax consequences of certain transactions under the plan based on current federal income tax laws. This summary is not intended to be exhaustive and does not describe state or local tax consequences. Additional or different federal tax consequences to the non-employee director or to us may result depending on considerations other than those described below.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nonstatutory Stock Options</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In general, optionholders will not recognize any taxable income at the time they are granted a nonstatutory stock option. When an optionholder exercises a nonstatutory stock option, he or she will recognize ordinary income measured by the excess of the then fair market value of the shares over the exercise price and we will be entitled to a deduction for a corresponding amount. Different rules apply to options that have a &#8220;readily ascertainable fair market value,&#8221; as that phrase is defined in regulations promulgated under Section 83 of the Internal Revenue Code of 1986.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When an optionholder sells or otherwise disposes of shares that were acquired by exercising a nonstatutory stock option, any amount the optionholder receives in excess of the sum of (1) the exercise price of the shares as of the date of exercise and (2) the amount includable in income with respect to such option, if any, such sum being the optionholder&#8217;s &#8220;basis&#8221; in the shares, will, in general, be treated as a long term or short term capital gain, depending on the holding period of the shares. We are not entitled to any tax deduction in connection with an optionholder&#8217;s sale or disposition of the shares. If an optionholder receives less than his or her basis in the shares, the loss will, in general, be treated as a long term or short term capital loss, depending on the holding period of the shares.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Unit Awards</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In general, an individual will not recognize any taxable income at the time he or she is granted a restricted stock unit award. Upon settlement of a restricted stock unit award, the individual will recognize ordinary income equal to the fair market value of the cash or shares actually received by the individual less the purchase price (if any) for such cash or shares. We will be generally entitled to a deduction for the corresponding amount.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Awards</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In general, an individual will not recognize any taxable income at the time he or she is granted an award of restricted stock, but upon the lapse of the restrictions applicable to such award, that person will recognize ordinary income equal to the fair market value of the shares on the date the restrictions on the award lapsed less the purchase price (if any) for such shares, and we will be entitled to a deduction for a corresponding amount. If the stockholder sells or otherwise disposes of such shares in a taxable disposition, the sale or disposition will be subject to the same treatment described above for a taxable disposition of shares acquired upon an exercise of a nonstatutory stock option.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing summary does not constitute a definitive statement of the federal income tax effects of awards granted under the plan.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New Plan Benefits Table</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our board of directors has not made any determinations with respect to future awards under the plan.  As a result, the benefits or amounts that will be received by or allocated to our non-employee directors in the future under the plan are not determinable.  Accordingly, the New Plan Benefits Table is not provided.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Previously Awarded Stock Options</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As only our non-employee directors are eligible to receive awards under the plan, please see footnotes 2 and 3 to the summary compensation table included in "Executive and Director Compensation - Director Compensation in 2024" for information regarding all shares of common stock underlying outstanding stock options previously granted under the plan.  No associate of any of our directors or executive officers holds or has held stock options granted under the plan.</span></div><div><span><br/></span></div><div id="i29f56aa9946248519609c20b75df062f_599"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PROPOSAL NUMBER 4:</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APPROVAL OF AMENDMENT TO OUR CERTIFICATE OF INCORPORATION TO EFFECT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REVERSE SPLIT OF OUR COMMON STOCK</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are asking that stockholders approve an amendment to our Sixth Amended and Restated Certificate of Incorporation to effect, at the discretion of our board of directors, a reverse split of our common stock, at a ratio within a range of 1-for-10 to 1-for-50, at any time prior to our 2026 annual meeting of stockholders and with the actual ratio to be determined within that range at the discretion of our board of directors.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The form of proposed amendment to our Sixth Amended and Restated Certificate of Incorporation was approved by our board of directors, subject to stockholder approval, on March 23, 2025 and is set forth in Appendix C to this proxy statement.  Our board of directors believes that stockholder approval of the reverse stock split within such range of ratios provides the board of directors with maximum flexibility to act in our best interest and in the best interest of our stockholders.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Upon stockholder approval of the proposed amendment, our board of directors will have the authority to effect a reverse stock split in its sole discretion until our 2026 annual meeting of stockholders and without further stockholder action.  The actual reverse stock split ratio will be selected by our board of directors within a range of 1-for-10 to 1-for-50.  Even if approved by our stockholders, our board of directors reserves the right not to effect any reverse stock split if it does not deem it to be in our best interest or in the best interest of our stockholders.  Our board of directors&#8217; decision as to whether, when and pursuant to which ratio to effect a reverse stock split will be based on a number of factors, including prevailing market conditions, the existing market price of our common stock, the likely effect of a reverse stock split on the market price of our common stock, the listing standards of The Nasdaq Stock Market, Inc. and the number of shares of our common stock which would be authorized but not issued or reserved for issuance.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If our board of directors elects to effect a reverse stock split following stockholder approval, the number of issued and outstanding shares of our common stock would be reduced in accordance with the reverse stock split ratio selected by our board of directors.  Except for any adjustments for fractional shares as described below, our stockholders will hold the same percentage of our outstanding common stock immediately following the reverse stock split as such stockholders held immediately prior to the reverse stock split.  Any reverse stock split will not change the relative voting power of our stockholders and will affect all of our stockholders uniformly.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The proposed reverse stock split is not being proposed in response to any effort of which we are aware to accumulate shares of our common stock or obtain control of our company, nor does it represent a plan by our management to recommend a series of similar actions to our board of directors or our stockholders.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">The Board of Directors recommends that stockholders vote &#8220;FOR&#8221; the approval of an amendment to our Sixth Amended and Restated Certificate of Incorporation to effect, at the discretion of our board of directors, a reverse split of our common stock.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reasons for Reverse Stock Split</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our board of directors believes that, should the appropriate circumstances arise, effecting a reverse stock split will provide benefits to us and our stockholders in a number of ways by increasing the per share market price of our common stock, including:</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Meeting Continued Nasdaq Listing Requirements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.  Our common stock trades on the Nasdaq Global Select Market, which has qualitative and quantitative listing criteria, including a requirement that our common stock maintain a minimum closing bid price of at least $1.00 per share.  On January 3, 2025, we received a written letter of non-compliance from Nasdaq based upon the closing bid price of our common stock for 31 consecutive business days.  Such letter required that we regain compliance by ensuring a closing bid price of our common stock of at least $1.00 per share for a minimum of ten consecutive business days during a period of 180 calendar days, or until July 2, 2025 (or during an additional compliance period of 180 calendar days, if such extension is granted by Nasdaq following a successful transfer by us to the Nasdaq Capital Markets).  We believe that a higher per share market price will remedy such non-compliance and that our ability to meet other Nasdaq listing requirements will not be compromised as a result.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Improving the Perception of Our Common Stock as an Investment Security</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.  We have been advised that lower-priced stocks have a perception in the investment community as being risky and speculative, which may negatively impact not only the price of our common stock, but also our market liquidity.  Per share market price is frequently used as a proxy for &#8220;quality&#8221; and lower-priced stocks are often considered to be of lower investing quality and less desirable relative to stocks with higher share prices.  We believe that a higher per share market price will increase the perceived quality and appeal of our common stock for investment purposes.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Appealing to a Broader Range of Investors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.  Many institutional investors have policies prohibiting them from holding lower-priced stocks in their portfolios.  Many brokerage firms also have policies discouraging individual brokers from recommending lower-priced stocks to their customers or restricting or limiting the ability to purchase such stocks on margin.  Investors may also be dissuaded from purchasing lower-priced stocks because the brokerage commissions, as a percentage of the total transaction value, tend to be higher for such lower-priced stocks. Each of these market dynamics has the effect of reducing the number of potential purchasers of our common stock, and we believe that a higher per share market price will increase the number of such potential purchasers.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Effects of a Reverse Stock Split</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Upon stockholder approval of the proposed amendment and the election by our board of directors to effect a reverse stock split, our issued and outstanding shares of common stock would decrease in accordance with the applicable reverse stock split ratio and the market value per share of our common stock would be expected to increase.  The reverse stock split would be effected simultaneously for all of our common stock, and the reverse stock split ratio would be the same for all shares of common stock.  The reverse stock split would affect all of our stockholders uniformly and would not affect any stockholder&#8217;s percentage ownership interests in our company, except to the extent that it results in a stockholder receiving cash in lieu of fractional shares.  A reverse stock split would not affect the relative voting or other rights that accompany the shares of our common stock, except to the extent that it results in a stockholder receiving cash in lieu of fractional shares.  Shares of common stock issued pursuant to a reverse stock split would remain fully paid and non-assessable.  The reverse stock split would not affect our securities law reporting and disclosure obligations, and we would continue to be subject to the periodic reporting requirements of the Securities Exchange Act of 1934, as amended.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition to the decrease in the number of shares of our common stock issued and outstanding and the expected increase in the market value per share of our common stock, a reverse stock split would have the following additional effects:</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Effective Increase in the Number of Authorized Shares of Common Stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.  By reducing the number of issued and outstanding shares of common stock without reducing the number of authorized shares of common stock, the proposed reverse stock split would effectively increase the number of  shares of common stock which are authorized and available for issuance.  As of April 3, 2025, of the 450,000,000 shares of our common stock authorized by our Sixth Amended and Restated Certificate of Incorporation, ___________ shares were issued and outstanding and an aggregate of ___________ shares were reserved for issuance, after giving effect to the amendments to our 2017 Equity Incentive Plan and 2017 Non-Employee Directors&#8217; Equity Incentive Plan described in this proxy statement.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We do not have any current plans, proposals or understandings that would require the use of any additional shares of our common stock which would be authorized, but not issued and outstanding or reserved for issuance, following any reverse stock split.  However, our board of directors may from time to time deem it to be in our best interest and in the best interest of our stockholders to enter into transactions or other arrangements that may include the issuance of shares of our common stock.  If our board of directors authorizes the issuances of additional shares of common stock subsequent to a reverse stock split described above, the dilution to the ownership interest of our existing stockholders may be greater than would occur had the reverse stock split not been effected.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Adjustment to Number of Shares of Common Stock Issuable upon Exercise of Warrants</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.  A reverse stock split would reduce the number of shares of common stock issuable upon exercise of our outstanding warrants in proportion to the applicable reverse stock split ratio.  As of April 3, 2025, there were 828,625 shares of common stock reserved for issuance upon exercise of our outstanding warrants.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Adjustment to Number of Shares of Common Stock Issuable under Equity Incentive Plans</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.  A reverse stock split would reduce the number of shares of common stock issuable under our 2017 Equity Incentive Plan and 2017 Non-Employee Directors&#8217; Equity Incentive Plan in proportion to the applicable reverse stock split ratio.  As of April 3, 2025, there were _________ shares of common stock authorized for issuance but unissued under our 2017 Equity Incentive Plan and __________ shares of common stock authorized for issuance but unissued under our 2017 Non-Employee Directors&#8217; Equity Incentive Plan, in each case reflecting the proposed amendments to such plans described in this proxy statement.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under the terms of our stock option agreements, restricted stock unit agreements and the applicable plans under which such stock options and restricted stock units were granted, a reverse stock split would effect a reduction in the number of shares of common stock issuable upon the exercise of such stock options or upon the vesting of such restricted stock units in </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">proportion to the applicable reverse stock split ratio.  A reverse stock split will also effect a proportionate increase in the exercise price applicable to such outstanding stock options.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table contains information relating to our common stock as of April 3, 2025:</span></div><div style="text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.590%"><tr><td style="width:1.0%"/><td style="width:41.757%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.850%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.975%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.060%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.437%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.480%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.441%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Pre-Reverse Stock Split</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">If Minimum 10:1 Ratio is Selected </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:112%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">If Maximum 50:1 Ratio is Selected </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:112%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Authorized</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">450,000,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">450,000,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">450,000,000</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Issued and Outstanding</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Reserved for issuance upon conversion of Outstanding Warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">828,625</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">82,862</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">16,572</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Reserved for issuance under 2017 Equity Incentive Plan </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:112%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Reserved for issuance under 2017 Non-Employee Directors&#8217; Equity Incentive Plan </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:112%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Available for Issuance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">____________________</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Reflects the proposed amendment to our 2017 Equity Incentive Plan described in this proxy statement.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Reflects the proposed amendment to our 2017 Non-Employee Directors&#8217; Equity Incentive Plan described in this proxy statement.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Excludes the effect of fractional share treatment.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Associated with a Reverse Stock Split</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Even if a reverse stock split is effected, some or all of the expected benefits of a reverse stock split described above may not be realized or maintained.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The market price of our common stock will continue to be based, in part, on our performance, prevailing market conditions and other factors unrelated to the number of shares of common stock outstanding.  The effect of a reverse stock split on the market price for our common stock cannot be accurately predicted, and the history of reverse stock splits for companies in similar circumstances is varied.  We cannot assure you that the market price of our common stock after a reverse stock split will rise in exact proportion to the reduction in the number of shares of common stock outstanding as a result of the reverse stock split.  Furthermore, there can be no assurance that the market price of our common stock immediately after the proposed reverse stock split will be maintained for any period of time.  Moreover, because some investors may view a reverse stock split negatively, we cannot assure you that approval of the reverse stock split will not adversely impact the market price per share of our common stock or, alternatively, that the market price per share following the reverse stock split will either exceed or remain in excess of the current market price per share.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, a reverse stock split may result in some stockholders owning &#8220;odd lots&#8221; of less than 100 shares of our common stock, which may be more difficult to sell and may cause those holders to incur greater brokerage commissions and other costs upon sale.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Any future issuance of additional authorized shares of our common stock could dilute future earnings per share, book value per share and voting power of existing stockholders.  Depending upon the circumstances under which such shares are issued, such issuance may reduce stockholders equity per share and may reduce the percentage ownership of common stock of existing stockholders.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Any future issuance of additional authorized shares also may have an anti-takeover effect by making it more difficult to engage in a merger, tender offer, proxy contest or assumption of control of a large voting block of our common stock.  Our board of directors could impede a takeover attempt by issuing additional shares and thereby diluting the voting power of other outstanding shares and increasing the cost of a takeover.  A future issuance of additional shares of common stock could render more difficult an attempt to obtain control of us, even if it appears to be desirable to a majority of stockholders, and it may be more difficult for our stockholders to obtain an acquisition premium for their shares or to remove incumbent management.  However, our board of directors has no present intention to use any additional authorized shares of common stock as a measure aimed at discouraging takeover efforts.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Effectiveness of Amendment</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Upon stockholder approval of the proposed amendment and the election by our board of directors to effect a reverse stock split, such reverse stock split would become effective as of the filing of a certificate of amendment to our Sixth Amended </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">and Restated Certificate of Incorporation, in substantially the form attached as Appendix C to this proxy statement, with the Secretary of State of the State of Delaware.  Upon filing of the certificate of amendment, and without any further action by us or our stockholders, the issued shares of common stock held by stockholders of record as of the effective date of the reverse stock split would be converted into a lesser number of shares of common stock calculated in accordance with the reverse stock split ratio selected by our board of directors and set forth in the certificate of amendment.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Beginning on the effective date of the reverse stock split, each stock certificate representing pre-split shares of our common stock will be deemed for all corporate purposes to evidence ownership of post-split shares of our common stock.  Stockholders will be notified that the reverse stock split has been effected as soon as practicable after the effective date of the reverse stock split.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reservation of Right to Abandon Reverse Stock Split</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Even if approved by our stockholders, our board of directors reserves the right to not effect any reverse stock split if it does not deem it to be in our best interest or in the best interest of our stockholders.  By voting in favor of the amendment, you are expressly also authorizing our board of directors to delay, not to proceed with, and abandon a reverse stock split if it should so decide, in its sole discretion, that such action is in the best interest of our company and our stockholders.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If our board of directors fails to effect a reverse stock split prior to our 2026 annual meeting of stockholders, then further stockholder approval would be required prior to effecting any reverse stock split.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Effect on Beneficial Holders</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Common stock held by stockholders in &#8220;street name,&#8221; through a bank, broker or other nominee, will be treated in the same manner as common stock held by stockholders whose shares are registered in their own names.  Banks, brokers or other nominees will be instructed to effect the reverse stock split for their customers holding common stock in &#8220;street name.&#8221;  However, these banks, brokers or other nominees may have different procedures than registered stockholders for processing the reverse stock split.  If you hold shares of common stock with a bank, broker or other nominee and have any questions in this regard, you are encouraged to contact your bank, broker or other nominee.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Effect on Registered Holders</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Some of our registered holders of common stock may hold some or all of their shares electronically in book-entry form with our transfer agent, Computershare, Inc.  These stockholders do not hold physical stock certificates evidencing their ownership of our common stock.  However, they are provided with a statement reflecting the number of shares of our common stock registered in their accounts.  If a stockholder holds registered shares in book-entry form with our transfer agent, no action needs to be taken to receive post-reverse stock split shares or payment in lieu of fractional shares, if applicable.  If a stockholder is entitled to post-reverse stock split shares, a transaction statement will automatically be sent to the stockholder&#8217;s address of record indicating the number of shares of our common stock held following the reverse stock split.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Effect on Holders of Stock Certificates</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Computershare will act as our exchange agent for purposes of implementing the exchange of stock certificates.  Stockholders holding shares of common stock in certificated form will be asked to surrender to the exchange agent the stock certificates representing such shares in exchange for stock certificates representing post-split shares in accordance with the procedures to be set forth in a letter of transmittal that will be delivered to our stockholders at such time.  No new certificates will be issued to a stockholder until the stockholder has surrendered such outstanding stock certificates, together with the properly completed and executed letter of transmittal, to our exchange agent.  STOCKHOLDERS SHOULD NOT DESTROY ANY STOCK CERTIFICATES AND SHOULD NOT SUBMIT THEIR STOCK CERTIFICATES UNTIL THEY RECEIVE A TRANSMITTAL FORM FROM OUR EXCHANGE AGENT.  STOCKHOLDERS ARE ENCOURAGED TO PROMPTLY SURRENDER CERTIFICATES TO OUR EXCHANGE AGENT PROMPTLY FOLLOWING RECEIPT OF A TRANSMITTAL FORM IN ORDER TO AVOID THE APPLICABILITY OF ESCHEAT LAWS TO SUCH SHARES.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fractional Shares</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">No fractional shares of common stock will be issued as a result of a reverse stock split.  In lieu of any fractional shares to which a stockholder would otherwise be entitled as a result of a reverse stock split, we will make cash payments equal to such fraction multiplied by the closing sales price of our common stock as reported on the Nasdaq Global Select Market on the last trading day immediately preceding the effective date of the reverse stock split.  As of April 3, 2025, there were ______ holders of record of our common stock.  We do not expect that such number will be reduced as a result of any such cash payments made in connection with the reverse stock split.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">No Appraisal Rights</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As a matter of Delaware law, our stockholders do not have a right to dissent and are not entitled to appraisal rights with respect to the proposed amendment to effect a reverse stock split, and we will not independently provide our stockholders with any such rights.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interests of Directors and Executive Officers</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our directors and executive officers have no substantial interests, directly or indirectly, in the matters set forth in this proposed amendment, except to the extent of their ownership in shares of our common stock.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounting Consequences</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The par value of our common stock will remain unchanged at $0.001 per share following a reverse stock split.  The capital account of our company will also remain unchanged, and we do not anticipate that any other accounting consequences will arise as a result of a reverse stock split.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Material United States Federal Income Tax Consequences</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following is a general summary of the material U.S. federal income tax considerations related to a reverse stock split that may be relevant to U.S. Holders (as defined below) of our common stock that hold our common stock as a &#8220;capital asset&#8221; (generally property held for investment), but does not purport to be a complete analysis of all potential tax considerations. This summary is based on the provisions of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), U.S. Treasury regulations promulgated thereunder (&#8220;Treasury Regulations&#8221;), administrative rulings and judicial decisions, all as in effect on the date hereof, and all of which are subject to change, possibly with retroactive effect. We have not sought and will not seek an opinion of counsel or any rulings from the Internal Revenue Service (the &#8220;IRS&#8221;) regarding the matters discussed below. There can be no assurance that the IRS or a court will not take a contrary position with respect to the tax consequences of a reverse stock split described below.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">This summary does not address all aspects of U.S. federal income taxation that may be relevant to a stockholder in light of their personal circumstances. In addition, this summary does not address the Medicare tax on certain investment income, U.S. federal estate or gift tax laws, any state, local or non-U.S. tax laws or any tax treaties. This summary also does not address tax consequences applicable to investors that may be subject to special treatment under the U.S. federal income tax laws, such as:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">persons that are not U.S. Holders;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">U.S. Holders who hold common stock through non-U.S. brokers or other non-U.S. intermediaries;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">banks, insurance companies or other financial institutions;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">tax-exempt or governmental organizations;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">dealers in securities or foreign currencies;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">persons whose functional currency is not the U.S. dollar;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">real estate investment trusts or regulated investment companies;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">corporations that accumulate earnings to avoid U.S. federal income tax;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">traders in securities that use the mark-to-market method of accounting for U.S. federal income tax purposes;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">persons subject to the alternative minimum tax;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">partnerships or other pass-through entities for U.S. federal income tax purposes or holders of interests therein;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">persons that acquired our common stock through the exercise of employee stock options or otherwise as compensation or through a tax-qualified retirement plan; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">persons that hold our common stock as part of a straddle, appreciated financial position, synthetic security, hedge, conversion transaction or other integrated investment or risk reduction transaction.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">THIS DISCUSSION IS FOR INFORMATIONAL PURPOSES ONLY AND IS NOT INTENDED AS TAX ADVICE. THE TAX CONSEQUENCES OF A REVERSE STOCK SPLIT MAY NOT BE THE SAME FOR ALL OF OUR STOCKHOLDERS. OUR STOCKHOLDERS ARE ENCOURAGED TO CONSULT THEIR TAX ADVISORS WITH RESPECT TO THE APPLICATION OF THE U.S. FEDERAL INCOME TAX LAWS TO THEIR PARTICULAR SITUATION AS WELL AS ANY TAX CONSEQUENCES OF A REVERSE STOCK SPLIT ARISING </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">UNDER OTHER U.S. FEDERAL TAX LAWS (INCLUDING ESTATE AND GIFT TAX LAWS), UNDER THE LAWS OF ANY STATE, LOCAL OR NON-U.S. TAXING JURISDICTION OR UNDER ANY APPLICABLE TAX TREATY.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For purposes of the discussion below, a &#8220;U.S. Holder&#8221; is a beneficial owner of shares of our common stock that for U.S. federal income tax purposes is: (a) an individual who is a citizen or resident of the United States; (b) a corporation (or other entity treated as a corporation for U.S. federal income tax purposes) created or organized in or under the laws of the United States, any state thereof, or the District of Columbia; (c) an estate the income of which is subject to U.S. federal income tax regardless of its source; or (d) a trust (1) the administration of which is subject to the primary supervision of a U.S. court and which has one or more United States persons who have the authority to control all substantial decisions of the trust or (2) which has made a valid election under applicable Treasury Regulations to be treated as a United States person.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If a partnership (including an entity or arrangement treated as a partnership for U.S. federal income tax purposes) holds our common stock, the tax treatment of a partner in the partnership generally will depend upon the status of the partner, upon the activities of the partnership and upon certain determinations made at the partner level. Accordingly, we urge partners in partnerships (including entities or arrangements treated as partnerships for U.S. federal income tax purposes) to consult their tax advisors regarding the U.S. federal income tax consequences of a reverse stock split to them.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A reverse stock split should be treated as a &#8220;recapitalization&#8221; for U.S. federal income tax purposes. As a result, a U.S. Holder generally should not recognize gain or loss as a result of a reverse stock split, except as described below with respect to cash received in lieu of a fractional share of our common stock. A U.S. Holder&#8217;s aggregate tax basis in its post-reverse stock split shares of our common stock should equal the aggregate tax basis of its pre-reverse stock split shares of our common stock (excluding any portion of such tax basis that is allocated to any fractional share of our common stock), and such U.S. Holder&#8217;s holding period in its post-reverse stock split shares of our common stock should include the holding period in its pre-reverse stock split shares of our common stock. A U.S. Holder that holds shares of our common stock acquired on different dates and at different prices should consult its tax advisor with regard to identifying the bases or holding periods of the particular shares of common stock it holds after a reverse stock split.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A U.S. Holder that receives cash in lieu of a fractional share of our common stock pursuant to a reverse stock split generally should recognize capital gain or loss in an amount equal to the difference, if any, between the amount of cash received and the portion of the U.S. Holder&#8217;s aggregate adjusted tax basis in its shares of our common stock allocable to the fractional share. Such capital gain or loss will constitute long-term capital gain or loss if the U.S. Holder&#8217;s holding period in the fractional share is greater than one year as of the effective date of a reverse stock split. Special rules may apply to certain U.S. Holders to cause all or a portion of the cash received in lieu of a fractional share to be treated as dividend income with respect to such U.S. Holder. Our stockholders should consult their own tax advisors regarding the tax effects to them of receiving cash in lieu of fractional shares based on their particular circumstances.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Information Reporting and Backup Withholding</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A U.S. Holder (other than one that is a corporation or other exempt recipient that certifies as to such status if requested) may be subject to information reporting and backup withholding when such holder receives cash in lieu of a fractional share of our common stock pursuant to a reverse stock split. A U.S. Holder will be subject to backup withholding if such stockholder is not otherwise exempt and such stockholder does not provide its taxpayer identification number in the manner required or otherwise fails to comply with applicable backup withholding tax rules. Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules may be refunded or allowed as a credit against the U.S. Holder&#8217;s U.S. federal income tax liability, if any, provided the required information is timely furnished to the IRS. U.S. Holders should consult their tax advisors regarding their qualification for an exemption from backup withholding and the procedures for obtaining such an exemption.</span></div><div id="i29f56aa9946248519609c20b75df062f_22"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PROPOSAL NUMBER 5:</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ADVISORY VOTE TO APPROVE COMPENSATION PAID TO NAMED EXECUTIVE OFFICERS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 14A of the Securities and Exchange Act of 1934, as amended, requires that we provide our stockholders with an opportunity to vote, on a non-binding and advisory basis, on the compensation of our named executive officers, as disclosed in this proxy statement in accordance with the compensation disclosure rules of the Securities and Exchange Commission.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described below under &#8220;Executive and Director Compensation - Compensation Discussion and Analysis,&#8221; we have developed a compensation policy that is designed to attract and retain key executives responsible for our success and motivate management to enhance long-term stockholder value.  We believe our compensation policy strikes an appropriate balance between the implementation of responsible, measured compensation practices and the effective provision of incentives for our named executive officers to exert maximum efforts for our success.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, we ask our stockholders to vote on the following resolution at the annual meeting:</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:36pt;padding-right:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;RESOLVED, that the Company&#8217;s stockholders hereby approve, on an advisory basis, the compensation of the named executive officers, as disclosed in the Company&#8217;s proxy statement for the 2025 annual meeting of stockholders pursuant to the compensation disclosure rules of the Securities and Exchange Commission, including the Compensation Discussion and Analysis, 2024 Summary Compensation Table and the other compensation related tables and disclosure.&#8221;</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As this vote is advisory, it will not be binding upon the board of directors or the compensation committee and neither the board of directors nor the compensation committee will be required to take any action as a result of the outcome of this vote.  However, the compensation committee will carefully consider the outcome of this vote when considering future executive compensation policies.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Board of Directors recommends that stockholders vote &#8220;FOR&#8221; the approval, on an advisory basis, of the compensation paid to our named executive officers, as disclosed in this proxy statement.</span></div><div id="i29f56aa9946248519609c20b75df062f_25"></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PROPOSAL NUMBER 6:</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RATIFICATION AND APPROVAL OF INDEPENDENT AUDITORS</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The board of directors has appointed the firm of Ernst &amp; Young LLP as our independent auditors to make an examination of our accounts for the fiscal year ending December 31, 2025, subject to ratification by our stockholders.  Representatives of Ernst &amp; Young LLP, are expected to be present at the annual meeting, will have an opportunity to make a statement if they desire to do so and are expected to be available to respond to appropriate questions.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Board of Directors recommends that stockholders vote &#8220;FOR&#8221; ratification and approval of the appointment of Ernst &amp; Young LLP as our independent auditors for the fiscal year ending December 31, 2025.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Compensation of Independent Auditors</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the estimated aggregate fees billed and to be billed by Ernst &amp; Young LLP for services performed during our last two fiscal years.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.479%"><tr><td style="width:1.0%"/><td style="width:65.625%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.486%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.612%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Audit fees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">853,220&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,056,408&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Audit-related fees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,850&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">892,670&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,094,258&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8220;Audit fees&#8221; include professional services rendered for (i) the audit of our annual financial statements for the fiscal years ended December 31, 2023 and 2024, (ii) the reviews of the financial statements included in our quarterly reports on Form 10-Q for such years and (iii) the issuance of consents and other matters relating to registration statements filed by us.</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8220;Audit-related fees&#8221; include assurance or related services reasonably related to our audit for the fiscal years ended December 31, 2023 and 2024.  These fees related to the audit of the financial statements of our 401(k) plan.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The audit committee reviewed and approved all the fees described above.  As part of its duties, the audit committee has determined that the provision by Ernst &amp; Young LLP of the services described above is compatible with maintaining the auditors&#8217; independence.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Audit Committee Pre-Approval Policies and Procedures</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The audit committee has adopted policies and procedures requiring the pre-approval of all audit and non-audit services rendered by our independent auditors, either as part of the audit committee&#8217;s approval of the scope of the engagement of the independent auditors or on a case-by-case basis before the independent auditors are engaged to provide each service.  The audit committee&#8217;s pre-approval authority may be delegated to one or more of its members, but any pre-approval decision must be reported to the full audit committee at its next regularly scheduled meeting.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Audit Committee Report</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The role of the audit committee is to assist the board of directors in its oversight of our financial reporting process.  The audit committee reviews our internal accounting procedures and consults with, and reviews the services provided by, our independent auditors. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The management of our company is responsible for the preparation, presentation and integrity of our financial statements, our accounting and financial reporting principles and internal controls and procedures designed to assure compliance with the accounting standards and applicable laws and regulations.  Our independent auditors are responsible for auditing our financial statements and expressing an opinion as to their conformity with generally accepted accounting principles.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the performance of its oversight function, the audit committee has reviewed and discussed the audited financial statements with management.  The committee has also discussed with our independent auditors the matters required to be discussed by PCAOB Auditing Standard No. 1301, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Communications with Audit Committees,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as currently in effect.  Finally, the committee has received the written disclosures and the letter from our independent auditors required by the applicable requirements of the Public Company Accounting Oversight Board regarding our independent auditors&#8217; communications with the audit committee concerning independence</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as currently in effect, and has discussed with our independent auditors their independence.  </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based upon the review and discussions described in this report, and subject to the limitations on the role and responsibilities of the audit committee referred to in the audit committee charter, the audit committee recommended to the board of directors that the audited financial statements be included in our annual report on Form 10-K for the year ended December 31, 2024.</span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Audit Committee</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Samuel L. Barker, Ph.D. (chair)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ivan H. Cheung</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diane E. Sullivan</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing audit committee report shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference by any general statement incorporating by reference this proxy statement into any filing under the Securities Act of 1933 or under the Securities Exchange Act of 1934, except to the extent that we specifically incorporate this audit committee report by reference, and shall not otherwise be deemed filed under such acts.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><div id="i29f56aa9946248519609c20b75df062f_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">STOCK OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents information regarding the beneficial ownership of our common stock as of April 3, 2025 by:</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:2pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">each of the individuals listed in &#8220;Executive and Director Compensation - Summary Compensation Table for 2024&#8221;;</span></div><div style="margin-bottom:2pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">each of our directors and nominees;</span></div><div style="margin-bottom:2pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">each person, or group of affiliated persons, who is known by us to own beneficially more than five percent of our common stock; and </span></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">all current directors and executive officers as a group. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beneficial ownership is determined in accordance with the rules of the Securities and Exchange Commission computing the number of shares beneficially owned by a person and the percentage ownership of that person.  Shares of common stock underlying stock options held by that person that are currently exercisable or exercisable within 60 days of April&#160;3, 2025 and restricted stock units held by that person that are scheduled to vest within 60 days of April 3, 2025 are considered outstanding.  These shares, however, are not considered outstanding when computing the percentage ownership of each other person. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as indicated in the footnotes to this table and pursuant to state community property laws, each stockholder named in the table has sole voting and investment power for the shares shown as beneficially owned by them. Percentage of ownership is based on _________ shares of common stock outstanding on April 3, 2025.  Unless otherwise indicated in the footnotes, the address of each of the individuals named below is: c/o Lexicon Pharmaceuticals,&#160;Inc., 2445 Technology Forest Blvd., 11th Floor, The Woodlands, Texas 77381.</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.076%"><tr><td style="width:1.0%"/><td style="width:51.309%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.381%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.541%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Beneficial Ownership</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares Beneficially Owned</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Issuable Pursuant to Options Exercisable or Restricted Stock Units Scheduled to Vest within 60 Days of April 3,&#160;2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage Ownership</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5% Stockholders</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Invus, L.P., Invus Public Equities, L.P., Invus US Partners, LLC and Artal Participations S.&#224; r.l. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,550,588&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FMR LLC </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,867,042&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Directors and Named Executive Officers</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael S. Exton, Ph.D.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brian T. Crum</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260,815&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">803,896&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Craig B. Granowitz, M.D., Ph.D.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">694,512&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alan J. Main, Ph.D.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339,104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,008,604&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lonnel Coats </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">798,068&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jeffrey L. Wade </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319,114&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,331,402&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Kristen L. Alexander</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,368&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,571&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thomas A. Garner </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,417&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Raymond Debbane </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,718,996&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Philippe J. Amouyal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248,364&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Samuel L. Barker, Ph.D.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,649&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ivan H. Cheung</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Christopher J. Sobecki</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167,055&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diane E. Sullivan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,951&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Judith L. Swain, M.D.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,364&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All current directors and executive officers as a group </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (16&#160;persons)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,204,190&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,796,221&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">* Represents beneficial ownership of less than 1 percent.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:112%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Based upon a Schedule 13D/A filed with the SEC on December 9, 2024, reflecting the beneficial ownership of our common stock and preferred stock by Invus, L.P., Invus Public Equities, L.P., Invus US Partners, LLC, Artal Participations S.&#224; r.l. and related parties.  Invus, L.P. and related parties may be deemed to have sole investment and voting power with respect to 35,402,689 of such shares and shared voting power with respect to 3,516,214 of such shares.  Invus Public Equities, L.P. and related parties may be deemed to have sole investment and shared voting power with respect to 3,516,214 of such shares.  Invus US Partners, LLC and related parties may be deemed to have sole investment and voting power with respect to 5,451,204 of such shares.  Artal Participations S.&#224; r.l. and related parties may be deemed to have sole investment and voting power with respect to 136,180,481 of such shares. The address for Invus, L.P., Invus Public Equities, L.P. and Invus Partners, LLC is c/o The Invus Group, LLC, 750 Lexington Avenue, 30th Floor, New York, New York 10022.  The address for Artal Participations S.&#224; r.l. is 44, Rue De La Vall&#233;e, L-2661, Luxembourg, Luxembourg.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:112%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Based upon a Schedule 13G/A filed with the SEC on November 12, 2024, reflecting 49,867,042 shares of our common stock held by funds and accounts managed by direct or indirect subsidiaries of FMR LLC and which securities are beneficially owned, or may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates and other companies.  Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC.  Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders&#8217; voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders&#8217; voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC.  The address of FMR LLC is 245 Summer Street, Boston, MA 02210.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Based upon certain representations made to us by Mr. Coats.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Based upon certain representations made to us by Mr. Wade.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Based upon our corporate records for Mr. Garner.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Includes 44,370,117 shares beneficially owned by Invus, L.P., Invus Public Equities, L.P., Invus US Partners, LLC and related parties. Mr. Debbane disclaims beneficial ownership of these shares.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div id="i29f56aa9946248519609c20b75df062f_31"></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EQUITY COMPENSATION PLAN INFORMATION</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents aggregate summary information as of December 31, 2024 regarding the common stock that may be issued upon exercise of options, warrants and rights under our 2017 Equity Incentive Plan and 2017 Non-Employee Directors&#8217; Equity Incentive Plan.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.959%"><tr><td style="width:1.0%"/><td style="width:28.311%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.707%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.680%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.594%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.594%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(a)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(b)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(c)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Plan Category</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of securities to be issued upon exercise of outstanding options, warrants and rights</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted average exercise price per share of outstanding options, warrants and rights </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a))</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity compensation plans approved by security holders </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,688,672&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2005&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,057,667&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity compensation plans not approved by security holders</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,688,672&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2005&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,057,667&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______________</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Consists of shares of our common stock issuable upon the exercise of outstanding stock options or vesting of outstanding restricted stock units granted under our 2017 Equity Incentive Plan and 2017 Non-Employee Directors&#8217; Equity Incentive Plan or remaining available for issuance under those plans.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Reflects only the weighted-average exercise price per share of outstanding stock options granted under our 2017 Equity Incentive Plan and 2017 Non-Employee Directors&#8217; Equity Incentive Plan and excludes from such calculation 6,299,757 restricted stock units granted under such plans pursuant to which shares of our common stock may be issued for no additional consideration.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><div id="i29f56aa9946248519609c20b75df062f_34"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CORPORATE GOVERNANCE</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Independence of the Board of Directors</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After reviewing all relevant transactions and relationships involving each member of the board of directors (and his or her family), the board of directors has affirmatively determined that Raymond Debbane, Philippe J. Amouyal, Samuel L. Barker, Ph.D., Ivan H. Cheung, Christopher J. Sobecki, Diane E. Sullivan and Judith L. Swain, M.D., which members constitute a majority of the board of directors, are &#8220;independent&#8221; in accordance with the applicable listing standards of The Nasdaq Stock Market, Inc.  In making such determinations, the board of directors considered the percentage of our outstanding common stock owned by Invus and its affiliates and the effect of such ownership on the independence of Mr. Debbane, Mr. Amouyal and Mr. Sobecki.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Board Committees </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Audit Committee.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Our audit committee has been established in accordance with Section 3(a)(58)(A) of the Securities Exchange Act of 1934 to oversee our accounting and financial reporting processes and the audits of our financial statements.  In that regard, the audit committee assists our board of directors in monitoring the integrity of our financial statements, the qualifications, independence and performance of our independent auditors and our compliance with legal and regulatory requirements.  The audit committee operates pursuant to a charter that was last amended and restated by the board of directors on July 27, 2023, a copy of which appears on our website at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.lexpharma.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> under the caption &#8220;Investors - Corporate Governance.&#8221;</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The current members of our audit committee are Samuel L. Barker, Ph.D. (chair), Ivan H. Cheung and Diane E. Sullivan.  The board of directors, in its business judgment, has determined that Dr. Barker, Mr. Cheung and Ms. Sullivan are &#8220;independent&#8221; in accordance with the applicable listing standards of The Nasdaq Stock Market, Inc.  The board of directors, in its business judgment, has also determined that Samuel L. Barker, Ph.D. is an &#8220;audit committee financial expert&#8221; as defined in Item 407(d)(5) of Regulation S-K.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation Committee.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Our compensation committee has been established to oversee the compensation of our employees, including our chief executive officer and other officers.  The compensation committee also has responsibility for the evaluation and approval of all compensation plans, policies and programs, including the issuance of stock options, restricted stock units and other awards under our 2017 Equity Incentive Plan.  The compensation committee operates pursuant to a charter that was last amended and restated by the board of directors on February 7, 2019, a copy of which appears on our website at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.lexpharma.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> under the caption &#8220;Investors - Corporate Governance.&#8221;</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The compensation committee may delegate any of its authority to subcommittees consisting of one or more compensation committee members, with all subcommittee decisions being presented to the full compensation committee at its next scheduled meeting.  The compensation committee did not delegate any such authority with respect to 2024 compensation matters.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The compensation committee may retain compensation consultants, legal counsel or other advisors when it deems appropriate to assist in its evaluation of executive compensation.  The compensation committee has engaged Pearl Meyer &amp; Partners, LLC as independent compensation consultants as described under the heading &#8220;Executive and Director Compensation - Compensation Discussion and Analysis.&#8221;</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The compensation committee meets in connection with most regularly scheduled meetings of the board of directors, and holds meetings after the commencement of each year specifically devoted to evaluating corporate and individual performance during the prior year and making compensation decisions on such basis.  In preparation for such decisions, our chief executive officer generally reviews the performance of officers other than himself and, in consultation with the compensation committee and at its direction, makes certain recommendations to the compensation committee relating to their compensation.  The compensation committee reviews such recommendations and makes changes to such recommendations as it deems appropriate.  All executive compensation determinations are made by the compensation committee independently from management.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The current members of our compensation committee are Philippe J. Amouyal (chair), Samuel L. Barker, Ph.D. and Judith L. Swain, M.D.  The board of directors, in its business judgment, has determined that Mr. Amouyal, Dr. Barker and Dr. Swain are &#8220;independent&#8221; in accordance with the applicable listing standards of The Nasdaq Stock Market, Inc.  In making such determinations, the board of directors considered the matters relating to Mr. Amouyal described under the heading &#8220;Corporate Governance - Independence of the Board of Directors.&#8221;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Corporate Governance Committee.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Our corporate governance committee has been established to oversee all aspects of our corporate governance functions.  In that regard, the corporate governance committee makes recommendations to the board of directors regarding the identification, evaluation and selection of candidates to serve on the board of directors, the composition of board committees and the development of other corporate governance functions.  The corporate governance committee operates pursuant to a charter that was last amended and restated by the board of directors on February 7, 2013, a copy of which appears on our website at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.lexpharma.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> under the caption &#8220;Investors - Corporate Governance.&#8221;</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The corporate governance committee has not established any specific minimum qualifications for membership on our board of directors.  Rather, the committee will generally consider all relevant factors, which may include independence, experience, diversity, leadership qualities and strength of character.  As the corporate governance committee does not uniquely consider diversity relative to the other factors, the committee has not established a policy with regard to the consideration of diversity in identifying potential director candidates.  The corporate governance committee uses its available network of contacts when compiling a list of potential director candidates and may also engage outside consultants when appropriate.  The committee also considers potential director candidates recommended by stockholders and other parties and all potential director candidates are evaluated based on the above criteria.  Because the corporate governance committee makes no distinction in its evaluation of candidates based on whether such candidates are recommended by stockholders or other parties, no formal policy or procedure has been established for the consideration of director candidates recommended by stockholders.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any stockholder wishing to propose a potential director candidate may submit a recommendation in writing within the time frame specified in our bylaws.  All such communications should be sent to 2445 Technology Forest Blvd., 11th Floor, The Woodlands, Texas 77381, Attn:  Corporate Governance Committee.  Submissions should include the full name of the proposed candidate and a detailed description of the candidate&#8217;s qualifications, business experience and other relevant biographical information.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The current members of our corporate governance committee are Raymond Debbane (chair) and Judith L. Swain, M.D.  The board of directors, in its business judgment, has determined that Mr. Debbane and Dr. Swain are &#8220;independent&#8221; in accordance with the applicable listing standards of The Nasdaq Stock Market, Inc.  In making such determinations, the board of directors considered the matters relating to Mr. Debbane described under the heading &#8220;Corporate Governance - Independence of the Board of Directors.&#8221;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Board Leadership Structure and Role in Risk Oversight</span></div><div><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The current leadership structure of our board of directors reflects a separation of the roles of chairman and principal executive officer.  This leadership structure is intended to provide our board of directors with an appropriate level of independence from management and encourage a high degree of autonomy within our board of directors.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our board of directors administers its risk oversight responsibilities by evaluating the material risks, including operational risks and liquidity risks, facing our company or inherent in our corporate strategy.  This is accomplished through regular discussions with management and by reference to the independent understanding and knowledge of many such risks possessed by members of our board of directors.  Our board of directors regularly reviews the viability and prudence of our corporate strategy in light of the evolving nature of such risks and makes adjustments to that strategy when appropriate.  Our board of directors oversees management&#8217;s implementation of our corporate strategy, remains alert for excessive risk-taking in such implementation and provides timely input to management regarding any critical risk issues.  Our board of directors receives regular presentations and reports from management on risks relating to cybersecurity, compliance and other operational aspects of our business and receives prompt and timely information regarding any specific incident posing a significant risk.  The efforts of our board of directors to oversee any risks relating to our financial reporting or internal accounting procedures are supplemented by the regular interactions of our audit committee with the individuals with day-to-day responsibilities for such functions.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Board and Committee Meetings and Attendance in 2024</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2024, the board of directors met eight times and took certain additional actions by unanimous written consent, the audit committee met six times, the compensation committee met four times and took certain additional actions by unanimous written consent and the corporate governance committee met two times and took certain additional actions by unanimous written consent.  During 2024, none of our incumbent directors attended fewer than 75&#160;percent of the aggregate number of meetings of the board of directors and committees during the period served.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is our policy to encourage the members of our board of directors to attend all annual meetings of stockholders. Six of the eight individuals who were members of our board of directors at such time attended our 2024 annual meeting of stockholders.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Code of Business Conduct and Ethics</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted a code of business conduct and ethics that applies to all of our directors, officers and employees, the text of which appears on our website at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.lexpharma.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> under the caption &#8220;Investors&#160;- Corporate Governance.&#8221;  We intend to disclose on our website the nature of any amendment to or waiver from our code of business conduct and ethics that applies to our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions within four business days following the date of such amendment or waiver.  In the case of any such waiver, including an implicit waiver, we also intend to disclose the name of the person to whom the waiver was granted and the date of the waiver.  To date, we have not granted any waivers under our code of business conduct and ethics.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Insider Trading Policy</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have <ix:nonNumeric contextRef="c-1" name="ecd:InsiderTrdPoliciesProcAdoptedFlag" format="ixt:fixed-true" id="f-5">adopted an insider trading policy</ix:nonNumeric> governing the purchase, sale, and other dispositions of our securities by our company and our directors, officers and employees that we believe is reasonably designed to promote compliance with insider trading laws, rules and regulations and NASDAQ listing rules.  Such insider trading policy also prohibits our employees, officers and directors, or any of their designees, from purchasing financial instruments (including prepaid variable forward contracts, equity swaps, collars and exchange funds), or otherwise engaging in transactions that hedge or offset, or are designed to hedge or offset, any decrease in the market value of any of our securities, and further provides that such individuals should not engage in the trading of options to purchase or sell our securities.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate Governance Guidelines</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted corporate governance guidelines, including, among other things, guidelines with respect to the structure of our board of directors, director selection and qualifications, and non-employee director compensation.  The text of our corporate governance guidelines appears on our website at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.lexpharma.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> under the caption &#8220;Investors&#160;- Corporate Governance.&#8221;</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stockholder Communications with the Board of Directors</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our stockholders are currently provided a reasonable means to communicate with our board of directors and individual directors.  As a result, our board of directors has not established a formal process for stockholders to send communications to the board of directors or individual directors.  However, the corporate governance committee will consider, from time to time, whether adoption of a formal process for such stockholder communications has become necessary or appropriate.  Stockholders may send communications to the board of directors or individual directors by mail at 2445 Technology Forest Blvd., 11th Floor, The Woodlands, Texas 77381, Attn: Board of Directors or any individual director.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Compensation Committee Interlocks and Insider Participation </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2024, Philippe J. Amouyal, Samuel L. Barker, Ph.D. and Judith L. Swain, M.D. served as members of the compensation committee of our board of directors.  Mr. Amouyal is a designee of Invus pursuant to our stockholders&#8217; agreement with Invus, L.P. described under the heading &#8220;Transactions with Related Persons - Arrangements with Invus.&#8221;  During 2024, none of our executive officers served as a member of the board of directors or compensation committee of another entity, one of whose executive officers served as a member of our board of directors or compensation committee.</span></div><div id="i29f56aa9946248519609c20b75df062f_37"></div><div style="margin-bottom:9pt;margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TRANSACTIONS WITH RELATED PERSONS</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Arrangements with Invus</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2007, we entered into a securities purchase agreement with Invus, L.P., under which Invus, L.P. made an initial investment in our common stock in August 2007.  Invus, L.P. and its affiliates, which we collectively refer to as Invus, have subsequently made additional investments in our common stock and currently own approximately 49.9% of our outstanding common stock.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Board of Directors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Concurrently with the execution of the securities purchase agreement, we entered into a stockholders&#8217; agreement with Invus, L.P. under which Invus has the right to designate a number of directors equal to the percentage of all the outstanding shares of our common stock owned by Invus, rounded up to the nearest whole number of directors.  Invus has designated three of the eight current members of our board of directors.  While Invus has not presently exercised its director designation rights in full, it may exercise them at any time in the future in its sole discretion.  To facilitate the exercise of such rights, we have agreed, upon written request from Invus, to take all necessary steps in accordance with our obligations under the stockholders&#8217; agreement to (1) increase the number of directors to the number specified by Invus (which number shall be no greater than reasonably necessary for the exercise of Invus&#8217; director designation rights under the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">stockholders&#8217; agreement) and (2) cause the appointment to the newly created directorships of directors so designated by Invus pursuant to its rights under the stockholders&#8217; agreement.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Invus also has the right to require proportionate representation of Invus-appointed directors on the audit, compensation and corporate governance committees of our board of directors, subject to certain restrictions.  Invus-designated directors currently serve as one of the three members of the compensation committee and one of the three members of the corporate governance committee of our board of directors.  No Invus-designated directors currently serve on the audit committee of our board of directors.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provisions of the stockholders&#8217; agreement relating to Invus&#8217; rights to designate members of our board of directors and its audit, compensation and corporate governance committees will terminate if the percentage of all the outstanding shares of our common stock owned by Invus and its affiliates falls below 10%.  Invus also has the right to terminate these provisions at any time in its discretion.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Registration Rights</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Concurrently with the execution of the securities purchase agreement, we also entered into a registration rights agreement with Invus, L.P., pursuant to which Invus has certain demand and piggyback registration rights with respect to shares of our common stock held by them.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Preemptive and Consent Rights.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">  Our Sixth Amended and Restated Certificate of Incorporation grants holders of 20% or more of our issued and outstanding common stock (a) customary preemptive rights related to the issuance of certain of our securities and (b) consent rights prior us taking any of the following actions: (i) creating or issuing any new class or series of shares of capital stock (or securities convertible into or exercisable for shares of capital stock) having rights, preferences or privileges senior to or on parity with the common stock, (ii) subject to certain exceptions, repurchasing, retiring, redeeming or otherwise acquiring any of our equity securities (or securities convertible into or exchangeable for equity securities) or any subsidiary and (iii) adopting, or proposing to adopt, or maintaining any shareholders&#8217; rights plan, &#8220;poison pill&#8221; or other similar plan or agreement, unless such stockholder is exempt from such plan or agreement.  Invus possesses such preemptive and consent rights based on its current ownership interest in our common stock.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">2024 Purchase Agreement.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March 2024, we entered into a purchase agreement with certain purchasers, including Invus, pursuant to which, among other things, we issued to such purchasers shares of our preferred stock in a private placement (referred to herein as the &#8220;preferred private placement&#8221;). Each share of preferred stock automatically converted into 50 shares of our common stock on May 10, 2024 upon the satisfaction of certain conditions. The purchase agreement contained customary representations, warranties and agreements made by us and customary obligations of the parties and termination provisions. The purchase agreement also contained customary registration rights whereby we agreed to file a registration statement with the Securities and Exchange Commission registering the resale of the shares of our common stock issuable upon the conversion of the shares of preferred stock issued in the preferred private placement. Following the conversion of the preferred stock issued in the preferred private placement, Invus held approximately the same percentage of our common stock as it did before the preferred private placement.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Related Party Transaction Policies</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted written policies and procedures for the review, approval and ratification of interested transactions with related parties.  Subject to certain exceptions provided in Item 404(a) of Regulation S-K, an &#8220;interested transaction&#8221; means any transaction, arrangement or relationship in which we are or will be a participant and the amount involved will or may be expected to exceed $120,000 in any calendar year, and in which any related party has or will have a direct or indirect material interest.  A &#8220;related party&#8221; means (a) any executive officer, director or nominee for election as a director, (b) any person beneficially owning five&#160;percent or more of our common stock or (c) any immediate family member of such parties.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All interested transactions are subject to the reasonable prior review and approval of our audit committee and if advance audit committee approval is not feasible, then the interested transaction will be considered for ratification at the audit committee&#8217;s next regularly scheduled meeting.  In determining whether to approve or ratify any interested transaction, the audit committee will consider, among other factors it may deem appropriate, whether the interested transaction is on terms no less favorable than terms generally available to an unaffiliated third party under similar circumstances and the extent of the related party&#8217;s interest in the transaction.  Any director may, if so requested by the audit committee, participate in discussions regarding a transaction in which such director may have an interest, as well as provide and discuss any information the audit committee may request from such director.  However, any director who has an interest in a transaction under discussion must abstain from voting on the approval of such transaction.  On at least an annual basis, the audit committee reviews and assesses any ongoing interested transactions to ensure that the transactions remain appropriate.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><div id="i29f56aa9946248519609c20b75df062f_40"></div><hr style="page-break-after:always"/><div style="min-height:47.25pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXECUTIVE AND DIRECTOR COMPENSATION</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Compensation Discussion and Analysis</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have developed a compensation policy that is designed to attract and retain key executives responsible for our success and motivate management to enhance long-term stockholder value.  All compensation decisions are made by our compensation committee pursuant to authority delegated by our board of directors.  The annual compensation package for executive and other officers typically consists primarily of three elements:</span></div><div style="margin-bottom:7pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a base salary, which reflects the responsibilities relating to the position and individual performance;</span></div><div style="margin-bottom:7pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">variable annual cash bonus awards, determined relative to pre-established bonus targets expressed as a percentage of base salary; and</span></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">long-term stock-based incentive awards, designed to provide a continuing proprietary interest in our success. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally seek to set targeted total cash compensation, consisting of base salaries and annual cash bonus award targets, and total direct compensation, consisting of targeted total cash compensation and long-term stock-based incentive awards, at or near the median of a peer group of biopharmaceutical companies if such compensation level is justified by company performance, individual performance and prevailing financial conditions.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining peer group compensation, we use available data from a comprehensive survey of the compensation practices of several hundred companies in the biopharmaceutical industry.  We expand on this survey data with reviews of the publicly-disclosed compensation practices of a group of biopharmaceutical companies selected for comparison purposes based on one or more factors, including market capitalization, revenues and stage of development.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For compensation decisions made in February 2022, this group of companies consisted of:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.982%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amarin Corporation plc</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EyePoint Pharmaceuticals, Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Omeros Corp</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cara Therapeutics, Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">G1 Therapeutics, Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Radius Health, Inc.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clovis Oncology, Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Harmony Biosciences Holdings, Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rigel Pharmaceuticals, Inc.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Crinetics Pharmaceuticals, Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intercept Pharmaceuticals, Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sage Therapeutics, Inc.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Epizyme, Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Karyopharm Therapeutics Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Theravance Biopharma, Inc.</span></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For compensation decisions made in February 2023, this group of companies consisted of:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.982%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2seventy bio, Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Enanta Pharmaceuticals, Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Karyopharm Therapeutics, Inc.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amarin Corporation plc</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Esperion Therapeutics, Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Madrigal Pharmaceuticals, Inc.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Arcutis Biotherapeutics, Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">G1 Therapeutics, Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reata Pharmaceuticals, Inc.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Catalyst Pharmaceuticals, Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Geron Corporation</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Y-mAbs Therapeutics, Inc.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chinook Therapeutics, Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inovio Pharmaceuticals, Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For compensation decisions made in February 2024, this group of companies consisted of:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.982%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2seventy bio, Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Enanta Pharmaceuticals, Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inovio Pharmaceuticals, Inc.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amarin Corporation plc</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Esperion Therapeutics, Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Karyopharm Therapeutics, Inc.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Arcutis Biotherapeutics, Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">G1 Therapeutics, Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Madrigal Pharmaceuticals, Inc.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Catalyst Pharmaceuticals, Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Geron Corporation</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Y-mAbs Therapeutics, Inc.</span></td></tr></table></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For compensation decisions made in February 2025, this group of companies consisted of:</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.982%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Altimmune, Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dianthus Therapeutics, Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Praxis Precision Medicines, Inc.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AnaptysBio, Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Entrada Therapeutics, Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prothena Corporation plc</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Arbutus Biopharma Corporation</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eyepoint Pharmaceuticals, Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stoke Therapeutics, Inc.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ARS Pharmaceuticals, Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Immunome, Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Syndax Pharmaceuticals, Inc.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Avadel Pharmaceuticals plc</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liquidia Corporation</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taysha Gene Therapies, Inc.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cartesian Therapeutics, Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pliant Therapeutics, Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">UroGen Pharma Ltd.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CorMedix Inc.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:47.25pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The peer group of biopharmaceutical companies for which we obtained survey data and the additional groups of companies listed above do not necessarily coincide with the companies comprising the Nasdaq Biotechnology Index.  Although we acknowledge the inherent limitations in comparing our compensation practices with the compensation practices of these companies, we believe that these comparisons are useful and important points of reference in making compensation determinations.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In making compensation determinations and reviewing comparative data, the compensation committee reviews total direct compensation in its totality, assigning dollar values to each of the elements of such compensation, including base salary, annual cash bonus award targets and long-term stock-based incentive awards.  The committee generally allocates a greater percentage of total direct compensation to long-term stock-based incentive awards in acknowledgment of the unique challenges present in the biopharmaceutical industry and in order to reinforce the alignment of interests between our executive and other officers and our stockholders. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the level and composition of compensation of each of our executive and other officers, we take into account various qualitative and quantitative indicators of corporate and individual performance.  In evaluating the performance of management, the compensation committee takes into consideration such factors as the commercial performance of our approved drug products, our efforts and preparations for regulatory approval and commercial launch of our drug candidates, the progress exhibited by our drug candidates in human clinical trials, the number and quality of drug candidates in clinical trials, the number and quality of preclinical drug candidates, the value and scope of strategic collaborations and alliances with leading pharmaceutical companies, and the ability to otherwise finance our operations from external sources.  In addition, the compensation committee recognizes performance and achievements that are more difficult to quantify, such as the successful supervision of major corporate projects and demonstrated leadership ability.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The compensation committee generally makes executive compensation determinations in February of each year, taking into account both company and individual performance over the preceding year, as well as prevailing financial conditions.  The compensation committee meets at least once in advance of the meeting in which executive compensation determinations are actually made to discuss considerations relating to those determinations.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The compensation committee may also retain compensation consultants, legal counsel or other advisors when it deems appropriate to assist in its evaluation of executive or director compensation.  In July 2022, the compensation committee engaged Pearl Meyer &amp; Partners, LLC as an independent compensation consultant to assess the market competitiveness of our executive compensation and provide the compensation committee with recommendations based on such assessment.  At the compensation committee's request, Pearl Meyer produced and reviewed market executive compensation data, participated in certain compensation committee meetings and prepared an assessment of and recommendations with respect to our executive compensation.  In July 2022, the committee assessed the independence of Pearl Meyer and concluded that no conflict of interest existed that would prevent Pearl Meyer from providing the services performed for the compensation committee under such engagement.  In August 2023, the compensation committee engaged Pearl Meyer as an independent compensation consultant to assess the market competitiveness of our non-employee director compensation and provide the compensation committee with recommendations based on such assessment.  At the compensation committee&#8217;s request, Pearl Meyer produced and reviewed market non-employee director compensation data, participated in certain compensation committee meetings and prepared an assessment of and recommendations with respect to our non-employee director compensation.  In August 2023, the committee assessed the independence of Pearl Meyer and concluded that no conflict of interest existed that would prevent Pearl Meyer from providing the services performed for the compensation committee under such engagement.  The compensation committee did not engage any other consultants with respect to 2022, 2023 or 2024 compensation matters.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We received a favorable advisory vote on the compensation of our named executive officers at our 2024 annual meeting of stockholders, with over 97% of the votes cast with respect to such matter voting in favor of such compensation.  The compensation committee believes those voting results affirm our stockholders&#8217; support of our approach to executive compensation and did not make any material changes to its approach.  The compensation committee will continue to consider the outcome of our advisory votes to approve executive compensation when making future decisions with respect to the compensation paid to our named executive officers.</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Corporate and Individual Performance Criteria</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">February 2022 Compensation Determinations</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, the compensation committee made determinations regarding 2021 cash bonus awards and 2022 base salaries, bonus targets and long-term stock-based incentive awards, taking into account the following factors in its evaluation of corporate performance in 2021:</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:47.25pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:5pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our submission of a new drug application for INPEFA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (sotagliflozin) for the treatment of heart failure with the United States Food and Drug Administration;</span></div><div style="margin-bottom:5pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our progress in preparing for the commercial launch of INPEFA for the treatment of heart failure in the United States;</span></div><div style="margin-bottom:5pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our progress relative to our objectives in advancing the clinical development of pilapavadin (LX9211) in neuropathic pain;</span></div><div style="margin-bottom:5pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our progress relative to our objectives in advancing our other clinical and preclinical drug development programs; and</span></div><div style="margin-bottom:5pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our performance relative to our objectives for financial performance and business development, specifically relating to our year-end cash and investments and management of our financial resources.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The committee&#8217;s compensation determinations in February 2022 reflected its assessment that we significantly achieved our objectives relating to INPEFA, pilavapadin, our other drug development programs and our financial performance.  Taking into account the balance of factors described above, it was the committee&#8217;s assessment that our overall corporate objectives were significantly achieved.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For named executive officers other than Mr. Coats, the compensation committee also took into account individual goals, which consisted principally of the expected individual contributions of each named executive officer towards the achievement of the year&#8217;s corporate goals, together with Mr. Coats&#8217; and the committee&#8217;s independent assessment of each named executive officer&#8217;s overall performance and contributions to the company during the year, in the course of making subjective judgments about individual performance in connection with compensation determinations.  Mr. Coats had no individual goals for 2021 apart from the corporate goals.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The committee&#8217;s determinations for Mr. Coats were based entirely upon its determination of achievement of the year&#8217;s corporate goals, together with the compensation committee&#8217;s assessment of his strategic and operational leadership.  For other named executive officers, the compensation committee based its determinations principally upon its determination of achievement of the year&#8217;s corporate goals, but also took into account, to a lesser extent, each named executive officer&#8217;s individual goals.  In the case of Mr. Wade, the compensation committee took into account his contributions toward our financial management, our capital raising efforts, the successful operation of our financial systems and our business development and alliance management activities, as well as his strategic and operational leadership.  In the case of Mr. Crum, the compensation committee took into account his contributions toward our legal and compliance oversight and our capital raising efforts, as well as his strategic and operational leadership.  In the case of Dr. Granowitz, the compensation committee took into account his contributions toward the medical support of INPEFA and our other drug development programs, as well as his strategic and operational leadership.  In the case of Dr. Main, the compensation committee took into account his contributions toward the clinical and preclinical supply of our development programs and the progress of our drug discovery programs, as well as his strategic and operational leadership.  In the case of Ms. Alexander, the compensation committee took into account her contributions toward our financial and accounting management and the successful operation of our financial systems, as well as her strategic and operational leadership.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">February 2023 Compensation Determinations</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2023, the compensation committee made determinations regarding 2022 cash bonus awards and 2023 base salaries, bonus targets and long-term stock-based incentive awards, taking into account the following factors in its evaluation of corporate performance in 2022:</span></div><div style="margin-bottom:5pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acceptance for review and filing by the United States Food and Drug Administration of our submission of a new drug application for INPEFA for the treatment of heart failure;</span></div><div style="margin-bottom:5pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our progress in preparing for the commercial launch of INPEFA for the treatment of heart failure in the United States;</span></div><div style="margin-bottom:5pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our announcement of positive top-line and full results from a Phase 2 proof-of-concept clinical trial of pilavapadin in diabetic peripheral neuropathic pain;</span></div><div style="margin-bottom:5pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our announcement of top-line results from a second Phase 2 proof-of-concept clinical trial of pilavapadin demonstrating clear evidence of effect in post-herpetic neuralgia;</span></div><div style="margin-bottom:5pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our progress relative to our objectives in advancing our other clinical and preclinical drug development programs; and</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:47.25pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:5pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our performance relative to our objectives for financial performance and business development, specifically relating to our year-end cash and investments and management of our financial resources.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The committee&#8217;s compensation determinations in February 2023 reflected its assessment that we achieved our objectives relating to INPEFA, pilavapadin, our other drug development programs and our financial performance.  Taking into account the balance of factors described above, it was the committee&#8217;s assessment that our overall corporate objectives were achieved.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For named executive officers other than Mr. Coats, the compensation committee also took into account individual goals, which consisted principally of the expected individual contributions of each named executive officer towards the achievement of the year&#8217;s corporate goals, together with Mr. Coats&#8217; and the committee&#8217;s independent assessment of each named executive officer&#8217;s overall performance and contributions to the company during the year, in the course of making subjective judgments about individual performance in connection with compensation determinations.  Mr. Coats had no individual goals for 2022 apart from the corporate goals.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The committee&#8217;s determinations for Mr. Coats were based entirely upon its determination of achievement of the year&#8217;s corporate goals, together with the compensation committee&#8217;s assessment of his strategic and operational leadership.  For other named executive officers, the compensation committee based its determinations principally upon its determination of achievement of the year&#8217;s corporate goals, but also took into account, to a lesser extent, each named executive officer&#8217;s individual goals.  In the case of Mr. Wade, the compensation committee took into account his contributions toward our preparations for the commercial launch of INPEFA for the treatment of heart failure in the United States, our financial management and capital raising efforts, the successful operation of our financial systems and our business development and alliance management activities, as well as his strategic and operational leadership.  In the case of Mr. Crum, the compensation committee took into account his contributions toward our legal and compliance oversight and our capital raising efforts, as well as his strategic and operational leadership.  In the case of Dr. Granowitz, the compensation committee took into account his contributions toward medical support of INPEFA in preparation for commercial launch for heart failure in the United States, the clinical progress and our medical support of our other drug development programs, as well as his strategic and operational leadership.  In the case of Dr. Main, the compensation committee took into account his contributions toward the commercial supply of INPEFA in preparation for launch, the clinical and preclinical supply of our development programs and the progress of our drug discovery programs, as well as his strategic and operational leadership.  In the case of Ms. Alexander, the compensation committee took into account her contributions toward our financial and accounting management and the successful operation of our financial systems, as well as her strategic and operational leadership.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">February 2024 Compensation Determinations</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2024, the compensation committee made determinations regarding 2023 cash bonus awards and 2024 base salaries, bonus targets and long-term stock-based incentive awards, taking into account the following factors in its evaluation of corporate performance in 2023:</span></div><div style="margin-bottom:5pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the approval of our application for regulatory approval to market INPEFA in the United States for the treatment of heart failure;</span></div><div style="margin-bottom:5pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our progress relative to our objectives for the launch and commercial performance of INPEFA;</span></div><div style="margin-bottom:5pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our progress relative to our objectives in advancing the clinical development of pilavapadin in diabetic peripheral neuropathic pain;</span></div><div style="margin-bottom:5pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our progress relative to our objectives in advancing our other clinical and preclinical drug development programs; and</span></div><div style="margin-bottom:5pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our performance relative to our objectives for financial performance and business development, specifically relating to our year-end cash and investments and management of our financial resources.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The committee&#8217;s compensation determinations in February 2024 reflected its assessment that we partially achieved our objectives relating to INPEFA and largely achieved our objectives relating to pilavapadin, our other drug development programs and our financial performance.  Taking into account the balance of factors described above, it was the committee&#8217;s assessment that our overall corporate objectives were significantly achieved.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For named executive officers other than Mr. Coats, the compensation committee also took into account individual goals, which consisted principally of the expected individual contributions of each named executive officer towards the achievement of the year&#8217;s corporate goals, together with Mr. Coats&#8217; and the committee&#8217;s independent assessment of each named executive officer&#8217;s overall performance and contributions to the company during the year, in the course of making subjective </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:47.25pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">judgments about individual performance in connection with compensation determinations.  Mr. Coats had no individual goals for 2023 apart from the corporate goals.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The committee&#8217;s determinations for Mr. Coats were based entirely upon its determination of achievement of the year&#8217;s corporate goals, together with the compensation committee&#8217;s assessment of his strategic and operational leadership.  For other named executive officers, the compensation committee based its determinations principally upon its determination of achievement of the year&#8217;s corporate goals, but also took into account, to a lesser extent, each named executive officer&#8217;s individual goals.  In the case of Mr. Wade, the compensation committee took into account his contributions toward our commercial launch of INPEFA for the treatment of heart failure in the United States, our financial management and capital raising efforts, the successful operation of our financial systems and our business development and alliance management activities, as well as his strategic and operational leadership.  In the case of Mr. Crum, the compensation committee took into account his contributions toward our legal and compliance oversight and our capital raising efforts, as well as his strategic and operational leadership.  In the case of Dr. Granowitz, the compensation committee took into account his contributions toward medical support of the commercial launch of INPEFA for heart failure in the United States, the clinical progress and our medical support of our other drug development programs, as well as his strategic and operational leadership.  In the case of Dr. Main, the compensation committee took into account his contributions toward the commercial supply of INPEFA, the clinical and preclinical supply of our development programs and the progress of our drug discovery programs, as well as his strategic and operational leadership.  In the case of Ms. Alexander, the compensation committee took into account her contributions toward our financial and accounting management and the successful operation of our financial systems, as well as her strategic and operational leadership.  In the case of Mr. Garner, the compensation committee took into account his contributions toward our commercial launch of INPEFA for the treatment of heart failure in the United States, as well as his strategic and operational leadership.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">February 2025 Compensation Determinations</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2025, the compensation committee made determinations regarding 2024 cash bonus awards and 2025 base salaries, bonus targets and long-term stock-based incentive awards, taking into account the following factors in its evaluation of corporate performance in 2024:</span></div><div style="margin-bottom:5pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our progress relative to our objectives for the launch and commercial performance of INPEFA;</span></div><div style="margin-bottom:5pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our progress relative to our objectives in obtaining regulatory approval to market ZYNQUISTA in the United States as an adjunct to insulin therapy for glycemic control in adults with type 1 diabetes and chronic kidney disease;</span></div><div style="margin-bottom:5pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our progress relative to our objectives in advancing the clinical development of pilavapadin in diabetic peripheral neuropathic pain;</span></div><div style="margin-bottom:5pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our progress relative to our objectives in advancing the clinical development of sotagliflozin in hypertrophic cardiomyopathy;</span></div><div style="margin-bottom:5pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our progress relative to our objectives in advancing our other clinical and preclinical drug development programs;</span></div><div style="margin-bottom:5pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our entry into an exclusive license agreement with Viatris, Inc. for the development and commercialization of sotagliflozin in all markets outside of the United States and Europe; and</span></div><div style="margin-bottom:5pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our performance relative to our objectives for financial performance, specifically relating to our year-end cash and investments and management of our financial resources.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The committee&#8217;s compensation determinations in February 2025 reflected its assessment that we did not achieve our objectives relating to INPEFA or ZYNQUISTA and largely achieved our objectives relating to pilavapadin, sotagliflozin, our other drug development programs and our financial and business development performance.  Taking into account the balance of factors described above, it was the committee&#8217;s assessment that our overall corporate objectives were significantly achieved.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For named executive officers other than Dr. Exton, the compensation committee also took into account individual goals, which consisted principally of the expected individual contributions of each named executive officer towards the achievement of the year&#8217;s corporate goals, together with Dr. Exton&#8217;s and the committee&#8217;s independent assessment of each named executive officer&#8217;s overall performance and contributions to the company during the year, in the course of making subjective judgments about individual performance in connection with compensation determinations.  Dr. Exton had no individual goals for 2024 apart from the corporate goals.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The committee&#8217;s determinations for Dr. Exton were based entirely upon its determination of achievement of the year&#8217;s corporate goals, together with the compensation committee&#8217;s assessment of his strategic and operational leadership.  For other </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:47.25pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">named executive officers, the compensation committee based its determinations principally upon its determination of achievement of the year&#8217;s corporate goals, but also took into account, to a lesser extent, each named executive officer&#8217;s individual goals.  In the case of Mr. Crum, the compensation committee took into account his contributions toward our legal and compliance oversight and our capital raising efforts, as well as his strategic and operational leadership.  In the case of Dr. Granowitz, the compensation committee took into account his contributions toward medical support of the commercial launch of INPEFA for heart failure in the United States, the clinical progress and our medical support of our other drug development programs, as well as his strategic and operational leadership.  In the case of Dr. Main, the compensation committee took into account his contributions toward the commercial supply of INPEFA, the clinical and preclinical supply of our development programs and the progress of our drug discovery programs, as well as his strategic and operational leadership.  In the case of Ms. Alexander, the compensation committee took into account her contributions toward our financial and accounting management and the successful operation of our financial systems, as well as her strategic and operational leadership.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation Elements</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Base Salary</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Base salary of executive and other officers is established through negotiation between the company and the officer at the time he or she is hired, and then subsequently adjusted when the officer&#8217;s base compensation is subject to review or reconsideration.  While we have entered into employment agreements with certain of our executive officers, these agreements provide that base salaries after the initial year will be reviewed and determined by the compensation committee.  When establishing base salary levels for executive and other officers, the compensation committee, in accordance with its general compensation policy, considers numerous factors, including the responsibilities relating to the position, the qualifications of the executive and the relevant experience the individual brings to the company, strategic goals for which the executive has responsibility, and compensation levels of companies at a comparable stage of commercialization and development who compete with us for business, scientific and executive talents.  When considering increases to base salary levels for officers, which typically occurs each February, we consider corporate and individual performance in addition to the foregoing factors. No pre-determined weights are given to any one of these factors.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, 2023, 2024 and 2025, we increased base salaries for each of our named executive officers following reviews of peer group salary data.  The base salaries of our named executive officers are generally competitive with those paid by our peer group companies, with most falling near the median for such peer group companies.  In establishing base salaries for 2022, 2023, 2024 and 2025, we considered the competitiveness of our cash compensation arrangements for executive officers and our cash position and needs for the applicable year.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Bonus Awards</span></div><div style="margin-bottom:7pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to base salary, we may award variable annual cash bonus awards to executive and other officers with reference to certain predefined corporate and personal performance goals.  These performance goals include those discussed generally above, as well as strategic and operational goals for the company as a whole.  We typically consider the award of cash bonuses each February relating to performance for the preceding year.  For each of our officers, the compensation committee establishes a bonus target, expressed as a percentage of base salary, which is used to determine the cash bonus amount, assuming that corporate and individual goals are fully achieved.  The compensation committee retains broad discretion over the amount and payment of such awards and is not bound by any pre-determined agreement, formula or other standard with respect to such decisions.</span></div><div style="margin-bottom:7pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the cash bonus awards paid in February 2023 with respect to 2022 performance, the compensation committee included the relevant factors described above under &#8220;- Corporate and Individual Performance Criteria - February 2023 Compensation Determinations&#8221; in its evaluation of corporate and individual performance.   After taking into account these factors, the compensation committee determined that our objectives for the year had been achieved, and awarded bonuses for 2022 performance to our named executive officers in amounts reflecting such level of achievement.</span></div><div style="margin-bottom:7pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the cash bonus awards paid in February 2024 with respect to 2023 performance, the compensation committee included the relevant factors described above under &#8220;- Corporate and Individual Performance Criteria - February 2024 Compensation Determinations&#8221; in its evaluation of corporate and individual performance.   After taking into account these factors, the compensation committee determined that our objectives for the year had been significantly achieved, and awarded bonuses for 2023 performance to our named executive officers in amounts reflecting such level of achievement.</span></div><div style="margin-bottom:7pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the cash bonus awards paid in February 2025 with respect to 2024 performance, the compensation committee included the relevant factors described above under &#8220;- Corporate and Individual Performance Criteria - February 2025 Compensation Determinations&#8221; in its evaluation of corporate and individual performance.   After taking into account these </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:47.25pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">factors, the compensation committee determined that our objectives for the year had been significantly achieved, and awarded bonuses for 2024 performance to our named executive officers in amounts reflecting such level of achievement.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-Term Stock-Based Incentive Awards</span></div><div style="margin-bottom:7pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our employees, including our named executive officers, are eligible to receive long-term stock-based incentive awards under our 2017 Equity Incentive Plan as a means of providing such individuals with a continuing proprietary interest in our success.  These grants are typically awarded each February and align the interests of our employees and our stockholders by providing significant incentives for our employees to achieve and maintain high levels of performance.  Our 2017 Equity Incentive Plan enhances our ability to attract and retain the services of qualified individuals.  Factors considered in determining whether, in what form and in what amounts such awards are granted to an employee include the employee&#8217;s position, his or her performance and responsibilities, the amount of stock options, restricted stock units and other stock awards currently held by the employee, the vesting schedules of any such stock options, restricted stock units and stock awards and the employee&#8217;s other compensation.  While we do not adhere to any firmly established formulas or schedules for the issuance of long-term stock-based incentive awards, we take into account, in making award decisions, the total direct compensation objectives described above.  In addition, we will generally tailor the terms of any such grant to achieve its goal as a long-term incentive award by providing for a vesting schedule encompassing several years.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, 2023, 2024 and 2025, the compensation committee approved a mix of annual stock option grants and restricted stock unit awards under our 2017 Equity Incentive Plan to eligible employees, with stock options comprising a larger portion of such mix in most years for executive and other officers.  In making such grants, the compensation committee considered corporate and individual performance in the prior year, total direct compensation objectives for individual officers, and information regarding stock incentive award grants made by other companies in the biopharmaceutical industry.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clawback Policy</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the requirements of the SEC and NASDAQ listing rules, the compensation committee adopted an incentive-based compensation clawback policy in October 2023. The policy generally provides that in the event we are required to prepare an accounting restatement of our financial statements due to our material noncompliance with any financial reporting requirement under securities laws, we will take reasonably prompt action to recoup all compensation that was granted, earned, vested or based upon the attainment of a financial reporting measure and received by any executive officer during the three-year period preceding the date that the restatement was required, to the extent such compensation exceeds the amount such executive officer would have received based on our restated financial statements.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-Term Stock-Based Incentive Awards in Relation to the Disclosure of Material Nonpublic Information</span></div><ix:nonNumeric contextRef="c-1" name="ecd:AwardTmgMnpiDiscTextBlock" id="f-6" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="ecd:AwardTmgMethodTextBlock" id="f-7" escape="true">Our long-term stock-based incentive awards are generally granted on <ix:nonNumeric contextRef="c-1" name="ecd:AwardTmgPredtrmndFlag" format="ixt:fixed-true" id="f-8">fixed dates determined in advance</ix:nonNumeric>. The compensation committee&#8217;s general practice is to complete its annual executive compensation review and determine target compensation for our executives, which coincides with our regularly scheduled meetings of the board of directors, then such long-term stock-based incentive awards are granted. Annual long-term stock-based incentive awards are typically granted to our executives in February of each fiscal year. On limited occasions, the compensation committee may grant long-term stock-based incentive awards outside of our annual grant cycle for new hires, promotions, recognition, retention, or other purposes. The compensation committee approves all long-term stock-based incentive award grants on or before the grant date and <ix:nonNumeric contextRef="c-1" name="ecd:AwardTmgMnpiCnsdrdFlag" format="ixt:fixed-true" id="f-9">does not grant</ix:nonNumeric> long-term stock-based incentive awards in anticipation of the release of material nonpublic information.</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="ecd:AwardTmgHowMnpiCnsdrdTextBlock" id="f-10" escape="true">Similarly, the compensation committee <ix:nonNumeric contextRef="c-1" name="ecd:MnpiDiscTimedForCompValFlag" format="ixt:fixed-false" id="f-11">does not time</ix:nonNumeric> the release of material nonpublic information based on long-term stock-based incentive award grant dates.</ix:nonNumeric></span></div></ix:nonNumeric><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary Compensation Table for 2024</span></div><div style="margin-bottom:7pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents summary information regarding the compensation of each of Michael S. Exton, Ph.D., our principal executive officer, and our three other most highly compensated executive officers who were serving as executive officers as of December 31, 2024.  The table also includes summary information regarding the compensation of Lonnel Coats, our principal executive officer until July 8, 2024, Jeffrey L. Wade, our principal financial officer until September 30, 2024, Kristen L. Alexander, our principal financial officer from October 1 until December 31, 2024, and Thomas A. Garner, our senior vice president and chief commercial officer until December 6, 2024.  We have entered into employment arrangements with certain of our named executive officers, the material terms of each of which are described below.</span></div><div style="margin-bottom:7pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the summary compensation information provided below, &#8220;Salary&#8221; accounted for approximately 21.5%, 26.9% and 23.7% of the total compensation paid to our named executive officers in 2024, 2023 and 2022, respectively, and &#8220;Bonus&#8221; accounted for approximately 4.6%, 11.3% and 11.3% of the total compensation paid to our named executive officers for 2024, 2023 and 2022, respectively.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:47.25pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:7pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:7pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"><tr><td style="width:1.0%"/><td style="width:24.571%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.452%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.004%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.855%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.337%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.098%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name and Position</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Salary</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Bonus</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock Awards </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Option</span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Awards </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">All Other</span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Compensation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Michael S. Exton, Ph.D.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">303,726&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">222,600&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,308,770&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">493&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,835,589&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Chief Executive Officer</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">and Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Brian T. Crum</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">473,503&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">125,442&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">447,544&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">366,947&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,171&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,430,607&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Senior Vice President and</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">457,936&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">122,404&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">243,899&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">580,897&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,139&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,421,275&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">General Counsel</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">438,989&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">155,015&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">250,528&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">590,686&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,099&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,450,317&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Craig B. Granowitz, M.D., Ph.D.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">501,686&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">199,373&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">478,762&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">392,543&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,019&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,588,383&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Senior Vice President and</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">487,628&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">149,650&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">260,909&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">621,431&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,205&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,534,823&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Chief Medical Officer</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">467,459&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">189,520&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">268,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">631,881&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,162&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,571,022&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Alan J. Main, Ph.D.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">457,802&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">123,372&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">440,170&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">360,901&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,278&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,396,523&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Executive Vice President,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">442,787&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">120,385&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">239,865&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">571,309&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,790&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,388,136&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Innovation and Chemical</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">426,169&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">152,457&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">246,400&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">580,928&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,775&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,418,729&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Sciences</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lonnel Coats</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">438,757&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,656,403&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,358,106&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59,507&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,512,773&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Former Chief Executive Officer</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">740,846&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">386,233&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">877,595&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,090,227&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,220&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,110,121&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">and Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">709,637&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">502,005&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">877,088&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,067,992&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,220&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,169,942&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Jeffrey L. Wade</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">485,525&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">675,788&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">977,247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">425,714&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,564,274&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Former President and Chief</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">535,729&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">200,097&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">358,036&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">852,786&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,220&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,962,868&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Financial Officer</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">513,354&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">260,075&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">357,824&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">843,690&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,220&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,990,163&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Kristen L. Alexander</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">295,588&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67,409&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">128,269&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">105,169&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,810&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">613,245&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Vice President, Finance and</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">285,359&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67,463&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">116,105&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">138,269&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,788&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">622,984&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Accounting</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">269,867&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82,044&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101,920&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">120,164&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,756&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">588,751&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thomas A. Garner</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">471,032&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">488,330&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">400,387&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">627,676&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,987,425&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Former Senior Vice President</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">214,564&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">276,119&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">219,003&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">568&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">710,254&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">and Chief Commercial Officer</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Reflects the aggregate grant date fair value, computed in accordance with FASB ASC Topic 718, of stock awards granted in 2024, 2023 and 2022, in each case based on the market price of our common stock on the date of grant, calculated in accordance with the process for determination of fair market value under our 2017 Equity Incentive Plan.</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Reflects the aggregate grant date fair value, computed in accordance with FASB ASC Topic 718, of stock options granted in 2024, 2023 and 2022. See the information appearing under the heading entitled &#8220;Stock-Based Compensation&#8221; in footnote 2 to our consolidated financial statements included as part of our Annual Report on Form 10-K for the year ended December 31, 2024 for certain assumptions made in the valuation of such stock options.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:47.25pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Includes the following amounts in respect of company matching contributions under our 401(k) plan, individual health savings accounts and company-paid premiums for group term life insurance.  The company-paid life insurance premiums reflect payments for group term life policies maintained for the benefit of all employees. </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.233%"><tr><td style="width:1.0%"/><td style="width:32.347%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.686%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.333%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.029%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.851%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.858%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.366%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.858%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.372%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Company 401(k)</span></div><div style="margin-top:0.1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Matching Contribution</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Company Health Savings Account</span></div><div style="margin-top:0.1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Matching Contribution</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Company-Paid</span></div><div style="margin-top:0.1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Group Term</span></div><div style="margin-top:0.1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Life Insurance Premiums</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Michael S. Exton, Ph.D.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">493&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Brian T. Crum</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">971&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,200&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">939&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,200&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">899&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Craig B. Granowitz, M.D., Ph.D.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,019&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,200&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,005&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,200&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">962&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Alan J. Main, Ph.D.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">478&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,200&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">590&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,200&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">575&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lonnel Coats</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">650&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">524&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,200&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,020&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,200&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,020&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Jeffrey L. Wade</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">764&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,200&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,020&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,200&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,020&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Kristen L. Alexander</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">610&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,200&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">588&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,200&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">556&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Thomas A. Garner</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">950&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">235&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Includes $44,533 as compensation for his unused paid time off which had accrued at the time of his retirement, which was calculated and paid to Mr. Coats in accordance with our policies applicable to all employees.</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Includes (a) $67,500 as compensation for his unused paid time off which had accrued at the time of his termination of employment and paid to Mr. Wade pursuant to his employment agreement, (b) $332,850 in salary continuation and other payments paid to Mr. Wade in 2024 pursuant to his separation agreement and (c) $9,000 in consulting fees paid to Mr. Wade in 2024 pursuant to his consulting agreement.  Does not include $472,050 in salary continuation and other payments payable to Mr. Wade in 2025 pursuant to his separation agreement and $15,000 in consulting fees payable to Mr. Wade in 2025 pursuant to his consulting agreement.</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Includes $610,626 in severance payments paid to Mr. Garner pursuant to his separation agreement.</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employment Arrangements</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="margin-bottom:7pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Michael S. Exton, Ph.D.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  In July 2024, we entered into an offer letter with Michael S. Exton, Ph.D. to serve as our chief executive officer.  Under the offer letter, Dr. Exton receives a base salary, currently $658,260 a year, subject to adjustment, with an annual discretionary bonus based upon specific objectives to be determined by the compensation committee.  The compensation committee has established a current bonus target for Dr. Exton of 70% of his base salary, subject to adjustment.  The offer letter provides for certain severance payments upon the termination of Dr. Exton&#8217;s employment and Dr. Exton separately participates in our management severance plan, each as described below under the heading &#8220;Executive and Director Compensation&#160;- Potential Payments upon Termination or Change in Control.&#8221;</span></div><div style="margin-bottom:7pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Brian T. Crum.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  In November 2001, we entered into an offer letter with Brian T. Crum to serve as our senior corporate counsel.  Mr. Crum has served as senior vice president and general counsel since October 2021. Under the offer letter, Mr. Crum receives a base salary, currently $494,600 a year, subject to adjustment, with an annual discretionary bonus based upon specific objectives to be determined by the compensation committee. The compensation committee has established a current bonus target for Mr. Crum of 35% of his base salary, subject to adjustment.  Mr. Crum participates in our management severance plan, as described below under the heading &#8220;Executive and Director Compensation&#160;- Potential Payments upon Termination or Change in Control.&#8221;</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Craig B. Granowitz, M.D., Ph.D.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  In July 2021, we entered into an offer letter with Craig B. Granowitz, M.D., Ph.D., to serve as our senior vice president and chief medical officer.  Under the offer letter, Dr. Granowitz receives a base salary, currently $529,104 a year, subject to adjustment, with an annual discretionary bonus based upon specific objectives to be determined by the compensation committee.  The compensation committee has established a current bonus target for Dr. Granowitz of 40% of his base salary, subject to adjustment.  The offer letter provides for certain severance payments upon the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:47.25pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">termination of Dr. Granowitz&#8217;s employment and Dr. Granowitz separately participates in our management severance plan, each as described below under the heading &#8220;Executive and Director Compensation&#160;- Potential Payments upon Termination or Change in Control.&#8221;</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:7pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Alan J. Main, Ph.D.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  In July 2001, we entered into an employment agreement with Alan J. Main, Ph.D. to serve as our senior vice president, Lexicon Pharmaceuticals.  Dr. Main has served as our executive vice president, innovation and chemical sciences since September 2020.  Under the employment agreement, Dr. Main receives a base salary, currently $486,437 a year, subject to adjustment, with an annual discretionary bonus based upon specific objectives to be determined by the compensation committee.  The compensation committee has established a current bonus target for Dr. Main of 35% of his base salary, subject to adjustment.  The employment agreement is at-will and contains a non-competition agreement.  The employment agreement also provides for certain severance payments upon the termination of Dr. Main&#8217;s employment and Dr. Main separately participates in our management severance plan, each as described below under the heading &#8220;Executive and Director Compensation&#160;- Potential Payments upon Termination or Change in Control.&#8221;</span></div><div style="margin-bottom:7pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lonnel Coats</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  In July 2014, we entered into an offer letter with Lonnel Coats to serve as our president and chief executive officer.  Mr. Coats had served as chief executive officer since October 2021.  Under the offer letter, Mr. Coats received a base salary with an annual discretionary bonus based upon specific objectives to be determined by the compensation committee.  The offer letter also provided for certain severance payments upon the termination of Mr. Coats&#8217; employment.  Mr. Coats retired from such position in July 2024 and no severance payments were payable in connection with his retirement.</span></div><div style="margin-bottom:7pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Jeffrey L. Wade.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 1998, we entered into an employment agreement with Jeffrey L. Wade to serve as our senior vice president and chief financial officer starting in January 1999.  Mr. Wade had served as president and chief financial officer since October 2021.  Under the employment agreement, Mr. Wade received a base salary with an annual discretionary bonus based upon specific objectives to be determined by the compensation committee.  The employment agreement was at-will and provided for certain severance payments upon the termination of Mr. Wade&#8217;s employment.  In connection with the termination of his employment in September 2024, we entered into a separation agreement with Mr. Wade providing for certain salary continuation and other payments in lieu of those contained in his employment agreement, as described below under the heading &#8220;Executive and Director Compensation - Potential Payments upon Termination or Change in Control.&#8221;  We also entered into a consulting agreement with Mr. Wade in September 2024 pursuant to which he is providing his consulting and advisory services for a period of eight months and we are paying Mr. Wade fees of $3,000 per month.</span></div><div style="margin-bottom:7pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Kristen L. Alexander</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  In May 2017, we entered into an offer letter with Kristen L. Alexander to serve as our controller.  Ms. Alexander has served as vice president, finance and accounting, since September 2021.  Under the offer letter, Ms. Alexander received a base salary, currently $310,078 a year, subject to adjustment, with an annual discretionary bonus based upon specific objectives to be determined by the compensation committee.  The compensation committee has established a current bonus target for Ms. Alexander of 30% of her base salary, subject to adjustment.  Ms. Alexander participates in our management severance plan, as described below under the heading &#8220;Executive and Director Compensation&#160;- Potential Payments upon Termination or Change in Control.&#8221;</span></div><div style="margin-bottom:7pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Thomas A. Garner</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  In October 2023, we entered into an offer letter with Thomas A. Garner to serve as our senior vice president and chief commercial officer.  Under the offer letter, Mr. Garner received a base salary with an annual discretionary bonus based upon specific objectives to be determined by the compensation committee.  The offer letter also provided for certain severance payments upon the termination of Mr. Garner&#8217;s employment.  In connection with the termination of his employment in December 2024, we entered into a separation agreement with Mr. Garner providing for certain severance and other payments in lieu of those contained in his offer letter, as described below under the heading &#8220;Executive and Director Compensation - Potential Payments upon Termination or Change in Control.&#8221;</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pay Ratio</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As required by Section 953(b) of the Dodd-Frank Wall Street Reform and Consumer Protection Act, we are providing the following information regarding the annual total compensation of our chief executive officer and our employees:</span></div><div style="margin-bottom:5pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">As disclosed in the Summary Compensation Table above, the annual total compensation of Michael S. Exton, Ph.D., our chief executive officer, was $2,835,589 in 2024, or $3,168,387 on an annualized basis; and</span></div><div style="margin-bottom:5pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The annual total compensation of the employee identified as the median compensated employee of our company (other than Dr. Exton) was $304,524 in 2024.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on this information, the ratio of the annualized total compensation of Dr. Exton to the median of the annual total compensation of all employees was 10 to 1.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:47.25pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We identified our median compensated employee using our total employee population as of December 31, 2024 and consistently applying payroll records reflecting taxable wages for 2024.  In making this identification, we annualized the compensation of all permanent employees who were newly hired during 2024.  We did not use any material estimates, assumptions, adjustments or statistical sampling to identify our median compensated employee.  Once identified, we calculated the annual total compensation of our median compensated employee in a manner consistent with that used to calculate the annual total compensation of Dr. Exton and disclosed in the Summary Compensation Table above.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SEC rules for identifying the median compensated employee and calculating the pay ratio based on that employee&#8217;s annual total compensation allow companies to adopt a variety of methodologies, apply certain exclusions and make reasonable estimates and assumptions that reflect their compensation practices.  As such, the pay ratio reported by other companies may not be comparable to the pay ratio reported above, as other companies may have different employment and compensation practices and may utilize different methodologies, exclusions, estimates and assumptions in calculating their pay ratios.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pay Versus Performance</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents compensation information for Lonnel Coats, who served as our chief executive officer during 2024, 2023 and 2022, and Michael S. Exton, Ph.D., who served as our chief executive officer during 2024, and average compensation information for the other individuals named in the summary compensation table for such years, as well as certain measures relating to company performance.</span></div><ix:nonNumeric contextRef="c-1" name="ecd:PvpTableTextBlock" id="f-12" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.625%"><tr><td style="width:1.0%"/><td style="width:5.368%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.499%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.564%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.674%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.913%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.499%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.913%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.499%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.913%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.499%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.913%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.499%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.913%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.499%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.913%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.499%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.923%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Summary Compensation Table Total for First PEO </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3.9pt;font-weight:700;line-height:100%;position:relative;top:-2.1pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Compensation Actually Paid to First PEO </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3.9pt;font-weight:700;line-height:100%;position:relative;top:-2.1pt;vertical-align:baseline">(1) (3)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Summary Compensation Table Total for Second PEO </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3.9pt;font-weight:700;line-height:100%;position:relative;top:-2.1pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Compensation Actually Paid to Second</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&#160;PEO </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3.9pt;font-weight:700;line-height:100%;position:relative;top:-2.1pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3.9pt;font-weight:700;line-height:100%;position:relative;top:-2.1pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Average Summary Compensation Table Total for Non-PEO</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&#160;NEOs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3.9pt;font-weight:700;line-height:100%;position:relative;top:-2.1pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Average Compensation Actually Paid to Non-PEO</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&#160;NEOs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3.9pt;font-weight:700;line-height:100%;position:relative;top:-2.1pt;vertical-align:baseline">(2) (5)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Value of Initial Fixed $100 Investment Based on Total Shareholder Return</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Net Income </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3.9pt;font-weight:700;line-height:100%;position:relative;top:-2.1pt;vertical-align:baseline">(6)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="0" name="ecd:PeoTotalCompAmt" format="ixt:num-dot-decimal" scale="0" id="f-13">3,467,590</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="0" sign="-" name="ecd:PeoActuallyPaidCompAmt" format="ixt:num-dot-decimal" scale="0" id="f-14">884,853</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="ecd:PeoTotalCompAmt" format="ixt:num-dot-decimal" scale="0" id="f-15">2,835,589</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="ecd:PeoActuallyPaidCompAmt" format="ixt:num-dot-decimal" scale="0" id="f-16">1,616,932</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="ecd:NonPeoNeoAvgTotalCompAmt" format="ixt:num-dot-decimal" scale="0" id="f-17">1,598,976</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="ecd:NonPeoNeoAvgCompActuallyPaidAmt" format="ixt:num-dot-decimal" scale="0" id="f-18">878,167</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="ecd:TotalShareholderRtnAmt" scale="0" id="f-19">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-20">200,403</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="ecd:PeoTotalCompAmt" format="ixt:num-dot-decimal" scale="0" id="f-21">4,110,121</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="ecd:PeoActuallyPaidCompAmt" format="ixt:num-dot-decimal" scale="0" id="f-22">3,055,451</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="ecd:NonPeoNeoAvgTotalCompAmt" format="ixt:num-dot-decimal" scale="0" id="f-23">1,576,776</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="ecd:NonPeoNeoAvgCompActuallyPaidAmt" format="ixt:num-dot-decimal" scale="0" id="f-24">1,233,210</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="ecd:TotalShareholderRtnAmt" scale="0" id="f-25">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-26">177,119</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="ecd:PeoTotalCompAmt" format="ixt:num-dot-decimal" scale="0" id="f-27">4,169,942</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="ecd:PeoActuallyPaidCompAmt" format="ixt:num-dot-decimal" scale="0" id="f-28">1,203,063</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="ecd:NonPeoNeoAvgTotalCompAmt" format="ixt:num-dot-decimal" scale="0" id="f-29">1,622,119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="ecd:NonPeoNeoAvgCompActuallyPaidAmt" format="ixt:num-dot-decimal" scale="0" id="f-30">828,645</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="ecd:TotalShareholderRtnAmt" scale="0" id="f-31">48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-32">101,944</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________</span></div><div style="margin-bottom:9pt;padding-left:22.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><ix:nonNumeric contextRef="c-1" name="ecd:NamedExecutiveOfficersFnTextBlock" id="f-33" continuedAt="f-33-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For 2024, our principal executive officers were <ix:nonNumeric contextRef="c-2" name="ecd:PeoName" id="f-34">Lonnel Coats</ix:nonNumeric> and <ix:nonNumeric contextRef="c-3" name="ecd:PeoName" id="f-35">Michael S. Exton, Ph.D</ix:nonNumeric>.  For 2023 and 2022, our principal executive officer was <ix:nonNumeric contextRef="c-5" name="ecd:PeoName" id="f-36"><ix:nonNumeric contextRef="c-4" name="ecd:PeoName" id="f-37">Lonnel Coats</ix:nonNumeric></ix:nonNumeric>.</span></ix:nonNumeric></div><ix:continuation id="f-33-1"><div style="margin-bottom:9pt;padding-left:22.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For 2024, our other named executive officers were Brian T. Crum, Craig B. Granowitz, M.D., Ph.D., Alan J. Main, Ph.D., Jeffrey L. Wade, Kristen L. Alexander and Thomas A. Garner.  For 2023, our other named executive officers were Jeffrey L. Wade, Brian T. Crum, Craig B. Granowitz, M.D., Ph.D and Alan J. Main, Ph.D.  For 2022, our other named executive officers were Jeffrey L. Wade, Brian T. Crum, Craig B. Granowitz, M.D., Ph.D. and Kenneth B. Kassler-Taub, M.D.</span></div></ix:continuation><div style="margin-bottom:3pt;margin-top:3pt;padding-left:22.5pt;text-align:justify;text-indent:-20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="ecd:AdjToPeoCompFnTextBlock" id="f-38" continuedAt="f-38-1" escape="true">The following table sets forth the adjustments made during each year to calculate Compensation Actually Paid to our first principal executive officer.</ix:nonNumeric></span></div><ix:continuation id="f-38-1"><div style="margin-bottom:9pt;padding-left:22.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"/><td style="width:70.021%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.116%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.414%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.116%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.414%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.119%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Summary Compensation Table Totals for First PEO</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="0" name="ecd:PeoTotalCompAmt" format="ixt:num-dot-decimal" scale="0" id="f-39">3,467,590</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="ecd:PeoTotalCompAmt" format="ixt:num-dot-decimal" scale="0" id="f-40">4,110,121</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="ecd:PeoTotalCompAmt" format="ixt:num-dot-decimal" scale="0" id="f-41">4,169,942</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Add (Subtract):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#160;&#160;&#160;Fair value of equity awards granted during the year from the Summary Compensation Table</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" sign="-" name="ecd:AdjToCompAmt" format="ixt:num-dot-decimal" scale="0" id="f-42">3,014,509</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" sign="-" name="ecd:AdjToCompAmt" format="ixt:num-dot-decimal" scale="0" id="f-43">2,967,821</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="0" sign="-" name="ecd:AdjToCompAmt" format="ixt:num-dot-decimal" scale="0" id="f-44">2,945,080</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#160;&#160;&#160;Fair value at year end of equity awards granted during the year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="0" name="ecd:AdjToCompAmt" format="ixt:fixed-zero" scale="0" id="f-45">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="0" name="ecd:AdjToCompAmt" format="ixt:num-dot-decimal" scale="0" id="f-46">1,989,880</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" name="ecd:AdjToCompAmt" format="ixt:num-dot-decimal" scale="0" id="f-47">1,847,145</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#160;&#160;&#160;Change in fair value of equity awards granted in prior years that were unvested as of the end of the year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="ecd:AdjToCompAmt" format="ixt:fixed-zero" scale="0" id="f-48">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" sign="-" name="ecd:AdjToCompAmt" format="ixt:num-dot-decimal" scale="0" id="f-49">283,105</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="0" sign="-" name="ecd:AdjToCompAmt" format="ixt:num-dot-decimal" scale="0" id="f-50">1,003,687</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#160;&#160;&#160;Change in fair value of equity awards granted in prior years that vested during the year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="0" name="ecd:AdjToCompAmt" format="ixt:num-dot-decimal" scale="0" id="f-51">608,241</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="0" name="ecd:AdjToCompAmt" format="ixt:num-dot-decimal" scale="0" id="f-52">206,376</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="0" sign="-" name="ecd:AdjToCompAmt" format="ixt:num-dot-decimal" scale="0" id="f-53">865,257</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#160;&#160;&#160;Equity awards granted in prior years that were forfeited during the year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="0" sign="-" name="ecd:AdjToCompAmt" format="ixt:num-dot-decimal" scale="0" id="f-54">1,946,175</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="0" name="ecd:AdjToCompAmt" format="ixt:fixed-zero" scale="0" id="f-55">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="0" name="ecd:AdjToCompAmt" format="ixt:fixed-zero" scale="0" id="f-56">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Compensation Actually Paid Totals</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="0" sign="-" name="ecd:PeoActuallyPaidCompAmt" format="ixt:num-dot-decimal" scale="0" id="f-57">884,853</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="ecd:PeoActuallyPaidCompAmt" format="ixt:num-dot-decimal" scale="0" id="f-58">3,055,451</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="ecd:PeoActuallyPaidCompAmt" format="ixt:num-dot-decimal" scale="0" id="f-59">1,203,063</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:22.5pt;text-align:justify;text-indent:-20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The following table sets forth the adjustments made during each year to calculate Compensation Actually Paid to our second principal executive officer.</span></div><div style="margin-bottom:9pt;padding-left:22.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.461%"><tr><td style="width:1.0%"/><td style="width:87.427%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.373%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2024</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Summary Compensation Table Totals for Second PEO</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="ecd:PeoTotalCompAmt" format="ixt:num-dot-decimal" scale="0" id="f-60">2,835,589</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Add (Subtract):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#160;&#160;&#160;Fair value of equity awards granted during the year from the Summary Compensation Table</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="0" sign="-" name="ecd:AdjToCompAmt" format="ixt:num-dot-decimal" scale="0" id="f-61">2,308,770</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#160;&#160;&#160;Fair value at year end of equity awards granted during the year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="0" name="ecd:AdjToCompAmt" format="ixt:num-dot-decimal" scale="0" id="f-62">1,090,113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#160;&#160;&#160;Change in fair value of equity awards granted in prior years that were unvested as of the end of the year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="0" name="ecd:AdjToCompAmt" format="ixt:fixed-zero" scale="0" id="f-63">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#160;&#160;&#160;Change in fair value of equity awards granted in prior years that vested during the year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="0" name="ecd:AdjToCompAmt" format="ixt:fixed-zero" scale="0" id="f-64">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#160;&#160;&#160;Equity awards granted in prior years that were forfeited during the year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="0" name="ecd:AdjToCompAmt" format="ixt:fixed-zero" scale="0" id="f-65">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Compensation Actually Paid Totals</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="ecd:PeoActuallyPaidCompAmt" format="ixt:num-dot-decimal" scale="0" id="f-66">1,616,932</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:47.25pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:22.5pt;text-align:justify;text-indent:-20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="ecd:AdjToNonPeoNeoCompFnTextBlock" id="f-67" continuedAt="f-67-1" escape="true">The following table sets forth the adjustments made during each year to calculate Average Compensation Actually Paid to our other named executive officers. </ix:nonNumeric></span></div><ix:continuation id="f-67-1"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.444%"><tr><td style="width:1.0%"/><td style="width:69.797%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.187%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.419%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.187%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.419%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.191%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Average Summary Compensation Table Totals for Non-PEO NEOs</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="ecd:NonPeoNeoAvgTotalCompAmt" format="ixt:num-dot-decimal" scale="0" id="f-68">1,598,976</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="ecd:NonPeoNeoAvgTotalCompAmt" format="ixt:num-dot-decimal" scale="0" id="f-69">1,576,776</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="ecd:NonPeoNeoAvgTotalCompAmt" format="ixt:num-dot-decimal" scale="0" id="f-70">1,622,119</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Add (Subtract):</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#160;&#160;&#160;Fair value of equity awards granted during the year from the Summary Compensation Table</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="0" sign="-" name="ecd:AdjToCompAmt" format="ixt:num-dot-decimal" scale="0" id="f-71">877,009</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="0" sign="-" name="ecd:AdjToCompAmt" format="ixt:num-dot-decimal" scale="0" id="f-72">932,283</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="0" sign="-" name="ecd:AdjToCompAmt" format="ixt:num-dot-decimal" scale="0" id="f-73">957,722</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#160;&#160;&#160;Fair value at year end of equity awards granted during the year </span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="0" name="ecd:AdjToCompAmt" format="ixt:num-dot-decimal" scale="0" id="f-74">263,789</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="0" name="ecd:AdjToCompAmt" format="ixt:num-dot-decimal" scale="0" id="f-75">625,082</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="0" name="ecd:AdjToCompAmt" format="ixt:num-dot-decimal" scale="0" id="f-76">600,680</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#160;&#160;&#160;Change in fair value of equity awards granted in prior years that were unvested as of the end of the year</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-32" decimals="0" sign="-" name="ecd:AdjToCompAmt" format="ixt:num-dot-decimal" scale="0" id="f-77">198,031</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-33" decimals="0" sign="-" name="ecd:AdjToCompAmt" format="ixt:num-dot-decimal" scale="0" id="f-78">94,405</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-34" decimals="0" sign="-" name="ecd:AdjToCompAmt" format="ixt:num-dot-decimal" scale="0" id="f-79">260,725</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#160;&#160;&#160;Change in fair value of equity awards granted in prior years that vested during the year</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="0" name="ecd:AdjToCompAmt" format="ixt:num-dot-decimal" scale="0" id="f-80">130,573</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="0" name="ecd:AdjToCompAmt" format="ixt:num-dot-decimal" scale="0" id="f-81">58,040</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-37" decimals="0" sign="-" name="ecd:AdjToCompAmt" format="ixt:num-dot-decimal" scale="0" id="f-82">175,708</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#160;&#160;&#160;Equity awards granted in prior years that were forfeited during the year</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-38" decimals="0" sign="-" name="ecd:AdjToCompAmt" format="ixt:num-dot-decimal" scale="0" id="f-83">40,132</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="0" name="ecd:AdjToCompAmt" format="ixt:fixed-zero" scale="0" id="f-84">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="0" name="ecd:AdjToCompAmt" format="ixt:fixed-zero" scale="0" id="f-85">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Average Compensation Actually Paid Totals</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="ecd:NonPeoNeoAvgCompActuallyPaidAmt" format="ixt:num-dot-decimal" scale="0" id="f-86">878,167</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="ecd:NonPeoNeoAvgCompActuallyPaidAmt" format="ixt:num-dot-decimal" scale="0" id="f-87">1,233,210</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="ecd:NonPeoNeoAvgCompActuallyPaidAmt" format="ixt:num-dot-decimal" scale="0" id="f-88">828,645</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-bottom:3pt;margin-top:3pt;padding-left:22.5pt;text-align:justify;text-indent:-20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><ix:nonNumeric contextRef="c-1" name="ecd:Additional402vDisclosureTextBlock" id="f-89" continuedAt="f-89-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In thousands.</span></ix:nonNumeric></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="ecd:CompActuallyPaidVsTotalShareholderRtnTextBlock" id="f-91" escape="true"><ix:nonNumeric contextRef="c-1" name="ecd:CompActuallyPaidVsTotalShareholderRtnTextBlock" id="f-90" escape="true">From 2022 to 2023, compensation actually paid to Mr. Coats as described in the pay versus performance table increased 154.0%, average compensation actually paid to our other named executive officers as described in the pay versus performance table increased 48.8%, our total shareholder return decreased 19.9% and our net income decreased 73.7%.  From 2023 to 2024, compensation actually paid to Mr. Coats and Dr. Exton as described in the pay versus performance table decreased 76.0%, average compensation actually paid to our other named executive officers as described in the pay versus performance table decreased 28.8%, our total shareholder return decreased 51.6% and our net income decreased 13.1%.</ix:nonNumeric></ix:nonNumeric>  </span></div><ix:continuation id="f-89-1"><div style="margin-bottom:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in compensation actually paid to Mr. Coats, Dr. Exton and our other named executive officers during such periods as described in the pay versus performance table were largely driven by equity award related adjustments as a result of turnover among our named executive officers and the volatility in the market price of our common stock, and to a lesser extent by variability in annual salary, bonus and equity incentive awards.  As a result, such changes are not directly related to the changes in our total shareholder return and net income during such periods.</span></div></ix:continuation><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Grants of Plan-Based Awards in 2024</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents each grant of restricted stock units and stock options in 2024 to the individuals named in the summary compensation table.</span></div><div style="text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.169%"><tr><td style="width:1.0%"/><td style="width:31.913%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.840%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.335%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.951%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.759%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.416%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.335%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.456%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.143%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.452%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Name</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Grant Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Restricted Stock Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Securities Underlying Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise Price of Option Awards</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Grant Date Fair Value of Stock and Option Awards</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Michael S. Exton, Ph.D.</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7/8/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,675,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.67</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,308,770&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Brian T. Crum</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/8/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">208,160&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">447,544&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/8/2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">208,160&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.15&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">366,947&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Craig B. Granowitz, M.D., Ph.D.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/8/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">222,680&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">478,762&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/8/2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">222,680&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.15&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">392,543&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Alan J. Main, Ph.D.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/8/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">204,730&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">440,170&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/8/2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">204,730&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.15&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">360,901&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lonnel Coats</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/8/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">770,420&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,656,403&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/8/2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">770,420&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.15&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,358,106&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Jeffrey L. Wade</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/8/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">314,320&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">675,788&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/8/2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">314,320&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.15&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">554,087&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7/8/2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">307,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.67&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">423,160&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Kristen L. Alexander</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/8/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59,660&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">128,269&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/8/2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59,660&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.15&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">105,169&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thomas A. Garner</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/8/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">227,130&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">488,330&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/8/2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">227,130&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.15&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">400,387&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of the restricted stock units in the foregoing table was granted under our 2017 Equity Incentive Plan.  Each restricted stock unit vested with respect to one third of the shares underlying the restricted stock unit on February 28, 2025 and will vest with respect to an additional one third of the shares underlying the restricted stock unit on February 28 of each of the two following years.  Each restricted stock unit becomes fully vested upon the termination of the named executive officer&#8217;s employment by us without cause or by the named executive officer for good reason, in either case following a change in control of our company.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:47.25pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of the stock options in the foregoing table was granted under our 2017 Equity Incentive Plan and expires on the tenth anniversary of the grant date.  Each option vests with respect to 25% of the shares underlying the option on the first anniversary of the grant date and 1/48</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> per month for each month of service thereafter.  Each option becomes fully vested with respect to all remaining unvested shares upon a change in control of our company.  In accordance with the process for determination of fair market value under the plan, the exercise price for each stock option is equal to the closing price of our common stock, as quoted on the Nasdaq Global Select Market, on the last trading day prior to the grant date.  The exercise price for each stock option may be paid in cash or in shares of our common stock valued at fair market value on the exercise date or through a cashless exercise procedure involving a same-day sale of the purchased shares.</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Outstanding Equity Awards at December 31, 2024</span></div><div style="margin-bottom:7pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents information about unexercised stock options and unvested restricted stock units that were held by each of the individuals listed in the summary compensation table as of December 31, 2024. No exercised stock options or unvested restricted stock units were held by Mr. Coats as of December 31, 2024.</span></div><div style="margin-bottom:7pt;text-align:justify;text-indent:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.719%"><tr><td style="width:1.0%"/><td style="width:28.733%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.133%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.133%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.133%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.133%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.133%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.571%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Option Awards</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Stock Awards</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number of</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Market Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Restricted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">of Restricted</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number of Securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Option</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Option</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Stock Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Stock Units</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Underlying Unexercised Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Exercise</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Expiration</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">That Have</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">That Have</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Exercisable</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unexercisable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Not Vested </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Not Vested </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(3)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Michael S. Exton, Ph.D.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,675,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.67&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7/8/2034</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Brian T. Crum</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,391&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/5/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,470&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.20&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/11/2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,160&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14.44&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/9/2027</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,040&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.79&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/8/2028</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49,950&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.16&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/7/2029</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">189,260&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.31&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/6/2030</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75,480&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,280&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.38&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/11/2031</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">166,368&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68,502&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.20&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/10/2032</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">138,006&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">163,094&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.43&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/9/2033</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">208,160&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.15&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/8/2034</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,097&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,273&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66,913&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49,415&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">208,160&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">153,726&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160; </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160; </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Craig B. Granowitz, M.D., Ph.D.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">208,336&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,664&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8/2/2031</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160; </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">177,974&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73,276&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.20&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/10/2032</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">147,638&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">174,472&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.43&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/9/2033</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">222,680&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.15&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/8/2034</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,917&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,617&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71,580&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52,862&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">222,680&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">164,449&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Alan J. Main, Ph.D.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84,342&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/5/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65,340&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.20&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/11/2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,960&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14.44&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/9/2027</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69,940&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.79&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/8/2028</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">124,640&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.16&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/7/2029</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">209,700&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.31&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/6/2030</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77,416&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,364&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.38&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/11/2031</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">163,622&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67,368&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.20&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/10/2032</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">135,733&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">160,397&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.43&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/9/2033</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">204,730&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.15&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/8/2034</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,667&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,955&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65,807&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48,598&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">204,730&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">151,193&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Jeffrey L. Wade</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">92,914&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/5/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71,940&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.20&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/11/2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,770&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14.44&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/9/2027</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79,550&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.79&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/8/2028</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:47.25pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:7pt;text-align:justify;text-indent:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.719%"><tr><td style="width:1.0%"/><td style="width:28.733%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.133%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.133%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.133%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.133%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.133%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.571%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Option Awards</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Stock Awards</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number of</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Market Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Restricted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">of Restricted</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number of Securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Option</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Option</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Stock Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Stock Units</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Underlying Unexercised Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Exercise</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Expiration</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">That Have</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">That Have</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Exercisable</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unexercisable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Not Vested </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Not Vested </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(3)</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">140,900&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.16&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/7/2029</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">274,200&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.31&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/6/2030</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96,410&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,190&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.38&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/11/2031</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">237,626&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97,844&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.20&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/10/2032</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">202,598&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">239,432&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.43&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/9/2033</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">314,320&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.15&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/8/2034</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">307,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.67&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7/8/2034</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,273&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,526&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98,227&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72,541&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">314,320&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">232,125&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Kristen L. Alexander</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,184&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6/12/2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.79&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/8/2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,800&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.16&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/7/2029</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,800&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.31&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/6/2030</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,834&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">166&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.38&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/11/2031</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,850&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,930&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.20&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/10/2032</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,852&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,818&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.43&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/9/2033</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59,660&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.15&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/8/2034</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,617&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,841&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,853&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,523&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59,660&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,059&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thomas A. Garner</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67,417&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.08&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12/6/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:22.5pt;text-align:justify;text-indent:-20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Each stock option vests with respect to 25% of the shares underlying the stock option on the first anniversary of the grant date and 1/48</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> per month for each month of service thereafter.</span></div><div style="margin-bottom:3pt;padding-left:22.5pt;text-align:justify;text-indent:-20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Each restricted stock unit vests with respect to one third of the shares underlying the restricted stock unit on February 28 of each of the three years following the year of grant.</span></div><div style="margin-bottom:7pt;padding-left:22.5pt;text-align:justify;text-indent:-20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Based on the closing price of our common stock on the Nasdaq Global Select Market of $0.7385 per share on December&#160;31, 2024.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Option Exercises and Stock Vested in 2024</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents information about stock option exercises and the vesting of restricted stock units in 2024 for each of the individuals listed in the summary compensation table.  Amounts shown under the columns &#8220;Value Realized on Exercise&#8221; and &#8220;Value Realized on Vesting&#8221; are based on the market price of our common stock on the date of exercise or vesting, as applicable, calculated in accordance with the process for determination of fair market value under our 2017 Equity Incentive Plan, without taking into account any taxes that may be payable in connection with the exercise or vesting event, subsequent sale of shares or any shares retained by us in satisfaction of any withholding obligations relating to such taxes.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.643%"><tr><td style="width:1.0%"/><td style="width:33.254%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.574%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.158%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.251%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.190%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.574%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.096%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Option Awards</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock Awards</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares Acquired on Exercise</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value Realized on Exercise </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares Acquired on Vesting</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value Realized on Vesting </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Michael S. Exton, Ph.D.</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Brian T. Crum</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68,303&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">178,954&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Craig B. Granowitz, M.D., Ph.D.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63,706&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">166,910&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Alan J. Main, Ph.D.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67,546&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">176,971&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lonnel Coats</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">245,080&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">642,110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Jeffrey L. Wade</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97,564&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">255,618&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Kristen L. Alexander</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,243&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76,617&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Thomas A. Garner</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:47.25pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Based on the closing price of our common stock on the Nasdaq Global Select Market of $2.62 per share on February 27, 2024, the last trading day prior to the date of vesting.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Potential Payments upon Termination or Change in Control</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Offer Letters and Employment Agreements</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Michael S. Exton, Ph.D.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Our offer letter with Dr. Exton provided that if we terminated Dr. Exton&#8217;s employment without &#8220;cause,&#8221; we would pay Dr. Exton his then-current salary for twelve months pursuant to our normal payroll procedures.  If such termination was in connection with a &#8220;change in control,&#8221; we would pay Dr. Exton an additional one-time payment equal to his bonus target for the year of termination.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Craig B. Granowitz, M.D., Ph.D.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Our offer letter with Dr. Granowitz provided that if we terminated his employment without &#8220;cause,&#8221; we would pay Dr. Granowitz his then-current salary for six months pursuant to our normal payroll procedures.  Such payments would be extended to twelve months if Dr. Granowitz&#8217;s employment was terminated without &#8220;cause&#8221; in connection with a &#8220;change in control.&#8221;</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Alan J. Main, Ph.D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Our employment agreement with Dr. Main provided that if we terminated his employment without &#8220;cause&#8221; or if Dr. Main terminated his employment for &#8220;good reason,&#8221; we would pay Dr. Main his then-current salary for twelve months pursuant to our normal payroll procedures, plus an additional single sum payment equal to 50% of his target bonus for the year in which the termination occurred. If his employment was terminated at the end of any renewal term through notice of non-renewal, we would pay Dr. Main his then-current salary for six months pursuant to our normal payroll procedures.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management Severance Plan</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2025, the compensation committee adopted a management severance plan, which will provide severance payments and benefits to our executive officers in connection with certain terminations of employment.  The terms of the plan supersede all potential severance payments and benefits contained within executive officers&#8217; individual offer letters and employment agreements.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the plan, in the event that an executive officer&#8217;s employment is terminated by us without &#8220;cause&#8221; or resigns for &#8220;good reason,&#8221; if the executive officer signs a release of all claims, then the executive officer would be entitled to lump sum payments equal to (a) 12 months of current base salary, (b) pro-rated amount of current target cash bonus (only if such termination occurs between September 1 and December&#160;31) and (c) an amount approximating 12 months of COBRA premiums for continued coverage under our group health plans, less the employee contribution amount that our similarly situated employees pay for such coverage (only if the executive officer is enrolled in our group health plans and elects to continue such coverage).  In the event that such termination of employment occurs within the 24-month period following a &#8220;change in control,&#8221; if the executive officer signs a release of all claims, then the executive officer would be entitled to lump sum payments equal to (x) 12 months of current base salary (or 18 months of current base salary in the case of our chief executive officer), (y) current target cash bonus and (z) an amount approximating 12 months of COBRA premiums for continued coverage under our group health plans (or 18 months in the case of our chief executive officer), less the employee contribution amount that our similarly situated employees pay for such coverage (only if the executive officer is enrolled in our group health plans and elects to continue such coverage).</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of the plan, a &#8220;change in control&#8221; shall have occurred upon any of the following events:</span></div><div style="margin-bottom:9pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any person other than Invus, L.P. and its affiliates becomes the beneficial owner of securities representing 35% or more of the combined voting power of our securities;</span></div><div style="margin-bottom:9pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the consummation of a reorganization, merger or consolidation pursuant to which our stockholders immediately prior to such reorganization, merger or consolidation do not, immediately thereafter, own or control more than 50% of the combined voting power of the surviving entity&#8217;s outstanding voting securities in substantially the same proportions as prior to such reorganization, merger or consolidation;</span></div><div style="margin-bottom:9pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our liquidation or dissolution or the sale of all or substantially all of our assets;</span></div><div style="margin-bottom:9pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">following the election or removal of directors, a majority of our board of directors consists of individuals who were not members of our board of directors two years before such election or removal; or</span></div><div style="margin-bottom:9pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any other corporate event deemed to be a &#8220;change in control&#8221; by the compensation committee.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:47.25pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Separation Agreements</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Jeffrey L. Wade</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Our separation agreement with Mr. Wade provides that we will pay Mr. Wade (a) salary continuation payments in an amount equal to his then-current base annual salary of $585,000 for a period of twelve months, (b) a single, lump sum payment equal to 50% of his then-current target cash bonus, or $175,500, and (c) monthly payments of $3,700 for a period of twelve months to provide for his cost of continued benefit coverage under COBRA.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Thomas A. Garner</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Our separation agreement with Mr. Garner provided that we would pay Mr. Garner (a) a single, lump sum severance payment of $559,494 and (b) a single, lump sum annual bonus payment for 2024 as determined by us and measured by reference to the payment Mr. Garner would have been eligible to receive after giving effect to individual and company performance for 2024, which amount was determined by the compensation committee to be $51,132.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Option Agreements</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our stock option agreements with the individuals named in the summary compensation table provide that all remaining unvested stock options shall become fully vested upon a &#8220;change in control,&#8221; or as a result of the named executive officer&#8217;s death or disability.  A &#8220;change in control&#8221; is defined in each individual stock option agreement, but generally occurs upon the following events:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any person other than Invus, L.P. and its affiliates becomes the beneficial owner of securities representing 35% or more of the combined voting power of our securities;</span></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the consummation of a reorganization, merger, or consolidation pursuant to which our stockholders immediately prior to such reorganization, merger or consolidation do not, immediately thereafter, own or control more than 50% of the combined voting power of the surviving entity&#8217;s outstanding voting securities in substantially the same proportions as prior to such reorganization, merger or consolidation;</span></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our liquidation or dissolution or the sale of all or substantially all of our assets;</span></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">following the election or removal of directors, a majority of the board of directors consists of individuals who were not members of the board of directors two years before such election or removal, unless the election of such individuals to the board of directors has been approved in advance by directors representing a majority of the directors then in office who were directors at the beginning of the two-year period; or</span></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any other corporate event deemed to be a &#8220;change in control&#8221; by the compensation committee.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Unit Agreements</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our restricted stock unit agreements with the individuals named in the summary compensation table provide that the interest of each named executive officer in the shares subject to the restricted stock unit shall become fully vested upon the termination of the named executive officer&#8217;s employment by us without &#8220;cause&#8221; or by the named executive officer for &#8220;good reason,&#8221; in either case within 24 months following a &#8220;change in control,&#8221; or as a result of the named executive officer&#8217;s death or disability.  A &#8220;change in control&#8221; is defined in each individual restricted stock unit agreement, but generally occurs upon the following events:</span></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any person other than Invus, L.P. and its affiliates becomes the beneficial owner of securities representing 35% or more of the combined voting power of our securities;</span></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the consummation of a reorganization, merger, or consolidation pursuant to which our stockholders immediately prior to such reorganization, merger or consolidation do not, immediately thereafter, own or control more than 50% of the combined voting power of the surviving entity&#8217;s outstanding voting securities in substantially the same proportions as prior to such reorganization, merger or consolidation;</span></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our liquidation or dissolution or the sale of all or substantially all of our assets;</span></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">following the election or removal of directors, a majority of the board of directors consists of individuals who were not members of the board of directors two years before such election or removal, unless the election of such individuals to the board of directors has been approved in advance by directors representing a majority of the directors then in office who were directors at the beginning of the two-year period; or</span></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any other corporate event  deemed to be a &#8220;change in control&#8221; by the compensation committee.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:47.25pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects the amounts Dr. Exton, Mr. Crum, Dr. Granowitz, Dr. Main and Ms. Alexander would have been entitled to receive if the foregoing termination or change in control events had occurred on December&#160;31, 2024, in each case without giving effect to the management severance plan adopted by the compensation committee in March 2025.  The table also reflects the amounts Mr. Wade and Mr. Garner received or are entitled to receive as a result of the terminations of their employment in September 2024 and December 2024, respectively.  Mr. Coats was not entitled to receive any such amounts in connection with his retirement in July 2024.  The table does not take into account any taxes that may have been payable in connection with any of those payments:</span></div><div style="margin-bottom:9pt;text-indent:49.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.906%"><tr><td style="width:1.0%"/><td style="width:23.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.019%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.391%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.781%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.265%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.710%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.942%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.391%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.704%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.086%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.474%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Salary Continuation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Bonus</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other Compensation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accelerated Portion of Stock Options </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accelerated Portion of Restricted Stock Units </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(7)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Michael S. Exton, Ph.D.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">636,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">445,200&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Brian T. Crum</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:2pt"><span><br/></span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">222,414&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Craig B. Granowitz, M.D., Ph.D.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">511,212&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">237,928&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Alan J. Main, Ph.D.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">469,987&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">82,248&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">218,746&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Jeffrey L. Wade</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">585,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">175,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Kristen L. Alexander</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75,423&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Thomas A. Garner</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt"><span><br/></span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">610,626&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Reflects aggregate salary continuation payments due as a result of our termination of Dr. Exton&#8217;s employment without &#8220;cause&#8221; and bonus payments due as a result of our termination of Dr. Exton&#8217;s employment without "cause" in connection with a &#8220;change in control.&#8221;</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Reflects aggregate salary continuation payments due as a result of our termination of Dr. Granowitz&#8217;s employment without &#8220;cause&#8221; in connection with a &#8220;change in control.&#8221; If Dr. Granowitz&#8217;s employment had been terminated without &#8220;cause&#8221; other than in connection with a &#8220;change in control,&#8221; the aggregate salary continuation payments for Dr. Granowitz would have been $255,606.</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Reflects aggregate salary continuation and partial bonus payments due as a result of our termination of Dr. Main&#8217;s employment without &#8220;cause&#8221; or Dr. Main&#8217;s termination of his employment for &#8220;good reason.&#8221;  If Dr. Main&#8217;s employment had been terminated at the end of a renewal term through notice of non-renewal, the aggregate salary continuation payment for Dr. Main would have been $234,994.</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Reflects salary continuation payments, bonus payments and payments to provide for the cost of continued benefit coverage under COBRA, each due as a result of the termination of Mr. Wade&#8217;s employment in September 2024.</span></div><div style="margin-bottom:6pt;margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Reflects aggregate severance and bonus payments due as a result of the termination of Mr. Garner&#8217;s employment in December 2024.</span></div><div style="margin-bottom:6pt;margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Reflects the value associated with accelerated vesting of stock options upon the occurrence of a &#8220;change of control&#8221; or as a result of death or disability, and based on the closing price of our common stock on the Nasdaq Global Select Market on December 31, 2024 of $0.7385 per share, less the exercise price payable with respect to the stock options for which vesting would have been accelerated.</span></div><div style="margin-bottom:6pt;margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(7)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Reflects the value associated with accelerated vesting of restricted stock units upon termination of employment without &#8220;cause&#8221; or for &#8220;good reason,&#8221; in each case following a &#8220;change of control,&#8221; or as a result of death or disability, and based on the closing price of our common stock on the Nasdaq Global Select Market on December 31, 2024 of $0.7385 per share.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Director Compensation in 2024</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each non-employee member of our board of directors currently receives the following cash compensation:</span></div><div style="margin-bottom:5pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an annual retainer of $50,000 for service on the board of directors ($75,000 for service as non-executive chairman of the board of directors), prorated for any partial year of service;</span></div><div style="margin-bottom:5pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an annual retainer of $10,000 for service on the audit committee of the board of directors ($20,000 for service as chair of the audit committee), prorated for any partial year of service;</span></div><div style="margin-bottom:5pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an annual retainer of $7,500 for service on the compensation committee of the board of directors ($15,000 for service as chair of the compensation committee), prorated for any partial year of service; and</span></div><div style="margin-bottom:5pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an annual retainer of $5,000 for service on the corporate governance committee of the board of directors ($10,000 for service as chair of the corporate governance committee), prorated for any partial year of service.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Michael S. Exton, Ph.D., our chief executive officer, does not receive additional compensation for his service as a director.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-employee directors may also be granted stock options, restricted stock awards or restricted stock unit awards under our 2017 Non-Employee Directors&#8217; Equity Incentive Plan.  Our board of directors determines the provision of each award granted under the plan, including the type of award, the number of shares subject to such award and any relevant vesting schedule.  In accordance with the process for determination of fair market value under the plan, the exercise price for each stock </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:47.25pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">option granted under the plan is equal to the closing price of our common stock, as quoted on the Nasdaq Global Select Market, on the last trading day prior to the grant date.  Non-employee directors may not be granted awards under the plan with an aggregate grant date fair value of more than $500,000 during any calendar year, taken together with the cash fees paid to such non-employee director in compensation for service on our board of directors during such calendar year.</span></div><div style="margin-bottom:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents summary information for the year ended December 31, 2024 regarding the compensation of the non-employee members of our board of directors.  Dr. Lefkowitz resigned as director and Mr. Cheung was elected as director, each on December 2, 2024.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.660%"><tr><td style="width:1.0%"/><td style="width:24.798%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.876%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.644%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.746%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.281%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fees Earned or Paid in Cash</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Option Awards </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1) (2) (3)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Stock Unit </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Awards </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1) (4)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">All Other Compensation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Raymond Debbane </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66,161&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65,890&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">217,051&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Philippe J. Amouyal </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66,161&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65,890&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">197,051&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Samuel L. Barker, Ph.D. </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66,161&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65,890&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">209,551&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ivan H. Cheung</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,891&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">125,344&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">130,235&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Robert J. Lefkowitz, M.D. </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,516&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66,161&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65,890&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">182,567&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Christopher J. Sobecki </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66,161&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65,890&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">182,051&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diane E. Sullivan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66,161&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65,890&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">192,051&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Judith L. Swain, M.D. </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70,902&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66,161&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65,890&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">202,953&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Reflects the aggregate grant date fair value, computed in accordance with FASB ASC Topic 718, of stock options and restricted stock unit awards granted in 2024.  See the information appearing under the heading entitled &#8220;Stock-Based Compensation&#8221; in footnote 2 to our consolidated financial statements included as part of our Annual Report on Form 10-K for the year ended December 31, 2024 for certain assumptions made in the valuation of such stock options and restricted stock unit awards.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The non-employee members of our board of directors who held such position on December 31, 2024 held the following aggregate number of unexercised stock options as of such date:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:45.175%"><tr><td style="width:1.0%"/><td style="width:51.974%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.107%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:41.619%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 7.75pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Number of Securities Underlying Unexercised Stock Options</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Raymond Debbane </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">114,503</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Philippe J. Amouyal </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">114,503</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Samuel L. Barker, Ph.D. </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">114,503</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ivan H. Cheung</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">186,685</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Christopher J. Sobecki</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">114,503</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diane E. Sullivan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">141,421</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Judith L. Swain, M.D. </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">114,503</span></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following table presents the fair value of each grant of stock options in 2024 to non-employee members of our board of directors, computed in accordance with FASB ASC Topic 718:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.403%"><tr><td style="width:1.0%"/><td style="width:22.588%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.661%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.661%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.312%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.661%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.999%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.913%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.999%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.088%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Grant Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Number of Securities Underlying Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Exercise Price</span></div><div style="margin-top:0.1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">of Option Awards</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Closing Market Price on the Grant Date of Option Awards</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Grant Date </span></div><div style="margin-top:0.1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Fair Value of Options</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Raymond Debbane</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5/13/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,906</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.79&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.87&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66,161&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Philippe Amouyal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5/13/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,906</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66,161&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Samuel L. Barker, Ph.D.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5/13/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,906</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.79&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66,161&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ivan H. Cheung</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/2/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">186,685</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8037&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8009&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">125,344&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Robert J. Lefkowitz, M.D.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5/13/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,906</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.79&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66,161&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Christopher J. Sobecki</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5/13/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,906</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66,161&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diane E. Sullivan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5/13/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,906</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.79&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66,161&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Judith L. Swain, M.D.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5/13/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,906</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66,161&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:47.25pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following table presents the fair value of each grant of restricted stock unit awards in 2024 to non-employee members of our board of directors, computed in accordance with FASB ASC Topic 718:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.239%"><tr><td style="width:1.0%"/><td style="width:28.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.922%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.796%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.922%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.460%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.693%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Grant Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Number of Restricted Stock Unit Awards</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Per Share Grant Date Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Grant Date </span></div><div style="margin-top:0.1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Fair Value of Restricted Stock Unit Awards</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Raymond Debbane</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5/13/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36,810</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.79&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65,890&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Philippe Amouyal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5/13/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36,810</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65,890&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Samuel L. Barker, Ph.D.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5/13/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36,810</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.79&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65,890&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ivan H. Cheung</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Robert J. Lefkowitz, M.D.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5/13/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36,810</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.79&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65,890&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Christopher J. Sobecki</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5/13/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36,810</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65,890&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diane E. Sullivan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5/13/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36,810</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.79&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65,890&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Judith L. Swain, M.D.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5/13/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36,810</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65,890&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Compensation Committee Report</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The compensation committee of our board of directors has been established to oversee the compensation of our employees, including our chief executive officer and other officers.  The compensation committee also has responsibility for the evaluation and approval of all compensation plans, policies and programs, including the issuance of stock options, restricted stock units and other awards under our 2017 Equity Incentive Plan.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In performing these functions, the compensation committee has reviewed and discussed with the management of our company the information set forth above under the heading &#8220;Executive and Director Compensation - Compensation Discussion and Analysis.&#8221;  Based upon that review and discussion, the compensation committee has recommended to the board of directors that the information set forth above under the heading &#8220;Executive and Director Compensation - Compensation Discussion and Analysis&#8221; be included in this proxy statement and incorporated by reference into our annual report on Form 10-K for the year ended December 31, 2024.</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Compensation Committee</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Philippe J. Amouyal (chair)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Samuel L. Barker, Ph.D.</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Judith L. Swain, M.D.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing compensation committee report shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference by any general statement incorporating by reference this proxy statement into any filing under the Securities Act of 1933 or under the Securities Exchange Act of 1934, except to the extent that we specifically incorporate this compensation committee report by reference.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><div id="i29f56aa9946248519609c20b75df062f_43"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PROPOSALS OF STOCKHOLDERS</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order for a stockholder proposal to be considered for inclusion in our proxy statement for next year&#8217;s annual meeting, we must receive the written proposal at our principal executive offices no later than November ___, 2025.  Any such proposal must also comply with the procedures in Rule 14a-8 under the Securities and Exchange Act of 1934.  Similarly, in order for any stockholder proposal to be otherwise raised during next year&#8217;s annual meeting, we must receive written notice of the proposal, containing the information required by our bylaws, at our principal executive offices no later than November ___, 2025.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our bylaws provide additional notice procedures for stockholders to nominate a person as a director and to propose business to be considered by stockholders at a meeting. A stockholder&#8217;s notice to our corporate secretary with respect to such business, to be timely, must be delivered to or mailed and received by our corporate secretary at our principal executive offices not less than 120 days nor more than 150 days in advance of the first anniversary date of our proxy statement released to stockholders in connection with the previous year&#8217;s annual meeting of stockholders; provided, however, that if no annual meeting was held in the previous year or the date of the annual meeting of stockholders has been changed by more than 30 calendar days from the date contemplated at the time of the previous year&#8217;s proxy statement, the notice must be received at least 80 days prior to the date we intend to distribute our proxy statement with respect to such meeting. To be timely, a stockholder&#8217;s notice given in the context of a special meeting of stockholders shall be delivered to or mailed and received at our principal executive office not earlier than the ninetieth day prior to such special meeting and not later than the close of business on the later of the seventieth day prior to such special meeting or the tenth day following the day on which public announcement is first made of the date of the special meeting and of the nominees proposed by our board of directors to be elected at such special meeting. Accordingly, for next year&#8217;s annual meeting, notice of a nomination or proposal must be delivered to us no later than the close of business on November ___, 2025 and no earlier than the close of business on October ___, 2025. Nominations and proposals also must satisfy other requirements set forth in our bylaws. You may contact our corporate secretary at our principal executive offices for a copy of the relevant bylaw provisions for making stockholder proposals.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the case of director nominations, in addition to satisfying the foregoing requirements, stockholders who intend to solicit proxies in support of director nominees other than our nominees must provide notice which sets forth the information required by Rule 14a-19 of the Securities and Exchange Act of 1934, and we must receive such notice no later than the earlier of the time provided in our bylaws or the time provided in Rule 14a-19. Thus, for next year&#8217;s annual meeting, such stockholders must provide proper written notice that sets forth all of the information required by Rule 14a-19 to our principal executive offices no later than the close of business on November ___, 2025 and no earlier than the close of business on October ___, 2025. However, the chairman of a meeting of our stockholders shall have the power and duty to determine whether a nomination was made in accordance with the procedures set forth in the foregoing provisions and, if any nomination is not in compliance, to declare that such defective nomination shall be disregarded.</span></div><div id="i29f56aa9946248519609c20b75df062f_46"></div><div style="margin-bottom:9pt;margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL INFORMATION</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our annual report to stockholders, including financial statements, accompanies this proxy statement but does not constitute a part of the proxy solicitation materials. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">You may obtain, without charge, a copy of our annual report on Form 10-K, including the financial statements and exhibits thereto, by written request to Corporate Communications, Lexicon Pharmaceuticals, Inc., 2445 Technology Forest Blvd., 11th Floor, The Woodlands, Texas 77381.</span></div><div style="margin-top:10pt;padding-left:216pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By order of the board of directors,</span></div><div style="padding-left:216pt;text-align:justify"><span><br/></span></div><div style="padding-left:216pt;text-align:justify"><span><br/></span></div><div style="padding-left:216pt;text-align:justify"><span><br/></span></div><div style="padding-left:216pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Brian T. Crum</span></div><div style="padding-left:216pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Secretary</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">April ___, 2025</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Woodlands, Texas</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><div id="i29f56aa9946248519609c20b75df062f_565"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:right;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Appendix A</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LEXICON PHARMACEUTICALS, INC.</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2017 EQUITY INCENTIVE PLAN</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Plan initially was established as the Lexicon Genetics Incorporated 1995 Stock Option Plan (the &#8220;1995 Stock Option Plan&#8221;), which was adopted by the Board and approved by the Company&#8217;s stockholders on September 13, 1995.  The 1995 Stock Option Plan was subsequently amended and restated in its entirety and renamed the Lexicon Genetics Incorporated 2000 Equity Incentive Plan (the &#8220;2000 Equity Incentive Plan&#8221;), which was adopted by the Board on February 3, 2000 and approved by the Company&#8217;s stockholders on March 15, 2000 and May 19, 2004. The 2000 Equity Incentive Plan was subsequently amended and restated in its entirety and renamed the Equity Incentive Plan (the &#8220;Equity Incentive Plan&#8221;), which was adopted by the Board on February 27, 2009 and approved by the Company&#8217;s stockholders on April 23, 2009.  The Equity Incentive Plan, as amended, was subsequently amended and restated in its entirety and renamed the 2017 Equity Incentive Plan (the &#8220;2017 Equity Incentive Plan&#8221;), which was adopted by the Board on February 9, 2017 and approved by the Company's stockholders on April&#160;27, 2017.  A subsequent amendment to the 2017 Equity Incentive Plan was adopted by the Board on February 7, 2019 and approved by the Company's stockholders on April 25, 2019.  The 2017 Equity Incentive Plan was subsequently amended by the Board, effective February 6, 2020, to remove the provisions formerly required by Section 162(m) of the Code.  A subsequent amendment to the 2017 Equity Incentive Plan was adopted by the Board on February 6, 2020 and approved by the Company&#8217;s stockholders on April 23, 2020.  An additional amendment to the 2017 Equity Incentive Plan was adopted by the Board on February 9, 2023 and approved by the Company&#8217;s stockholders on April 27, 2023.  An additional amendment to the 2017 Equity Incentive Plan was adopted by the Board on February 13, 2025, subject to approval by the Company&#8217;s stockholders.  The terms of this 2017 Equity Incentive Plan, as amended, shall supersede the terms of the 1995 Stock Option Plan, the 2000 Equity Incentive Plan and the Equity Incentive Plan in their entirety; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">provided, however,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> that nothing herein shall operate or be construed as modifying the terms of an Incentive Stock Option granted under the 1995 Stock Option Plan, the 2000 Equity Incentive Plan or the Equity Incentive Plan in a manner that would treat the option as being a new grant for purpose of Section 424(h) of the Code.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt">PURPOSES.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">ELIGIBLE STOCK AWARD RECIPIENTS. The persons eligible to receive Stock Awards are the Employees, Directors and Consultants of the Company and its Affiliates.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">AVAILABLE STOCK AWARDS. The purpose of the Plan is to provide a means by which eligible recipients of Stock Awards may be given an opportunity to benefit from increases in value of the Common Stock through the granting of the following Stock Awards: (i) Incentive Stock Options, (ii) Nonstatutory Stock Options, (iii) Stock Bonus Awards, (iv) Restricted Stock Awards, (v) Restricted Stock Unit Awards, (vi) Stock Appreciation Rights and (vii) Performance Stock Awards.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">GENERAL PURPOSE. The Company, by means of the Plan, seeks to retain the services of the group of persons eligible to receive Stock Awards, to secure and retain the services of new members of this group and to provide incentives for such persons to exert maximum efforts for the success of the Company and its Affiliates.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt">DEFINITIONS.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">&#8220;AFFILIATE&#8221; means any parent corporation or subsidiary corporation of the Company, whether now or hereafter existing, as those terms are defined in Sections&#160;424(e) and (f), respectively, of the Code.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">&#8220;BOARD&#8221; means the Board of Directors of the Company.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">&#8220;CODE&#8221; means the Internal Revenue Code of 1986, as amended.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">&#8220;COMMITTEE&#8221; means a committee of one or more members of the Board appointed by the Board in accordance with subsection 3(c).</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">&#8220;COMMON STOCK&#8221; means the common stock, par value $.001 per share, of the Company.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(f)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.01pt">&#8220;COMPANY&#8221; means Lexicon Pharmaceuticals, Inc. a Delaware corporation.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A-1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(g)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">&#8220;CONSULTANT&#8221; means any person other than a Director or Employee who is engaged by the Company or an Affiliate to render consulting or advisory services and who is compensated for such services.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(h)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">&#8220;CONTINUOUS SERVICE&#8221; means that the Participant&#8217;s service with the Company or an Affiliate, whether as an Employee, Director or Consultant, is not interrupted or terminated. The Participant&#8217;s Continuous Service shall not be deemed to have terminated merely because of a change in the capacity in which the Participant renders service to the Company or an Affiliate as an Employee, Consultant or Director or a change in the entity for which the Participant renders such service, provided that there is no interruption or termination of the Participant&#8217;s Continuous Service. For example, a change in status from an Employee of the Company to a Consultant of an Affiliate or a Director will not constitute an interruption of Continuous Service. The Board or the chief executive officer of the Company, in that party&#8217;s sole discretion, may determine whether Continuous Service shall be considered interrupted in the case of any leave of absence approved by that party, including sick leave, military leave or any other personal leave.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.57pt">&#8220;DIRECTOR&#8221; means a member of the Board of Directors of the Company.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(j)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.57pt">&#8220;DISABILITY&#8221; means the permanent and total disability of a person within the meaning of Section 22(e)(3) of the Code.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(k)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">&#8220;EMPLOYEE&#8221; means any person (which may include a Director) who is employed by the Company or an Affiliate.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(l)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.57pt">&#8220;EXCHANGE ACT&#8221; means the Securities Exchange Act of 1934, as amended.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(m)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:21.57pt">&#8220;FAIR MARKET VALUE&#8221; means, as of any date, the value of the Common Stock determined as follows:</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:26.57pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)   If the Common Stock is listed on any established stock exchange or traded on the Nasdaq Stock Market, the Fair Market Value of a share of Common Stock shall be the closing sales price for such stock (or the closing bid, if no sales were reported) as quoted on such exchange or market (or the exchange or market with the greatest volume of trading in the Common Stock) on the last market trading day prior to the day of determination, as reported in The Wall Street Journal or such other source as the Board deems reliable.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:23.8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)   In the absence of such markets for the Common Stock, the Fair Market Value shall be determined in good faith by the Board in such manner as it deems appropriate and as is consistent with the requirements of Section 409A of the Code.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(n)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">&#8220;INCENTIVE STOCK OPTION&#8221; means an option to purchase Common Stock that is intended to qualify as an incentive stock option within the meaning of Section 422 of the Code and the regulations promulgated thereunder.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(o)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">&#8220;NON-EMPLOYEE DIRECTOR&#8221; means a Director who either (i) is not a current Employee or Officer of the Company or its parent or a subsidiary, does not receive compensation (directly or indirectly) from the Company or its parent for a subsidiary for services rendered as a consultant or in any capacity other than as a Director (except for an amount as to which disclosure would not be required under Item 404(a) of Regulation S-K promulgated pursuant to the Securities Act (&#8220;Regulation S-K&#8221;)), does not possess an interest in any other transaction as to which disclosure would be required under Item 404(a) of Regulation S-K and is not engaged in a business relationship as to which disclosure would be required under Item 404(b) of Regulation S-K; or (ii) is otherwise considered a &#8220;non-employee director&#8221; for purposes of Rule 16b-3.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(p)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">&#8220;NONSTATUTORY STOCK OPTION&#8221; means an option to purchase Common Stock other than an Incentive Stock Option.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(q)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">&#8220;OFFICER&#8221; means a person who is an officer of the Company within the meaning of Section 16 of the Exchange Act and the rules and regulations promulgated thereunder.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(r)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.01pt">&#8220;OPTION&#8221; means an Incentive Stock Option or a Nonstatutory Stock Option granted pursuant to Section 6 of the Plan.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(s)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.45pt">&#8220;OPTION AGREEMENT&#8221; means a written agreement between the Company and an Optionholder evidencing the terms and conditions of an individual Option grant. Each Option Agreement shall be subject to the terms and conditions of the Plan.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(t)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.57pt">&#8220;OPTIONHOLDER&#8221; means a person to whom an Option is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding Option.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A-2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(u)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">&#8220;PARTICIPANT&#8221; means a person to whom a Stock Award is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding Stock Award.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(v)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">&#8220;PERFORMANCE STOCK AWARD&#8221; means a right to receive a Stock Award based upon performance criteria specified by the Committee.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(w)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.12pt">&#8220;PLAN&#8221; means this Lexicon Pharmaceuticals, Inc. 2017 Equity Incentive Plan.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(x)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">&#8220;RESTRICTED STOCK AWARD&#8221; means a right to purchase restricted Common Stock granted pursuant to Section 7(b) of the Plan.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(y)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">&#8220;RESTRICTED STOCK UNIT AWARD&#8221; means a right to receive shares of Common Stock (or a cash payment equal to the Fair Market Value thereof) granted pursuant to Section 7(c) of the Plan.</span></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(z)&#160;&#160;&#160;&#160;&#8220;RULE 16B-3&#8221; means Rule 16b-3 promulgated under the Exchange Act or any successor to Rule 16b&#8209;3, as in effect from time to time.</span></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(aa)&#160;&#160;&#160;&#160;&#8220;SECURITIES ACT&#8221; means the Securities Act of 1933, as amended.</span></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(bb)&#160;&#160;&#160;&#160;&#8220;STOCK APPRECIATION RIGHT&#8221; means a right to receive an amount equal to any appreciation or increase in the Fair Market Value of Common Stock over a specified period of time granted pursuant to Section 7(d) of the Plan, payable in shares of Common Stock or cash.</span></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(cc)&#160;&#160;&#160;&#160;&#8220;STOCK AWARD&#8221; means any right granted under the Plan, including an Option, a Stock Bonus Award, a Restricted Stock Award, a Restricted Stock Unit Award, a Stock Appreciation Right or a Performance Stock Award.</span></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(dd)&#160;&#160;&#160;&#160;&#8220;STOCK AWARD AGREEMENT&#8221; means a written agreement between the Company and a holder of a Stock Award evidencing the terms and conditions of an individual Stock Award grant. Each Stock Award Agreement shall be subject to the terms and conditions of the Plan.</span></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ee)&#160;&#160;&#160;&#160;&#8220;STOCK BONUS AWARD&#8221; means an award of Common Stock granted pursuant to Section&#160;7(a) of the Plan.</span></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ff)&#160;&#160;&#160;&#160;&#8220;TEN PERCENT STOCKHOLDER&#8221; means a person who owns (or is deemed to own pursuant to Section 424(d) of the Code) stock possessing more than ten percent (10%) of the total combined voting power of all classes of stock of the Company or of any of its Affiliates.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt">ADMINISTRATION.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">ADMINISTRATION BY BOARD. The Board shall administer the Plan unless and until the Board delegates administration to a Committee, as provided in subsection 3(c).</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">POWERS OF BOARD. The Board shall have the power, subject to, and within the limitations of, the express provisions of the Plan:</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:26.57pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)   To determine from time to time which of the persons eligible under the Plan shall be granted Stock Awards; when and how each Stock Award shall be granted; what type or combination of types of Stock Award shall be granted; the provisions of each Stock Award granted (which need not be identical), including the time or times when a person shall be permitted to receive Common Stock pursuant to a Stock Award; and the number of shares of Common Stock with respect to which a Stock Award shall be granted to each such person.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:23.8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)   To construe and interpret the Plan and Stock Awards granted under it, and to establish, amend and revoke rules and regulations for its administration. The Board, in the exercise of this power, may correct any defect, omission or inconsistency in the Plan or in any Stock Award Agreement or other agreement evidencing a Stock Award, in a manner and to the extent it shall deem necessary or expedient to make the Plan fully effective.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:21.03pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)   To amend the Plan or a Stock Award as provided in Section 13.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:21.57pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iv)   To terminate or suspend the Plan as provided in Section 14.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:24.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(v)   Generally, to exercise such powers and to perform such acts as the Board deems necessary or expedient to promote the best interests of the Company that are not in conflict with the provisions of the Plan.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A-3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">DELEGATION TO COMMITTEE.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:26.57pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)   GENERAL. The Board may delegate administration of the Plan to a Committee or Committees of one (1) or more members of the Board, and the term &#8220;Committee&#8221; shall apply to any person or persons to whom such authority has been delegated. If administration is delegated to a Committee, the Committee shall have, in connection with the administration of the Plan, the powers theretofore possessed by the Board, including the power to delegate to a subcommittee any of the administrative powers the Committee is authorized to exercise (and references in this Plan to the Board shall thereafter be to the Committee or subcommittee), subject, however, to such resolutions, not inconsistent with the provisions of the Plan, as may be adopted from time to time by the Board. The Board may abolish the Committee at any time and revest in the Board the administration of the Plan.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:23.8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)   COMMITTEE COMPOSITION WHEN COMMON STOCK IS PUBLICLY TRADED.  At such time as the Common Stock is publicly traded, in the discretion of the Board, a Committee may consist solely of two or more Non-Employee Directors, in accordance with Rule 16b-3. Within the scope of such authority, the Board or the Committee may delegate to a committee of one or more members of the Board who are not Non-Employee Directors the authority to grant Stock Awards to eligible persons who are not then subject to Section 16 of the Exchange Act.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">EFFECT OF BOARD&#8217;S DECISION. All determinations, interpretations and constructions made by the Board in good faith shall not be subject to review by any person and shall be final, binding and conclusive on all persons.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt">SHARES SUBJECT TO THE PLAN.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">SHARE RESERVE. Subject to the provisions of Section 12 relating to adjustments upon changes in Common Stock, the Common Stock that may be issued pursuant to Stock Awards shall not exceed in the aggregate seventy five million (75,000,000) shares and the Common Stock that may be issued pursuant to Incentive Stock Options shall not exceed in the aggregate seventy five million (75,000,000) shares. </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">REVERSION OF SHARES TO THE SHARE RESERVE. If any Stock Award shall for any reason expire or otherwise terminate, in whole or in part, without having been exercised in full or shares of Common Stock issued to a Participant pursuant to a Stock Award are forfeited to or repurchased by the Company, including any repurchase or forfeiture caused by the failure to meet a contingency or condition required for the vesting of such shares, the shares of Common Stock not issued under such Stock Award or forfeited to or repurchased by the Company shall revert to and again become available for issuance under the Plan; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">provided, however,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> that shares subject to a Stock Award that are not delivered to a Participant because (i) such Participant&#8217;s right to purchase such shares subject to an Option are surrendered in payment of the exercise price for other shares subject to such Option in a &#8220;net exercise,&#8221; or (ii) such shares are withheld in satisfaction of the withholding of taxes incurred in connection with the exercise of an Option or Stock Appreciation Right, or the issuance of shares under a Stock Bonus Award, Restricted Stock Award, Restricted Stock Unit Award or Performance Stock Award, the shares so surrendered or withheld shall not remain available for subsequent issuance under the Plan.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">SOURCE OF SHARES. The shares of Common Stock subject to the Plan may be unissued shares or reacquired shares, bought on the market or otherwise.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt">ELIGIBILITY.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">ELIGIBILITY FOR SPECIFIC STOCK AWARDS. Incentive Stock Options may be granted only to Employees.  Stock Awards other than Incentive Stock Options may be granted to Employees, Directors and Consultants.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">TEN PERCENT STOCKHOLDERS.  A Ten Percent Stockholder shall not be granted an Incentive Stock Option unless the exercise price of such Option is at least one hundred ten percent (110%) of the Fair Market Value of the Common Stock at the date of grant and the Option is not exercisable after the expiration of five (5) years from the date of grant. </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt">OPTION PROVISIONS.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each Option shall be in such form and shall contain such terms and conditions as the Board shall deem appropriate. All Options shall be separately designated Incentive Stock Options or Nonstatutory Stock Options at the time of grant, and, if certificates are issued, a separate certificate or certificates will be issued for shares of Common Stock purchased on exercise of each type of Option. The provisions of separate Options need not be identical, but each Option shall include (through incorporation of provisions hereof by reference in the Option or otherwise) the substance of each of the following provisions:</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">TERM. Subject to the provisions of subsection 5(b) regarding Ten Percent Stockholders, no Option shall be exercisable after the expiration of ten (10) years from the date it was granted. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A-4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">EXERCISE PRICE. Subject to the provisions of subsection 5(b) regarding Ten Percent Stockholders, the exercise price of each Option shall be not less than one hundred percent (100%) of the Fair Market Value of the Common Stock subject to the Option on the date the Option is granted. Notwithstanding the foregoing, an Option may be granted with an exercise price lower than that set forth in the preceding sentence if such Option is granted pursuant to an assumption or substitution for another option in a manner satisfying the provisions of Section 424(a) of the Code.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">CONSIDERATION. The purchase price of Common Stock acquired pursuant to an Option shall be paid, to the extent permitted by applicable statutes and regulations, either (i) in cash at the time the Option is exercised or (ii) at the discretion of the Board (1) by delivery to the Company of other Common Stock, (2) according to a deferred payment or other similar arrangement with the Optionholder, (3) by surrender of Optionholder&#8217;s right to purchase shares subject to an Option (valued, for such purposes, as the Fair Market Value of such surrendered shares on the date of exercise less the exercise price for such surrendered shares) in payment of the exercise price for other shares subject to such Option in a &#8220;net exercise&#8221; of such Option, or (4)&#160;in any other form of legal consideration that may be acceptable to the Board.  At any time that the Company is incorporated in Delaware, payment of the Common Stock&#8217;s &#8220;par value,&#8221; as defined in the Delaware General Corporation Law, shall not be made by deferred payment.  In the case of any deferred payment arrangement, interest shall be compounded at least annually and shall be charged at the minimum rate of interest necessary to avoid the treatment as interest, under any applicable provisions of the Code, of any amounts other than amounts stated to be interest under the deferred payment arrangement.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">TRANSFERABILITY. An Incentive Stock Option shall not be transferable except by will or by the laws of descent and distribution and shall be exercisable during the lifetime of the Optionholder only by the Optionholder. A Nonstatutory Stock Option shall be transferable to the extent provided in the Option Agreement; provided that, if the Nonstatutory Stock Option does not provide for transferability, then the Nonstatutory Stock Option shall not be transferable except by will or by the laws of descent and distribution and shall be exercisable during the lifetime of the Optionholder only by the Optionholder. Notwithstanding the foregoing, the Optionholder may, by delivering written notice to the Company, in a form satisfactory to the Company, designate a third party who, in the event of the death of the Optionholder, shall thereafter be entitled to exercise the Option.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">VESTING GENERALLY. The total number of shares of Common Stock subject to an Option may, but need not, vest and therefore become exercisable in periodic installments that may, but need not, be equal. The Option may be subject to such other terms and conditions on the time or times when it may be exercised (which may be based on performance or other criteria) as the Board may deem appropriate. The vesting provisions of individual Options may vary. </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(f)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.01pt">TERMINATION OF CONTINUOUS SERVICE. In the event an Optionholder&#8217;s Continuous Service terminates (other than upon the Optionholder&#8217;s death or Disability), the Optionholder may exercise his or her Option (to the extent that the Optionholder was entitled to exercise such Option as of the date of termination) but only within such period of time ending on the earlier of (i) the date three (3) months following the termination of the Optionholder&#8217;s Continuous Service (or such longer or shorter period specified in the Option Agreement), or (ii) the expiration of the term of the Option as set forth in the Option Agreement.  If, after termination, the Optionholder does not exercise his or her Option within the time specified in the Option Agreement, the Option shall terminate.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(g)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">EXTENSION OF TERMINATION DATE. An Optionholder&#8217;s Option Agreement may also provide that if the exercise of the Option following the termination of the Optionholder&#8217;s Continuous Service (other than upon the Optionholder&#8217;s death or Disability) would be prohibited at any time solely because the issuance of shares of Common Stock would violate the registration requirements under the Securities Act, then the Option shall terminate on the earlier of (i) the expiration of the term of the Option set forth in subsection 6(a) or (ii) the expiration of a period of three (3) months after the termination of the Optionholder&#8217;s Continuous Service during which the exercise of the Option would not be in violation of such registration requirements.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(h)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">DISABILITY OF OPTIONHOLDER. In the event that an Optionholder&#8217;s Continuous Service terminates as a result of the Optionholder&#8217;s Disability, the Optionholder may exercise his or her Option (to the extent that the Optionholder was entitled to exercise such Option as of the date of termination), but only within such period of time ending on the earlier of (i) the date twelve (12) months following such termination (or such longer or shorter period specified in the Option Agreement,) or (ii) the expiration of the term of the Option as set forth in the Option Agreement. If, after termination, the Optionholder does not exercise his or her Option within the time specified herein, the Option shall terminate.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.57pt">DEATH OF OPTIONHOLDER. In the event (i) an Optionholder&#8217;s Continuous Service terminates as a result of the Optionholder&#8217;s death or (ii) the Optionholder dies within the period (if any) specified in the Option Agreement after the termination of the Optionholder&#8217;s Continuous Service for a reason other than death, then the Option may be exercised (to the extent the Optionholder was entitled to exercise such Option as of the date of death) by the Optionholder&#8217;s estate, by a person who acquired the right to exercise the Option by bequest or inheritance or by a person designated to exercise the Option upon </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A-5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Optionholder&#8217;s death pursuant to subsection 6(d), but only within the period ending on the earlier of (1) the date eighteen (18) months following the date of death (or such longer or shorter period specified in the Option Agreement) or (2) the expiration of the term of such Option as set forth in the Option Agreement. If, after death, the Option is not exercised within the time specified herein, the Option shall terminate.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt">STOCK BONUS AWARD, RESTRICTED STOCK AWARD, RESTRICTED STOCK UNIT AWARD AND STOCK APPRECIATION RIGHT PROVISIONS.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">STOCK BONUS AWARDS. Each Stock Bonus Award agreement shall be in such form and shall contain such terms and conditions as the Board shall deem appropriate. The terms and conditions of Stock Bonus Award agreements may change from time to time, and the terms and conditions of separate Stock Bonus Award agreements need not be identical, but each Stock Bonus Award agreement shall include (through incorporation of provisions hereof by reference in the agreement or otherwise) the substance of each of the following provisions:</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:26.57pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)   CONSIDERATION. A Stock Bonus Award may be granted in consideration for past services actually rendered to the Company or an Affiliate for its benefit.  Unless otherwise provided in the Stock Bonus Award agreement, no further consideration will be payable by Participant upon grant of the Stock Bonus Award.  Any such consideration to be paid by the Participant may be paid in any form of legal consideration that may be acceptable to the Board in its discretion and permissible under applicable law.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:23.8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)   VESTING. Shares of Common Stock awarded under the Stock Bonus Award agreement may, but need not, be subject to a share repurchase option or forfeiture restrictions in favor of the Company in accordance with a vesting schedule to be determined by the Board.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:21.03pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)   TERMINATION OF PARTICIPANT&#8217;S CONTINUOUS SERVICE. In the event a Participant&#8217;s Continuous Service terminates, the Company may reacquire any or all of the shares of Common Stock held by the Participant which have not vested as of the date of termination under the terms of the Stock Bonus Award agreement.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:21.57pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iv)   TRANSFERABILITY. Rights to acquire shares of Common Stock under the Stock Bonus Award agreement shall be transferable by the Participant only upon such terms and conditions as are set forth in the Stock Bonus Award agreement, as the Board shall determine in its discretion, so long as Common Stock awarded under the Stock Bonus Award agreement remains subject to the terms of the Stock Bonus Award agreement.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">RESTRICTED STOCK AWARDS. Each Restricted Stock Award agreement shall be in such form and shall contain such terms and conditions as the Board shall deem appropriate. The terms and conditions of the Restricted Stock Award agreement may change from time to time, and the terms and conditions of separate Restricted Stock Award agreements need not be identical, but each Restricted Stock Award agreement shall include (through incorporation of provisions hereof by reference in the agreement or otherwise) the substance of each of the following provisions:</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:26.57pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)   CONSIDERATION. Unless otherwise provided in the Restricted Stock Award agreement, no further consideration will be payable by Participant upon grant of the Restricted Stock Award.  Any such consideration to be paid by the Participant may be paid in any form of legal consideration that may be acceptable to the Board in its discretion and permissible under applicable law.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:23.8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)   VESTING. Shares of Common Stock acquired under the Restricted Stock Award agreement may, but need not, be subject to a share repurchase option in favor of the Company in accordance with a vesting schedule to be determined by the Board.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:21.03pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)   TERMINATION OF PARTICIPANT&#8217;S CONTINUOUS SERVICE. In the event a Participant&#8217;s Continuous Service terminates, the Company may repurchase or otherwise reacquire any or all of the shares of Common Stock held by the Participant which have not vested as of the date of termination under the terms of the Restricted Stock Award agreement.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:21.57pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iv)   TRANSFERABILITY. Rights to acquire shares of Common Stock under the Restricted Stock Award agreement shall be transferable by the Participant only upon such terms and conditions as are set forth in the Restricted Stock Award agreement, as the Board shall determine in its discretion, so long as Common Stock awarded under the Restricted Stock Award agreement remains subject to the terms of the Restricted Stock Award agreement.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">RESTRICTED STOCK UNIT AWARDS. Each Restricted Stock Unit Award agreement shall be in such form and shall contain such terms and conditions as the Board shall deem appropriate. The terms and conditions of Restricted Stock Unit Award agreements may change from time to time, and the terms and conditions of separate Restricted Stock Unit </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A-6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Award agreements need not be identical, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">provided, however,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> that each Restricted Stock Unit Award agreement shall include (through incorporation of the provisions hereof by reference in the agreement or otherwise) the substance of each of the following provisions:</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:26.57pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)   CONSIDERATION. At the time of grant of a Restricted Stock Unit Award, the Board will determine the consideration, if any, to be paid by the Participant upon delivery of each share of Common Stock subject to the Restricted Stock Unit Award. The consideration to be paid (if any) by the Participant for each share of Common Stock subject to a Restricted Stock Unit Award may be paid in any form of legal consideration that may be acceptable to the Board in its sole discretion and permissible under applicable law.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:23.8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)   VESTING. At the time of the grant of a Restricted Stock Unit Award, the Board may impose such restrictions or conditions to the vesting of the Restricted Stock Unit Award as it, in its sole discretion, deems appropriate.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:21.03pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)   PAYMENT. A Restricted Stock Unit Award may be settled by the delivery of shares of Common Stock, their cash equivalent, any combination thereof or in any other form of consideration, as determined by the Board and contained in the Restricted Stock Unit Award agreement.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:21.57pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iv)   DIVIDEND EQUIVALENTS. Dividend equivalents may be credited in respect of shares of Common Stock covered by a Restricted Stock Unit Award, as determined by the Board and contained in the Restricted Stock Unit Award agreement. At the sole discretion of the Board, such dividend equivalents may be converted into additional shares of Common Stock covered by the Restricted Stock Unit Award in such manner as determined by the Board. Any additional shares covered by the Restricted Stock Unit Award credited by reason of such dividend equivalents will be subject to all the terms and conditions of the underlying Restricted Stock Unit Award agreement to which they relate.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:24.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(v)   TERMINATION OF PARTICIPANT&#8217;S CONTINUOUS SERVICE. Except as otherwise provided in the applicable Restricted Stock Unit Award agreement, such portion of the Restricted Stock Unit Award that has not vested will be forfeited upon the Participant&#8217;s termination of Continuous Service. </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:21.57pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(vi)   TRANSFERABILITY. Rights under the Restricted Stock Unit Award agreement shall be transferable by the Participant only upon such terms and conditions as are set forth in the Restricted Stock Unit Award agreement, as the Board shall determine in its discretion.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">STOCK APPRECIATION RIGHTS. Each Stock Appreciation Right agreement shall be in such form and shall contain such terms and conditions as the Board shall deem appropriate. The terms and conditions of the Stock Appreciation Right agreements may change from time to time, and the terms and conditions of separate Stock Appreciation Right agreements need not be identical, but each Stock Appreciation Right agreement shall include (through incorporation of provisions hereof by reference in the agreement or otherwise) the substance of each of the following provisions:</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:26.57pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)   CALCULATION OF APPRECIATION.  Each Stock Appreciation Right will be denominated in shares of Common Stock equivalents. The appreciation distribution payable on the exercise of a Stock Appreciation Right will be not greater than an amount equal to the excess of (i)&#160;the aggregate Fair Market Value (on the date of the exercise of the Stock Appreciation Right) of a number of shares of Common Stock equal to the number of shares of Common Stock equivalents in which the Participant is vested under such Stock Appreciation Right, and with respect to which the Participant is exercising the Stock Appreciation Right on such date, over (ii)&#160;an amount (the strike price) that will be determined by the Board at the time of grant of the Stock Appreciation Right for such number of shares of Common Stock, provided that the strike price of a Stock Appreciation Right shall be not less than one hundred percent (100%) of the Fair Market Value of the Common Stock equal to the number of shares of Common Stock equivalents subject to the Stock Appreciation Right on the date the Stock Appreciation Right is granted.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:23.8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)   VESTING. At the time of the grant of a Stock Appreciation Right, the Board may impose such restrictions or conditions to the vesting of such Stock Appreciation Right as it, in its sole discretion, deems appropriate.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:21.03pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)   EXERCISE. To exercise any outstanding Stock Appreciation Right, the Participant must provide written notice of exercise to the Company in compliance with the provisions of the Stock Appreciation Right agreement evidencing such Stock Appreciation Right.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:21.57pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iv)   PAYMENT. The appreciation distribution in respect to a Stock Appreciation Right may be paid in cash, shares of Common Stock, a combination of cash and shares of Common Stock or in any other form of consideration, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A-7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as determined by the Board and contained in the Stock Appreciation Right agreement evidencing such Stock Appreciation Right.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:24.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(v)   TERMINATION OF PARTICIPANT&#8217;S CONTINUOUS SERVICE. In the event that a Participant&#8217;s Continuous Service terminates, the Participant may exercise his or her Stock Appreciation Right (to the extent that the Participant was entitled to exercise such Stock Appreciation Right as of the date of termination) but only within such period of time ending on the earlier of (i)&#160;the date three (3)&#160;months following the termination of the Participant&#8217;s Continuous Service (or such longer or shorter period specified in the Stock Appreciation Right agreement), or (ii)&#160;the expiration of the term of the Stock Appreciation Right as set forth in the Stock Appreciation Right agreement. If, after termination, the Participant does not exercise his or her Stock Appreciation Right within the time specified herein or in the Stock Appreciation Right agreement (as applicable), the Stock Appreciation Right shall terminate. </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:21.57pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(vi)   TRANSFERABILITY. Rights under the Stock Appreciation Right agreement shall be transferable by the Participant only upon such terms and conditions as are set forth in the Stock Appreciation Right agreement, as the Board shall determine in its discretion.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt">PERFORMANCE STOCK AWARDS. </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Committee is authorized to designate any of the Stock Awards granted under the Plan as Performance Stock Awards.  The Committee may use such business criteria and other measures of performance as it may deem appropriate in establishing any performance conditions applicable to a Performance Stock Award, and may exercise its discretion to reduce or increase the number of shares issuable under any Performance Stock Award.  Performance conditions may differ for Performance Stock Awards granted to any one Participant or to different Participants.  The performance period applicable to any Performance Stock Award shall be set by the Committee in its discretion, but shall not exceed ten years.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt">COVENANTS OF THE COMPANY.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">AVAILABILITY OF SHARES. During the terms of the Stock Awards, the Company shall keep available at all times the number of shares of Common Stock required to satisfy such Stock Awards.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">SECURITIES LAW COMPLIANCE. The Company shall seek to obtain from each regulatory commission or agency having jurisdiction over the Plan such authority as may be required to grant Stock Awards and to issue and sell shares of Common Stock upon exercise of the Stock Awards; provided, however, that this undertaking shall not require the Company to register under the Securities Act the Plan, any Stock Award or any Common Stock issued or issuable pursuant to any such Stock Award. If, after reasonable efforts, the Company is unable to obtain from any such regulatory commission or agency the authority which counsel for the Company deems necessary for the lawful issuance and sale of Common Stock under the Plan, the Company shall be relieved from any liability for failure to issue and sell Common Stock upon exercise of such Stock Awards unless and until such authority is obtained.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt">USE OF PROCEEDS FROM STOCK.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds from the sale of Common Stock pursuant to Stock Awards shall constitute general funds of the Company.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt">MISCELLANEOUS.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">ACCELERATION OF EXERCISABILITY AND VESTING. Subject to the limitations of Section 8, the Board shall have the power to accelerate the time at which a Stock Award may first be exercised or the time during which a Stock Award or any part thereof will vest in accordance with the Plan, notwithstanding the provisions in the Stock Award stating the time at which it may first be exercised or the time during which it will vest.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">STOCKHOLDER RIGHTS. No Participant shall be deemed to be the holder of, or to have any of the rights of a holder with respect to, any shares of Common Stock subject to such Stock Award unless and until such Participant has satisfied all requirements for exercise of the Stock Award pursuant to its terms.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">NO EMPLOYMENT OR OTHER SERVICE RIGHTS. Nothing in the Plan or any instrument executed or Stock Award granted pursuant thereto shall confer upon any Participant any right to continue to serve the Company or an Affiliate in the capacity in effect at the time the Stock Award was granted or shall affect the right of the Company or an Affiliate to terminate (i) the employment of an Employee with or without notice and with or without cause, (ii) the service of a Consultant pursuant to the terms of such Consultant&#8217;s agreement with the Company or an Affiliate or (iii) the service of a Director pursuant to the Bylaws of the Company or an Affiliate, and any applicable provisions of the corporate law of the state in which the Company or the Affiliate is incorporated, as the case may be.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A-8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">INCENTIVE STOCK OPTION $100,000 LIMITATION. To the extent that the aggregate Fair Market Value (determined at the time of grant) of Common Stock with respect to which Incentive Stock Options are exercisable for the first time by any Optionholder during any calendar year (under all plans of the Company and its Affiliates) exceeds one hundred thousand dollars ($100,000), the Options or portions thereof which exceed such limit (according to the order in which they were granted) shall be treated as Nonstatutory Stock Options.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">INVESTMENT ASSURANCES. The Company may require a Participant, as a condition of exercising or acquiring Common Stock under any Stock Award, (i) to give written assurances satisfactory to the Company as to the Participant&#8217;s knowledge and experience in financial and business matters and/or to employ a purchaser representative reasonably satisfactory to the Company who is knowledgeable and experienced in financial and business matters and that he or she is capable of evaluating, alone or together with the purchaser representative, the merits and risks of exercising the Stock Award; and (ii) to give written assurances satisfactory to the Company stating that the Participant is acquiring Common Stock subject to the Stock Award for the Participant&#8217;s own account and not with any present intention of selling or otherwise distributing the Common Stock. The foregoing requirements, and any assurances given pursuant to such requirements, shall be inoperative if (1) the issuance of the shares of Common Stock upon the exercise or acquisition of Common Stock under the Stock Award has been registered under a then currently effective registration statement under the Securities Act or (2) as to any particular requirement, a determination is made by counsel for the Company that such requirement need not be met in the circumstances under the then applicable securities laws. The Company may, upon advice of counsel to the Company, place legends on stock certificates issued under the Plan as such counsel deems necessary or appropriate in order to comply with applicable securities laws, including, but not limited to, legends restricting the transfer of the Common Stock.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(f)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.01pt">WITHHOLDING OBLIGATIONS. To the extent provided by the terms of a Stock Award Agreement, the Participant may satisfy any federal, state or local tax withholding obligation relating to the exercise or acquisition of Common Stock under a Stock Award by any of the following means (in addition to the Company&#8217;s right to withhold from any compensation paid to the Participant by the Company) or by a combination of such means: (i) tendering a cash payment; (ii) authorizing the Company to withhold shares of Common Stock from the shares of Common Stock otherwise issuable to the Participant as a result of the exercise or acquisition of Common Stock under the Stock Award; or (iii) delivering to the Company owned and unencumbered shares of Common Stock.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt">ADJUSTMENTS UPON CHANGES IN STOCK.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">CAPITALIZATION ADJUSTMENTS.  If any change is made in the Common Stock subject to the Plan, or subject to any Stock Award, without the receipt of consideration by the Company (through merger, consolidation, reorganization, recapitalization, reincorporation, stock dividend, dividend in property other than cash, stock split, liquidating dividend, combination of shares, exchange of shares, change in corporate structure or other transaction not involving the receipt of consideration by the Company), the Plan will be appropriately adjusted in the class(es) and the number of securities subject to the Plan pursuant to subsection 4(a) and the maximum number of securities subject to award to any person pursuant to subsection 5(c), and the outstanding Stock Awards will be appropriately adjusted in the class(es) and number of securities and price per share of Common Stock subject to such outstanding Stock Awards. The Board shall make such adjustments, and its determination shall be final, binding and conclusive. For clarity, the conversion of any convertible securities of the Company shall not be treated as a transaction &#8220;without receipt of consideration&#8221; by the Company.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">DISSOLUTION OR LIQUIDATION.  In the event of a dissolution or liquidation of the Company, then all outstanding Stock Awards shall terminate immediately prior to such event.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">ASSET SALE, MERGER, CONSOLIDATION OR REVERSE MERGER.  In the event of (i) a sale, lease or other disposition of all or substantially all of the assets of the Company, (ii) a merger or consolidation in which the Company is not the surviving corporation or (iii) a reverse merger in which the Company is the surviving corporation but the shares of Common Stock outstanding immediately preceding the merger are converted by virtue of the merger into other property, whether in the form of securities, cash or otherwise, then any surviving corporation or acquiring corporation shall assume any Stock Awards outstanding under the Plan or shall substitute similar stock awards (including an award to acquire the same consideration paid to the stockholders in the transaction described in this subsection 12(c) for those outstanding under the Plan). In the event any surviving corporation or acquiring corporation fails to assume such Stock Awards or to substitute similar stock awards for those outstanding under the Plan, then with respect to Stock Awards held by Participants whose Continuous Service has not terminated, the vesting of such Stock Awards (and, if applicable, the time during which such Stock Awards may be exercised) shall be accelerated in full, and the Stock Awards shall terminate if not exercised (if applicable) at or prior to such event. With respect to any other Stock Awards outstanding under the Plan, such Stock Awards shall terminate if not exercised (if applicable) prior to such event.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A-9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt">AMENDMENT OF THE PLAN AND STOCK AWARDS.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">AMENDMENT OF PLAN. The Board at any time, and from time to time, may amend the Plan. However, except as provided in Section 12 relating to adjustments upon changes in Common Stock, no amendment shall be effective unless approved by the stockholders of the Company to the extent stockholder approval is necessary to satisfy the requirements of Section 422 of the Code, Rule 16b-3 or any Nasdaq or securities exchange listing requirements.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">STOCKHOLDER APPROVAL. The Board may, in its sole discretion, submit any other amendment to the Plan for stockholder approval.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">CONTEMPLATED AMENDMENTS. It is expressly contemplated that the Board may amend the Plan in any respect the Board deems necessary or advisable to provide eligible Employees with the maximum benefits provided or to be provided under the provisions of the Code and the regulations promulgated thereunder relating to Incentive Stock Options and/or to bring the Plan and/or Incentive Stock Options granted under it into compliance therewith.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">NO IMPAIRMENT OF RIGHTS. Rights under any Stock Award granted before amendment of the Plan shall not be impaired by any amendment of the Plan unless (i) the Company requests the consent of the Participant and (ii) the Participant consents in writing.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">AMENDMENT OF STOCK AWARDS. The Board at any time, and from time to time, may amend the terms of any one or more Stock Awards; provided, however, that the rights under any Stock Award shall not be impaired by any such amendment unless (i) the Company requests the consent of the Participant and (ii) the Participant consents in writing.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(f)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.01pt">SUBSTITUTE AWARDS; NO REPRICING.  Stock Awards may be granted in substitution or exchange for any other Stock Award granted under the Plan or under another plan of the Company or an Affiliate or any other right of an eligible person to receive payment from the Company or an Affiliate.  Stock Awards may also be granted under the Plan in substitution for awards held by individuals who become eligible persons as a result of a merger, consolidation or acquisition of another entity or the assets of another entity by or with the Company or an Affiliate (&#8220;Substitute Awards&#8221;).  Such Substitute Awards referred to in the immediately preceding sentence that are Options or Stock Appreciation Rights may have an exercise price that is less than the Fair Market Value of a share of Common Stock on the date of the substitution if such substitution complies with applicable laws (including rules regarding nonqualified deferred compensation) and exchange rules.  Except as provided in this Section 13(f) or in Section 12, without the approval of the stockholders of the Company, the terms of outstanding Stock Awards may not be amended to (i) reduce the exercise price or grant price of an outstanding Option or Stock Appreciation Right, (ii) grant a new Option, Stock Appreciation Right or other Stock Award in substitution for, or upon the cancellation of, any previously granted Option or Stock Appreciation Right that has the effect of reducing the exercise price or grant price thereof, (iii) exchange any Option or Stock Appreciation Right for Common Stock, cash or other consideration when the exercise price or grant price per share of Common Stock under such Option or Stock Appreciation Right exceeds the Fair Market Value of a share of Common Stock.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt">TERMINATION OR SUSPENSION OF THE PLAN.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">PLAN TERM. The Board may suspend or terminate the Plan at any time. Unless sooner terminated, the Plan shall terminate on the day before the tenth (10th) anniversary of the date the Plan is adopted by the Board or approved by the stockholders of the Company, whichever is earlier. No Stock Awards may be granted under the Plan while the Plan is suspended or after it is terminated.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">NO IMPAIRMENT OF RIGHTS. Suspension or termination of the Plan shall not impair rights and obligations under any Stock Award granted while the Plan is in effect except with the written consent of the Participant.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt">EFFECTIVE DATE OF PLAN.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Plan shall become effective upon its adoption by the Board, but no Stock Award shall be exercised (or, in the case of a stock bonus, shall be granted) unless and until the Plan has been approved by the stockholders of the Company, which approval shall be within twelve (12) months before or after the date the Plan is adopted by the Board.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt">CHOICE OF LAW.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The law of the State of Delaware shall govern all questions concerning the construction, validity and interpretation of this Plan, without regard to such state&#8217;s conflict of laws rules.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A-10</span></div></div></div><div id="i29f56aa9946248519609c20b75df062f_576"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Appendix B</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LEXICON PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2017 NON-EMPLOYEE DIRECTORS&#8217; EQUITY INCENTIVE PLAN</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">This Plan initially was established as the 2000 Non-Employee Directors&#8217; Stock Option Plan, effective as of April 12, 2000 (the &#8220;2000 Non-Employee Directors&#8217; Stock Option Plan&#8221;) which was adopted by the Board on February 3, 2000 and approved by the Company&#8217;s stockholders on March 15, 2000.  The 2000 Non-Employee Directors&#8217; Stock Option Plan, as amended, was subsequently amended and restated in its entirety and renamed the Non-Employee Directors&#8217; Stock Option Plan (the &#8220;Non-Employee Directors&#8217; Stock Option Plan&#8221;), which was adopted by the Board on February 27, 2009 and approved by the Company&#8217;s stockholders on April 23, 2009.  A subsequent amendment to the Non-Employee Directors&#8217; Stock Option Plan pursuant to which it was renamed the Non-Employee Directors&#8217; Equity Incentive Plan (the &#8220;Non-Employee Directors&#8217; Equity Incentive Plan&#8221;) was adopted by the Board on February 16, 2012 and approved by the Company&#8217;s stockholders on April 26, 2012.  The Non-Employee Directors&#8217; Equity Incentive Plan, as amended, was subsequently amended and restated in its entirety and renamed the 2017 Non-Employee Directors&#8217; Equity Incentive Plan, which was adopted by the Board on February 9, 2017 and approved by the Company&#8217;s stockholders on April 27, 2017.  A subsequent amendment to the 2017 Non-Employee Directors&#8217; Equity Incentive Plan was adopted by the Board on October 25, 2018.  An additional amendment to the 2017 Non-Employee Directors&#8217; Equity Incentive Plan was adopted by the Board on February 11, 2021 and approved by the Company&#8217;s stockholders on April 29, 2021.  An additional amendment to the 2017 Non-Employee Directors&#8217; Equity Incentive Plan was adopted by the Board on February 9, 2023 and approved by the Company&#8217;s stockholders on April 27, 2023.  An additional amendment to the 2017 Non-Employee Directors&#8217; Equity Incentive Plan was adopted by the Board on February 13, 2025, subject to approval by the Company&#8217;s stockholders.  The terms of this 2017 Non-Employee Directors&#8217; Equity Incentive Plan, as amended, shall supersede the terms of the 2000 Non-Employee Directors&#8217; Stock Option Plan, Non-Employee Directors&#8217; Stock Option Plan and Non-Employee Directors&#8217; Equity Incentive Plan in their entirety.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt">PURPOSES.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(a)&#160;&#160;&#160;&#160;ELIGIBLE STOCK AWARD RECIPIENTS. The persons eligible to receive Stock Awards are the Non-Employee Directors of the Company.</span></div><div style="padding-left:72pt;text-indent:-36pt"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(b)&#160;&#160;&#160;&#160;AVAILABLE STOCK AWARDS. The purpose of the Plan is to provide a means by which Non-Employee Directors may be given an opportunity to benefit from increases in value of the Common Stock through the granting of the following Stock Awards:  (i) Nonstatutory Stock Options, (ii) Restricted Stock Awards and (iii) Restricted Stock Unit Awards.</span></div><div style="padding-left:72pt;text-indent:-36pt"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(c)&#160;&#160;&#160;&#160;GENERAL PURPOSE. The Company, by means of the Plan, seeks to retain the services of its Non-Employee Directors, to secure and retain the services of new Non-Employee Directors and to provide incentives for such persons to exert maximum efforts for the success of the Company and its Affiliates.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt">DEFINITIONS.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(a)&#160;&#160;&#160;&#160;&#8220;AFFILIATE&#8221; means any parent corporation or subsidiary corporation of the Company, whether now or hereafter existing, as those terms are defined in Sections 424(e) and (f), respectively, of the Code.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(b)&#160;&#160;&#160;&#160;&#8220;BOARD&#8221; means the Board of Directors of the Company.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(c)&#160;&#160;&#160;&#160;&#8220;CODE&#8221; means the Internal Revenue Code of 1986, as amended.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(d)&#160;&#160;&#160;&#160;&#8220;COMMON STOCK&#8221; means the common stock, par value $.001 per share, of the Company.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(e)&#160;&#160;&#160;&#160;&#8220;COMPANY&#8221; means Lexicon Pharmaceuticals, Inc., a Delaware corporation.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(f)&#160;&#160;&#160;&#160;&#8220;CONSULTANT&#8221; means any person other than a Director or Employee who is engaged by the Company or an Affiliate to render consulting or advisory services and who is compensated for such services.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(g)&#160;&#160;&#160;&#160;&#8220;CONTINUOUS SERVICE&#8221; means that the Participant&#8217;s service with the Company or an Affiliate, whether as an Employee, Director or Consultant, is not interrupted or terminated. The Participant&#8217;s Continuous Service shall not be deemed to have terminated merely because of a change in the capacity in which the Participant renders service to the Company or an Affiliate as an Employee, Consultant or Director or a change in the entity for which the Participant renders such service, provided that there is no interruption or termination of the Participant&#8217;s Continuous Service. For example, a change in status </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">B-1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">from a Non-Employee Director of the Company to a Consultant of an Affiliate or an Employee of the Company will not constitute an interruption of Continuous Service. The Board or the chief executive officer of the Company, in that party&#8217;s sole discretion, may determine whether Continuous Service shall be considered interrupted in the case of any leave of absence approved by that party, including sick leave, military leave or any other personal leave.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(h)&#160;&#160;&#160;&#160;&#8220;DIRECTOR&#8221; means a member of the Board of Directors of the Company.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(i)&#160;&#160;&#160;&#160;&#8220;DISABILITY&#8221; means the permanent and total disability of a person within the meaning of Section 22(e)(3) of the Code.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(j)&#160;&#160;&#160;&#160;&#8220;EMPLOYEE&#8221; means any person employed by the Company or an Affiliate. Mere service as a Director or payment of a director&#8217;s fee by the Company or an Affiliate shall not be sufficient to constitute &#8220;employment&#8221; by the Company or an Affiliate.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(k)&#160;&#160;&#160;&#160;&#8220;EXCHANGE ACT&#8221; means the Securities Exchange Act of 1934, as amended.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(l) &#160;&#160;&#160;&#160;&#8220;FAIR MARKET VALUE&#8221; means, as of any date, the value of the Common Stock determined as follows:</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(i)&#160;&#160;&#160;&#160;If the Common Stock is listed on any established stock exchange or traded on the Nasdaq Stock Market, the Fair Market Value of a share of Common Stock shall be the closing sales price for such stock (or the closing bid, if no sales were reported) as quoted on such exchange or market (or the exchange or market with the greatest volume of trading in the Common Stock) on the last market trading day prior to the day of determination, as reported in The Wall Street Journal or such other source as the Board deems reliable.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(ii)&#160;&#160;&#160;&#160;In the absence of such markets for the Common Stock, the Fair Market Value shall be determined in good faith by the Board in such manner as it deems appropriate and as is consistent with the requirements of section 409A of the Code.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(m)&#160;&#160;&#160;&#160;&#8220;NON-EMPLOYEE DIRECTOR&#8221; means a Director who is not an Employee.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(n)&#160;&#160;&#160;&#160;&#8220;NONSTATUTORY STOCK OPTION&#8221; means an option to purchase Common Stock that is not intended to qualify as an incentive stock option within the meaning of Section 422 of the Code and the regulations promulgated thereunder.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(o) &#160;&#160;&#160;&#160;&#8220;OPTION&#8221; means a Nonstatutory Stock Option to purchase Common Stock granted pursuant to Section 6 of the Plan.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(p)&#160;&#160;&#160;&#160;&#8220;PARTICIPANT&#8221; means any Non-Employee Director to whom a Stock Award is granted pursuant to the Plan.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(q)&#160;&#160;&#160;&#160;&#8220;PLAN&#8221; means this Lexicon Pharmaceuticals, Inc. 2017 Non-Employee Directors&#8217; Equity Incentive Plan.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(r)&#160;&#160;&#160;&#160;&#8220;RESTRICTED STOCK AWARD&#8221; means a right to receive restricted Common Stock granted pursuant to Section 7(a) of the Plan.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(s)&#160;&#160;&#160;&#160;&#8220;RESTRICTED STOCK UNIT AWARD&#8221; means a right to receive shares of Common Stock (or a cash payment equal to the Fair Market Value thereof) granted pursuant to Section 7(b) of the Plan.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(t) &#160;&#160;&#160;&#160;&#8220;RULE 16B-3&#8221; means Rule 16b-3 promulgated under the Exchange Act or any successor to Rule 16b-3, as in effect from time to time.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(u)&#160;&#160;&#160;&#160;&#8220;SECURITIES ACT&#8221; means the Securities Act of 1933, as amended.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(v)&#160;&#160;&#160;&#160;&#8220;STOCK AWARD&#8221; means any right granted under the Plan, including an Option, a Restricted Stock Award or a Restricted Stock Unit Award.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(w)&#160;&#160;&#160;&#160;&#8220;STOCK AWARD AGREEMENT&#8221; means a written agreement between the Company and a holder of a Stock Award evidencing the terms and conditions of an individual Stock Award grant.  Each Stock Award Agreement shall be subject to the terms and conditions of the Plan.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">B-2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt">ADMINISTRATION.</span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(a)&#160;&#160;&#160;&#160;ADMINISTRATION BY BOARD. The Board shall administer the Plan.  The Board may not delegate administration of the Plan to a committee.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(b)&#160;&#160;&#160;&#160;POWERS OF BOARD. The Board shall have the power, subject to, and within the limitations of, the express provisions of the Plan:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(i)&#160;&#160;&#160;&#160; To determine from time to time which of the Non-Employee Directors shall be granted Stock Awards; when and how each Stock Award shall be granted; what type or combination of types of Stock Award shall be granted; the provisions of each Stock Award granted (which need not be identical), including the time or times when a Non-Employee Director shall be permitted to receive Common Stock pursuant to a Stock Award; and the number of shares of Common Stock with respect to which a Stock Award shall be granted to each such Non-Employee Director.</span></div><div style="padding-left:36pt;text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(ii)&#160;&#160;&#160;&#160;To construe and interpret the Plan and Stock Awards granted under it, and to establish, amend and revoke rules and regulations for its administration. The Board, in the exercise of this power, may correct any defect, omission or inconsistency in the Plan or in any Stock Award Agreement, in a manner and to the extent it shall deem necessary or expedient to make the Plan fully effective.</span></div><div style="padding-left:36pt;text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(iii)&#160;&#160;&#160;&#160;To amend the Plan or a Stock Award as provided in Section 12.</span></div><div style="padding-left:36pt;text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(iv)&#160;&#160;&#160;&#160;Generally, to exercise such powers and to perform such acts as the Board deems necessary or expedient to promote the best interests of the Company that are not in conflict with the provisions of the Plan.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(c) &#160;&#160;&#160;&#160;EFFECT OF BOARD&#8217;S DECISION. All determinations, interpretations and constructions made by the Board in good faith shall not be subject to review by any person and shall be final, binding and conclusive on all persons.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt">SHARES SUBJECT TO THE PLAN.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(a)&#160;&#160;&#160;&#160;SHARE RESERVE. Subject to the provisions of Section 11 relating to adjustments upon changes in the Common Stock, the Common Stock that may be issued pursuant to Stock Awards shall not exceed in the aggregate four million (4,000,000) shares of Common Stock.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(b)&#160;&#160;&#160;&#160;ANNUAL LIMIT ON STOCK AWARDS. No Participant shall be eligible to be granted Stock Awards with an aggregate grant date fair value (computed in accordance with the Company&#8217;s financial reporting policies) of more than $500,000 during any calendar year, taken together with any cash fees paid to such Participant in compensation for such Participant&#8217;s service on the Board during such calendar year.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(c)&#160;&#160;&#160;&#160;REVERSION OF SHARES TO THE SHARE RESERVE. If any Stock Award shall for any reason expire or otherwise terminate, in whole or in part, without the shares of Common Stock issuable thereunder being issued in full, the shares of Common Stock not issued under such Stock Award shall revert to and again become available for issuance under the Plan.  For clarity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> shares subject to a Stock Award that are not delivered to a Participant because (i) such Participant&#8217;s right to purchase such shares subject to an Option are surrendered in payment of the exercise price for other shares subject to such Option in a &#8220;net exercise,&#8221; or (ii) such shares are withheld in satisfaction of the withholding of taxes incurred in connection with the exercise of an Option, or the issuance of shares under a Restricted Stock Award or Restricted Stock Unit Award, the shares so surrendered or withheld shall not remain available for subsequent issuance under the Plan.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(d)&#160;&#160;&#160;&#160;SOURCE OF SHARES. The shares of Common Stock subject to the Plan may be unissued shares or reacquired shares, bought on the market or otherwise.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt">ELIGIBILITY.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Stock Awards may be granted under the Plan to all Non-Employee Directors.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt">OPTION PROVISIONS.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Each Option shall be in such form and shall contain such terms and conditions, not inconsistent with the Plan, as the Board shall deem appropriate. The provisions of separate Options need not be identical, but each Option shall include (through incorporation of provisions hereof by reference in the Option or otherwise) the substance of each of the following provisions:</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">B-3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(a) &#160;&#160;&#160;&#160;TERM. No Option shall be exercisable after the expiration of ten (10) years from the date it was granted.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(b)&#160;&#160;&#160;&#160;EXERCISE PRICE. The exercise price of each Option shall be one hundred percent (100%) of the Fair Market Value of the stock subject to the Option on the date the Option is granted. Notwithstanding the foregoing, an Option may be granted with an exercise price lower than that set forth in the preceding sentence if such Option is granted pursuant to an assumption or substitution for another option in a manner satisfying the provisions of Section 424(a) of the Code.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(c)&#160;&#160;&#160;&#160;CONSIDERATION. The purchase price of stock acquired pursuant to an Option may be paid, to the extent permitted by applicable statutes and regulations, in any combination of (i) cash or check, (ii) delivery to the Company of other Common Stock, or (iii) surrender of Participant&#8217;s right to purchase shares subject to any Option with a term expiring in less than one (1) year from the date of exercise(valued, for such purposes, as the Fair Market Value of such surrendered shares on the date of exercise less the exercise price for such surrendered shares) in payment of the exercise price for other shares subject to such Option in a &#8220;net exercise&#8221; of such Option.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(d)&#160;&#160;&#160;&#160;TRANSFERABILITY. An Option is not transferable, except (i) by will or by the laws of descent and distribution, (ii) by instrument to an inter vivos or testamentary trust, in a form accepted by the Company, in which the Option is to be passed to beneficiaries upon the death of the trustor (settlor) and (iii) by gift, in a form accepted by the Company, to a member of the &#8220;immediate family&#8221; of the Participant as that term is defined in 17 C.F.R. 240.16a-1(e). In addition, the Participant may, by delivering written notice to the Company, in a form satisfactory to the Company, designate a third party who, in the event of the death of the Participant, shall thereafter be entitled to exercise the Option.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(e)&#160;&#160;&#160;&#160;VESTING. The total number of shares of Common Stock subject to an Option may, but need not, vest and therefore become exercisable in periodic installments that may, but need not, be equal. The Option may be subject to such other terms and conditions on the time or times when it may be exercised (which may be based on performance or other criteria) as the Board may deem appropriate. The vesting provisions of individual Options may vary.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(f) &#160;&#160;&#160;&#160;TERMINATION OF CONTINUOUS SERVICE. In the event an Participant&#8217;s Continuous Service terminates (other than upon the Participant&#8217;s death or Disability), the Participant may exercise his or her Option (to the extent that the Participant was entitled to exercise it as of the date of termination) but only within such period of time ending on the earlier of (i) the date six (6) months following the termination of the Participant&#8217;s Continuous Service, or (ii) the expiration of the term of the Option as set forth in the Stock Award Agreement. If, after termination, the Participant does not exercise his or her Option within the time specified in the Stock Award Agreement, the Option shall terminate.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(g)&#160;&#160;&#160;&#160;EXTENSION OF TERMINATION DATE. If the exercise of the Option following the termination of the Participant&#8217;s Continuous Service (other than upon the Participant&#8217;s death or Disability) would be prohibited at any time solely because the issuance of shares would violate the registration requirements under the Securities Act, then the Option shall terminate on the earlier of (i) the expiration of the term of the Option set forth in Section 6(a) or (ii) the expiration of a period of three (3) months after the termination of the Participant&#8217;s Continuous Service during which the exercise of the Option would not be in violation of such registration requirements.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(h)&#160;&#160;&#160;&#160;DISABILITY OF PARTICIPANT. In the event an Participant&#8217;s Continuous Service terminates as a result of the Participant&#8217;s Disability, the Participant may exercise his or her Option (to the extent that the Participant was entitled to exercise it as of the date of termination), but only within such period of time ending on the earlier of (i) the date twelve (12) months following such termination or (ii) the expiration of the term of the Option as set forth in the Stock Award Agreement. If, after termination, the Participant does not exercise his or her Option within the time specified herein, the Option shall terminate.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(i)&#160;&#160;&#160;&#160;DEATH OF PARTICIPANT. In the event (i) an Participant&#8217;s Continuous Service terminates as a result of the Participant&#8217;s death or (ii) the Participant dies within the three-month period after the termination of the Participant&#8217;s Continuous Service for a reason other than death, then the Option may be exercised (to the extent the Participant was entitled to exercise the Option as of the date of death) by the Participant&#8217;s estate, by a person who acquired the right to exercise the Option by bequest or inheritance or by a person designated to exercise the Option upon the Participant&#8217;s death, but only within the period ending on the earlier of (A) the date eighteen (18) months</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">following the date of death or (B) the expiration of the term of such Option as set forth in the Stock Award Agreement. If, after death, the Option is not exercised within the time specified herein, the Option shall terminate.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt">PROVISION OF STOCK AWARDS OTHER THAN OPTIONS.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(a)&#160;&#160;&#160;&#160;RESTRICTED STOCK AWARDS.  Each Restricted Stock Award shall be in such form and shall contain such terms and conditions, not inconsistent with the Plan, as the Board shall deem appropriate.  The provisions of separate Restricted Stock Awards need not be identical, but each Restricted Stock Award shall include (through incorporation of provisions hereof by reference in the Restricted Stock Award or otherwise) the substance of each of the following provisions:</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">B-4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="text-align:justify;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(i)&#160;&#160;&#160;&#160;CONSIDERATION. Except as otherwise determined by the Board, no further consideration will be payable by the Participant upon grant of the Restricted Stock Award or delivery of each share of Common Stock subject to the Restricted Stock Award. Any such consideration to be paid by the Participant may be paid in any form of legal consideration that may be acceptable to the Board in its sole discretion and permissible under applicable law.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(ii)&#160;&#160;&#160;&#160;VESTING.  At the time of the grant of a Restricted Stock Award, the Board may, but need not, determine that Shares of Common Stock acquired under a Restricted Stock Award shall be subject to a share repurchase option in favor of the Company in accordance with a vesting schedule to be determined by the Board in its sole discretion.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(iii)&#160;&#160;&#160;&#160;TERMINATION OF PARTICIPANT&#8217;S CONTINUOUS SERVICE. In the event a Participant&#8217;s Continuous Service terminates, the Company may repurchase or otherwise reacquire any or all of the shares of Common Stock held by the Participant which have not vested as of the date of termination under the terms of the Restricted Stock Award.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(iv)&#160;&#160;&#160;&#160;TRANSFERABILITY.  Rights under the Restricted Stock Award shall be transferable by the Participant only upon such terms and conditions as the Board shall determine in its sole discretion.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(b)&#160;&#160;&#160;&#160;RESTRICTED STOCK UNIT AWARDS. Each Restricted Stock Unit Award shall be in such form and shall contain such terms and conditions as the Board shall deem appropriate. The provisions of separate Restricted Stock Unit Awards need not be identical, but each Restricted Stock Unit Award shall include (through incorporation of provisions hereof by reference in the Restricted Stock Unit Award or otherwise) the substance of each of the following provisions:</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(i)&#160;&#160;&#160;&#160;CONSIDERATION. Except as otherwise determined by the Board, no further consideration will be payable by the Participant upon grant of the Restricted Stock Unit Award or delivery of each share of Common Stock subject to the Restricted Stock Unit Award. Any such consideration to be paid by the Participant may be paid in any form of legal consideration that may be acceptable to the Board in its sole discretion and permissible under applicable law.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(ii) &#160;&#160;&#160;&#160;VESTING. At the time of the grant of a Restricted Stock Unit Award, the Board may, but need not, impose such restrictions or conditions to the vesting of the Restricted Stock Unit Award as determined by the Board in its sole discretion.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(iii)&#160;&#160;&#160;&#160;PAYMENT. A Restricted Stock Unit Award may be settled by the delivery of shares of Common Stock, their cash equivalent, any combination thereof or in any other form of consideration, as determined by the Board in its sole discretion.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(iv)&#160;&#160;&#160;&#160;DIVIDEND EQUIVALENTS. Except as otherwise determined by the Board, dividend equivalents shall not be credited in respect of shares of Common Stock subject to a Restricted Stock Unit Award.  If any such dividend equivalents are so credited, such dividend equivalents may be converted into additional shares of Common Stock subject to the Restricted Stock Unit Award in such manner as determined by the Board in its sole discretion.  Any additional shares of Common Stock subject to the Restricted Stock Unit Award credited by reason of such dividend equivalents will be subject to all the terms and conditions of the underlying Restricted Stock Unit Award to which they relate.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(v)&#160;&#160;&#160;&#160;TERMINATION OF PARTICIPANT&#8217;S CONTINUOUS SERVICE. Except as otherwise determined by the Board, such portion of the Restricted Stock Unit Award that has not vested will be forfeited upon the Participant&#8217;s termination of Continuous Service. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(vi)&#160;&#160;&#160;&#160;TRANSFERABILITY. Rights under the Restricted Stock Unit Award shall be transferable by the Participant only upon such terms and conditions as the Board shall determine in its sole discretion.</span></div><div style="text-align:justify;text-indent:72pt"><span><br/></span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt">COVENANTS OF THE COMPANY.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(a)&#160;&#160;&#160;&#160;AVAILABILITY OF SHARES. During the terms of the Stock Awards, the Company shall keep available at all times the number of shares of Common Stock required to satisfy such Stock Awards.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(b)&#160;&#160;&#160;&#160;SECURITIES LAW COMPLIANCE. The Company shall seek to obtain from each regulatory commission or agency having jurisdiction over the Plan such authority as may be required to grant Stock Awards and to issue and sell shares of Common Stock upon exercise, grant or vesting of the Stock Awards; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">provided, however</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, that this undertaking shall not require the Company to register under the Securities Act the Plan, any Stock Award or any stock issued or issuable pursuant to any such Stock Award. If, after reasonable efforts, the Company is unable to obtain from any such regulatory commission or agency the authority which counsel for the Company deems necessary for the lawful issuance and sale of Common Stock under the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">B-5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Plan, the Company shall be relieved from any liability for failure to issue and sell Common Stock upon exercise or grant of such Stock Awards unless and until such authority is obtained.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt">USE OF PROCEEDS FROM STOCK.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds from the sale of Common Stock pursuant to any Stock Awards shall constitute general funds of the Company.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt">MISCELLANEOUS.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(a)&#160;&#160;&#160;&#160;STOCKHOLDER RIGHTS. No Participant shall be deemed to be the holder of, or to have any of the rights of a holder with respect to, any shares subject to such Stock Award unless and until such Participant has satisfied all requirements for the acquisition of shares of Common Stock underlying the Stock Award pursuant to its terms.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(b)&#160;&#160;&#160;&#160;NO SERVICE RIGHTS. Nothing in the Plan or any instrument executed or Stock Award granted pursuant thereto shall confer upon any Participant any right to continue to serve the Company as a Non-Employee Director or shall affect the right of the Company or an Affiliate to terminate (i) the employment of an Employee with or without notice and with or without cause, (ii) the service of a Consultant pursuant to the terms of such Consultant&#8217;s agreement with the Company or an Affiliate or (iii) the service of a Director pursuant to the Bylaws of the Company or an Affiliate, and any applicable provisions of the corporate law of the state in which the Company or the Affiliate is incorporated, as the case may be.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(c)&#160;&#160;&#160;&#160;INVESTMENT ASSURANCES. The Company may require a Participant, as a condition of exercising or acquiring Common Stock under any Stock Award, (i) to give written assurances satisfactory to the Company as to the Participant&#8217;s knowledge and experience in financial and business matters and/or to employ a purchaser representative reasonably satisfactory to the Company who is knowledgeable and experienced in financial and business matters and that he or she is capable of evaluating, alone or together with the purchaser representative, the merits and risks of the Stock Award; and (ii) to give written assurances satisfactory to the Company stating that the Participant is acquiring the Common Stock subject to the Stock Award for the Participant&#8217;s own account and not with any present intention of selling or otherwise distributing the Common Stock.  The foregoing requirements, and any assurances given pursuant to such requirements, shall be inoperative if (iii) the issuance of the shares upon the exercise or acquisition of Common Stock under the Stock Award has been registered under a then currently effective registration statement under the Securities Act or (iv) as to any particular requirement, a determination is made by counsel for the Company that such requirement need not be met in the circumstances under the then applicable securities laws. The Company may, upon advice of counsel to the Company, place legends on stock certificates issued under the Plan as such counsel deems necessary or appropriate in order to comply with applicable securities laws, including, but not limited to, legends restricting the transfer of the Common Stock.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(d)&#160;&#160;&#160;&#160;WITHHOLDING OBLIGATIONS. The Participant may satisfy any federal, state or local tax withholding obligation relating to the exercise or acquisition of Common Stock under a Stock Award by any of the following means (in addition to the Company&#8217;s right to withhold from any compensation paid to the Participant by the Company) or by a combination of such means: (i) tendering a cash payment; (ii) authorizing the Company to withhold shares from the shares of the Common Stock otherwise issuable to the Participant as a result of the exercise or acquisition of stock under the Stock Award; or (iii) delivering to the Company owned and unencumbered shares of the Common Stock.&#160;&#160;&#160;&#160;</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt">ADJUSTMENTS UPON CHANGES IN STOCK.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(a)&#160;&#160;&#160;&#160;CAPITALIZATION ADJUSTMENTS. If any change is made in the stock subject to the Plan, or subject to any Stock Award, without the receipt of consideration by the Company (through merger, consolidation, reorganization, recapitalization, reincorporation, stock dividend, dividend in property other than cash, stock split, liquidating dividend, combination of shares, exchange of shares, change in corporate structure or other transaction not involving the receipt of consideration by the Company), the Plan will be appropriately adjusted in the class(es) and number of securities subject to the Plan pursuant to Section 4(a) and the outstanding Stock Awards will be appropriately adjusted in the class(es) and number of securities and price per share of stock subject to such outstanding Stock Awards. The Board shall make such adjustments, and its determination shall be final, binding and conclusive. For clarity, the conversion of any convertible securities of the Company shall not be treated as a transaction &#8220;without receipt of consideration&#8221; by the Company.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(b)&#160;&#160;&#160;&#160;DISSOLUTION OR LIQUIDATION. In the event of a dissolution or liquidation of the Company, then all outstanding Stock Awards shall terminate immediately prior to such event.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(c)&#160;&#160;&#160;&#160;ASSET SALE, MERGER, CONSOLIDATION OR REVERSE MERGER.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">B-6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(i)&#160;&#160;&#160;&#160;In the event of (i) a sale, lease or other disposition of all or substantially all of the assets of the Company, (ii) a merger or consolidation in which the Company is not the surviving corporation or (iii) a reverse merger in which the Company is the surviving corporation but the shares of Common Stock outstanding immediately preceding the merger are converted by virtue of the merger into other property, whether in the form of securities, cash or otherwise, then any surviving corporation or acquiring corporation shall assume any Stock Awards outstanding under the Plan or shall substitute similar stock awards (including an award to acquire the same consideration paid to the stockholders in the transaction described in this subsection 11(c) for those outstanding under the Plan).</span></div><div style="padding-left:36pt;text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(ii)&#160;&#160;&#160;&#160;In the event any surviving corporation or acquiring corporation refuses to assume such Stock Awards or to substitute similar stock awards for those outstanding under the Plan, then the vesting of such Stock Awards shall be accelerated in full, and the Stock Awards shall terminate if not exercised (if applicable) at or prior to such event.</span></div><div style="padding-left:36pt;text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(iii)&#160;&#160;&#160;&#160;In the event any surviving corporation or acquiring corporation assumes such Stock Awards or substitutes similar stock awards for those outstanding under the Plan but the Participant is not elected or appointed to the board of directors of the surviving corporation or acquiring corporation at the first meeting of such board of directors after such change in control event, then the vesting of such Stock Awards shall be accelerated by eighteen (18) months on the day after the first meeting of the board of directors of the surviving corporation or acquiring corporation.</span></div><div style="padding-left:36pt;text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(iv)&#160;&#160;&#160;&#160;In the event any surviving corporation or acquiring corporation assumes such Stock Awards or substitutes similar stock awards for those outstanding under the Plan and the Participant is elected or appointed to the board of directors of the surviving corporation or acquiring corporation at the first meeting of such board of directors after such change in control event, then the vesting of such Stock Awards shall not be accelerated.</span></div><div style="text-align:justify;text-indent:108pt"><span><br/></span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt">AMENDMENT OF THE PLAN AND STOCK AWARDS.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(a)&#160;&#160;&#160;&#160;AMENDMENT OF PLAN. The Board at any time, and from time to time, may amend the Plan. However, except as provided in Section 11 relating to adjustments upon changes in stock, no amendment shall be effective unless approved by the stockholders of the Company to the extent stockholder approval is necessary to satisfy the requirements of Rule 16b-3 or any Nasdaq or other securities exchange listing requirements.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(b)&#160;&#160;&#160;&#160;STOCKHOLDER APPROVAL. The Board may, in its sole discretion, submit any other amendment to the Plan for stockholder approval.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(c)&#160;&#160;&#160;&#160;NO IMPAIRMENT OF RIGHTS. Rights under any Option granted before amendment of the Plan shall not be impaired by any amendment of the Plan unless (i) the Company requests the consent of the Participant and (ii) the Participant consents in writing.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(d)&#160;&#160;&#160;&#160;AMENDMENT OF STOCK AWARDS. The Board at any time, and from time to time, may amend the terms of any one or more Stock Awards; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">provided, however, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">that the rights under any Stock Award shall not be impaired by any such amendment unless (i) the Company requests the consent of the Participant and (ii) the Participant consents in writing.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(e) &#160;&#160;&#160;&#160;SUBSTITUTE AWARDS; NO REPRICING.  Stock Awards may be granted in substitution or exchange for any other Stock Award granted under the Plan or under another plan of the Company or an Affiliate or any other right of an eligible person to receive payment from the Company or an Affiliate.  Stock Awards may also be granted under the Plan in substitution for awards held by individuals who become eligible persons as a result of a merger, consolidation or acquisition of another entity or the assets of another entity by or with the Company or an Affiliate (&#8220;Substitute Awards&#8221;).  Such Substitute Awards referred to in the immediately preceding sentence that are Options may have an exercise price that is less than the Fair Market Value of a share of Common Stock on the date of the substitution if such substitution complies with applicable laws (including rules regarding nonqualified deferred compensation) and exchange rules.  Except as provided in this Section 12(e) or in Section 11, without the approval of the stockholders of the Company, the terms of outstanding Stock Awards may not be amended to (i) reduce the exercise price of an outstanding Option, (ii) grant a new Option or other Stock Award in substitution for, or upon the cancellation of, any previously granted Option that has the effect of reducing the exercise price thereof, (iii) exchange any Option for Common Stock, cash or other consideration when the exercise price or grant price per share of Common Stock under such Option exceeds the Fair Market Value of a share of Common Stock.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt">TERMINATION OR SUSPENSION OF THE PLAN.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(a)&#160;&#160;&#160;&#160;PLAN TERM. The Board may suspend or terminate the Plan at any time. Unless sooner terminated, the Plan shall terminate on the day before the tenth (10th) anniversary of the date the Plan is adopted by the Board or approved by the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">B-7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">stockholders of the Company, whichever is earlier. No Stock Awards may be granted under the Plan while the Plan is suspended or after it is terminated.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(b)&#160;&#160;&#160;&#160;NO IMPAIRMENT OF RIGHTS. Suspension or termination of the Plan shall not impair rights and obligations under any Stock Award granted while the Plan is in effect except with the written consent of the Participant.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt">EFFECTIVE DATE OF PLAN.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Plan shall become effective as determined by the Board, but no Option shall be exercised and no Restricted Stock Award or Restricted Stock Unit Award shall be granted unless and until the Plan has been approved by the stockholders of the Company, which approval shall be within twelve (12) months before or after the date the Plan is adopted by the Board.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt">CHOICE OF LAW.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">All questions concerning the construction, validity and interpretation of this Plan shall be governed by the law of the State of Delaware, without regard to such state&#8217;s conflict of laws rules.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">B-8</span></div></div></div><div id="i29f56aa9946248519609c20b75df062f_533"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:right;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Appendix C</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORM OF</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATE OF AMENDMENT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TO</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIXTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OF</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LEXICON PHARMACEUTICALS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> INC.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LEXICON PHARMACEUTICALS, INC. (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Corporation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">DGCL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), hereby certifies as follows pursuant to Section 242 of the DGCL:</span></div><div style="margin-bottom:12pt;padding-left:58.5pt;text-align:justify;text-indent:-58.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FIRST: &#160;&#160;&#160;&#160;That at a meeting of the Board of Directors of the Corporation, resolutions were duly adopted to amend the Corporation&#8217;s Sixth Amended and Restated Certificate of Incorporation to insert the following provision to the end of Section 4.01(a) of Article IV thereof:</span></div><div style="padding-left:72pt;padding-right:72pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Effective as of 5:00 p.m. Eastern time on the date this Certificate of Amendment is filed with the Secretary of State of the State of Delaware, each _____ (___) shares of the Corporation&#8217;s Common Stock issued and outstanding shall, automatically and without any action on the part of the respective holders thereof, be combined and converted into one (1) share of the Corporation&#8217;s Common Stock; provided that the Corporation shall issue no fractional shares as a result of the actions set forth herein but shall instead pay to the holder of such fractional share a sum in cash equal to such fraction multiplied by the closing price of the Corporation&#8217;s Common Stock as reported on the Nasdaq Global Select Market on the last trading day before the date this Certificate of Amendment is filed with the Secretary of State of Delaware.&#8221;</span></div><div style="padding-left:72pt;text-align:justify"><span><br/></span></div><div style="padding-left:58.5pt;text-align:justify;text-indent:-58.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECOND: &#160;&#160;&#160;&#160;That pursuant to a resolution of its Board of Directors, an annual meeting of the Corporation&#8217;s stockholders was duly called and held upon notice in accordance with the provisions of Section 222 of the DGCL, at which meeting the necessary number of shares as required by applicable law were voted in favor of such amendment.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:58.5pt;text-align:justify;text-indent:-58.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">THIRD: &#160;&#160;&#160;&#160;That such amendment was duly adopted in accordance with the provisions of Section 242 of the DGCL.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, the Corporation has caused this Certificate of Amendment to be signed by Brian T. Crum, its Senior Vice President, General Counsel and Secretary, this ____ day of ________________, 2025.</span></div><div style="margin-bottom:12pt;padding-left:216pt;text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:216pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LEXICON PHARMACEUTICALS, INC.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:216pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By:&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</span></div><div style="padding-left:256.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Brian T. Crum</span></div><div style="margin-bottom:30pt;padding-left:256.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Senior Vice President, General Counsel and Secretary</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C-1</span></div></div></div><div id="i29f56aa9946248519609c20b75df062f_52"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"/><td style="width:38.632%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.025%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:56.043%"/><td style="width:0.1%"/></tr><tr style="height:59pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"><div style="text-align:center"><img src="lxrx-20250325_g2.gif" alt="Screenshot 2025-03-21 092841.gif" style="height:66px;margin-bottom:5pt;vertical-align:text-bottom;width:329px"/></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">VOTE BY INTERNET - www.proxyvote.com or scan the QR Barcode above</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Use the Internet to transmit your voting instructions and for electronic delivery of information.  Vote by 11:59 P.M. ET on June 1, 2025.  Have your proxy card in hand when you access the web site and follow the instructions to obtain your records and to create an electronic voting instruction form.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">LEXICON PHARMACEUTICALS, INC.<br/>2445 TECHNOLOGY FOREST BLVD., 11th FLOOR<br/>THE WOODLANDS, TX  77381</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">During The Meeting - Go to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">www.virtualshareholdermeeting.com/LXRX2025</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">You may attend the meeting via the Internet and vote during the meeting. Have the information that is printed in the box marked by the arrow available and follow the instructions.</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">VOTE BY PHONE - 1-800-690-6903</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Use any touch-tone telephone to transmit your voting instructions.  Vote by 11:59 P.M. ET on June 1, 2025.  Have your proxy card in hand when you call and then follow the instructions.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">VOTE BY MAIL</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mark, sign and date your proxy card and return it in the postage-paid envelope we have provided or return it to Vote Processing, c/o Broadridge, 51 Mercedes Way, Edgewood, NY  11717</span></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:20.391%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.391%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.636%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.405%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TO VOTE, MARK BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%">x</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">KEEP THIS PORTION FOR YOUR RECORDS</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">DETACH AND RETURN THIS PORTION ONLY</span></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED</span></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:2.419%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.228%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.152%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.791%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.468%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.178%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.351%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.791%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.713%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">For <br/>All</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Withhold All</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">For All Except</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">To withhold authority to vote for any individual nominee(s), mark "For All Except" and write the number(s) of the nominee(s) on the line below</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:100%">o</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:100%">o</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:100%">o</span></td><td colspan="9" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="12" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">The Board of Directors recommends you vote FOR the following:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Election of Directors</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Nominees</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">01</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Raymond Debbane</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">02 Ivan H. Cheung</span></td><td colspan="12" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="24" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">The Board of Directors recommends you vote FOR the following proposals.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">For</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Against</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Abstain</span></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.</span></td><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Ratification and approval of the amendment to the Company&#8217;s 2017 Equity Incentive Plan</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:100%">o</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:100%">o</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:100%">o</span></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3.</span></td><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Ratification and approval of the amendment to the Company&#8217;s 2017 Non-Employee Directors&#8217; Equity Incentive Plan</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:100%">o</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:100%">o</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:100%">o</span></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4.</span></td><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Approval of an amendment to the Company&#8217;s Sixth Amended and Restated Certificate of Incorporation to effect, at the discretion of the Company&#8217;s board of directors, a reverse split of its common stock, at a ratio within a range of 1-for-10 to 1-for-50, at any time prior to the Company&#8217;s 2026 annual meeting of stockholders and with the actual ratio to be determined within that range at the discretion of the Company&#8217;s board of directors</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:100%">o</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:100%">o</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:100%">o</span></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5.</span></td><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Advisory vote to approve the compensation paid to the Company&#8217;s named executive officers</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:100%">o</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:100%">o</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:100%">o</span></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6.</span></td><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Ratification and approval of the appointment of Ernst &amp; Young LLP as the Company's independent auditors for the fiscal year ending December 31, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:100%">o</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:100%">o</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:100%">o</span></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:6pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="24" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Note:</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">  In their discretion, upon such other matters that may properly come before the meeting or any adjournment or adjournments thereof.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="24" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Please sign exactly as your name(s) appear(s) hereon.  When signing as attorney, executor, administrator, or other fiduciary, please give full title as such.  Joint owners should each sign personally.  All holders much sign.  If a corporation or partnership, please sign in full corporate or partnership name, by authorized officer.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"/><td colspan="12" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:18pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"/><td colspan="12" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"/><td colspan="12" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"/><td colspan="12" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Signature (PLEASE SIGN WITHIN BOX)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Signature (Joint Owners)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Date</span></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-right:1pt solid #000000;padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.222%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting: </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> The Notice &amp; Proxy Statement and Annual Report are available at </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">www.proxyvote.com.</span></div></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"><tr><td style="width:1.0%"/><td style="width:4.346%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:85.435%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.919%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lexicon Pharmaceuticals, Inc.<br/>Annual Meeting of Stockholders<br/>June 2, 2025<br/>This Proxy is solicited by the Board of Directors</span></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The stockholder(s) hereby appoint(s) Michael S. Exton, Ph.D. and Scott M. Coiante, or either of them, as proxies, each with the power to appoint his substitute, and hereby authorizes them to represent and to vote, as designated on the reverse side of this ballot, all of the shares of Common Stock of Lexicon Pharmaceuticals, Inc. that the stockholder(s) is/are entitled to vote at the Annual Meeting of Stockholders to be held at 8:00 a.m. CDT on June 2, 2025, and any adjournment or postponement thereof.</span></div></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">THIS PROXY, WHEN PROPERLY EXECUTED, WILL BE VOTED AS DIRECTED BY THE STOCKHOLDER(S).  IF NO SUCH DIRECTIONS ARE MADE, THIS PROXY WILL BE VOTED FOR THE ELECTION OF THE NOMINEES LISTED ON THE REVERSE SIDE FOR THE BOARD OF DIRECTORS AND FOR EACH OTHER PROPOSAL.</span></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Continued and to be signed on reverse side</span></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-right:1pt solid #000000;padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>2
<FILENAME>lxrx-20250325.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:2b1dddfe-05bf-4b11-93bd-da68508bbfaf,g:4ab81c16-7e5c-4f22-90a2-d745a11935f6-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:lxrx="http://www.lexpharma.com/20250325" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.lexpharma.com/20250325">
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei-sub/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-sub-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd-sub/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lxrx-20250325_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lxrx-20250325_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lxrx-20250325_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="lxrx_LonnelCoatsMember" abstract="true" name="LonnelCoatsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lxrx_MichaelS.ExtonPh.D.Member" abstract="true" name="MichaelS.ExtonPh.D.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>3
<FILENAME>lxrx-20250325_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:2b1dddfe-05bf-4b11-93bd-da68508bbfaf,g:4ab81c16-7e5c-4f22-90a2-d745a11935f6-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#IndividualsOnly"/>
  <link:definitionLink xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_LonnelCoatsMember_b708bb80-6cf2-4b8c-9427-7103b98dedcb" xlink:href="lxrx-20250325.xsd#lxrx_LonnelCoatsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_lxrx_LonnelCoatsMember_b708bb80-6cf2-4b8c-9427-7103b98dedcb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_MichaelS.ExtonPh.D.Member_0e5f31ee-f543-4566-83c1-d24ba38e9f2f" xlink:href="lxrx-20250325.xsd#lxrx_MichaelS.ExtonPh.D.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_lxrx_MichaelS.ExtonPh.D.Member_0e5f31ee-f543-4566-83c1-d24ba38e9f2f" xlink:type="arc" order="3"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>lxrx-20250325_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:2b1dddfe-05bf-4b11-93bd-da68508bbfaf,g:4ab81c16-7e5c-4f22-90a2-d745a11935f6-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_lxrx_MichaelS.ExtonPh.D.Member_label_en-US" xlink:label="lab_lxrx_MichaelS.ExtonPh.D.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Michael S. Exton, Ph.D. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_MichaelS.ExtonPh.D.Member" xlink:href="lxrx-20250325.xsd#lxrx_MichaelS.ExtonPh.D.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_MichaelS.ExtonPh.D.Member" xlink:to="lab_lxrx_MichaelS.ExtonPh.D.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_LonnelCoatsMember_label_en-US" xlink:label="lab_lxrx_LonnelCoatsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lonnel Coats [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_LonnelCoatsMember" xlink:href="lxrx-20250325.xsd#lxrx_LonnelCoatsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_LonnelCoatsMember" xlink:to="lab_lxrx_LonnelCoatsMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>lxrx-20250325_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:2b1dddfe-05bf-4b11-93bd-da68508bbfaf,g:4ab81c16-7e5c-4f22-90a2-d745a11935f6-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_LonnelCoatsMember" xlink:href="lxrx-20250325.xsd#lxrx_LonnelCoatsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_lxrx_LonnelCoatsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_MichaelS.ExtonPh.D.Member" xlink:href="lxrx-20250325.xsd#lxrx_MichaelS.ExtonPh.D.Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_lxrx_MichaelS.ExtonPh.D.Member" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>lxrx-20250325_g1.jpg
<TEXT>
begin 644 lxrx-20250325_g1.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_X0JH17AI9@  34T *@    @ !P$2  ,
M   !  $   $:  4    !    8@$;  4    !    :@$H  ,    !  (   $Q
M  (   !I    <@$R  (    4    VX=I  0    !    \    1P +<;    G
M$  MQL   "<0061O8F4@4&AO=&]S:&]P($-3,R H,3 N,'@R,# V,3(P."!;
M,C P-C$R,#@N8F5T82XQ,C4Q(#(P,#8O,3(O,#@Z,#(Z,# Z,# @8W5T;V9F
M.R!M(&)R86YC:%TI("!-86-I;G1O<V@ ,C P-SHP-#HQ,R Q,#HU,#HP-
M  .@ 0 #     0 !  "@ @ $     0  !'Z@ P $     0   9D
M!@$#  ,    !  8   $:  4    !   !:@$;  4    !   !<@$H  ,    !
M  (   (!  0    !   !>@("  0    !   ))@        !(     0   $@
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M1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_V@ , P$
M A$#$0 _ /54DDDE*20[[ZL:BS(N=LJJ:7O<>P DKE:.L9'5LDV/EF.'?HJ.
MP'9UG[]G^K%+CPRF"=HQW+#FYB&,QB=9S^6/_=/6@@B09'BG0Z/YEGP1%$=V
M8;*22224I))))2DDDDE*22224I))))2DDDDE*22224__T/4[)]-T:':?R+&N
MR,ANK;7CYG^*V7B6.'D5A9'"@Y@D 45DW-ZYU?,'1\RNPMM8:_SA!Y;^<S_R
M"S?JQE4WZ,,/:9<P\@>/\IJ-U_\ Y*R_^+_[\U97U-_I[O\ BS_U3$_D>9R@
M'&3Q0E.O5_=Z2<WF!?,8Y'<1K\7TEQ(P'D$@BMQ!&AX*Q?J%?D7]"]3(MLO?
MZSAOM>Y[HVLTWV%SEM/_ .3W_P#%._(5@_XO?_$__P!>?_U-:E.Y=0;#R>G2
M27(XMW4?K7GY+F9=N#TC%=Z=;<9VRRT_O.NC\YOZ3_B[*J_YSU+4$O7)+E0<
MWZN=<PL1V9=F=,ZD34UN0[U+*[!M:W;9I[7/L9_JQ3^M%W6.E9V/UK'NLNP*
MXKR,.0&-GV[O;MW>M^9;;_1\CT_\#:DIZ=97UCQNMY."VOHM[<?(%@+W$[26
M0[VMLV7;?TGIO^@LKJ'5LGKV9C]*Z%D.JI+69&=FUDM=6P^YE+7?Z;]^O]_]
M%9^C^UHOUZR,K#Z'6_%OMIL%S6FRMQ:\C9;])S-O[J2GHJ1:VFMMS@^T- L>
M! +H][@W\W<Y36/U[K?[&Z.,L 67OVUTM=,%Y:7[[(]VRMC'V/\ W_H*AA_5
MKJF;0W*ZQU7,9DV@/]''L])M<_F%K6[/4;^=L8S_ *Y_.)*>G26!U#-N^K'0
M-UN0_J&3O-=%E\22XN>SU=GN>RBINYWN]2W9]-5\/ZM=1S,9F7U3JV:S-M&_
M91;Z3*]PEK/2:W9O;^?M24].DN9Z#U7J./U>_P"KW5K1D6UC=BY40Y[0 _:_
M^5Z3M_\ UN[WV?35&NWK69]:>I=.Q<ZRBD_3>27^E6T5?T2JP^BRZU[]F_9^
MC9ZCTE/:)+C>O=+ZET+&'5>G=3R[34]HNKR;#:T[CL8[;[6.;ZCFL>S9^?\
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M0.PD.:]L!['#Z-E;G![=W]E ROJ[TS*Z73TJYMAQ,?;Z8]1^X;0YC?TN[?\
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M;&ES=#X*.$))30/M       0 2P    !  $!+     $  3A"24T$)@
M#@             _@   .$))300-       $    >#A"24T$&0      !
M !XX0DE- _,       D           $ .$))300*       !   X0DE-)Q
M      H  0         !.$))30/U      !( "]F9@ ! &QF9@ &       !
M "]F9@ ! *&9F@ &       ! #(    ! %H    &       ! #4    ! "T
M   &       !.$))30/X      !P  #_____________________________
M ^@     _____________________________P/H     /______________
M______________\#Z     #_____________________________ ^@  #A"
M24T$         @  .$))300"       "   X0DE-!#        $! #A"24T$
M+0      !@ !     CA"24T$"       $     $   )    "0      X0DE-
M!!X       0     .$))300:      --    !@             !F0  !'X
M   , &P 90!X &D 8P!O &X 7P!C &T >0!K     0
M       !              1^   !F0                     !
M                 !     !        ;G5L;     (    &8F]U;F1S3V)J
M8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F=&QO
M;F<          $)T;VUL;VYG   !F0    !29VAT;&]N9P  !'X    &<VQI
M8V5S5FQ,<P    %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$
M;&]N9P         '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,
M15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *
M15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T
M,0    0     5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M
M;&]N9P   9D     4F=H=&QO;F<   1^     W5R;%1%6%0    !
M;G5L;%1%6%0    !        37-G951%6%0    !       &86QT5&%G5$58
M5     $       YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$58
M5     $       EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@
M  =D969A=6QT    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N
M    !V1E9F%U;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L
M;W)4>7!E     $YO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U
M='-E=&QO;F<         #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT
M3W5T<V5T;&]N9P      .$))300H       ,     3_P        .$))3004
M       $     CA"24T$#      )0@    $   "@    .0   >   &K@   )
M)@ 8  '_V/_@ !!*1DE&  $"  !( $@  /_M  Q!9&]B95]#30 !_^X #D%D
M;V)E &2      ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,
M# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0
M% X.#A04#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,_\  $0@ .0"@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$!
M 0$!          ,  0($!08'" D*"P$  04! 0$! 0$          0 " P0%
M!@<("0H+$  !! $# @0"!0<&" 4###,!  (1 P0A$C$%05%A$R)Q@3(&%)&A
ML4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U%J*R@R9$DU1D1<*C=#87TE7B9?*S
MA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]C='5V=WAY>GM\?7
MY_<1  (" 0($! ,$!08'!P8%-0$  A$#(3$2!$%187$B$P4R@9$4H;%"(\%2
MT? S)&+A<H*20U,58W,T\24&%J*R@P<F-<+21)-4HQ=D154V=&7B\K.$P]-U
MX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:  P#
M 0 "$0,1 #\ ]522224I)#OOJQJ+,BYVRJII>]Q[ "2N5HZQD=6R38^68X=^
MBH[ =G6?OV?ZL4N/#*8)VC'<L.;F(8S&)UG/Y8_]T]:"")!D>*=#H_F6?!$4
M1W9ALI))))2DDDDE*22224I))))2DDDDE*22224I))))3__0]3LGTW1H=I_(
ML:[(R&ZMM>/F?XK9>)8X>16%D<*#F"0!163<WKG5\P='S*["VUAK_.$'EOYS
M/_(+-^K&53?HPP]IES#R!X_RFHW7_P#DK+_XO_OS5E?4W^GN_P"+/_5,3^1Y
MG* <9/%"4Z]7]WI)S>8%\QCD=Q&OQ?27$C >02"*W$$:'@K%^H5^1?T+U,BV
MR]_K.&^U[GNC:S3?87.6T_\ Y/?_ ,4[\A6#_B]_\3__ %Y__4UJ4[EU!L/)
MZ=))<CBW=1^M>?DN9EVX/2,5WIUMQG;++3^\ZZ/SF_I/^+LJK_G/4M02]<DN
M5!S?JYUS"Q'9EV9TSJ1-36Y#O4LKL&UK=MFGM<^QG^K%/ZT7=8Z5G8_6L>ZR
M[ KBO(PY 8V?;N]NW=ZWYEMO]'R/3_P-J2GIUE?6/&ZWDX+:^BWMQ\@6 O<3
MM)9#O:VS9=M_2>F_Z"RNH=6R>O9F/TKH60ZJDM9D9V;62UU;#[F4M=_IOWZ_
MW_T5GZ/[6B_7K(RL/H=;\6^VFP7-:;*W%KR-EOTG,V_NI*>BI%K::VW.#[0T
M"QX$ NCWN#?S=SE-8_7NM_L;HXRP!9>_;72UTP7EI?OLCW;*V,?8_P#?^@J&
M']6NJ9M#<KK'5<QF3: _T<>STFUS^86M;L]1OYVQC/\ KG\XDIZ=)8'4,V[Z
ML= W6Y#^H9.\UT67Q)+BY[/5V>Y[**F[G>[U+=GTU7P_JUU',QF9?5.K9K,V
MT;]E%OI,KW"6L])K=F]OY^U)3TZ2YGH/5>HX_5[_ *O=6M&1;6-V+E1#GM #
M]K_Y7I.W_P#6[O?9]-4:[>M9GUIZET[%SK**3]-Y)?Z5;15_1*K#Z++K7OV;
M]GZ-GJ/24]HDN-Z]TOJ70L8=5Z=U/+M-3VBZO)L-K3N.QCMOM8YOJ.:Q[-GY
M_P"CLJV+J\+)&7A8^6!M&14RT-YC>T/C_I)*?__1]4/"P<CA;ZR;NG93IVM:
M?[7^Q0YXD@4+63%O,=?_ .2LL#4FN !XES4WU(Z,:\YQRS#_ $2?2;V]U>EC
MQ^=_46IE].SZP7.H<1XLA_X,W.2^JY!ZG;':EP/^?6J>*<X980HQN?%KOLUC
MC!RQE(>%%Z3):&XEK6B *W0/D5SG^+^RMG0(>]K2;G\D#\VM=/8P65NK=P\%
MICF"(7,C_%YT* #9D.V@ $O83 _ZTM)N/2>O0[VBQI)T #A.JX/ZK=%Z-F6Y
M73>JTEV?BO(:/4L9+&Q6]K6U/8UWIV-W_P#%W5+=QOJ'T3&R:<FMUWJ8]C+6
M2YL;F.%C=WZ/]YJN=5^K'3.IWMRW^ICY;8C)QW>G9[=&SHYNYO[^WU$E(Z?J
M?]7<>^J^K'<VVI[;*R;K3[V'U&>UUI:[Z*%]:>K65L;T7 8+^I=1!K:PZAE;
MI;9;8/=^8+/_  6W_ HV)]5<*G*JS,G)RNH7XYW4.RKB\5N_?K8W8W=_65K&
MZ'@8W5,CJK ]V5D@!Q>XO#?WO2W^YF_;7_VW^B]-)3S6#;;]3^K?8<PBSIF=
M#F9>W:6O: QSW\^UGT;F;OYOT\G_ +D*[_C$_P"06?\ 'M_ZBY;G5NE8G5L-
MV'E ["0YKVP'L</HV5N<'MW?V4#*^KO3,KI=/2KFV'$Q]OICU'[AM#F-_2[M
M_P!%Z2G%^O>-:_HN)DL&YN/8W>.P#V&MCG?]=].O_KBZ;"S*,[$JR\=VZJYH
M<T^'[S7?RV.]C_Y:FZBI])HL8+*G-V.8\;@6D;2U[7?2]JPA]2L&E[W8.;FX
M++#+ZL>XM:?\YKW_ .>])2#_ !A8UEO1J[F#<,>X&SR#VOI#C_URRM=#A9=.
M;B59=!W57-#VGX_FG^4WZ+T#IW1L#I^'9A4L-E-Q<Z_UG&PV.> RQUOJ;MWJ
M-;[_ ,Q9G_,O"K+VX>;G85%A)?CT7D5Z_P!=KW?]))31K=]O_P 8!MQ_=7@5
M%MSQQ(9926_UO5R/3_ZQ;^XI]#_\6W6/ZG_I%;_2NC]/Z1C^A@U;&N@O>3+W
MD:;K'E#Q.AXF)U7)ZK6^PWY8BQKB"P?1^@W:'?X/]Y)34^NG_B;ROZU/_GZI
M7NA?\B=/_P#"M/\ Y[8I]4Z;1U3!LP<ASVU6EI<:R [V.;:V"X._.8BXF-7B
M8M.+62:\>MM3"[5Q# &-W<>[VI*?_]+U5))))2D+[/0+_M(K:+RW8; /<6F#
MM<?SOHHJ2!K2ZWTON@UU4DDDBE22222E))))*4DDDDI22222E))))*4DDDDI
M22222G__V3A"24T$(0      50    $!    #P!! &0 ;P!B &4 ( !0 &@
M;P!T &\ <P!H &\ <    !, 00!D &\ 8@!E "  4 !H &\ = !O ', : !O
M '  ( !# %, ,P    $ .$))300&       '  8    ! 0#_X3Q_:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@
M:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM
M;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R
M92 T+C$M8S R-R Q+C(V,S0R-RP@1G)I($1E8R P,2 R,# V(#$P.C$U.C$U
M(CX*(" @/')D9CI21$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q
M.3DY+S R+S(R+7)D9BUS>6YT87@M;G,C(CX*(" @(" @/')D9CI$97-C<FEP
M=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z9&,](FAT=' Z
M+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q+C$O(CX*(" @(" @(" @/&1C.F9O
M<FUA=#YI;6%G92]J<&5G/"]D8SIF;W)M870^"B @(" @(" @(#QD8SIT:71L
M93X*(" @(" @(" @(" @/')D9CI!;'0^"B @(" @(" @(" @(" @(#QR9&8Z
M;&D@>&UL.FQA;F<](G@M9&5F875L="(^;&5X,#(X7S-C;VQO<CPO<F1F.FQI
M/@H@(" @(" @(" @(" \+W)D9CI!;'0^"B @(" @(" @(#PO9&,Z=&ET;&4^
M"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T
M:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIX87 ](FAT=' Z
M+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\B/@H@(" @(" @(" \>&%P.D-R96%T
M;W)4;V]L/D%D;V)E(%!H;W1O<VAO<"!#4S,@*#$P+C!X,C P-C$R,#@@6S(P
M,#8Q,C X+F)E=&$N,3(U,2 R,# V+S$R+S X.C R.C P.C P(&-U=&]F9CL@
M;2!B<F%N8VA=*2 @36%C:6YT;W-H/"]X87 Z0W)E871O<E1O;VP^"B @(" @
M(" @(#QX87 Z0W)E871E1&%T93XR,# W+3 T+3$S5#$P.C4P.C T+3 U.C P
M/"]X87 Z0W)E871E1&%T93X*(" @(" @(" @/'AA<#I-;V1I9GE$871E/C(P
M,#<M,#0M,3-4,3 Z-3 Z,#0M,#4Z,# \+WAA<#I-;V1I9GE$871E/@H@(" @
M(" @(" \>&%P.DUE=&%D871A1&%T93XR,# W+3 T+3$S5#$P.C4P.C T+3 U
M.C P/"]X87 Z365T861A=&%$871E/@H@(" @(" \+W)D9CI$97-C<FEP=&EO
M;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @
M(" @(" @>&UL;G,Z>&%P34T](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N
M,"]M;2\B"B @(" @(" @(" @('AM;&YS.G-T4F5F/2)H='1P.B\O;G,N861O
M8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V52968C(CX*(" @(" @(" @
M/'AA<$U-.D1O8W5M96YT240^=75I9#HT13<S,C)"-T-#14%$0C$Q0C="1CDQ
M-$%&1C5&03A$.#PO>&%P34TZ1&]C=6UE;G1)1#X*(" @(" @(" @/'AA<$U-
M.DEN<W1A;F-E240^=75I9#HT1C<S,C)"-T-#14%$0C$Q0C="1CDQ-$%&1C5&
M03A$.#PO>&%P34TZ26YS=&%N8V5)1#X*(" @(" @(" @/'AA<$U-.D1E<FEV
M961&<F]M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @
M/'-T4F5F.FEN<W1A;F-E240^=75I9#IB,3@Q-S@U92UE.6,U+3$Q9&(M.3@Q
M,BTP,#$W9C)C-3@R.#0\+W-T4F5F.FEN<W1A;F-E240^"B @(" @(" @(" @
M(#QS=%)E9CID;V-U;65N=$E$/G5U:60Z.#DT0SDT,#%%.4$S,3%$0C@V-CA"
M.39%0T,S-$5#03D\+W-T4F5F.F1O8W5M96YT240^"B @(" @(" @(#PO>&%P
M34TZ1&5R:79E9$9R;VT^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @
M(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X
M;6QN<SIP9&8](FAT=' Z+R]N<RYA9&]B92YC;VTO<&1F+S$N,R\B/@H@(" @
M(" @(" \<&1F.E!R;V1U8V5R/D%D;V)E(%!$1B!L:6)R87)Y(#<N-S<\+W!D
M9CI0<F]D=6-E<CX*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR
M9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS
M.G!H;W1O<VAO<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]P:&]T;W-H;W O,2XP
M+R(^"B @(" @(" @(#QP:&]T;W-H;W Z0V]L;W)-;V1E/C,\+W!H;W1O<VAO
M<#I#;VQO<DUO9&4^"B @(" @(" @(#QP:&]T;W-H;W Z24-#4')O9FEL93YS
M4D="($E%0S8Q.38V+3(N,3PO<&AO=&]S:&]P.DE#0U!R;V9I;&4^"B @(" @
M(" @(#QP:&]T;W-H;W Z2&ES=&]R>2\^"B @(" @(#PO<F1F.D1E<V-R:7!T
M:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @
M(" @(" @("!X;6QN<SIT:69F/2)H='1P.B\O;G,N861O8F4N8V]M+W1I9F8O
M,2XP+R(^"B @(" @(" @(#QT:69F.D]R:65N=&%T:6]N/C$\+W1I9F8Z3W)I
M96YT871I;VX^"B @(" @(" @(#QT:69F.EA297-O;'5T:6]N/C,P,# P,# O
M,3 P,# \+W1I9F8Z6%)E<V]L=71I;VX^"B @(" @(" @(#QT:69F.EE297-O
M;'5T:6]N/C,P,# P,# O,3 P,# \+W1I9F8Z65)E<V]L=71I;VX^"B @(" @
M(" @(#QT:69F.E)E<V]L=71I;VY5;FET/C(\+W1I9F8Z4F5S;VQU=&EO;E5N
M:70^"B @(" @(" @(#QT:69F.DYA=&EV941I9V5S=#XR-38L,C4W+#(U."PR
M-3DL,C8R+#(W-"PR-S<L,C@T+#4S,"PU,S$L,C@R+#(X,RPR.38L,S Q+#,Q
M."PS,3DL-3(Y+#4S,BPS,#8L,C<P+#(W,2PR-S(L,S U+#,Q-2PS,S0S,CM%
M13=#.$4R0D(S0C0V-D(W.40Y,44U.3-#1#DX,#DP03PO=&EF9CI.871I=F5$
M:6=E<W0^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E
M<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIE>&EF
M/2)H='1P.B\O;G,N861O8F4N8V]M+V5X:68O,2XP+R(^"B @(" @(" @(#QE
M>&EF.E!I>&5L6$1I;65N<VEO;CXQ,34P/"]E>&EF.E!I>&5L6$1I;65N<VEO
M;CX*(" @(" @(" @/&5X:68Z4&EX96Q91&EM96YS:6]N/C0P.3PO97AI9CI0
M:7AE;%E$:6UE;G-I;VX^"B @(" @(" @(#QE>&EF.D-O;&]R4W!A8V4^,3PO
M97AI9CI#;VQO<E-P86-E/@H@(" @(" @(" \97AI9CI.871I=F5$:6=E<W0^
M,S8X-C0L-# Y-C L-# Y-C$L,S<Q,C$L,S<Q,C(L-# Y-C(L-# Y-C,L,S<U
M,3 L-# Y-C0L,S8X-C<L,S8X-C@L,S,T,S0L,S,T,S<L,S0X-3 L,S0X-3(L
M,S0X-34L,S0X-38L,S<S-S<L,S<S-S@L,S<S-SDL,S<S.# L,S<S.#$L,S<S
M.#(L,S<S.#,L,S<S.#0L,S<S.#4L,S<S.#8L,S<S.38L-#$T.#,L-#$T.#0L
M-#$T.#8L-#$T.#<L-#$T.#@L-#$T.3(L-#$T.3,L-#$T.34L-#$W,C@L-#$W
M,CDL-#$W,S L-#$Y.#4L-#$Y.#8L-#$Y.#<L-#$Y.#@L-#$Y.#DL-#$Y.3 L
M-#$Y.3$L-#$Y.3(L-#$Y.3,L-#$Y.30L-#$Y.34L-#$Y.38L-#(P,38L,"PR
M+#0L-2PV+#<L."PY+#$P+#$Q+#$R+#$S+#$T+#$U+#$V+#$W+#$X+#(P+#(R
M+#(S+#(T+#(U+#(V+#(W+#(X+#,P.SE!.3$V,4%#,D%!048V-3=".$5#,#4R
M,4)"0D$R0S(W/"]E>&EF.DYA=&EV941I9V5S=#X*(" @(" @/"]R9&8Z1&5S
M8W)I<'1I;VX^"B @(#PO<F1F.E)$1CX*/"]X.GAM<&UE=&$^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"CP_>'!A8VME="!E;F0](G<B/S[_
MX@Q824-#7U!23T9)3$4  0$   Q(3&EN;P(0  !M;G1R4D="(%A96B 'S@ "
M  D !@ Q  !A8W-P35-&5     !)14,@<U)'0@               0  ]M8
M 0    #3+4A0("
M                 !%C<')T   !4    #-D97-C   !A    &QW='!T   !
M\    !1B:W!T   "!    !1R6%E:   "&    !1G6%E:   "+    !1B6%E:
M   "0    !1D;6YD   "5    '!D;61D   "Q    (AV=65D   #3    (9V
M:65W   #U    "1L=6UI   #^    !1M96%S   $#    "1T96-H   $,
M  QR5%)#   $/   " QG5%)#   $/   " QB5%)#   $/   " QT97AT
M $-O<'ER:6=H=" H8RD@,3DY."!(97=L971T+5!A8VMA<F0@0V]M<&%N>0
M9&5S8P         2<U)'0B!)14,V,3DV-BTR+C$              !)S4D="
M($E%0S8Q.38V+3(N,0
M                        6%E:(        /-1  $    !%LQ865H@
M                 %A96B        !OH@  ./4   .06%E:(        &*9
M  "WA0  &-I865H@        )*    ^$  "VSV1E<V,         %DE%0R!H
M='1P.B\O=W=W+FEE8RYC:               %DE%0R!H='1P.B\O=W=W+FEE
M8RYC:
M      !D97-C         "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O
M;&]U<B!S<&%C92 M('-21T(              "Y)14,@-C$Y-C8M,BXQ($1E
M9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M        9&5S8P         L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N
M(&EN($E%0S8Q.38V+3(N,0              +%)E9F5R96YC92!6:65W:6YG
M($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M         '9I97<      !.D_@ 47RX $,\4  /MS  $$PL  UR>     5A9
M6B       $P)5@!0    5Q_G;65A<P         !
M     H\    "<VEG(     !#4E0@8W5R=@        0     !0 *  \ %  9
M !X (P H "T ,@ W #L 0 !% $H 3P!4 %D 7@!C &@ ;0!R '< ? "! (8
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MR)_,;\I+B"#2]3;6?+*L/K'E347:2UX5^+T#4M U*T*;5W96Z8D6K]9_R?\
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M!0"..7SK^8#M,P_>V&B6H55/M<W));_D2,CQ)IZW9_\ .#_Y*6J<9W\PZBU
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MDCY,/GAXEI\E_F5_SA5^8WD^"YU3RE=P^?M)@!=[>VC,&I*H_P"74LXDH/\
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MLI\E><M>\@>9](\V^6[KZIJVCS"6$FI213M)#*H(Y)(I*L*]#XXJ_=_\L_S
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M2N*L#U17& E(?M<    * ; #();Q5V*NQ5V*NQ5V*OS"_P"<X?RCBTO4M/\
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M.1D4A^DN12[%78J[%78J[%7QQ_SG)_Y):U_\"2Q_Y,W.2B@OR"R2'8J^_O\
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MY6[TZ1CMD9)#]&LBEV*NQ5V*NQ5V*O\ _]/[^8J[%78J[%78J[%4JUP$Z1J
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MWEJ_OM)D:M319?K,:GPXQW"@>P&0ES2'U/@2[%7P#_SG[_RB'Y?_ /;8NO\
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M*),"E\O?*),"@)>^428E^9/YQ?\ DSO.'_,8O_)I,]3[!_Q#%[C]Y?,^VO\
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M??O_ !Q_S._YC-+_ .3=SD9)#]$,BEV*NQ5V*NQ5V*NQ5\3?\YY_^2@\N?\
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M #[]_P"./^9W_,9I?_)NYR,DA^B&12[%78J[%78J[%78J^)O^<\__)0>7/\
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MP$)M]B^6?^<[_P MM1BC3S/Y<UKRU=D#U&@$5_; ]Z2*T4A_Y%8.%;>G0_\
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M(I=BKXX_YSD_\DM:_P#@26/_ "9N<E%!?D%DD.Q5]_?\X!?\IA^8'_;'MO\
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M"NQ5V*O+/S7_ "?\F_G!H/Z'\T6?&[M@[:-KL "W=E(PW:-R-U-!R1OA:GB
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MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*O\
M_]3[^8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%7__5^_F*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5__UOOYBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5?_]?[^8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%7__0^_F*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5__T?OYBKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5?_]+[^8J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
>%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>lxrx-20250325_g2.gif
<TEXT>
begin 644 lxrx-20250325_g2.gif
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MS/85M'4H@PH!& 3BB)(YLLAZFPQF92JUKP14P G(3"8R00.^&/YH?SRKC01
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M>!!=P&B(:8D,40\1V)+Y!Q/SZ ((*3D6H =4%F(.H <60)A3V8]<>1>181!
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M))]2$-*#*PD@G0<" ;*CPC#:3N\$MS]E;*@:$_+&9"^I>E/W@@*1@$G:9A_
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M2OMT=.-N7ZW+(6:"*$W2C<@!Z%N(H_G,K!S+_]MO<T,W*[[#/2P3L>FT%C$
M'7 "1VYD>O!*',$ IJ*=X[RU=V$B&6PHA'%8JB+A3]0X"F$"S'O?3235'B&W
M0E75*+"J !=__ROG?Z'[N/FK=F('E$=VC"@WN$VP$."&;<V&I>HK %_\>B6]
M<CL+@PB*B-D*="CP 'J(>^=-!?<PY"V1B?08TPRAH1WZ:)"\$0S (].%$+=+
MH[ERTZ9450<QHR^6*7NA*B60);6XR0K+YAVA5CKQ988P?-O&<L?*UQCMGT;F
MB\9*!7 68.[8@(D;4DB'F,GGGD%'-QS0TF 8""W[UYP)Y)$KY TQ ([PZ[RW
MXD;V!J]I?=S:Z1]1@\_VQ]0WCEV5%5C>(2% 0])]-0N@ #O4[P$NVOX^HZ[D
M)[53 LQQP=5R*?7S%0/N-DU2)8N57?,.Y4ITWZ1:;."U$R4 9=YP O\AQ$%.
M4)*:+AI"Y@U.X/$/X/$GP-N7*&]$YO$58*$AI6XG/\058&AJ]O)LB- 26O,!
MRJ8CX//=-M)/5FT>3P4A= (Q7XT>YHD%$-\?T0&MRV]5[NFB\2T6TB0(X*[H
MBB$*0@ 1EB55Y5^TB$VL+AKJ:K ,<@-=KZ[^U0"=4@'N6ARJHES39 5Z=>L1
MX5HC"N)[>1/)^!2B[!#BQ0.=!LN"=U%"<=96*<7JWJV#OQ$AT,<(![L1X1FM
M,Q>8/1 AS--$(D!T(2B&4C+*.:-E&\&ZVQLB$P%E+ZJ2Q#OX;*HO?-N]I4F<
M?@-.[A'6W&^[*Q&80:E^H?JP @(D<IY7OR+_O1\E3>($-B6\=?'9J&\8R9'3
M!LF<_N+AN?Z\&%O[OI4 4Q?9N;BZGMB!KVOE$.&)QRUF#X  Z^]"X@P /! '
MA&!K4 %8"%  )L #\4_\=J$X !&'4(0!  Q2H8) SX 2 &Y "!!  0(%!0@8
M).#B 96-&T%$P!B!$ ^!$4SH0:@ 8@ 0%PV^A!D39@=_$1UTD)E3YTZ>+PGH
MB6A 3T^B18T>19I4Z5*F39T^A1HUYP(G"A3<<"D5YH (4Q)8+:#@! @3_9::
M,-'!@H6T:#LP.!$Q $@ $?0X<9+ 204G-TRP3<#WJURY#O ZD>!R %H+#%ZZ
MD.MW[<L!<=IV2.NX_V"'O(<3))" V86"B"!*%$S:P8%-G%J/E@ :P$ "U[5M
MW\:=6_?NJ 02.#C@(L1M B9<4*EH58\$NDL; G@>$X1<NA%6$PX@X3D5[-T#
M\ N0($1TF0T,1&00O2#JG3?D@@^ P(1!$]Q9,E0ZI68 "/-YR_0M(@B&^J]
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M _\<Y+&/%-QC9H:HQ;R2HX  -J(',%Q%W5IX06E(TPL%F$ TC3; "^8PC1>
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M<X%.ZV7H(]H(0\QS%=VF@ !$/\0X>UQE\JCR+R^ND^>VTXH#X(&L-%@%CGI
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M!KB!JK"C]*N2)$E3-8T(ILH.+-.8AE& X7P)/PV [P0 $[B.1C0(3%R @EB
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M@)60G__*-:13Y J,; B-38 9-C"W,E% \Y94?!2Y8[&G( !7**J$P:KGZ(<
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$ 0$ .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">PRE 14A<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">LEXICON PHARMACEUTICALS, INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001062822<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTableTextBlock', window );">Pay vs Performance Disclosure, Table</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.625%"><tr><td style="width:1.0%"></td><td style="width:5.368%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.499%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.564%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.674%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.913%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.499%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.913%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.499%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.913%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.499%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.913%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.499%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.913%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.499%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.913%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.499%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.923%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Summary Compensation Table Total for First PEO </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3.9pt;font-weight:700;line-height:100%;position:relative;top:-2.1pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Compensation Actually Paid to First PEO </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3.9pt;font-weight:700;line-height:100%;position:relative;top:-2.1pt;vertical-align:baseline">(1) (3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Summary Compensation Table Total for Second PEO </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3.9pt;font-weight:700;line-height:100%;position:relative;top:-2.1pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Compensation Actually Paid to Second</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&#160;PEO </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3.9pt;font-weight:700;line-height:100%;position:relative;top:-2.1pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3.9pt;font-weight:700;line-height:100%;position:relative;top:-2.1pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Average Summary Compensation Table Total for Non-PEO</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&#160;NEOs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3.9pt;font-weight:700;line-height:100%;position:relative;top:-2.1pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Average Compensation Actually Paid to Non-PEO</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&#160;NEOs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3.9pt;font-weight:700;line-height:100%;position:relative;top:-2.1pt;vertical-align:baseline">(2) (5)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Value of Initial Fixed $100 Investment Based on Total Shareholder Return</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Net Income </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3.9pt;font-weight:700;line-height:100%;position:relative;top:-2.1pt;vertical-align:baseline">(6)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,467,590&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(884,853)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,835,589&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,616,932&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,598,976&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">878,167&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(200,403)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,110,121&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,055,451&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,576,776&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,233,210&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(177,119)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,169,942&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,203,063&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,622,119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">828,645&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(101,944)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NamedExecutiveOfficersFnTextBlock', window );">Named Executive Officers, Footnote</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For 2024, our principal executive officers were Lonnel Coats and Michael S. Exton, Ph.D.  For 2023 and 2022, our principal executive officer was Lonnel Coats.</span><div style="margin-bottom:9pt;padding-left:22.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For 2024, our other named executive officers were Brian T. Crum, Craig B. Granowitz, M.D., Ph.D., Alan J. Main, Ph.D., Jeffrey L. Wade, Kristen L. Alexander and Thomas A. Garner.  For 2023, our other named executive officers were Jeffrey L. Wade, Brian T. Crum, Craig B. Granowitz, M.D., Ph.D and Alan J. Main, Ph.D.  For 2022, our other named executive officers were Jeffrey L. Wade, Brian T. Crum, Craig B. Granowitz, M.D., Ph.D. and Kenneth B. Kassler-Taub, M.D.</span></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PeoTotalCompAmt', window );">PEO Total Compensation Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,110,121<span></span>
</td>
<td class="nump">$ 4,169,942<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PeoActuallyPaidCompAmt', window );">PEO Actually Paid Compensation Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,055,451<span></span>
</td>
<td class="nump">1,203,063<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToPeoCompFnTextBlock', window );">Adjustment To PEO Compensation, Footnote</a></td>
<td class="text">The following table sets forth the adjustments made during each year to calculate Compensation Actually Paid to our first principal executive officer.<div style="margin-bottom:9pt;padding-left:22.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"></td><td style="width:70.021%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.116%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.414%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.116%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.414%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Summary Compensation Table Totals for First PEO</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">3,467,590&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">4,110,121&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">4,169,942&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Add (Subtract):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#160;&#160;&#160;Fair value of equity awards granted during the year from the Summary Compensation Table</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(3,014,509)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(2,967,821)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(2,945,080)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#160;&#160;&#160;Fair value at year end of equity awards granted during the year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,989,880&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,847,145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#160;&#160;&#160;Change in fair value of equity awards granted in prior years that were unvested as of the end of the year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(283,105)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,003,687)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#160;&#160;&#160;Change in fair value of equity awards granted in prior years that vested during the year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">608,241&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">206,376&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(865,257)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#160;&#160;&#160;Equity awards granted in prior years that were forfeited during the year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,946,175)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Compensation Actually Paid Totals</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(884,853)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,055,451&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,203,063&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:22.5pt;text-align:justify;text-indent:-20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The following table sets forth the adjustments made during each year to calculate Compensation Actually Paid to our second principal executive officer.</span></div><div style="margin-bottom:9pt;padding-left:22.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.461%"><tr><td style="width:1.0%"></td><td style="width:87.427%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.373%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2024</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Summary Compensation Table Totals for Second PEO</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">2,835,589&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Add (Subtract):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#160;&#160;&#160;Fair value of equity awards granted during the year from the Summary Compensation Table</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(2,308,770)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#160;&#160;&#160;Fair value at year end of equity awards granted during the year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,090,113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#160;&#160;&#160;Change in fair value of equity awards granted in prior years that were unvested as of the end of the year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#160;&#160;&#160;Change in fair value of equity awards granted in prior years that vested during the year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#160;&#160;&#160;Equity awards granted in prior years that were forfeited during the year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Compensation Actually Paid Totals</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,616,932&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonPeoNeoAvgTotalCompAmt', window );">Non-PEO NEO Average Total Compensation Amount</a></td>
<td class="nump">$ 1,598,976<span></span>
</td>
<td class="nump">1,576,776<span></span>
</td>
<td class="nump">1,622,119<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonPeoNeoAvgCompActuallyPaidAmt', window );">Non-PEO NEO Average Compensation Actually Paid Amount</a></td>
<td class="nump">$ 878,167<span></span>
</td>
<td class="nump">1,233,210<span></span>
</td>
<td class="nump">828,645<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToNonPeoNeoCompFnTextBlock', window );">Adjustment to Non-PEO NEO Compensation Footnote</a></td>
<td class="text">The following table sets forth the adjustments made during each year to calculate Average Compensation Actually Paid to our other named executive officers. <div style="margin-bottom:3pt;margin-top:3pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.444%"><tr><td style="width:1.0%"></td><td style="width:69.797%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.187%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.187%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.191%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Average Summary Compensation Table Totals for Non-PEO NEOs</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">1,598,976&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">1,576,776&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">1,622,119&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Add (Subtract):</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#160;&#160;&#160;Fair value of equity awards granted during the year from the Summary Compensation Table</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(877,009)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(932,283)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(957,722)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#160;&#160;&#160;Fair value at year end of equity awards granted during the year </span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">263,789</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">625,082</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">600,680</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#160;&#160;&#160;Change in fair value of equity awards granted in prior years that were unvested as of the end of the year</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(198,031)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(94,405)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(260,725)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#160;&#160;&#160;Change in fair value of equity awards granted in prior years that vested during the year</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">130,573</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58,040</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(175,708)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#160;&#160;&#160;Equity awards granted in prior years that were forfeited during the year</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(40,132)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Average Compensation Actually Paid Totals</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">878,167&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,233,210&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">828,645&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock', window );">Compensation Actually Paid vs. Total Shareholder Return</a></td>
<td class="text">From 2022 to 2023, compensation actually paid to Mr. Coats as described in the pay versus performance table increased 154.0%, average compensation actually paid to our other named executive officers as described in the pay versus performance table increased 48.8%, our total shareholder return decreased 19.9% and our net income decreased 73.7%.  From 2023 to 2024, compensation actually paid to Mr. Coats and Dr. Exton as described in the pay versus performance table decreased 76.0%, average compensation actually paid to our other named executive officers as described in the pay versus performance table decreased 28.8%, our total shareholder return decreased 51.6% and our net income decreased 13.1%.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TotalShareholderRtnAmt', window );">Total Shareholder Return Amount</a></td>
<td class="nump">$ 19<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (200,403,000)<span></span>
</td>
<td class="num">$ (177,119,000)<span></span>
</td>
<td class="num">$ (101,944,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PeoName', window );">PEO Name</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Lonnel Coats<span></span>
</td>
<td class="text">Lonnel Coats<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Additional402vDisclosureTextBlock', window );">Additional 402(v) Disclosure</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In thousands.</span><div style="margin-bottom:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in compensation actually paid to Mr. Coats, Dr. Exton and our other named executive officers during such periods as described in the pay versus performance table were largely driven by equity award related adjustments as a result of turnover among our named executive officers and the volatility in the market price of our common stock, and to a lesser extent by variability in annual salary, bonus and equity incentive awards.  As a result, such changes are not directly related to the changes in our total shareholder return and net income during such periods.</span></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=lxrx_LonnelCoatsMember', window );">Lonnel Coats [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PeoTotalCompAmt', window );">PEO Total Compensation Amount</a></td>
<td class="nump">$ 3,467,590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PeoActuallyPaidCompAmt', window );">PEO Actually Paid Compensation Amount</a></td>
<td class="num">$ (884,853)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PeoName', window );">PEO Name</a></td>
<td class="text">Lonnel Coats<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=lxrx_MichaelS.ExtonPh.D.Member', window );">Michael S. Exton, Ph.D. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PeoTotalCompAmt', window );">PEO Total Compensation Amount</a></td>
<td class="nump">$ 2,835,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PeoActuallyPaidCompAmt', window );">PEO Actually Paid Compensation Amount</a></td>
<td class="nump">$ 1,616,932<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PeoName', window );">PEO Name</a></td>
<td class="text">Michael S. Exton, Ph.D<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_ExecutiveCategoryAxis=ecd_PeoMember', window );">PEO | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,967,821)<span></span>
</td>
<td class="num">$ (2,945,080)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_ExecutiveCategoryAxis=ecd_PeoMember', window );">PEO | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,989,880<span></span>
</td>
<td class="nump">1,847,145<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_ExecutiveCategoryAxis=ecd_PeoMember', window );">PEO | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(283,105)<span></span>
</td>
<td class="num">(1,003,687)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_ExecutiveCategoryAxis=ecd_PeoMember', window );">PEO | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">206,376<span></span>
</td>
<td class="num">(865,257)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_ExecutiveCategoryAxis=ecd_PeoMember', window );">PEO | Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_ExecutiveCategoryAxis=ecd_PeoMember', window );">PEO | Lonnel Coats [Member] | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation, Amount</a></td>
<td class="num">$ (3,014,509)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_ExecutiveCategoryAxis=ecd_PeoMember', window );">PEO | Lonnel Coats [Member] | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation, Amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_ExecutiveCategoryAxis=ecd_PeoMember', window );">PEO | Lonnel Coats [Member] | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation, Amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_ExecutiveCategoryAxis=ecd_PeoMember', window );">PEO | Lonnel Coats [Member] | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation, Amount</a></td>
<td class="nump">608,241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_ExecutiveCategoryAxis=ecd_PeoMember', window );">PEO | Lonnel Coats [Member] | Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation, Amount</a></td>
<td class="num">(1,946,175)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_ExecutiveCategoryAxis=ecd_PeoMember', window );">PEO | Michael S. Exton, Ph.D. [Member] | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation, Amount</a></td>
<td class="num">(2,308,770)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_ExecutiveCategoryAxis=ecd_PeoMember', window );">PEO | Michael S. Exton, Ph.D. [Member] | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation, Amount</a></td>
<td class="nump">1,090,113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_ExecutiveCategoryAxis=ecd_PeoMember', window );">PEO | Michael S. Exton, Ph.D. [Member] | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation, Amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_ExecutiveCategoryAxis=ecd_PeoMember', window );">PEO | Michael S. Exton, Ph.D. [Member] | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation, Amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_ExecutiveCategoryAxis=ecd_PeoMember', window );">PEO | Michael S. Exton, Ph.D. [Member] | Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation, Amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_ExecutiveCategoryAxis=ecd_NonPeoNeoMember', window );">Non-PEO NEO | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation, Amount</a></td>
<td class="num">(877,009)<span></span>
</td>
<td class="num">(932,283)<span></span>
</td>
<td class="num">(957,722)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_ExecutiveCategoryAxis=ecd_NonPeoNeoMember', window );">Non-PEO NEO | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation, Amount</a></td>
<td class="nump">263,789<span></span>
</td>
<td class="nump">625,082<span></span>
</td>
<td class="nump">600,680<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_ExecutiveCategoryAxis=ecd_NonPeoNeoMember', window );">Non-PEO NEO | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation, Amount</a></td>
<td class="num">(198,031)<span></span>
</td>
<td class="num">(94,405)<span></span>
</td>
<td class="num">(260,725)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_ExecutiveCategoryAxis=ecd_NonPeoNeoMember', window );">Non-PEO NEO | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation, Amount</a></td>
<td class="nump">130,573<span></span>
</td>
<td class="nump">58,040<span></span>
</td>
<td class="num">(175,708)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_ExecutiveCategoryAxis=ecd_NonPeoNeoMember', window );">Non-PEO NEO | Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation, Amount</a></td>
<td class="num">$ (40,132)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Additional402vDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Additional402vDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToCompAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToCompAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToNonPeoNeoCompFnTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToNonPeoNeoCompFnTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToPeoCompFnTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToPeoCompFnTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 5<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NamedExecutiveOfficersFnTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NamedExecutiveOfficersFnTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonPeoNeoAvgCompActuallyPaidAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonPeoNeoAvgCompActuallyPaidAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonPeoNeoAvgTotalCompAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonPeoNeoAvgTotalCompAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PeoActuallyPaidCompAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PeoActuallyPaidCompAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PeoName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PeoName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PeoTotalCompAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PeoTotalCompAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TotalShareholderRtnAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 2<br> -Subparagraph iv<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TotalShareholderRtnAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=lxrx_LonnelCoatsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=lxrx_LonnelCoatsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=lxrx_MichaelS.ExtonPh.D.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=lxrx_MichaelS.ExtonPh.D.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_ExecutiveCategoryAxis=ecd_PeoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_ExecutiveCategoryAxis=ecd_PeoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToCompAxis=ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToCompAxis=ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToCompAxis=ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToCompAxis=ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToCompAxis=ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToCompAxis=ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToCompAxis=ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToCompAxis=ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToCompAxis=ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToCompAxis=ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_ExecutiveCategoryAxis=ecd_NonPeoNeoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_ExecutiveCategoryAxis=ecd_NonPeoNeoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Award Timing Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AwardTmgDiscLineItems', window );"><strong>Award Timing Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AwardTmgMnpiDiscTextBlock', window );">Award Timing MNPI Disclosure</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our long-term stock-based incentive awards are generally granted on fixed dates determined in advance. The compensation committee&#8217;s general practice is to complete its annual executive compensation review and determine target compensation for our executives, which coincides with our regularly scheduled meetings of the board of directors, then such long-term stock-based incentive awards are granted. Annual long-term stock-based incentive awards are typically granted to our executives in February of each fiscal year. On limited occasions, the compensation committee may grant long-term stock-based incentive awards outside of our annual grant cycle for new hires, promotions, recognition, retention, or other purposes. The compensation committee approves all long-term stock-based incentive award grants on or before the grant date and does not grant long-term stock-based incentive awards in anticipation of the release of material nonpublic information. Similarly, the compensation committee does not time the release of material nonpublic information based on long-term stock-based incentive award grant dates.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AwardTmgMethodTextBlock', window );">Award Timing Method</a></td>
<td class="text">Our long-term stock-based incentive awards are generally granted on fixed dates determined in advance. The compensation committee&#8217;s general practice is to complete its annual executive compensation review and determine target compensation for our executives, which coincides with our regularly scheduled meetings of the board of directors, then such long-term stock-based incentive awards are granted. Annual long-term stock-based incentive awards are typically granted to our executives in February of each fiscal year. On limited occasions, the compensation committee may grant long-term stock-based incentive awards outside of our annual grant cycle for new hires, promotions, recognition, retention, or other purposes. The compensation committee approves all long-term stock-based incentive award grants on or before the grant date and does not grant long-term stock-based incentive awards in anticipation of the release of material nonpublic information.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AwardTmgPredtrmndFlag', window );">Award Timing Predetermined</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AwardTmgMnpiCnsdrdFlag', window );">Award Timing MNPI Considered</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AwardTmgHowMnpiCnsdrdTextBlock', window );">Award Timing, How MNPI Considered</a></td>
<td class="text">Similarly, the compensation committee does not time the release of material nonpublic information based on long-term stock-based incentive award grant dates.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MnpiDiscTimedForCompValFlag', window );">MNPI Disclosure Timed for Compensation Value</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AwardTmgDiscLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AwardTmgDiscLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AwardTmgHowMnpiCnsdrdTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AwardTmgHowMnpiCnsdrdTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AwardTmgMethodTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AwardTmgMethodTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AwardTmgMnpiCnsdrdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AwardTmgMnpiCnsdrdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AwardTmgMnpiDiscTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AwardTmgMnpiDiscTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AwardTmgPredtrmndFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AwardTmgPredtrmndFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_MnpiDiscTimedForCompValFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_MnpiDiscTimedForCompValFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Policies and Procedures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingPoliciesProcLineItems', window );"><strong>Insider Trading Policies and Procedures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTrdPoliciesProcAdoptedFlag', window );">Insider Trading Policies and Procedures Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingPoliciesProcLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingPoliciesProcLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTrdPoliciesProcAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTrdPoliciesProcAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>13
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( *N >5I&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    ( *N >5IH@\ER\0   "L"   1
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M(9J=X)(W4E1OL^L/OZNP"\;N[3\S%M^,+X)="[_NHOL$4$L#!!0    ( *N
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MVX$O7(M2VZ*,5N/8GF>YGKS^ZU\XH^QOVA7@!KX55+C48HYC,2IE<BID&@2
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ML+\'C^ZC8'M/!;L_G^E/4$L#!!0    ( *N >5J7BKL<P    !,"   +
M7W)E;',O+G)E;'.=DKENPS ,0'_%T)XP!] AB#-E\18$^0%6H@_8$@6*19V_
MK]JE<9 +&7D]/!+<'FE [3BDMHNI&/T04FE:U;@!2+8ECVG.D4*NU"P>-8?2
M0$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^ KSI,<4)I2$LS#O#-
MTG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE?QW']I#3Z:]C(K1Z
M6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ JX!Y6OV<!5>' 0
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M              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @
MJX!Y6FB#R7+Q    *P(  !$              ( !PP   &1O8U!R;W!S+V-O
M<F4N>&UL4$L! A0#%     @ JX!Y6IE<G",0!@  G"<  !,
M ( !XP$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " "K@'E:V=CB
MWH,"  #_!@  &               @($D"   >&PO=V]R:W-H965T<R]S:&5E
M=#$N>&UL4$L! A0#%     @ JX!Y6D;57HFX$   RH0  !@
M ("!W0H  'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( *N
M>5JX$>SS'P0  %@0   8              " @<L;  !X;"]W;W)K<VAE971S
M+W-H965T,RYX;6Q02P$"% ,4    " "K@'E:/*4S.!$"  #=!   &
M        @($@(   >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%
M  @ JX!Y6K+WPF_N @  B0X   T              ( !9R(  'AL+W-T>6QE
M<RYX;6Q02P$"% ,4    " "K@'E:EXJ[',     3 @  "P
M@ & )0  7W)E;',O+G)E;'-02P$"% ,4    " "K@'E:_9P%5X<!   '!
M#P              @ %I)@  >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @
MJX!Y6@%EQ>[     JP,  !H              ( !'2@  'AL+U]R96QS+W=O
M<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ JX!Y6HZPI]8G 0  9P4  !,
M             ( !%2D  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      P
,#  0 P  ;2H

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>40</ContextCount>
  <ElementCount>25</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>9</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>1</UnitCount>
  <MyReports>
    <Report instance="lxrx-20250325.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>995100 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/dei/role/document/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="lxrx-20250325.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="lxrx-20250325.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>995443 - Disclosure - Award Timing Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure</Role>
      <ShortName>Award Timing Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="lxrx-20250325.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>995447 - Disclosure - Insider Trading Policies and Procedures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc</Role>
      <ShortName>Insider Trading Policies and Procedures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="PRE 14A" isUsgaap="true" original="lxrx-20250325.htm">lxrx-20250325.htm</File>
    <File>lxrx-20250325.xsd</File>
    <File>lxrx-20250325_def.xml</File>
    <File>lxrx-20250325_lab.xml</File>
    <File>lxrx-20250325_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>lxrx-20250325_g1.jpg</File>
    <File>lxrx-20250325_g2.gif</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="3">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="84">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>19
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "lxrx-20250325.htm": {
   "nsprefix": "lxrx",
   "nsuri": "http://www.lexpharma.com/20250325",
   "dts": {
    "inline": {
     "local": [
      "lxrx-20250325.htm"
     ]
    },
    "schema": {
     "local": [
      "lxrx-20250325.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024_def.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024_lab.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024_pre.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-sub-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "lxrx-20250325_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "lxrx-20250325_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "lxrx-20250325_pre.xml"
     ]
    }
   },
   "keyStandard": 25,
   "keyCustom": 0,
   "axisStandard": 3,
   "axisCustom": 0,
   "memberStandard": 7,
   "memberCustom": 2,
   "hidden": {
    "total": 3,
    "http://xbrl.sec.gov/dei/2024": 3
   },
   "contextCount": 40,
   "entityCount": 1,
   "segmentCount": 9,
   "elementCount": 268,
   "unitCount": 1,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/ecd/2024": 84,
    "http://xbrl.sec.gov/dei/2024": 4,
    "http://fasb.org/us-gaap/2024": 3
   },
   "report": {
    "R1": {
     "role": "http://xbrl.sec.gov/dei/role/document/Cover",
     "longName": "995100 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxrx-20250325.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxrx-20250325.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ecd:PvpTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxrx-20250325.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ecd:PvpTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxrx-20250325.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
     "longName": "995443 - Disclosure - Award Timing Disclosure",
     "shortName": "Award Timing Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ecd:AwardTmgMnpiDiscTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxrx-20250325.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ecd:AwardTmgMnpiDiscTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxrx-20250325.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc",
     "longName": "995447 - Disclosure - Insider Trading Policies and Procedures",
     "shortName": "Insider Trading Policies and Procedures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxrx-20250325.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxrx-20250325.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r119"
     ]
    },
    "dei_AdditionalSecurities462b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AdditionalSecurities462b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities. 462(b)"
       }
      }
     },
     "auth_ref": [
      "r175"
     ]
    },
    "dei_AdditionalSecurities462bFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AdditionalSecurities462bFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities, 462(b), File Number"
       }
      }
     },
     "auth_ref": [
      "r175"
     ]
    },
    "dei_AdditionalSecuritiesEffective413b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AdditionalSecuritiesEffective413b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities Effective, 413(b)"
       }
      }
     },
     "auth_ref": [
      "r173"
     ]
    },
    "dei_AddressTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AddressTypeDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Address Type [Domain]",
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r132"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r132"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r132"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r132"
     ]
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r166"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r82",
      "r93",
      "r109",
      "r144"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r85",
      "r96",
      "r112",
      "r147"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Pension Adjustments Service Cost [Member]",
        "terseLabel": "Aggregate Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r167"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r132"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r86",
      "r97",
      "r113",
      "r139",
      "r148",
      "r152",
      "r160"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r158"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "dei_ApproximateDateOfCommencementOfProposedSaleToThePublic": {
     "xbrltype": "dateOrAsapItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ApproximateDateOfCommencementOfProposedSaleToThePublic",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Approximate Date of Commencement of Proposed Sale to Public",
        "documentation": "The approximate date of a commencement of a proposed sale of securities to the public. This element is disclosed in S-1, S-3, S-4, S-11, F-1, F-3 and F-10 filings."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r74",
      "r77",
      "r89"
     ]
    },
    "dei_AuditorLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLocation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r74",
      "r77",
      "r89"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r74",
      "r77",
      "r89"
     ]
    },
    "dei_AuditorOpinionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorOpinionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Opinion [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r171"
     ]
    },
    "dei_AuditorTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r155"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r156"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r28",
      "r29",
      "r30",
      "r31",
      "r32",
      "r33",
      "r34",
      "r35",
      "r36",
      "r37",
      "r38",
      "r39",
      "r40",
      "r41",
      "r42",
      "r43",
      "r44",
      "r45",
      "r46",
      "r47",
      "r48",
      "r49",
      "r50",
      "r51",
      "r52"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r154"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r153"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r152"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r152"
     ]
    },
    "dei_BusinessContactMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "BusinessContactMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Contact [Member]",
        "documentation": "Business contact for the entity"
       }
      }
     },
     "auth_ref": [
      "r77",
      "r89"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r127"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r136"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r135"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "dei_ContactPersonnelEmailAddress": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContactPersonnelEmailAddress",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Email Address",
        "documentation": "Email address of contact personnel."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContactPersonnelFaxNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContactPersonnelFaxNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Fax Number",
        "documentation": "Fax Number of contact personnel."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "dei_ContactPersonnelName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContactPersonnelName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Name",
        "documentation": "Name of contact personnel"
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContainedFileInformationFileDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Description",
        "documentation": "The description of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContainedFileInformationFileName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Name",
        "documentation": "The name of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContainedFileInformationFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Number",
        "documentation": "The SEC Document Number of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileType": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContainedFileInformationFileType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Type",
        "documentation": "The type or format of the contained file (usually XBRL but may be used for other types such as HTML, Word, PDF, GIF/JPG, etc.)."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CountryRegion",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DelayedOrContinuousOffering": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DelayedOrContinuousOffering",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Delayed or Continuous Offering"
       }
      }
     },
     "auth_ref": [
      "r101",
      "r102",
      "r116"
     ]
    },
    "dei_DividendOrInterestReinvestmentPlanOnly": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DividendOrInterestReinvestmentPlanOnly",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend or Interest Reinvestment Plan Only"
       }
      }
     },
     "auth_ref": [
      "r101",
      "r102",
      "r116"
     ]
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r77",
      "r89"
     ]
    },
    "dei_DocumentCopyrightInformation": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentCopyrightInformation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Copyright Information",
        "documentation": "The copyright information for the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentCreationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentCreationDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Creation Date",
        "documentation": "The date the document was made available and submitted, in YYYY-MM-DD format. The date of submission, date of acceptance by the recipient, and the document effective date are all potentially different."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Description",
        "documentation": "The description of the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document [Domain]",
        "documentation": "Type of the document as assigned by the filer, corresponding to SEC document naming convention standards."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentEffectiveDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentEffectiveDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Effective Date",
        "documentation": "The date when a document, upon receipt and acceptance, becomes officially effective, in YYYY-MM-DD format. Usually it is a system-assigned date time value, but it may be declared by the submitter in some cases."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r77",
      "r89",
      "r140"
     ]
    },
    "dei_DocumentFinStmtRestatementRecoveryAnalysisFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtRestatementRecoveryAnalysisFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Restatement Recovery Analysis [Flag]",
        "documentation": "Indicates whether any of the financial statement periods include restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to \u00a7240.10D-1(b)."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r77",
      "r89",
      "r140"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationDocumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationDocumentAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information, Document [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Text Block]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Name",
        "documentation": "Name of the document as assigned by the filer, corresponding to SEC document naming convention standards. Examples appear in the &lt;FILENAME> field of EDGAR filings, such as 'htm_25911.htm', 'exhibit1.htm', 'v105727_8k.txt'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "dei_DocumentSubtitle": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentSubtitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Subtitle",
        "documentation": "The subtitle given to the document resource by the creator or publisher. An example is 'A New Period of Growth'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentSynopsis": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentSynopsis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Synopsis",
        "documentation": "A synopsis or description of the document provided by the creator or publisher. Examples are 'This is the 2006 annual report for Company. During this period we saw revenue grow by 10% and earnings per share grow by 15% over the prior period'"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTitle": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Title",
        "documentation": "The name or title given to the document resource by the creator or publisher. An example is '2002 Annual Report'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r117"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentVersion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentVersion",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Version",
        "documentation": "The version identifier of the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
       }
      }
     },
     "auth_ref": [
      "r129"
     ]
    },
    "dei_EffectiveAfter60Days486a": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveAfter60Days486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective after 60 Days, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r179"
     ]
    },
    "dei_EffectiveOnDate486a": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveOnDate486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Date, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r179"
     ]
    },
    "dei_EffectiveOnDate486b": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveOnDate486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Date, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r180"
     ]
    },
    "dei_EffectiveOnSetDate486a": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveOnSetDate486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Set Date, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r179"
     ]
    },
    "dei_EffectiveOnSetDate486b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveOnSetDate486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Set Date, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r180"
     ]
    },
    "dei_EffectiveUponFiling462e": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveUponFiling462e",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Upon Filing, 462(e)"
       }
      }
     },
     "auth_ref": [
      "r178"
     ]
    },
    "dei_EffectiveUponFiling486b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveUponFiling486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective upon Filing, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r180"
     ]
    },
    "dei_EffectiveWhenDeclaredSection8c": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveWhenDeclaredSection8c",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective when Declared, Section 8(c)"
       }
      }
     },
     "auth_ref": [
      "r182"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitiesTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entities [Table]",
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAccountingStandard": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAccountingStandard",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Accounting Standard",
        "documentation": "The standardized abbreviation of the accounting standard used by the entity. This can either be US GAAP as promulgated by the FASB or IFRS as promulgated by the IASB. Example: 'US GAAP', 'IFRS'. This is distinct from the Document Accounting Standard element."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Description",
        "documentation": "Description of the kind of address for the entity, if needed to distinguish more finely among mailing, principal, legal, accounting, contact or other addresses."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressesAddressTypeAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses, Address Type [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressesLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressesTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses [Table]",
        "documentation": "Container of address information for the entity"
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityContactPersonnelLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityContactPersonnelLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Contact Personnel [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r181"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "dei_EntityHomeCountryISOCode": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityHomeCountryISOCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Home Country ISO Code",
        "documentation": "ISO 3166-1 alpha-2 country code for the Entity's home country. If home country is different from country of legal incorporation, then also provide country of legal incorporation in the 'Entity Incorporation, State Country Code' element."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationDateOfIncorporation": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationDateOfIncorporation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, Date of Incorporation",
        "documentation": "Date when an entity was incorporated"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationFormerLegalOrRegisteredName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInformationFormerLegalOrRegisteredName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Information, Former Legal or Registered Name",
        "documentation": "Former Legal or Registered Name of an entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInformationLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r170"
     ]
    },
    "dei_EntityInvCompanyType": {
     "xbrltype": "invCompanyType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInvCompanyType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Inv Company Type",
        "documentation": "One of: N-1A (Mutual Fund), N-1 (Open-End Separate Account with No Variable Annuities), N-2 (Closed-End Investment Company), N-3 (Separate Account Registered as Open-End Management Investment Company), N-4 (Variable Annuity UIT Separate Account), N-5 (Small Business Investment Company), N-6 (Variable Life UIT Separate Account), S-1 or S-3 (Face Amount Certificate Company), S-6 (UIT, Non-Insurance Product)."
       }
      }
     },
     "auth_ref": [
      "r169"
     ]
    },
    "dei_EntityLegalForm": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityLegalForm",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Legal Form",
        "documentation": "The details of the entity's legal form. Examples are partnership, limited liability company, trust, etc."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingDepositoryReceiptRatio": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingDepositoryReceiptRatio",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Depository Receipt Ratio",
        "documentation": "The number of underlying shares represented by one American Depository Receipt (ADR) or Global Depository Receipt (GDR). A value of '3' means that one ADR represents 3 underlying shares. If one underlying share represents 2 ADR's then the value would be represented as '0.5'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Description",
        "documentation": "Description of the kind of listing the entity has on the exchange, if necessary to further describe different instruments that are already distinguished by Entity, Exchange and Security."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingForeign": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingForeign",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Foreign",
        "documentation": "Yes or No value indicating whether this is a listing that is a foreign listing or depository receipt."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingParValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingParValuePerShare",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Par Value Per Share",
        "documentation": "The par value per share of security quoted in same currency as Trading currency. Example: '0.01'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingPrimary": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingPrimary",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Primary",
        "documentation": "Yes or No value indicating whether a listing of an instrument on an exchange is primary for the entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingSecurityTradingCurrency": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingSecurityTradingCurrency",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Security Trading Currency",
        "documentation": "The three character ISO 4217 code for the currency in which the security is quoted. Example: 'USD'"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsExchangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingsExchangeAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings, Exchange [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingsLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingsTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings [Table]",
        "documentation": "Container for exchange listing information for an entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityNumberOfEmployees": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityNumberOfEmployees",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Number of Employees",
        "documentation": "Number of persons employed by the Entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPhoneFaxNumbersLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPhoneFaxNumbersLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Phone Fax Numbers [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "dei_EntityReportingCurrencyISOCode": {
     "xbrltype": "currencyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityReportingCurrencyISOCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Reporting Currency ISO Code",
        "documentation": "The three character ISO 4217 code for the currency used for reporting purposes. Example: 'USD'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "dei_EntityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Text Block]",
        "documentation": "Container to serve as parent of six Entity related Table concepts."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r172"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote [Text Block]",
        "terseLabel": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r123"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r165"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments [Member]",
        "terseLabel": "Equity Awards Adjustments"
       }
      }
     },
     "auth_ref": [
      "r165"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r165"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r133"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r82",
      "r93",
      "r109",
      "r144"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r79",
      "r90",
      "r106",
      "r141"
     ]
    },
    "dei_ExchangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ExchangeDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exchange [Domain]",
        "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "dei_ExhibitsOnly462d": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ExhibitsOnly462d",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exhibits Only, 462(d)"
       }
      }
     },
     "auth_ref": [
      "r177"
     ]
    },
    "dei_ExhibitsOnly462dFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ExhibitsOnly462dFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exhibits Only, 462(d), File Number"
       }
      }
     },
     "auth_ref": [
      "r177"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Extension",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r86",
      "r97",
      "r113",
      "r148"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r86",
      "r97",
      "r113",
      "r148"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r86",
      "r97",
      "r113",
      "r148"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r86",
      "r97",
      "r113",
      "r148"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r86",
      "r97",
      "r113",
      "r148"
     ]
    },
    "dei_FormerAddressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "FormerAddressMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Former Address [Member]",
        "documentation": "Former address for entity"
       }
      }
     },
     "auth_ref": [
      "r76",
      "r100"
     ]
    },
    "dei_FormerFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "FormerFiscalYearEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Former Fiscal Year End Date",
        "documentation": "Former end date of previous fiscal years"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r74",
      "r77",
      "r89"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r86",
      "r97",
      "r113",
      "r139",
      "r148",
      "r152",
      "r160"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r158"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r78",
      "r164"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r78",
      "r164"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r78",
      "r164"
     ]
    },
    "dei_InvestmentCompanyActFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "InvestmentCompanyActFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Act File Number"
       }
      }
     },
     "auth_ref": [
      "r102",
      "r103",
      "r104",
      "r105"
     ]
    },
    "dei_InvestmentCompanyActRegistration": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "InvestmentCompanyActRegistration",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Act Registration"
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "dei_InvestmentCompanyRegistrationAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "InvestmentCompanyRegistrationAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Registration Amendment"
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "dei_InvestmentCompanyRegistrationAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "InvestmentCompanyRegistrationAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Registration Amendment Number"
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityIdentifier": {
     "xbrltype": "legalEntityIdentifierItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityIdentifier",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity Identifier",
        "documentation": "A globally unique ISO 17442 value to identify entities, commonly abbreviated as LEI."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "lxrx_LonnelCoatsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lexpharma.com/20250325",
     "localname": "LonnelCoatsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lonnel Coats [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "lxrx_MichaelS.ExtonPh.D.Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lexpharma.com/20250325",
     "localname": "MichaelS.ExtonPh.D.Member",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Michael S. Exton, Ph.D. [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r159"
     ]
    },
    "dei_NameChangeEventDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NameChangeEventDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event Date [Axis]",
        "documentation": "For a sequence of name change event related facts, use this typed dimension to distinguish them. The axis members are restricted to be a valid for xml schema 'date' or 'datetime' data type."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NameChangeEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NameChangeEventLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event [Line Items]",
        "documentation": "Line items represent concepts included in a table. Name change event line item concepts are used for information qualified by domain members of axes in the Name Change Event table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NameChangeEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NameChangeEventTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event [Table]",
        "documentation": "For a set of related facts in a sequence of name change events, use this table when the events occurred within a single reporting period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r132"
     ]
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r5",
      "r6",
      "r7",
      "r8",
      "r9",
      "r10",
      "r11",
      "r12",
      "r13",
      "r14",
      "r15",
      "r16",
      "r17",
      "r18",
      "r19",
      "r20",
      "r21",
      "r22",
      "r23",
      "r24",
      "r25",
      "r26",
      "r53",
      "r54",
      "r55",
      "r56",
      "r57",
      "r58",
      "r59",
      "r60",
      "r61",
      "r183"
     ]
    },
    "dei_NewEffectiveDateForPreviousFiling": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NewEffectiveDateForPreviousFiling",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Effective Date for Previous Filing"
       }
      }
     },
     "auth_ref": [
      "r102",
      "r103",
      "r104",
      "r105"
     ]
    },
    "dei_NoSubstantiveChanges462c": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoSubstantiveChanges462c",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Substantive Changes, 462(c)"
       }
      }
     },
     "auth_ref": [
      "r176"
     ]
    },
    "dei_NoSubstantiveChanges462cFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoSubstantiveChanges462cFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Substantive Changes, 462(c), File Number"
       }
      }
     },
     "auth_ref": [
      "r176"
     ]
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r86",
      "r97",
      "r113",
      "r139",
      "r148"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r159"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r159"
     ]
    },
    "dei_OtherAddressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherAddressMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Address [Member]",
        "documentation": "Other address for entity"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r84",
      "r95",
      "r111",
      "r146"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r87",
      "r98",
      "r114",
      "r149"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r87",
      "r98",
      "r114",
      "r149"
     ]
    },
    "dei_ParentEntityLegalName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ParentEntityLegalName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Parent Entity Legal Name",
        "documentation": "If the entity which the financial information concerns is a subsidiary of another company, then provide to full legal name of the parent entity"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r120"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r132"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "dei_PhoneFaxNumberDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PhoneFaxNumberDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Phone Fax Number Description",
        "documentation": "Description of Phone or Fax Number"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Prior Service Cost [Member]",
        "terseLabel": "Pension Adjustments Prior Service Cost"
       }
      }
     },
     "auth_ref": [
      "r123"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Service Cost [Member]",
        "terseLabel": "Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r168"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote [Text Block]",
        "terseLabel": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "dei_PostEffectiveAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PostEffectiveAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post-Effective Amendment"
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "dei_PostEffectiveAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PostEffectiveAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post-Effective Amendment Number",
        "documentation": "Amendment number to registration statement under the Securities Act of 1933 after the registration becomes effective."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "dei_PreEffectiveAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreEffectiveAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Effective Amendment"
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "dei_PreEffectiveAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreEffectiveAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Effective Amendment Number",
        "documentation": "Amendment number to registration statement under the Securities Act of 1933 before the registration becomes effective."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r120"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r120"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r79",
      "r90",
      "r106",
      "r141"
     ]
    },
    "dei_RegistrationStatementAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "RegistrationStatementAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registration Statement Amendment Number",
        "documentation": "Amendment number to registration statement under the Investment Company Act of 1940."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r80",
      "r91",
      "r107",
      "r142"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r81",
      "r92",
      "r108",
      "r143"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r88",
      "r99",
      "r115",
      "r150"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r159"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r159"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12gTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r28",
      "r29",
      "r30",
      "r31",
      "r32",
      "r33",
      "r34",
      "r35",
      "r36",
      "r37",
      "r38",
      "r39",
      "r40",
      "r41",
      "r42",
      "r43",
      "r44",
      "r45",
      "r46",
      "r47",
      "r48",
      "r49",
      "r50",
      "r51",
      "r52"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r83",
      "r94",
      "r110",
      "r145"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r158"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r160"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r161"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r162"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r162"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r160"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r160"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r163"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r161"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r157"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r126"
     ]
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r174"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r124"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r20": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r21": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r22": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r23": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r24": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r25": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r26": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r27": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r28": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r29": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r30": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r31": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r32": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r33": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r34": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r35": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r36": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r37": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r38": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r39": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r40": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r41": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r42": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r43": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r44": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r45": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r46": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r47": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r48": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r49": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r50": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r51": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r52": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r53": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r54": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r55": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r56": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r57": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r58": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r59": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r60": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r61": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r62": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "Global LEI Foundation"
  },
  "r63": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r64": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r65": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r66": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r67": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r68": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r69": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r70": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r71": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r72": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r73": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r74": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r75": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r76": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "249",
   "Section": "308",
   "Subsection": "a"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Number": "249",
   "Section": "308"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form F-3"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-3"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-4"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-6"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form S-3"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Investment Company Act",
   "Number": "270"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "313"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-X",
   "Number": "210",
   "Section": "2",
   "Subsection": "2"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "413",
   "Subsection": "b"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "b"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "c"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "d"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "e"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "486",
   "Subsection": "a"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "486",
   "Subsection": "b"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Section": "8",
   "Subsection": "c"
  },
  "r183": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>20
<FILENAME>0001062822-25-000016-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001062822-25-000016-xbrl.zip
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MG(*M(+F-.3\Q8>'+QK%=2&L 3GYL.@0R!K30/-*!&QI(.G9FA:9\W5H<WXJ
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MATHNU.TPC^NI;,\9D;)>-@VH1Q3)3(JS7$&O[E%& BE3^%I[(1WM@+-%U!B
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M_)A9J+2K(*=@K*JDWG3&@:R7(B< 6RI>YO)G>4).OCAFX"BHUQ70*;Y345&
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M'?C?)'X\F/BQ,._YSCCZ:O">RZ$?^..Q=/[6=+JC*)N G;R"%-_Y'HI_;-K
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MPLM(_1$-S*U9K[ S2B(@J2?'DDBC1FEE!REL 4>SZKL6.D_A K!$06(?MU$
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M33_^0RBDGC"*;9TV9/+*"M5M*B$5356(*[TBGP$QLU[<4)1JA#C1A67:D_!
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MECJ=ZTK9[W]0T@-?##CA)%'@>XX^^E+PE<,Y0/GFES/?'0H9.-=-Y^0^Q9R
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MC>!ZU-E_N//L5KO=[.P^?6?A.5HE=IZB5>(R8<6S[*G<)[-Z2SPD0LT*<@.
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MC/698XH:CU%T'HW)2$8\!Q5>KP<4ZJ%]>)&!3/%=]V;V*5T4H$0"QATR=Q0
M.+H:[M._=S[R?2+*Q-$]SK97HU-Q&I)#4^-<))98]M%*-.AHT"$?EBAZ@ :K
M=E_5NC_>UT>-Q^9F:+3T"$^>5/"PVP@ KX;H?;ZXTG,:$5K$WGPW;PJB$5_?
M48&ZOD<;_3[POQ"TNQYH=S[(?S,\60_?G<=(7$)2UR0GU,' R)G)'EGA0R:=
M2)(^2HNJG9=%2&3&8?$W<#CZV*?IG_@IB?R$9GK"*D3(/'%:R2M[VAE)PLE8
MFO?E#Q5'ABHY9K-S,W&:$3N<P$8">8N[!PV3&$;B#J67!3*IQ\[Y[[/.4[0"
M:%Z^R9D8/CW8:P5P?HP(F2:E(;"(6M:@[7GGO.Z6G=V;.8</SSD,<22Z2#-@
M+).B^37O(-8-V!\!]EE3J6FXYP;X/Q#X#/=54T6K8=Z=:66B.2#1M <MD*=;
M#F))^CL-PPRCE-Q$K*V.04/H3UC:DS&"$MN-0IZCJ243*R/PT(165R_&\N?@
M 9.7;1.C&M2^!WY$TY;'3I/Z.QX'H![C$$RS_WS[QKP9KZJ">Q+@$'JRW=<)
M)]%!$H4!>4DT2L"]5SLDIYQ"U_)6&F6?5I_#XX\HEKNU),&5A\.:>:VIU&BU
MLOBBIAU>%VEI 75QN='GIM[Q!C\5'(\/..*JC2-8BWQ=.*79E1:;&0!S&2""
ME+UP#D4>M(M;]OL6V.M='62@5V Z[A??;I%%]4;)]8>,TVR,S3X*F?>%'^?>
M[=QA^U^[:NM>%OLT7GGBN"* 38K8F4@1@]$FO@%II=% PJMB_1I\+!DZ?30Q
MQ\+WC/E6[17TPZ)C$$,"*NZ [KH: E6;HG4+NUH/:7S:Y]G39/#*^[%/+ER:
MSPS_CU!+'+;*!5X[_ ' UI<^_H( 9/M8))&*&TX;U(3QO#Y-KT9AZ8>9Y$B(
M]@,'DI9[V%/0T+Y_CU?V#:GI2>8><-%;\E HA%?.65PQ5#OI25=DB73>MM^Q
MKX'8-3RO!FOS?:N%T==(+-JC50&/A/:+A9(FI\>NGTCM(,/W%"P5A-K;SKO"
MFKA91..A#&A%Q,FD+US;842?P]Y5["D5]Q0E(G'A,3J'H>2O&*>[WDWU-O )
M9#O4X"#G4@QB,1VT@J_,L 34E5NPB>+\5&IMNG3%/8J7#4B2R+\RY$1F3V6A
M>FPS3\4P!:F"*O6G<-Y*IJ2X+> L\@Z1I<.(?<VHAL%A>%'-K_' POTK\V/S
MQ_6@]"X)H^XX]@-GV\IV0D3$_T19"H9V2-A6@B!22<'T)OTDB]TA>M*%DGVP
MNDXAG!%Z:Q IS#(O;3*L6'O6XG2E;[??842PSHARG LD8. BB(0CX?1$XJN7
M4DB B40'U92HG1+L\"_(#L4%:]"WD6_ZS_Q[(S85BK1@$V4(%U[C)4V9Z:$\
MA8-\Q@ RNZ:R4+,)A,DF:\/.VMC>9&TL##34E%"V _JW#P]W'6R"$^3(UZBD
MS-FT25Q&<=L*[S^Z6<? ="7F9Y!]-58LGA2"AL7I8^.)SYE^3:A^):TE M<%
ML]JUD#W7!>'QQ*Z?*IMK&OG(":14 2VZ/&2HPG%E3(E(O*B/)EFLW33*M>-$
MI#Q4>7\:*F24&*0D]X[2F54&@HI<L=,IF1<:W^M[*FA_3^B(>CXLHA7GZ@W"
M?B@T6/(H]$T.]-=#-I0-*P@YR$H 0QG-TX33RZ82U@NY*_!<X"N\UMAJV&[D
MLF.*E1)-).CD2@&13T-4LNBW!EA8=_ 3&.I(8"6KHY?KZ)YE]>?[9%>%V2BG
MXM%7?7/H541.9N#8G)W%UB4RE37$2Q+ =7@9YF+;5'&@KJ1M7'(*C;A2HS;S
M4=MZQ<H+RN>J_+[091[]J66$\JMF@8AY/4 R,$)!D]%Y8#$(H2A+L/!#I:8D
MIA(E$0$ZF^@D;Y4]K3_K^4IP-- I <3!#Y/:$TM,8)/>.WWNPK[\JK\E3H"9
M%E0,@YH8"!=@ZGXR- :-O <I%@Y((<)JE;QP1M7#\#UQ'0Q0;%^9>[ TV4<#
M L(X@U5=4^ZB8*F=,473K?;&JK9OTCEFI(J@T!I$D8>K<B*7@+7#4"("A FU
MJDW9N7&M/!T[K<.N?N4IFA4AW-T5,B+8RG'D+9*QM32\XA@/"^23>R9/++_&
M.JF"-X0I]FG9#T@.7/(*F=32W$5.,JG>LU5._1G)=!@1HHW%A'/_M.8';VEH
M2@> ('9QCD?*:!J(.TH4).]R-.IIJ0AKH1<$'<[LP5!>Q@GQ*U(.9_D\T .X
M_>XAKV%8S'!0?FX6[>2;Q0/"Y@+,8"<I&H62I.BTL-?KKZ0%=)7[;IB'?47W
M$$?IUH8*<G6^F-HVTS?&H2!TI9828'//N1_"]S-$^Z;C7,U:S"(*\D%7AJP:
M"NE%F1ZF'&_\'+IFB1X*5-[ #1<E NYX6B+ GK^&A."TRAT2_#S?:\"/9#QZ
M*,[]6PS5I.S73ZP &AS7C:7GJ] NAR\JBS@X;F$E#*P%(;U6&GHD^:C =5'%
MK8B3<%0)Z*GA]++TQ^03/5#E^1)7$DKIO=[#,WNQS&M$%!,FR4.G6/_& 4<R
MCP$E^Y8.K=VNPG6CV*.8@-(#RNG'&F_)"&?;1>>,A*DQ772(6R7BFS?8<=V5
MY&T7)&4N#=W/>89VYP<?8D%3X(M/&<> &C? CY(^NS;7B&^?@LDG0ZS?:M2E
M5NF$DT0&\- XD-X 0PY) L=IH*FJX!+;2H*?C%7AM,EH2+3?%G7EM_X[5!\H
M'JVL6]#V25Q@(HSRC'I8M^$#$R>EY:T/7\)(N_)^N7[L9B.,D[J8']&;6.*"
M]0FN 7=N_=N(W-8IVNWXL0!; 9Y,N&DQ+,S;&?A]Q2LX68S\V+5)+(:J_=$(
MM!A.J\$[FI>"Z8Z6&/N['NY(.?U#YY@<'.0F.!9C7 7TF#ASB8=R$L"Q\H%@
M"^@PC:-@/8BD[]Q)G;BEK=UD'/@I5AU384WQC_R+UH'Q(0^PA['84MSQ S=
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ML_+BIG/7M-=SG&-([1P,##(F2>3ZRI.%_%H5P%DY&.105D>->'9J0MX+]J
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MIRK'F\[OK6\9,A_[A1>?8#]NKNLHD*Y]C%K8JOZ.29YA21:X!5HJ':\ ;A^
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M06X<+S8)Q<ADVE6B#E6Z/:'YG:02C]O']F&[5[7:4EFW^M)KYBXP-S6AEAH
MN\??M-?G-)F>\U[,&9#%?58-%2&DGD -'%V5!O,&ZU.\[Q%$)80YFD8R1)>C
M,)-E/D(;:Z A,M_VQ8S]HKO)>72@:6:IL:L.& AL0-E52&CZ&]E<CXQ]F:!\
MI&RP9DFI;&IVX%9-GB0^EL4^B^,;1MS<@$)\A#KC:$RF%TH6C$:]^JHQ(8%[
M!<LW FNIZW3,.IVC;:[3>:$;^WA-45TA3.E??7FR-]#TG4*PK(@W/(_45@FA
ML1LB\S87/V4<$PRK.UX0%Z!'\.IR(<5\H&E>;Z^$8E%&C-8Q$8.7HL5"!/+V
M (A">'5OU7^\0S@VWYF]]0+:&OWH79[^>'GN,;8U='SY6GH=?RSOU>%)HW="
M5RN)X']=]6)YZQKPT4_S?^^VX&X>E7[4;+36_/MQK_PE5;^H6E2KW3@YZCW)
MHN 5AT^TJ.-&M_,TE&HUNL=/MZCNXI?_1.S + %,AQS]CU>=5YDT=ZD9H&FU
M@&E_>J*OM:??\(OOYC1;D8^9A9]:<APO[4QJ,\34P:*:B,1]/FKX8C1WIS4M
M?J1IL!JISD?69UF8WFJ^;5G7E+ '(_Q&]94^BY?9:[176%Z)<9:$T[<'[<;Q
MO.#$Y@%\P*M_ONZ\*5@=]8'G#EQB9?1V^\"7R,>!,_QZ%X7@+1W(W0V' DRS
M=PO.6MD$19T=3I_[,.<M)#S,+(NZ@FQ;NN$E=Z#R]]("PI."!R"ZA^=::N\+
MJ$F%*1M#2R-O61.S)N86$'-M 3>B_]DF 7>>Y50O,V?W42Q5V/S:+%7_OOSW
MSZ!FRTRJ%V/!Z^J$UC ,T,G0C5E9-*:8@GP)X;<U\DUF%&M:K40K^_BP79-J
M!5*U#NW>4?NY-6:UK-*!\,T06)056I!4_$%N7]F:'^OVM5;W\[='GV[[[W^H
M/;"Q=^PQU0E;> /;WW,#GU@AU;]_[ W\'BWW$E&O7%GZN;Q]M5.X0;\G%OR)
M4I[;E?3_WY+_J9C\\$-%=.\)C*0G7?118_EEK5YTE[9<N6@+_^=9EKW*HE&]
MCR0^;'F3\?+.CD=4M6T55[5KKGI6KOI!#4%;Q7.=FN?6YKFS;]1_4T3G*'9C
M9S,FUYUSM$DJO0+PU(N_QE9?38N2TTUV%S5#3Q^H0F16C42V%>,LRPS;(=<:
MG8TKK'I4<1HIP6TQ>EZ$R$9_,;Z\PIG<HLZEI66)R]!8N=JS@ % \)94+C]U
MHH2&LN#OIB*B4D;J"5PTO8!;"ZG93LX]L-* I!$C?:Q4?FW4C$I0A,<,-AA)
M5.O<HX=.((\?T;HC!<DN7(^Y356L@V:B:;.$$C3W/D8F9I@*CV?I*K#M/#(O
M</*]$WG 5H16)M_NQ 3,, M3;D)<92:#[.==@.R+(,#4Y_ -$>3F*X/7+X//
M=21G^)+J&I9W@W[D<2>3,!*J]V2(N.4XXY-W3G&HU3=N@N<S$9:WF\MY'-FU
MUG,%,F11[$)%'"]8:$CMJPK!BB2.EX/$NO?@7I;3/@/O(US9BB->;<"0A/9T
M7/HP@P.<H]-BC)T0-N/X0*E KZR<W";^Z[+I!K0ZX='51N 5-9B#@$V([1!A
M5>U/M3^7OVXWA*P!!%+5B8*\(R\-R@ADK%S3;?@0(,TEVF+H(KQB$BNX1<1.
MY,'BL+G60JP"$TX2&1^8VG(]'">)[TYH!H=/T@V_H9#:X )91O^T%V"CK^H
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M>)Z!BCQNP!R<O(C\NV%XOQ>P5/*G%6C#JL=I,SB(/!B#2'K\'L\&% =\"HM
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MJ1]\4J!]#L0WZ@=&18N-J0$J+=*J=W!D?SGUN;S N;C"\655;RR&:>0E\O*
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M^DZV]:-%KM"-LKR$FO6D)G,LV4FDLROX5$(1E_K-&83H;T8@NF'QL/3W8N@
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MS%]GOYS);YI=72N<]U9Z3.<R^7\;<93]BFRIG9+^_^U]>PNV^44Z@><,Z9[
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M)V/#J9-B1!04$&@(=$;C,6Q9&*JZ,X-9CI SBARH1?')R@"<JDJD_]:008I
M6%:JB)9[8)Y62'!\9TG[G\Z(P?\+0D2"DQZ$KF^/]5JPKA'=1GR4[(@;B$#
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M>^DX,S%PWWC"T,Q@OC=$D1.G$8ITE;&O,.RE-Y>?F#<492H$!.,TDY9E+4]
MP/8]@:+-"U#>H:C-161/!&+H23IPWV=B//'#J1"QRHKED_[17#Q%0 W<[/;Y
M)!;7Q2\O!EX,=)E>>X%<#?G2BYSO<IEFKV-8\EWV=<[?'> 4TT06SP,9><<Y
M]ZNPNL_7/S<-U;3<TJ\T5=_K<UUU.LZ>;Y0/JJ.:.),#C,E0-:-[D#'IEMJQ
M]^M\<Q<=NW.80=FJZ>Q'\],,RC6V-E4QWG;8Z,69CS$X*_+7+0W2_1\87B<Y
MP;$U7EEN <#JE9'O/(1ZG>N>3+54\19K-?P/A<I\O: R5XPQ6O[=R_^OS(*X
MS2V(/ $.P>$RX7#U&4R^QBW^K]+J_ I69^.&_AZMY'<SZ_IS;EV7(+?1MUYW
M^DX9$WO]$1<^NU79V^])"*[.YY'Z1JV@SH]V^37W.A WN'$I T:L($1-#*-J
MQ#W'S=C*U#OS48!J%-S[S'GUZ9_I $&U>3_IGN,^#%3'RT($88(P0;A&2WFI
M$+:ZVX]SG@>^Y0E_3$KX<Z(S1.UV"%Y%'O3Y566OHW1\3C> +/T]"-1.-=(<
M3:&;2D>C5!&U68\60\U0+$):?9:CQ4CKNMLS5Y[[/GRKMEHKVQGMN3'^- 9K
M#A]AX<D=(ON2+X5="@P,12,47#P*NN9Q4P:0[KR(.CN7PBZZ0;J38$"ZDU"
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M#_O?GH$\_^>SX95N/ ,>[O,)&LQ1*IX=!*[9O&>F>S00$6;O\_DD%M?%+R]
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ME$RS^4J'DFG28Z2L#5MQ'/)F+EVQZ!VE:Q]7M9  J^UC319@CJUT-!)@ER[
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M/FX"^@N()[V.N'?'7JGLUX@'X8.7_%=A']0WZ@'B2LV3.70?J&;H;.1]H,O
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M1F4)MXB-CLQ&LU2%^[+2HT#.WE7H=<0'60WV8KABL'4DH:RTFD"?^PU**1K
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MI(SHE6UGET(7.[GY?(ZR&[I,&KF Y)V+5B_P?=F$FQ==L <J#Z;GWMMF4$A
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MZ5/>U(X^Y<H9OA\,+]O]CI,IFMO!5,&81SC W?*PA>TJ92J;/0$O,8UKG]H
M:;)*/9(%(X/9*QYDM:1?/719-M\*U_%*7)235<(&F222P1Q/$%GZ"\]-5MPE
MT%G/T1<OY#:'8P'L99/ 3V[A@H-IZ%_5CZ9*0:)[4S)^"MH9)D2F'(I]._9F
M*R(W\\,I9*F]XH@14LQJ>"DVNI+7LE6[*AXWSMN?S\D5*EUVO4<U;F:8T5XQ
M;C@^"-2>]C>Q9?K"\0L]LVCEX]=;M*9">VJ2ER\R --']<B $#)OIHQ-(O=$
MO9W73KUU!I^</C/,1T@6_=%AAODE,]1?>M@_49%%^U.[V].X=$<?VT,' $NJ
M0TM!%3R=8;.&C ['5\];6NZ=ZP?48C4E> O.8Z,H-:=+1L7 FQ :/@LI[5W<
M_1H6W(^<SO6P.^XZ(ZO7_HQGJ]<%4Z(A+D5M:Q//^PJ[$DTPKXV99$R:\LZ
MT!UG"BHT23CYBWOCA=,'*/@#6?H/$ZED1O%NR@/)^QDWF-_UZ0/<H#QHITL#
M1=N-2P13UQ$UK:8@G1>4(LC0%BY)VN'C5/<E53L@O&N?F^FI^Q6C)?(FX",T
MC@)>N4 !SN98QK,N)T^P3/UNBNCJ-0;/^W+#%2XN:;/18_Z4Z)XB0=.HG=,<
M3/W,X<7IB7M3WV#YX'6;C!E4N8.4-9Q&JY#M"/6DTMY&Z0C5)T[\/7#OYZM
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M@7KF(,_Y'+*"!(@]@,K,%<<1NE-FO\ZPQ6>VME!AQ9FB#*>^&W $(DC<,@H
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M66A9<C9+A&L?Y::"#\/,AV4XL;'X?WV.;/O0@VUL)B@!?>OU"D19TF*)!D0
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MNB+HK.5O7-3 @<\TS4Q)?N#SX@44T3F[CE>Q5Z"&RY4OG! 9:LQ=P$R0D>,
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MH+L(G)RBS:Q,(6TY17K]W(^3E-TVGB'T!6\AX#0E+[2H0IC&44 +_5V'B%V
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M>D&"_0CBU$O?59B3(?[3 G63DL-"^9L68A_I(=5GF+WW'3;N_0902P,$%
M  @ JX!Y6@^, 4;-B0  1"0! !0   !L>')X+3(P,C4P,S(U7V<Q+FIP9^Q]
M"2!47?__'?N:2 IA["F,&?LZV0F1?4FR#,8RHS'VK5U1"44(B9(424AAVNUD
MK4A:[)&RU5AF_G=&BWIZGO=YWM_SOK_W__[<W#/G?,\YW^_W?,_G;/>>>R(_
M([\"UFXW,#8 (#00B#1$&@#(KUDNZX>B/0' S S8 @  $\ (X0)H01\$_ =
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M6[]NW49.-NKUY>?7%X2=E95]#?O:-6O6<J]9LX:;XJSA7L["^6<8D.\"G$R
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M!GTS^D8%3]6)E"5)>>S[O/P+>8X]OOXM'#<56 7I:$8^W5*>#E$U<Y]]7['
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M%.0J V:0]<![B(#REL7\H!=(]4"[X[58F#5\46%:((LOS )PX(Q7UL+5"V6
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M%P0#"8)$0@Y"XB%)D'1(#J0 4@*IA-R#U$/:(,\AKR&CD"G(/ TM#1L--XT
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MVC=]NHEX^\"Q78\R=II-J'NNL8/1*C\)VCHA,<6ZI/9Z G,>FG<T^H.A#D<
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M9,)_]/(;Y3^2)A;0%7594P/J6 -"+F=I*I;DM.1.2KI&!BX)<CL11F(B<\A
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MN80!NTI7QT:)PBL,2*T-VY%L/+9G#=.0PXS(S67V0C/T+TL'G1JBAXR*Z%\
M'86U 5?'U9\8W0I-R6:.WAO3(A^]AV0A=OM:TUYB<H/V_>(T_"P&CE/8&0(I
MU#&>M-W^)+#@TEI_;N)3ECOKHS- $&^,CC"[HI-]6LNG:A8F[8K62(Z2*C3&
MKAT4CU_7^?!\5<S E,MS"W?HJ25VZA,S:\&<_&=CW1O2=^>CUY,R+]^?>]IM
M=3ET,,YFR\A8L/#^G(V%'V$DW-8IG84IKQ8.]@LF@0/-05EO&^:3;6Y=\YE+
MJEB8XCM!!M#>?3YT]\K%IU]2.A%8'4>+^F1]L4;O.[IZ9$H9AB?:K\,J4+QB
MR]7+^5A+KC#8T8$RR$DQ1\+>FQ,&M7;7;W3A&V\5@WZF]WY8USUMC6Q7> 4V
M!K$QB6[U.$[%01C',':H.YFH/A QB7CYH;(+L]5W\)I8YOMB!^-MVUX8G!X8
MOLZ]H*\-=22P*4Z$V$YKE1408YVKDW=VS<;'WNZ$B2'7U0L7//,#1H!G+)#K
M]27;X78U,2V:I.T^0N=>XDXVV*3T-CAN-=P[=&VGTEM.R<-5_J3%C&.T=QDP
MG5(*Q;V9,)..&3.E!X;M?F\Z9IIE7ZH[:SWF?*R2<TQ'9/,'P&JK1\)R[T;9
M&@;VBTF.3\D C8D043X0Q/P4*P7S!,(P0!B46[Q+!LHU*Y;T-G$91>=Z<'U]
MZA-+!H8WQPQ+@BV"9KA.<-MM8XUW6R!7WYD\UFMO>Z3GS:Z=N;_HS5'VZ#;N
M4TSB1/W P,"(O9J#@P\K0D(L%2J4K523C,4";4."Q4K$.I-P1A:@0M7Q4_U3
M_-.ZT^:'2+93 P>-9!XM/HJ.+G13SGF[-:Y1MU.OR'#O,87BDLABL!W0 R=5
M(]\1]TW(<[Q\YIV28V->UEPO3A@PJOLHD54!+@15D$0IGW->,7)C,MLT3>(_
M=T[T?UJKITQT?WCS8"=AF)X,2&)I^65,FM)-LJ\+5QVPYK?:JUA:(D#JUC Q
MYYZV6WPE6XG=5$J$M::$Y[*<G5G:_7R";U]4HH:,BEN$#3?(ALC?FIW4G]:?
M<G427"^]?&9?:.$KMS_0S7<NIGT/C"_YN?V1N7I'(1L0[)PD\^BT[J(8)<5&
MBQZOU+P(\RV/H#U.4[E=MW+&A TN9 _[G.B@B].=%8)2Y@Z[T<1KQ/S![ ;8
MEEW$W"9<&GL4NZCQT83=<R,%6]F"1I0*X<\-EKR9:;H^IQ*SB3E#Q<W9\B^(
M&<T;4'W'S.1-CF<7.CAU%[(Q[7CP<-:]$AS_X6'=8/<T4SMHM_BF> @[%%5=
M=-W_PE1JBJQWFV_X9518KDC5Q+5]LV*,/O WL:6;Z"YEHXF^I "[J0K3D\K3
M@J77PBZ,HL<N)ZGS>^:#T[6;!P@?3[]ZXQ@N%C-]U&4Z <V7&\8^N&>SI[^=
M-5M4*_]UPA'6K:9(9[!K$5I,[WSC>M'X&A'S)OM.4L^''6?.+QCCDY*T3+5"
MP>Y#G(2*:5D?[1ZFQ9IIU6 70%PPWK<A(L*[B2_I,AE(M6P1.T\&HBK=%\_J
MI61O,F,KGVJD^ZBQ[N[$IB=U%YT%S'@=S)B@<6L#<LS7[UBL'#(+;%#KBCT;
M65'0FN>KYG'!2?U=\)L&0PM# UM^Q'7A(P_!2; 7<EB0, S%)[1DLE][GZ()
M:^53V!(TP>O#97/9Y9J3=9*[>Y>OM3K?@:M/1-*T3MS]Q[.!CJIJ8O%0]I8P
MQJ9H[:G9VI$[2*7=XH_O%-Q_A!';+S)#NGI<ZIY@7B7_]<_!N[73[<Z^N?JI
MSB5%,'RQN7-'Q@!!]L4[CG6;JZHL1,O*V9^T!@RZFUW9)G$IFTDEJ?A6528(
M9Y9);CO!Z.G6BUL!5/O,1EVP\>86)E:2@2SD#L-C"G,F2.)]CGIU[\^FD?<N
M*P*S1; V)PP9J#PB3&@4%,_+MP.K8MWBI:J3NA=]H]W;BMBC8#/Q$4?UPVW$
M]JG2+NU-X.H8@C6Y$.^[-,5LT=Y;$&8PW]]Z&P_<<71Z[!^T-I?HGY;I<7X\
MB4<SE8.KXZU3?-B$9'KW&+-,D7]?[JV*,]O5U-(1-Z[3K0V&OM8Y"8)MSF[Q
M=>TP'<EXNFFW7E=1W51%EJ>]__]K[SV@FNK6_.$H*C9$$40!C0C2BR!%:D2D
M2Y<N1&E2I#<CD""H"(J4T%ND=Q"DB)2H2.^]"1$E!%! $UI"RG?B>XNO][UW
M_G-GYKNS9F8MS5HGY)R]][.?\GO:/D/JVZ(U1KO?"HT7E*D<-RX2T.L.5>$F
M;<3H_&1(::#?%[*8RBY46G/W"K==E_XVBVJ_L(&9";)\&2S.F]3LQ#N7]Z_+
M3PE6K0".).!;=I8U!!&.N/N"\TGT\N2EP\],_X7)I(HN#+$7W%??^+8"C=5(
M6ML_$%0OA$YUB*A]/6+FQ7!L5'0G>@OK(A3I[;5?/,PS:Z+D*X8(@)*V.6*&
M;_-=0KQ8YM6AU4L6$QPE+N/'P!%" E<E,M*CJ^&[!B-#C<!E8_[^J7YY-8]0
MKFP)4>DZ3'GI^RM;69TN%9\3V'5Y=\CA4,-+]&D4L\N,C=<2)F>M6@.<_3C5
M?%PE#_#$R;+:^]Y4W<VTGX<-+HWH,X:K%6#Y4^=&&]''$:&*8WBM/&[,LIGP
M=QTG7>4.QG@_3)0Z]L#%?0-0X;DK;L^_I*(2_<J$>^1%NRV67XN.F*4&=VUH
MW;JYK+DJ)* R$?5,B$(F-Q$2PA>8XX)J<$HR3]P6#IU<Y>!&YUTHUC^@+-%5
M&O[!X4Y*X@]:@<B]Y/H!B+0BJH@(Z9$8FMV 34+/A8GF#3$LW5"#3AD%@*L/
M&%>^9X.S$;<ZIF@@;'OJAH< +'%ZF928( XV=+'-Y)L5G+/3TSJWRFS3]N"H
MB&T+?0,& 6E<Z]<OZD,AJ<Y->673U9D:32F%/"D1SB):2KF\C0BLMS51H*.#
M%W+-&T"222ZDVK3G2_<>U93.MA8X6YHT)ED^7&^+8#44O.VH_,8?PP;GI ;!
M/9>AZ9EW7X^?E[2"(?1PSEAKP=IU456SM!#-C?,\2%3<6*3D&\$GK1*F%O.(
M\ZZ89!OG(<4<;(.Q7[$+8?] *LFS33;.V9RAE<?R)?A(@M3)DBU]_$O\L JY
M .^>@F7:RU#V8L-/5RM>I*[.G;'$Z[QPPS$U-L7K>U=B^":5V'?_QF/?V\DX
M?JJ6*Y1\0 0QW]L',&F'"+T\@PKHF-TT4'P+@8$ZL8G9..JIQ4V*^I-H0R\!
MAE";ZJ\&(*-$^3N/J3X$@;CA;IF%J,4!9M/O(U]-C[8\/CO:%>F%O;+W.9K5
MO;S< _CGX<[;T-B8@&MXG?*D4Z1*XG: 8Y&CK1;OAIP4]W<3UT#8*BYT;.R
MF'NYO7E96;817HLGIOAQ\0%>Y&7&&R:D,"(@-I?\\IQJ-VW<R9,OH\W&SYND
MMG<.&:Z(M!P,\Y?7%8\,?KC60TF.2PW>8#5\R^79PM%R6(A%(&:OB0GKP>=W
M0*?WJ0E__TW&2A,%<,\T':,<'SD(BN@Q" L?9+OI?_99#IN*\SV]I*R)EKS%
MUV[EL?G3[#*DX'C!/<=23N?"C[6QF2$E[%1&D)'Y)P$@>R*O<&*1Y$<M*YHY
MGYB6;]5-[Y/)5CLL9*-A]['XP*62;^V$:4*8"7F>T#1;KZ#E@:4H-E4D2#V2
ML@J\C'%+K-YP?.[,W.G::B:R.[G1"M@2BB! >+J"MZD,/*U 4"#PZ[(;6WO5
MT^W[=2F= VS/\,LR.]<V2IW40#D<<;O?QX=0.$ @$"O#S7UJHI_^9-Z2 //&
M"1"K/P?NO%37?!O?E"L/71#-5==<>"KBY9(M+16*RR8]N!.7T=;5'G4IQE"_
M_4FW0IGRZO([TJR.PO2IS%G\D(,@K]'[UM.G=?<[W%1AS.K,8HJL0IV'==O@
M&5/6HV6([E^64VNC+R2RN!BI*6@=+MX_'R<H]*Z)&9!;#/DE^<T@^B(Y*1O6
M?U51=$,3/50Z6:]4UH,XO+GV8H;K*),RMSKGL83$:X0??/B-F8Q;(V>#@8EO
M3KRF@0J]Z/@5!^!7@-MT &Z30_0INT#221]2'^4.+36K#BR8C-7P<MG7)]ZG
M%MW1+)#,9?>8,&(V-5"12OH:D!A4 1AVOL4Q.!3?AO3(7MP4.C';-;F[S&F7
MOY+U5(*CK7E&I]R>@NT_.>.<@/)"],E/P&\Y!<S>Q6>FOX#MJ#_H]6%ZO8MD
M.<5M&C$27)2@L3I=5,  #7]Z7X6Y@U[#5*PJ4HMO5621,K[RA5<R*T=8L/@%
M3Q8C&YP*-R+V4TW9L77(H(\]95YESI7*62U?G[PJ81JP]#^N_M'^$'_VS=\9
MR=]5SET/Z_EB?6*1!A)\2@.U%%+EGI2!7T.8FRK$AVP@XD&XW+E_82''?T]#
MF0SWIM[4(-H171<J+GE#RR<L3U8[??!F#O:\:OJFPI/W9@\DGHL;&BHK*\M>
M)\N>Y*/4._JA0KKW_8.7G;P/7C8<K^=-12)MLR)?(KH1O%"J'?%S-UQG6$MK
M8[KUD6N(\.)TH>2-:QH(O?..6_GGH<W--@-2%<).]\R2I!34JH:DK)Q6I'9,
M,$^]RO9J?4".(.L5TLOBO/XRP7:$,OD^^X(^UBQ-\37WAI_ BI7!@!XYD=1S
MZM8A;<KKDWTS)^?V0L/J9<1:H848PGVXK^N:,!'=$6"$1UYNC+X^-/J:8K/.
MFL ^R?M88@NY^C0.C/ASA50/FH"$Q,H 2N/,==)F[&$OV%JWEV(J6^_NM,*Z
MVY6QM9-]B_J3"%"O$=-9](E5MU615?[JAH<KY67V3NYN6*-HKL?:59*I1U58
MS\X/Y$263-_X8'%C>M:B_WS93&Z1=%G/-2/-^:>/--19SQ:!0B7,5E#DSQXX
M:S2./<XND&@$D2/ZV=40U J?;QS8H^8?*?BMAS4.--ER)+YT?[Y^]@MA/(;J
M(T[ K%-SQ+&R"14PI]>*<XUSL$-!LF:51TU'C@9HGC1IAX&HNKBCH=O,!]EN
M/7)-R:ZKB\"]RAB[=#9*1Z&!0Z@X,DY+"F1;,8DFMC%W."$$R!4DJ'6=.F$M
MY9;9&-=@<]XNQ;@NF3.<I_9/-$\_-([A&P(;W?PS$FT&#%;Z/,#JHJXTT/WS
MT>24^DZUO<2]]* P!D,(@>*3X3<1TV>FJ=E'#O!"#*L.T+=-VSFK]I'5DPC3
MDV?5XYS3'UY78W.T]0?M,HY$[T<HH2^60V0@DGZ8BZ1RW[NHY3,6=2[1.OIU
MCL>"^+-B$F/#"1+=H'SQ,_3"6'T([C#ZG.@Z109#".@U%>8K*-I' ^VUZ*DA
M-=5-RC9:Y72_>KJI_SBX4K,C%W+E#P)2VSQ4GR2"LBY[]ST(-C'!U[:98$9"
M)-_ED%SZIG3N*>I OI'_RBE&Q\ZK9]$B59K^0B0SJM=M?"JD%])38E=B2;'K
MRC2^/D)^\U28JX<C<:S,,E+[4RGS=;.3!S3AXX !.;CK!</9Q.]_'9'\#J#9
M'#GGB<Y(-0W4&\4R/EPSEFL-Z8U5KS9I.$2-]KY, \&SX^V&XRK\.Z\^1RM+
M L/N^% ]DP@JY)>XDHKN&>W/SY[@0J!Z1T8T_32/QI]K8+:4%@A,//:4Y0#S
MV-/0?\,5*P[&(L26;=P)9\*QP><DQ HJ,"JW[ N^AF>\VV<K+S16&@C2$Z)L
MX=GCJCVZT0*+<+T!V[F"Q<3N_?$A9V#ZK2)X8W?O>I%97(NP???/*U,#5I9'
M;@[#$PCA-M4O0JP69^VNCOL^OFYH*#;YON/YG=U]<7L9LH?Y3B;UO0+V80,-
MN,\V;AKX-+/!/.]^[ Q\[JSEUQ?6:JS=^L1%^XY.[LWRGTJ ?E\^>AW9<_GT
MB6TP5G5+/KUME ;R$V\W;41KW?W01,A /OB_7-O?M#ZD0PDHN(=?>$>F:J@E
M;YER0U&+3:.PFXOS>B\]DFM'CVH-Z!/?1 MHP!8@"K#93V(:5U^&:0];/-0H
MNM?+VU/P4NA*"9Y>15IXBO5G9PJ'(>BH0(6I]D1"]R!_@4>NZ]3#INSAZ-43
M<Y3C>J-Z_"*'S<\(D=JIG@T]HMG4NTNI,.0#9>=A\?7.75)&1I!R_AJ8%4C9
M=RWT1ARX"O:71 \AC>K#CV<8UT'W,?-/FCK%RV:N=YBMG O9]SQ2H9 U-:.0
MDIX"B(@T7436*[J@/;VW\6E])+-TJ="AO(9[',T9W9$V%IH:90Q!BZ>T%M]:
MU?(*K[<0"%1O'U4\#OLH-GB>R<2]L9T88?<%YN_+,U)9?2^WSDB,;*^^3]IX
MZ/*];SSG=KL1CZSB%3IYJN,T6S,F1BH5XK26];0.>9D!2((\5S</\G$FOEW8
M$2H>(;)?RP@,4RV41#&]E]Y"S,N=8@U?$ON)A?\9OZ B&8T3"]J<U2*GCJVL
M.*[7Z%_J2&5*8'[/\\K4-?_Y;&:H_'CEK0=[V#^UZ1YIM4DB*LT+(BY")!5+
MYK&FI/R\NQ4EFC5[19[OLTHL7 R6YD9T\;!48#AU=%P/6;ER"M]=$?F:K2DJ
M:FL0V\KJPG:,]<[N$!"#L/WC/VA$ !@-=U9QA1]% \D&?:DXT.1ZL@*C-[BH
M?\S9CAI]S$#K.7R?ZFJ[R&$;67JK11< ,#EA'!!!JMX2Z?W @U'%-2^^,M_Y
MH"L?CC,5F[6$W@NC^,3$J2Z3#_PTCCGC BKN.;F%W$CP0.9'V>BZZB6(G%JZ
MVOCT7F(5P/TB'>%'*W D\]Q'6MPI''*VMG%M[QY:Z.[G><]5&9DIE.)$*EL-
M*W&^-YLFGE6XN.4Y.Z%+1EJ]BI.9RCBE+D1]$)2WP*DO0X1V-SM5%HPJMA18
MN1P5D/XD=L[B$LJOC+G9M#,&P/M0$#!Y. W4Q4U$T$!N3RI(X:< H1/SIBMC
M"-73IROV"S1-=M;VU9-T9?TAOLQ)TL.&QG-3\C10/U_2GCAP>?V>GT6DCYFX
MO2\<7$!T6[AJP,=4Z%RG6V.A^<A)(_K=510" SQ:AFY>* !H107?Z-A$IXXY
M9CYE67RI,=:89X5U7U\ZN1(;I[KN^I-H _CV=R7*UTMN[%GB" &OQ<%7\%'Z
M6]Y;%SK7DR*[,7+UE_Z?F_?^MR2BMIL  QE5UEQ!_+Z@8TN>PU,R4?G3J%T;
M]O5>Z ?(%YWM<8>P/0*_;4DZA#Q(KB"CR2]'[RB.XTY#KHS5B%^X,2N=,7P!
M.4!JJC9$/=0;C2I:G]?4#+:B@53!1,!/3!+7H('"$,2<O:P-U$<0O"P-)&83
M30,!&(6@+F6"69>@@6+11.]UQ#;PIU2)['(:*"N:'$4#=2?ET$!OT>3!*+8
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M>EM\]+O0VR</8C^$''\& $5OWO53ETB/ "7722]!06NB<1@PT0RR L#! "X
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MSOQ:@E:96%+^=7/6/4WTI*1OQA%CO@-!]5=_5&< G\#7$1+B/:@^<7+*K">
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ME"592HUELB9:*30DM!EM2(N__WW.<Y]SO_-^Y]SG?;_O?/?:V%D;&GDC8 $
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M_&VCU/!1-5Q*#1=5TYU)ARC&A=UC8_PQ>MQB>:!Q=Z)N8'=@8+=&]S:!W93
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MP&7#R EM:HSU\'EI97"TZ+>^*540-C5%S(9F-!=W!+>X,Q&2X9S6)Z;'I^O
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M&VHV*:\+]X8Z$.N&CFWEW \H4:T@I[KPL%]]K*M0Q+WG66>6%4^ZP-2;TV+
M)G,T+>:  IY3I=)3)Y\V[#9T8[=Z:2A#PI/\JNOUSUOA#L#=*^A.V6D.(BJL
M=\K^O>B;?1_8 .T#C/JQ.W[NQ2UZVTV%:-<*?1F_?*UF9?DO4V[9.CQDAE"Z
MMGS1+J-C^UCTF+.\:YI:Z2+.!)'R$;+3Y0-6=ODV-$^T];[7Q^(]\C$$4H]8
M"&S\@WC*[KK70I,4)?>%"2LSX8#\7_&I1Z+WU]WM.V)[0(#77S1*;]V/!^3D
MYI#"*AQ,4^H 09+\\F82!RNVW2U(\ RD,$OB"P*0TV;H(>T("@WN@W%_M[28
M/T_1 ,]2UL5W6,&6E1(.E-V4*!N?N^Y8>7_"G"\^#_$JM#EH02<&SA,2'.F]
MUM&GL2OQ@1O85Q>9X^Q5@*@ODRX)W@4ON7;E7. IMSOY?NVF3 N"-0V&D,8'
MRYGV8*E8P:.)A4(6__68*E 7SJL#H*L3&39+.YDDS,8J10,2_0T,3'_O$)J9
M(*+.!C0);)@W^;O9 U,8PND8Y$T(5(HD@WM^&XU<O$LO'OB3>*0)+7)DDHE;
M]/8#.3M&7*,%&-]'Q ZNC0TZYI(SPWL9CG&;S]C(-O1_YUA<Q5=Q1'L&W%I>
M\"?WT3/U[^$AR/$<5/AF96)+1%V4P\>MXV]C7V;T%@EHYTZ]*-510^E;%LM[
M 39+CL$A=Y,&>;QD8P.9X-#JR].OXT6-9.$BWSK(J>]4 ;AI51\].8&HDVL"
MTCCC*+29A'0C0X# 1GOMT"C-*C\W\\OD#7#17/N19N[Z"GOFW]@,J+@?%?)L
MH<]:(>IV?3&.8K*@M<-B_L6C5[E-J:/SA(F:')OY$6/%XS.3CC'@YBX#$6%3
M-T\2_.%OA^\7;&1FD'.]$J5_/XO?ER-^E%QO-2*A\I+8$DHTQC0\5-13T1TN
ME?H&G)>,Z'C\^*/K;@Y"9S715.H^1FE\\^$1D7.:_;]4BVMC+IMQ@-R1@G?(
MYC,6)Y1LN\2W"'?D'HJ]0[7E=FM9KH0MQ=7^4_E,K[%L+1U-NS\5]!WC#L*5
M4F.G9Q_7EJ['31\=N/\<NXHLQRG#<PV!U@$O0#.>,Y<O9/QPYWYPGVOT+':)
MW-X]C<*:FKSY/-8%"WO"%QH7F"6B^DW##OV)]=W_'L/C3 5^\[9) ."NN882
MRN,-976'BMZ-Z-1EOKM3[R!"_#6SUT+YG83'3N5\4]7W@U;.8;/#\/?.1SF=
MZ#TG+)ZS, >D4KLL/']V6!DKM,ZA7*@H[RC_[U'03P+LJ(W!PB)H)1C^Z53\
MWU>QZ6"D5A3@M10I )YRB?)OXL7 =0$OI]-B:H $X4SK8<2+EQ>W8#10YSI3
MR=LNU&67::Z\2Y2!&CET+^@D3Y7',@SD!("(=4675=OH.0?9$J@Z2>K6A&A6
MGX!.VX'7*=";%UZ:H*MS(NZD*DQL +P5!?VV\D:DP,0Y8<,IL543*&,:K,+@
MM->XP-](F.AX4$V*D*+2B4^/Z.%],5>D8($, 3<W -44CR6R##E!BTB6 )8N
M%@6<=H?^$OQ2 B)@)-!'';=3TN>%HHP\#VZ#-$ [^>@U)]*]#Q^(EII2/)CN
MFQC%E%G3D]<!-#VP2>U^6AUM%XB'PP+]<8>.1IQ+#B&J&/UD"%!L@CWO0O-<
M(  5'.GK)T< L=$@B@2VD\YMK;T*R3\:W,&@"S@AU-CAV1L@"050(R/BI4-Z
MHR)67M)09J<?&*9N[,,5UP*7#77$G/S^+L)LHWURYLY?A"4&YCG=%]L#4)6C
MFP\)YUE%]CC&806-K*4(;)=\U^AW =C4J""#'L3=]IA3CS!_&0=I#-B[4R&X
M589X<Q*O-/4(D/*S-OX"*\7\^KFI4Y%AJJP?JJG)M<QD]\RT5 A=>B[;-E5"
M-7[2+>UD:AJA%M ^ KVW1'0>!8S4+VCW) A,G,%20;[?:=M"Z2N'8T4)[@0N
M@":=NC('8'KW=;T\D[@J[IPD12GQGVLI#O3.%4(G '2W+O^@%2D<+Q(\JF:P
M]0,X+<PY08Y"_(9\AI8B)+ P=5[&\+K_+#6[<4"5=,D$U11PI%W4%<BL B,?
M&Z8&3$+4M4OGHB$O3D#JF33APZ+8R?Q?@KCORS"4AI$D6]!5TD>$+2A)+G69
MRO&,D<KSALA[U.QL(1<>GL*2,: YF*HH7A4')" E,8ZH;J&$:2Z@U>NX3RFH
M/S+)C'M,C\A"#(;5#/ACR;3\9ZC]3;$XJI!4'H.&\Q&7SL\\S5IU@\P,#*1(
MH M;X#N'?FK1CT@K:RXY;3R%*%!/S6$D9P[ELZ21Z:E7>PV"4:0X6Z.$@Y:
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MJ9?"3@B^JCEA\J_KS6G##VL%(X"4:;D.H/9'+[5[R2FNS@2&4613>S4#@B?
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MH&89@0>!4+3?=_)VT[^(@)=R=CG10/A];YK %B,!I?HM]55H#P1C]PJ>$&1
MX3V:<BB+\,_Z+*'1$)8GU ,NK#,+C59A_RPJ8;90BLZH4A*&Q]AEWG1@BPB
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M/0:,YKU5$BL+S)!;/'^BQE=O3-=8RO#2A[^59%K7U;2$'^?>9E8=0P,.1<V
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MXJ^H8Q&EK /-0%OIV,3VN2B5Q;3.&A*4.O1(^**W>_"M3$[NWR=.6A,&?S_
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M!T1HL+]B_RO,?[30RST4K/K2.UAB5( D$GO-D3JFQ]'-!4L6Z(J#O@_,!DG
MBYMG]#_;J.])%8$KX'8'_S'\MC"L5"P]_N<7L/2TTN#M5'PT&D:_;5$R&V+(
MN(ILO=?_.'?)]8OIR%:\(>1SH&0B1^=VR-9___YLRO8BIQY>C!8YLC[N^J-3
M:B(>=ZD=%_G;:(.0B*48$A-!$##Y'U!+ P04    " "K@'E:>:^K J0"  "O
M"P  %0   &QX<G@M,C R-3 S,C5?;&%B+GAM;+V6VT[C,!"&[_L4WNPMSJD'
MFHH6[0(KK500HJ!%6JTJ)YXT$8Y=.8:&MR=V&FBVA(,HW+2)\WO^;\8CVP>'
M1<;0'<@\%7QL>;9K(>"1H"E?C*VKRU]X:!U..IV#;QA?_[R8HF,1W6; %3J2
M0!10M$I5@E0"Z(^0-^D=0>>,J%C(#..)F78DEO<R720*^:[?KV7U5SGR0X]2
M&@-V^V&,>Z'GX: ;4DS)8-AWAV$8DWAO,>J1<.A%W@#O0S_"O=CW<> 2']/]
M7I]X7M#MQP,3E*7\9J1_0I(#*M/CN7D=6XE2RY'CK%8KNP@ELX5<.+[K=IU:
M;:WEQ99^U35J+P@"QWQ]E.;I<\(RK.=<GTYG40(9P2G/%>&1-LC346X&IR(B
MRE3]52[4JM!ON)9A/80]'W<]N\BI->D@5)5#"@87$"/]?W7QN]4R<+3"X;#0
M:WL.,A5TIHA44Q("*^E--'6_A+&5I]F203V62(B?#\ND;$35E(&F] ::\GN;
MF?,!_!WQJFW6'<"9=,]VQ?A23<]VAGM9[A#P^< ;-A]&KAKJA-.OZMU'JP^C
M?S[QKMI"*,*^H"V>;#:0F1Z8ED]K&QWHA<W4^*RW[@U4*!1P"M5NV0B-4CJV
MRJ<Y*V0Q/TVCA ";V2>%$OP\L8_M4\A"D',CG@/'5[,ZM!EZRV3K/>S;=9:0
MBUL950=7Z:H/[0IDLK9$,QL9TSUD;-'?ROC?@?-$VDA=1 T+IH\I(?_/3$1O
MS*Q:?*W%^OQWNW[?+.TKLYVMY?@A:S BHU?JM58XD2@/W:7"C=+%4F3OR4")
M]ZQD5;42P$)"4I#EI>J99)J]-16< SL21.5O[ZFM29_72Y45,EZ[;J#6-%YL
MG.U97]<PK<2-1FE7M37(9D'UME;>99W&97;2>0!02P,$%     @ JX!Y6I"Q
MCH8] @  R08  !4   !L>')X+3(P,C4P,S(U7W!R92YX;6S%5-%.VS 4?>]7
M>-GK'"=I VU%BQAL$E*1$ R--^38-XV%8T>V:</?$[N$K:(5C$W:2V)?GWON
M\;G6/3IN:XE68*S0:A:E<1(A4$QSH9:SZ.;'=SR.CN>#P=$GC&^_7BW0F68/
M-2B'3@U0!QRMA:N0JP#]U.9>K"BZE-25VM08ST/:J6X>C5A6#F5)EO>P_M1,
MLR+EG)> D[PH\:A(4SP9%AQS>C#.DW%1E+3\LIR.:#%.67J #R%G>%1F&9XD
M-,/\<)33-)T,\_(@D$JA[J?^4U +J+N>LF$[BRKGFBDAZ_4Z;@LC8VV6)$N2
M(>G1T3.\?85?#P,ZG4PF))R^0*W8!>QH4W)[L;AF%=04"V4=5<P7L&)J0W"A
M&77!]3=UH;T(O\,]#/L03C,\3./6\F@^0&ACA]$2KJ!$_G]S=?Y2,I!98/%2
MKP@P3CR 7*Z:,V&9U/;!>,F!PCTV,(NLJ!OY$JL,E!LNNXNLZ_?(+[!?>$6?
MMYG)+X&- =N]JF#(H@L\%_!R/BX66@>*P\:(OI+4; LD?1NTZ3,E+4"&Z%U7
MXNY$RG/%Q4KP!RKM!=0%F _??B\A^9A V9KV;J&5 GFJJ=LISV.\@CP99GE0
ML2=K2\/O[3@Q#&G#P73CH>>FAFVUYO7#?$:0AIJ."+-*2-YGET;7[[/8Z??<
M=.-35S%"G? 2C &^V-BT5U\0%[S\*_<O!*LHR.OX6^NTNJSBL_@/NK _^SW=
MR/YK-]Z\^;_HRA'9.1VZ*4^VQOQ\\ 102P$"% ,4    " "K@'E:AUB'1,"O
M 0";XA( $0              @ $     ;'AR>"TR,#(U,#,R-2YH=&U02P$"
M% ,4    " "K@'E:]'3;U- "  "K"0  $0              @ 'OKP$ ;'AR
M>"TR,#(U,#,R-2YX<V102P$"% ,4    " "K@'E:!9<$.;<"  !J"@  %0
M            @ 'NL@$ ;'AR>"TR,#(U,#,R-5]D968N>&UL4$L! A0#%
M  @ JX!Y6@^, 4;-B0  1"0! !0              ( !V+4! &QX<G@M,C R
M-3 S,C5?9S$N:G!G4$L! A0#%     @ JX!Y6LWO*YI1+@  QBX  !0
M         ( !US\" &QX<G@M,C R-3 S,C5?9S(N9VEF4$L! A0#%     @
MJX!Y6GFOJP*D @  KPL  !4              ( !6FX" &QX<G@M,C R-3 S
M,C5?;&%B+GAM;%!+ 0(4 Q0    ( *N >5J0L8Z&/0(  ,D&   5
M      "  3%Q @!L>')X+3(P,C4P,S(U7W!R92YX;6Q02P4&      < !P#+
) 0  H7,"

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>lxrx-20250325_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:lxrx="http://www.lexpharma.com/20250325"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="lxrx-20250325.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">lxrx:LonnelCoatsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">lxrx:MichaelS.ExtonPh.D.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:EqtyAwrdsInSummryCompstnTblForAplblYrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">lxrx:LonnelCoatsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:EqtyAwrdsInSummryCompstnTblForAplblYrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:EqtyAwrdsInSummryCompstnTblForAplblYrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">lxrx:LonnelCoatsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">lxrx:LonnelCoatsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">lxrx:LonnelCoatsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">lxrx:LonnelCoatsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:EqtyAwrdsInSummryCompstnTblForAplblYrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">lxrx:MichaelS.ExtonPh.D.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">lxrx:MichaelS.ExtonPh.D.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">lxrx:MichaelS.ExtonPh.D.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">lxrx:MichaelS.ExtonPh.D.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">lxrx:MichaelS.ExtonPh.D.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:EqtyAwrdsInSummryCompstnTblForAplblYrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:EqtyAwrdsInSummryCompstnTblForAplblYrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:EqtyAwrdsInSummryCompstnTblForAplblYrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <dei:DocumentType contextRef="c-1" id="f-2">PRE 14A</dei:DocumentType>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-3">0001062822</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-4">false</dei:AmendmentFlag>
    <dei:EntityRegistrantName contextRef="c-1" id="f-1">LEXICON PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag contextRef="c-1" id="f-5">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
    <ecd:AwardTmgMnpiDiscTextBlock contextRef="c-1" id="f-6">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our long-term stock-based incentive awards are generally granted on fixed dates determined in advance. The compensation committee&#x2019;s general practice is to complete its annual executive compensation review and determine target compensation for our executives, which coincides with our regularly scheduled meetings of the board of directors, then such long-term stock-based incentive awards are granted. Annual long-term stock-based incentive awards are typically granted to our executives in February of each fiscal year. On limited occasions, the compensation committee may grant long-term stock-based incentive awards outside of our annual grant cycle for new hires, promotions, recognition, retention, or other purposes. The compensation committee approves all long-term stock-based incentive award grants on or before the grant date and does not grant long-term stock-based incentive awards in anticipation of the release of material nonpublic information. Similarly, the compensation committee does not time the release of material nonpublic information based on long-term stock-based incentive award grant dates.&lt;/span&gt;&lt;/div&gt;</ecd:AwardTmgMnpiDiscTextBlock>
    <ecd:AwardTmgMethodTextBlock contextRef="c-1" id="f-7">Our long-term stock-based incentive awards are generally granted on fixed dates determined in advance. The compensation committee&#x2019;s general practice is to complete its annual executive compensation review and determine target compensation for our executives, which coincides with our regularly scheduled meetings of the board of directors, then such long-term stock-based incentive awards are granted. Annual long-term stock-based incentive awards are typically granted to our executives in February of each fiscal year. On limited occasions, the compensation committee may grant long-term stock-based incentive awards outside of our annual grant cycle for new hires, promotions, recognition, retention, or other purposes. The compensation committee approves all long-term stock-based incentive award grants on or before the grant date and does not grant long-term stock-based incentive awards in anticipation of the release of material nonpublic information.</ecd:AwardTmgMethodTextBlock>
    <ecd:AwardTmgPredtrmndFlag contextRef="c-1" id="f-8">true</ecd:AwardTmgPredtrmndFlag>
    <ecd:AwardTmgMnpiCnsdrdFlag contextRef="c-1" id="f-9">true</ecd:AwardTmgMnpiCnsdrdFlag>
    <ecd:AwardTmgHowMnpiCnsdrdTextBlock contextRef="c-1" id="f-10">Similarly, the compensation committee does not time the release of material nonpublic information based on long-term stock-based incentive award grant dates.</ecd:AwardTmgHowMnpiCnsdrdTextBlock>
    <ecd:MnpiDiscTimedForCompValFlag contextRef="c-1" id="f-11">false</ecd:MnpiDiscTimedForCompValFlag>
    <ecd:PvpTableTextBlock contextRef="c-1" id="f-12">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.625%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.368%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.499%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.564%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.674%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.913%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.499%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.913%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.499%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.913%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.499%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.913%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.499%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.913%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.499%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.913%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.499%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.923%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;Summary Compensation Table Total for First PEO &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3.9pt;font-weight:700;line-height:100%;position:relative;top:-2.1pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;Compensation Actually Paid to First PEO &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3.9pt;font-weight:700;line-height:100%;position:relative;top:-2.1pt;vertical-align:baseline"&gt;(1) (3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;Summary Compensation Table Total for Second PEO &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3.9pt;font-weight:700;line-height:100%;position:relative;top:-2.1pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;Compensation Actually Paid to Second&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;&#160;PEO &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3.9pt;font-weight:700;line-height:100%;position:relative;top:-2.1pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3.9pt;font-weight:700;line-height:100%;position:relative;top:-2.1pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;Average Summary Compensation Table Total for Non-PEO&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;&#160;NEOs &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3.9pt;font-weight:700;line-height:100%;position:relative;top:-2.1pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;Average Compensation Actually Paid to Non-PEO&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;&#160;NEOs &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3.9pt;font-weight:700;line-height:100%;position:relative;top:-2.1pt;vertical-align:baseline"&gt;(2) (5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;Value of Initial Fixed $100 Investment Based on Total Shareholder Return&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;Net Income &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3.9pt;font-weight:700;line-height:100%;position:relative;top:-2.1pt;vertical-align:baseline"&gt;(6)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,467,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(884,853)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,835,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,616,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,598,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;878,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(200,403)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,110,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,055,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,576,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,233,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(177,119)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,169,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,203,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,622,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;828,645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(101,944)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ecd:PvpTableTextBlock>
    <ecd:PeoTotalCompAmt contextRef="c-2" decimals="0" id="f-13" unitRef="usd">3467590</ecd:PeoTotalCompAmt>
    <ecd:PeoActuallyPaidCompAmt contextRef="c-2" decimals="0" id="f-14" unitRef="usd">-884853</ecd:PeoActuallyPaidCompAmt>
    <ecd:PeoTotalCompAmt contextRef="c-3" decimals="0" id="f-15" unitRef="usd">2835589</ecd:PeoTotalCompAmt>
    <ecd:PeoActuallyPaidCompAmt contextRef="c-3" decimals="0" id="f-16" unitRef="usd">1616932</ecd:PeoActuallyPaidCompAmt>
    <ecd:NonPeoNeoAvgTotalCompAmt contextRef="c-1" decimals="0" id="f-17" unitRef="usd">1598976</ecd:NonPeoNeoAvgTotalCompAmt>
    <ecd:NonPeoNeoAvgCompActuallyPaidAmt contextRef="c-1" decimals="0" id="f-18" unitRef="usd">878167</ecd:NonPeoNeoAvgCompActuallyPaidAmt>
    <ecd:TotalShareholderRtnAmt contextRef="c-1" decimals="0" id="f-19" unitRef="usd">19</ecd:TotalShareholderRtnAmt>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-20" unitRef="usd">-200403000</us-gaap:NetIncomeLoss>
    <ecd:PeoTotalCompAmt contextRef="c-4" decimals="0" id="f-21" unitRef="usd">4110121</ecd:PeoTotalCompAmt>
    <ecd:PeoActuallyPaidCompAmt contextRef="c-4" decimals="0" id="f-22" unitRef="usd">3055451</ecd:PeoActuallyPaidCompAmt>
    <ecd:NonPeoNeoAvgTotalCompAmt contextRef="c-4" decimals="0" id="f-23" unitRef="usd">1576776</ecd:NonPeoNeoAvgTotalCompAmt>
    <ecd:NonPeoNeoAvgCompActuallyPaidAmt contextRef="c-4" decimals="0" id="f-24" unitRef="usd">1233210</ecd:NonPeoNeoAvgCompActuallyPaidAmt>
    <ecd:TotalShareholderRtnAmt contextRef="c-4" decimals="0" id="f-25" unitRef="usd">39</ecd:TotalShareholderRtnAmt>
    <us-gaap:NetIncomeLoss contextRef="c-4" decimals="-3" id="f-26" unitRef="usd">-177119000</us-gaap:NetIncomeLoss>
    <ecd:PeoTotalCompAmt contextRef="c-5" decimals="0" id="f-27" unitRef="usd">4169942</ecd:PeoTotalCompAmt>
    <ecd:PeoActuallyPaidCompAmt contextRef="c-5" decimals="0" id="f-28" unitRef="usd">1203063</ecd:PeoActuallyPaidCompAmt>
    <ecd:NonPeoNeoAvgTotalCompAmt contextRef="c-5" decimals="0" id="f-29" unitRef="usd">1622119</ecd:NonPeoNeoAvgTotalCompAmt>
    <ecd:NonPeoNeoAvgCompActuallyPaidAmt contextRef="c-5" decimals="0" id="f-30" unitRef="usd">828645</ecd:NonPeoNeoAvgCompActuallyPaidAmt>
    <ecd:TotalShareholderRtnAmt contextRef="c-5" decimals="0" id="f-31" unitRef="usd">48</ecd:TotalShareholderRtnAmt>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-3" id="f-32" unitRef="usd">-101944000</us-gaap:NetIncomeLoss>
    <ecd:NamedExecutiveOfficersFnTextBlock contextRef="c-1" id="f-33">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;For 2024, our principal executive officers were Lonnel Coats and Michael S. Exton, Ph.D.  For 2023 and 2022, our principal executive officer was Lonnel Coats.&lt;/span&gt;&lt;div style="margin-bottom:9pt;padding-left:22.5pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;For 2024, our other named executive officers were Brian T. Crum, Craig B. Granowitz, M.D., Ph.D., Alan J. Main, Ph.D., Jeffrey L. Wade, Kristen L. Alexander and Thomas A. Garner.  For 2023, our other named executive officers were Jeffrey L. Wade, Brian T. Crum, Craig B. Granowitz, M.D., Ph.D and Alan J. Main, Ph.D.  For 2022, our other named executive officers were Jeffrey L. Wade, Brian T. Crum, Craig B. Granowitz, M.D., Ph.D. and Kenneth B. Kassler-Taub, M.D.&lt;/span&gt;&lt;/div&gt;</ecd:NamedExecutiveOfficersFnTextBlock>
    <ecd:PeoName contextRef="c-2" id="f-34">Lonnel Coats</ecd:PeoName>
    <ecd:PeoName contextRef="c-3" id="f-35">Michael S. Exton, Ph.D</ecd:PeoName>
    <ecd:PeoName contextRef="c-5" id="f-36">Lonnel Coats</ecd:PeoName>
    <ecd:PeoName contextRef="c-4" id="f-37">Lonnel Coats</ecd:PeoName>
    <ecd:AdjToPeoCompFnTextBlock contextRef="c-1" id="f-38">The following table sets forth the adjustments made during each year to calculate Compensation Actually Paid to our first principal executive officer.&lt;div style="margin-bottom:9pt;padding-left:22.5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.116%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.414%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.116%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.414%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.119%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Summary Compensation Table Totals for First PEO&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;3,467,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;4,110,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;4,169,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Add (Subtract):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;&#160;&#160;&#160;Fair value of equity awards granted during the year from the Summary Compensation Table&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;(3,014,509)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;(2,967,821)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;(2,945,080)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;&#160;&#160;&#160;Fair value at year end of equity awards granted during the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,989,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,847,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;&#160;&#160;&#160;Change in fair value of equity awards granted in prior years that were unvested as of the end of the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(283,105)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,003,687)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;&#160;&#160;&#160;Change in fair value of equity awards granted in prior years that vested during the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;608,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;206,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(865,257)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;&#160;&#160;&#160;Equity awards granted in prior years that were forfeited during the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,946,175)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Compensation Actually Paid Totals&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(884,853)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,055,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,203,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:22.5pt;text-align:justify;text-indent:-20.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The following table sets forth the adjustments made during each year to calculate Compensation Actually Paid to our second principal executive officer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:22.5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.461%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:87.427%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.373%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Summary Compensation Table Totals for Second PEO&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;2,835,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Add (Subtract):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;&#160;&#160;&#160;Fair value of equity awards granted during the year from the Summary Compensation Table&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;(2,308,770)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;&#160;&#160;&#160;Fair value at year end of equity awards granted during the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,090,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;&#160;&#160;&#160;Change in fair value of equity awards granted in prior years that were unvested as of the end of the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;&#160;&#160;&#160;Change in fair value of equity awards granted in prior years that vested during the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;&#160;&#160;&#160;Equity awards granted in prior years that were forfeited during the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Compensation Actually Paid Totals&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,616,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ecd:AdjToPeoCompFnTextBlock>
    <ecd:PeoTotalCompAmt contextRef="c-2" decimals="0" id="f-39" unitRef="usd">3467590</ecd:PeoTotalCompAmt>
    <ecd:PeoTotalCompAmt contextRef="c-4" decimals="0" id="f-40" unitRef="usd">4110121</ecd:PeoTotalCompAmt>
    <ecd:PeoTotalCompAmt contextRef="c-5" decimals="0" id="f-41" unitRef="usd">4169942</ecd:PeoTotalCompAmt>
    <ecd:AdjToCompAmt contextRef="c-6" decimals="0" id="f-42" unitRef="usd">-3014509</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c-7" decimals="0" id="f-43" unitRef="usd">-2967821</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c-8" decimals="0" id="f-44" unitRef="usd">-2945080</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c-9" decimals="0" id="f-45" unitRef="usd">0</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c-10" decimals="0" id="f-46" unitRef="usd">1989880</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c-11" decimals="0" id="f-47" unitRef="usd">1847145</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c-12" decimals="0" id="f-48" unitRef="usd">0</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c-13" decimals="0" id="f-49" unitRef="usd">-283105</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c-14" decimals="0" id="f-50" unitRef="usd">-1003687</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c-15" decimals="0" id="f-51" unitRef="usd">608241</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c-16" decimals="0" id="f-52" unitRef="usd">206376</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c-17" decimals="0" id="f-53" unitRef="usd">-865257</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c-18" decimals="0" id="f-54" unitRef="usd">-1946175</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c-19" decimals="0" id="f-55" unitRef="usd">0</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c-20" decimals="0" id="f-56" unitRef="usd">0</ecd:AdjToCompAmt>
    <ecd:PeoActuallyPaidCompAmt contextRef="c-2" decimals="0" id="f-57" unitRef="usd">-884853</ecd:PeoActuallyPaidCompAmt>
    <ecd:PeoActuallyPaidCompAmt contextRef="c-4" decimals="0" id="f-58" unitRef="usd">3055451</ecd:PeoActuallyPaidCompAmt>
    <ecd:PeoActuallyPaidCompAmt contextRef="c-5" decimals="0" id="f-59" unitRef="usd">1203063</ecd:PeoActuallyPaidCompAmt>
    <ecd:PeoTotalCompAmt contextRef="c-3" decimals="0" id="f-60" unitRef="usd">2835589</ecd:PeoTotalCompAmt>
    <ecd:AdjToCompAmt contextRef="c-21" decimals="0" id="f-61" unitRef="usd">-2308770</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c-22" decimals="0" id="f-62" unitRef="usd">1090113</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c-23" decimals="0" id="f-63" unitRef="usd">0</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c-24" decimals="0" id="f-64" unitRef="usd">0</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c-25" decimals="0" id="f-65" unitRef="usd">0</ecd:AdjToCompAmt>
    <ecd:PeoActuallyPaidCompAmt contextRef="c-3" decimals="0" id="f-66" unitRef="usd">1616932</ecd:PeoActuallyPaidCompAmt>
    <ecd:AdjToNonPeoNeoCompFnTextBlock contextRef="c-1" id="f-67">The following table sets forth the adjustments made during each year to calculate Average Compensation Actually Paid to our other named executive officers. &lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.444%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.797%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.187%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.419%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.187%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.419%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.191%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Average Summary Compensation Table Totals for Non-PEO NEOs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;1,598,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;1,576,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;1,622,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Add (Subtract):&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;&#160;&#160;&#160;Fair value of equity awards granted during the year from the Summary Compensation Table&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;(877,009)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;(932,283)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;(957,722)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;&#160;&#160;&#160;Fair value at year end of equity awards granted during the year &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;263,789&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;625,082&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;600,680&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;&#160;&#160;&#160;Change in fair value of equity awards granted in prior years that were unvested as of the end of the year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(198,031)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(94,405)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(260,725)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;&#160;&#160;&#160;Change in fair value of equity awards granted in prior years that vested during the year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;130,573&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58,040&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(175,708)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;&#160;&#160;&#160;Equity awards granted in prior years that were forfeited during the year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(40,132)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Average Compensation Actually Paid Totals&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;878,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,233,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;828,645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ecd:AdjToNonPeoNeoCompFnTextBlock>
    <ecd:NonPeoNeoAvgTotalCompAmt contextRef="c-1" decimals="0" id="f-68" unitRef="usd">1598976</ecd:NonPeoNeoAvgTotalCompAmt>
    <ecd:NonPeoNeoAvgTotalCompAmt contextRef="c-4" decimals="0" id="f-69" unitRef="usd">1576776</ecd:NonPeoNeoAvgTotalCompAmt>
    <ecd:NonPeoNeoAvgTotalCompAmt contextRef="c-5" decimals="0" id="f-70" unitRef="usd">1622119</ecd:NonPeoNeoAvgTotalCompAmt>
    <ecd:AdjToCompAmt contextRef="c-26" decimals="0" id="f-71" unitRef="usd">-877009</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c-27" decimals="0" id="f-72" unitRef="usd">-932283</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c-28" decimals="0" id="f-73" unitRef="usd">-957722</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c-29" decimals="0" id="f-74" unitRef="usd">263789</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c-30" decimals="0" id="f-75" unitRef="usd">625082</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c-31" decimals="0" id="f-76" unitRef="usd">600680</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c-32" decimals="0" id="f-77" unitRef="usd">-198031</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c-33" decimals="0" id="f-78" unitRef="usd">-94405</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c-34" decimals="0" id="f-79" unitRef="usd">-260725</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c-35" decimals="0" id="f-80" unitRef="usd">130573</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c-36" decimals="0" id="f-81" unitRef="usd">58040</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c-37" decimals="0" id="f-82" unitRef="usd">-175708</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c-38" decimals="0" id="f-83" unitRef="usd">-40132</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c-39" decimals="0" id="f-84" unitRef="usd">0</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c-40" decimals="0" id="f-85" unitRef="usd">0</ecd:AdjToCompAmt>
    <ecd:NonPeoNeoAvgCompActuallyPaidAmt contextRef="c-1" decimals="0" id="f-86" unitRef="usd">878167</ecd:NonPeoNeoAvgCompActuallyPaidAmt>
    <ecd:NonPeoNeoAvgCompActuallyPaidAmt contextRef="c-4" decimals="0" id="f-87" unitRef="usd">1233210</ecd:NonPeoNeoAvgCompActuallyPaidAmt>
    <ecd:NonPeoNeoAvgCompActuallyPaidAmt contextRef="c-5" decimals="0" id="f-88" unitRef="usd">828645</ecd:NonPeoNeoAvgCompActuallyPaidAmt>
    <ecd:Additional402vDisclosureTextBlock contextRef="c-1" id="f-89">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;In thousands.&lt;/span&gt;&lt;div style="margin-bottom:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The changes in compensation actually paid to Mr. Coats, Dr. Exton and our other named executive officers during such periods as described in the pay versus performance table were largely driven by equity award related adjustments as a result of turnover among our named executive officers and the volatility in the market price of our common stock, and to a lesser extent by variability in annual salary, bonus and equity incentive awards.  As a result, such changes are not directly related to the changes in our total shareholder return and net income during such periods.&lt;/span&gt;&lt;/div&gt;</ecd:Additional402vDisclosureTextBlock>
    <ecd:CompActuallyPaidVsTotalShareholderRtnTextBlock contextRef="c-1" id="f-91">From 2022 to 2023, compensation actually paid to Mr. Coats as described in the pay versus performance table increased 154.0%, average compensation actually paid to our other named executive officers as described in the pay versus performance table increased 48.8%, our total shareholder return decreased 19.9% and our net income decreased 73.7%.  From 2023 to 2024, compensation actually paid to Mr. Coats and Dr. Exton as described in the pay versus performance table decreased 76.0%, average compensation actually paid to our other named executive officers as described in the pay versus performance table decreased 28.8%, our total shareholder return decreased 51.6% and our net income decreased 13.1%.</ecd:CompActuallyPaidVsTotalShareholderRtnTextBlock>
    <ecd:CompActuallyPaidVsTotalShareholderRtnTextBlock contextRef="c-1" id="f-90">From 2022 to 2023, compensation actually paid to Mr. Coats as described in the pay versus performance table increased 154.0%, average compensation actually paid to our other named executive officers as described in the pay versus performance table increased 48.8%, our total shareholder return decreased 19.9% and our net income decreased 73.7%.  From 2023 to 2024, compensation actually paid to Mr. Coats and Dr. Exton as described in the pay versus performance table decreased 76.0%, average compensation actually paid to our other named executive officers as described in the pay versus performance table decreased 28.8%, our total shareholder return decreased 51.6% and our net income decreased 13.1%.</ecd:CompActuallyPaidVsTotalShareholderRtnTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
